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Abstract
The  Anthony  Nolan  Register  provides  donors  for  allogeneic  stem  cell 
transplantation for haematological  disorders.  A clinical  database  and  sample 
bank  were  established  for  the  ongoing  analysis  of  transplants  from  Register 
donors.  Clinical  data  and  blood  samples  were  collected  from  donors  and 
patients transplanted in the UK from 1996 onwards.
DNA  was  extracted  from all  samples  received,  and  used  for  the  detection  of 
HLA  mismatches  at  six  loci  (HLA-A,  -B,  -C,  -DRB1,  -DQB1,  and  -DPB1)  by 
RSCA,  and  HA-1  by  SSP.  138  donor/patient  pairs  were  selected  for  a  pilot 
study.  HLA matching between patient and donor, along with the diagnosis of 
the  patient,  donor  and  patient  age,  CMV  status  and  gender,  and  the  T  cell 
depletion status of the  transplant were analysed  for their effect on transplant 
outcome.  The outcome variables studied included overall survival, disease free 
survival, transplant related mortality, relapse incidence, and the occurrence of 
acute and chronic GvHD.
Patients  with  AML  had  decreased  overall  and  disease  free  survival,  and 
patients with CML had increased risk of relapse.  Transplant from a same sex 
donor increased the risk of death or relapse, and male patients receiving stem 
cells from female donors showed  reduced  overall  survival.  Developing acute 
GvHD increased the risk of transplant related mortality.  A mismatch at HLA 
class I and at class II was associated with unfavourable outcome for all survival 
variables.  The inclusion of HLA-DPB1  matching did not alter the effects seen 
when other mismatches were present.  Matching at the allele level  for all loci 
gave an increased risk of relapse compared with patients mismatched with their
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donor  for  HLA-DPB1  only,  indicating  that  a  mismatch  for  HLA-DPB1  alone 
may protect from relapse.
The  data  from  this  study  was  used  to  calculate  the  numbers  required  for  a 
definitive  study,  for  the  optimisation  of  donor  selection  from  the  Register.
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Chapter 1
Introduction
Bone  marrow transplantation  (BMT)  between  unrelated  individuals  is  now  a 
routine treatment for a variety of haematological and immunological diseases. 
One of the main complications following this therapeutic procedure, however, 
is rejection of either the host tissue by the bone marrow graft (graft-versus-host 
disease), or of graft tissue by the host (graft rejection).  Graft-versus-host disease 
(GvHD) comes about when the T cells of the allogeneic bone marrow recognise 
the  cells  of  the  recipient  as  foreign,  causing  a  severe  inflammatory  response 
(Deeg  1993).  These  conditions  occur  due  to  interactions  between  donor  and 
recipient immune systems.  Graft rejection can be avoided through suppression 
of the patient's  immune  system,  and  it has also been shown that removing T 
cells  from  the  bone  marrow  graft  can  reduce  the  extent  of  graft-versus-host 
disease  seen  (Hale  and  Waldmann  1994).  The  Major  Histocompatibility 
Complex  (MHC)  antigens  are  the  main  targets  of  the  graft  versus  host  and 
rejection responses.  Therefore, patients and donors are typed and matched for 
their MHC encoded HLA molecules prior to transplantation in order to try and 
limit an allo-reactive response.
The history of bone marrow transplantation
Mouse models
The effects of radiation on humans following the use of atomic bombs during 
World  War  II  led  to  research  experiments  on  mice,  to  identify  the  effects  of 
radiation  and  discover  potential  curative  treatments.  Through  experiments 
where  mice  were  exposed  to  whole  body  irradiation,  it  was  found  that 
protection  of  the  spleen  with  lead  foil,  or  subsequent  infusion  of  autologous
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bone marrow protected from radiation damage (Jacobson et al. 1951; Lorenz et 
al.  1951).  These experiments were developed further, showing that if marrow 
were  successfully  transplanted  between  mouse  strains,  a  skin  graft  could  be 
given from the same donor and not rejected (Main and Prehn 1955).  The skin 
would only be accepted if given from the donor strain, and the marrow in the 
transplanted mice had the same immunogenetics as that of the donor (Ford et al. 
1956; Trentin 1956).
When  transplants  were  carried  out  between  mice  of  different  strains,  it  was 
found that in some cases, the bone marrow elicited an immune response against 
the  recipient,  giving  a  secondary  disease,  now  known  as  graft-versus-host 
disease (GvHD) (Barnes et al. 1956).  The severity of this disease was found to be 
due  to  genetic  differences  between  the  donor  and  recipient  (Uphoff  1957), 
which  agreed  with  discoveries  previously  seen  in  solid  organ  transplant 
rejection (Gorer et al. 1948; Snell 1948).  These genetic factors are discussed later. 
To try to reduce the severity and occurrence of the GvHD, immune suppressive 
drugs such as methotrexate  (MTX) were administered with the bone marrow, 
resulting in a reduced GvHD response (Lochte et al. 1962; Uphoff 1958).  In an 
effort to move away from using lethal dose irradiation for myeloablation, other 
methods of T-cell depletion were developed, using immune suppressive drugs, 
such  as  cyclophosphamide  (Santos  and  Owens  1969),  and  also  antibodies 
specific  for  lymphocytes  and  thymocytes  (Brent  et  al.  1967).  Once  the 
complications  following  allogeneic  bone  marrow  transplantation  could  be 
controlled  in the mouse,  this treatment was used  in an attempt to cure firstly 
immune  deficiency  disorders  (Steinmuller  and  Motulsky  1967),  and  later 
autoimmune diseases in murine models of human diseases (van Bekkum 1993).
Canine transplantation
Although  bone  marrow  transplantation  could  be  successfully  carried  out  in 
mouse  models  of  human  disease,  the  transition  from  this  to  human 
transplantation was not simple.  The mice used were inbred and raised under 
laboratory  conditions,  not  representative  of  the  human  situation.  Therefore,
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experiments  had  to  be  carried  out  in  outbred  animal  populations  to  give  a 
greater  experience  of the  genetic  variability  faced.  Larger  animals  were  also 
required  to  test  the  level  of  radiation  and  the  dose  of  immune  suppressive 
drugs that could be  given  safely.  These experiments were carried  out in the 
dog,  as  these  animals  were  readily  available  and  inexpensive  to  keep  in  a 
laboratory environment.  Large families could be studied, with the availability 
of  matched  littermate  pairs.  In  early  experiments,  similar  GvHD  responses 
were  seen  to  those  already  observed  in  mouse  BMT  (Thomas  et  al.  1962), 
leading  to  the  discovery  of  the  genes  of  the  canine  major  histocompatibility 
complex, the Dog Leukocyte Antigens (DLA)  (Epstein et al.  1968).  One of the 
discoveries that came from these experiments was that dogs receiving previous 
donor  blood  transfusions  developed  acute  rejection  of  bone  marrow  when 
subsequently  transplanted  from  littermates  (Storb  and  Deeg  1986).  This 
transfusion-induced sensitisation was overcome by the use of alkylating agents 
(such  as  Cyclophosphamide)  in  conjunction  with  antithymocyte  globulin. 
Canine transplantation was also key  in the use of other prophylactic immune 
suppressive  drugs  used  in  combination,  such  as  cyclosporin  along  with 
methotrexate,  a  combination  which  was  shown  in  dogs  to  give  a  good 
protection against the development of GvHD (Deeg et al. 1984; Deeg et al. 1982).
Bone marrow transplantation in humans
While  experiments  were  being  carried  out  in  dogs,  to  identify  methods  of 
transplantation  that  could  be  safely  carried  out  in  individuals  with  different 
genetic backgrounds, some human transplantation had already been attempted. 
After the first discoveries in mice that marrow could be successfully engrafted 
after  total  body  irradiation,  it  was  attempted  for  the  treatment  of  human 
haematological malignancies (Thomas et al.  1957).  Although engraftment was 
not achieved in most cases, it was seen that the actual process could be tolerated 
in humans, leading the way for further investigation.  The first successful bone 
marrow  engraftment  was  seen  in  two  acute  lymphoblastic  leukaemia  (ALL) 
patients transplanted, after total body irradiation (TBI), with marrow from their
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identical  twin  (Thomas  et  al.  1959).  Engraftment  was  maintained  but  the 
leukaemia  recurred  within  a  few  months,  indicating  that  TBI  alone  was  not 
enough  to  eradicate  the  leukaemia.  This  also  supported  the  views  seen  in 
murine transplants where it was thought that to cure leukaemia, some genetic 
differences were required (Barnes et al. 1956).  Autologous transplantation was 
also  attempted  in acute lymphocytic  leukaemia  (ALL)  patients,  with  marrow 
stored from a previous remission.  Remission was achieved, but the patient later 
relapsed, perhaps because there were still some leukaemic cells present in the 
graft, or a lack of antileukaemic response  (McGovern et al.  1959).  Due to the 
staggering  lack  of  success  in  the  maintenance  of  engraftment,  studies  were 
carried out to test the tolerance level for radiation exposure, and chemotherapy 
alone and in combination in the hope of extending the life of the bone marrow 
graft (Buckner et al. 1974).
Transplant work  in  animal  models,  and  blood  transfusion  anomalies  led  the 
way  to  the  discovery  of  the  Major  Histocompatibility  Complex,  which 
explained many of the transplant results seen in these early experiments.  Using 
the knowledge gained from early transplantation experiments, and new found 
information  about  histocompatibility  antigens,  more  success  was  had  with 
transplantation  in  patients  with  diseases  that  did  not  require  extensive 
conditioning before transplantation to avoid graft rejection (Bach et al. 1968; De 
Koning  et  al.  1969;  Gatti  et  al.  1968).  Following  these  encouraging  results, 
matched  sibling transplants were  also performed  in leukaemic  patients  given 
lethal total body irradiation  (Thomas et al.  1971), and later the first unrelated 
transplant for a patient with aplastic anaemia (Speck et al. 1973).  Unfortunately, 
this  and  following  unrelated  transplants  were  unsuccessful  (Horowitz  et  al. 
1975; Lohrmann et al. 1975; O'Reilly et al. 1977), and the spirits of the transplant 
physicians  were  severly  dampened.  The  first  successful  unrelated  bone 
marrow  transplant  was  finally  carried  out  in  a  child  with  ALL  in  second 
remission,  although  the  patient  eventually  relapsed  and  died  2  years  post 
transplant (Hansen et al. 1980).  These transplants began the path towards the 
way stem cell transplants are carried out today.
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Other sources of stem cells
Sources  of  stem  cells  for  allogeneic  transplantation  today  have  extended  to 
umbilical cord blood  and  mobilised  peripheral blood from adult donors.  An 
HLA matched cord blood unit, once identified, can be acquired rapidly as it is 
cryopreserved, and already typically intermediate or high resolution typed for 
HLA-A, -B and -DRB1 loci at collection (Barker et al. 2002).  Total nucleated cell 
dose of a cord blood graft has shown to be critical with regard to engraftment 
and  survival  post  transplant  (Gluckman  et  al.  1997;  Rubinstein  et  al.  1998), 
therefore, the fixed cell count of the cord blood unit presents a limiting factor 
especially for adult patients.  However, cord blood has a higher frequency  of 
progenitor  cells  compared  with  adult  peripheral  blood  or  bone  marrow 
(Broxmeyer et al. 1992).  Despite early findings that a 0-3 HLA antigen mismatch 
did not increase the risk of developing acute or chronic GvHD (Gluckman et al. 
1997;  Laughlin  et  al.  2001),  larger  studies  have  reported  significantly  higher 
rates of acute GvHD with mismatched grafts (Rubinstein et al. 1998).  The naive 
status of cord blood lymphocytes has raised concerns for a reduced graft versus 
leukaemia effect after cord blood transplant (Linch and Brent 1989), but studies 
so  far  have  not  shown  a  relationship  with  increased  relapse  compared  with 
bone marrow transplants (Barker et al. 2001a; Rocha et al. 2001).  Comparisons 
between  cord  blood  and  marrow  stem  cell  transplants  in  children  have 
determined  no  significant  difference  with  respect  to  survival  (Barker  et  al. 
2001a; Rocha et al. 2001).  The main challenges with respect to adult patients are 
associated  with  the  cell  dose  available  form  a  cord  blood  unit.  Studies  are 
ongoing to try and overcome this problem with ex vivo expansion of cord blood 
haematopoietic cells (Jaroscak et al. 2003), and the transplantation of more than 
one cord blood unit (Barker et al. 2001b).
Recombinant  granulocyte  colony-stimulating  factor  (G-CSF)  -  mobilised 
peripheral  blood  stem  cells  (PBSC)  are  now  widely  used  for  allogeneic 
transplantation  from  HLA-identical  related  donors.  Results  have  shown 
improved immune reconstitution compared to related bone marrow transplants 
(Bensinger  et  al.  2001;  Champlin  et  al.  2000),  and  reduced  risk  of  relapse  in
15C hapter 1
patients with CML in first chronic phase (Elmaagacli et al. 1999).  In studies of 
unrelated PBSC transplant, neutrophil and platelet recovery were more rapid in 
recipients of PBSC compared with bone marrow (Elmaagacli et al. 2002; Fauser 
et  al.  2000;  Ringden  et  al.  1999).  With  accelerated  immune  reconstitution 
demonstrated  by  a  reduced  risk  for  interstitial  pneumonia  cause  by  CMV 
following PBSC transplant  (Trenschel et al.  2000).  Although it was  originally 
though there would be an increased risk of acute GvHD with PBSC due to the 
larger number of lymphocytes present compared to bone marrow (Korbling et 
al.  1995),  a  lower  incidence  of  severe  acute  GvHD  has  been  reported  in 
unrelated  transplants  compared  with  bone  marrow  in  CML  patients 
(Elmaagacli et al. 2002), but not in related transplants with other disease groups 
(Bensinger et al.  2001; Champlin et al.  2000).  Reduced incidence of transplant 
related  mortality  in recipients  of PBSC has  also been reported,  thought to be 
due to superior immune reconstitution and  lower rate of severe acute GvHD 
(Elmaagacli et al.  2002).  PBSC transplantation also offers practical advantages 
for the  donor  over conventional  allogeneic bone  marrow  transplants,  namely 
the  ability  to  harvest  stem  cells  in  an  outpatient  setting,  thereby  avoiding 
hospitalisation and the risks of general anaesthesia.
Graft versus Host disease
The  first  description  of  graft-versus-host  disease  was  published  in  1955,  in  a 
mouse model, where it was originally named secondary disease, to separate it 
from the primary disease of radiation sickness seen post allogeneic transplant 
(Barnes  and  Loutit  1955).  Later  described  as  a  disease  resulting  from  the 
presence of immunocompetant donor cells in an immunocompromised host, it 
was termed graft versus host disease (Billingham and Brent 1957), the effect of 
which was also later seen in human transplantation (Graw et al. 1970; Mathe et 
al. 1963).  HLA disparity between the haematopoietic cell donor and transplant 
recipient  is  the  most  powerful  factor  governing  the  severity  and  kinetics  of 
GvHD.  Donor  T  lymphocytes  proliferate  and  differentiate  in  response  to 
disparate histocompatibility  antigens  in host tissues,  and  directly,  or  through 
secondary  mechanisms,  attack  recipient  cells,  producing  the  signs  and
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symptoms  of GvHD.  It  has  been  shown  that  the  incidence  of  acute  GvHD 
increases with HLA disparity between donor and recipient (Beatty et al.  1985; 
Kernan et al. 1993).
Graft  versus  host  disease  can  be  split  into  two  parts,  acute  GvHD,  which 
encompasses the dermatitis, hepatitis and enteritis seen to develop within 100 
days post transplant, and chronic GvHD, which describes a more diverse and 
widespread syndrome developing after day 100.
In  1966,  Billingham  defined  the  criteria  for  the  development  of  GvHD 
(Billingham 1966):
1.  "The graft must contain immunologically competent cells.
2.  The  host  must  possess  important  transplantation  alloantigens  that  are 
lacking  in  the  donor  graft,  and  is,  therefore,  capable  of  stimulating  it 
antigenically.
3.  The  host  must  be  incapable  of  mounting  an  effective  immunological 
reaction  against  the  graft,  at  least  for  sufficient  time  for  the  latter  to 
manifest its immunological capabilities; that is, it must have the security 
of tenure."
The  afferent  phase  of GvHD  consists  of antigen  presentation,  activation  of T 
cells,  clonal  proliferation  and  differentiation  (reviewed  in  Ferrara  and  Deeg 
1991), resulting in host cell death.  In the efferent phase, activated lymphocytes 
release  cytokines,  leading  to  cell  death  directly  or  through  recruitment  and 
activation of secondary effectors such as NK cells (Piguet et al. 1987).  NK cells 
can express inhibitory receptors that signal killing when they do not bind their 
specific  ligand,  for example,  an  HLA class  I  molecule  (Bottino et al.  1995).  If 
donor and recipient are mismatched for this ligand, killing by NK cells may be 
induced  (Colonna et al.  1993),  contributing  to  the GvH  effect.  NK  cells  have 
been found in cutaneous GvHD (Acevedo et al. 1991).
Administration  of  high-dose  chemotherapy  is  followed  by  an  increase  in 
circulating  cytokines  (known  as  "cytokine  storm"),  which  are  thought  to
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increase the ability of graft immune cells to recognize host antigens (reviewed 
in (Ferrara 1993), and can also lead to localized tissue damage, thus exposing 
cryptic antigens in certain organs (eg, the MIC antigens in the gut) which may 
activate NK and T cells (Bauer et al. 1999).  Administration of non-myeloablative 
but immune-suppressive chemotherapy followed by allogeneic transplants (ie, 
mini-dose  transplant,  transplant-light)  decreases  the  original  cytokine  storm 
and tissue damage, leading to lower incidence of GVHD, hopefully maintaining 
a graft versus tumor effect (Slavin et al. 1998).
Graft versus leukaemia effect
Although the  effects  of GvHD  can  be  detrimental  to  the  patient,  it  has  been 
observed that in some cases, alongside GvHD, a second effect can occur which 
is  favourable  to  transplant  outcome  (Weiden  et  al.  1979).  Termed  the  Graft 
versus  leukaemia  effect  (GvL)  (Bortin et al.  1973),  it has  been postulated  that 
some histocompatibility antigen mismatches between donor and recipient may 
lead to recognition of disparate antigens on the malignant cells of the patient by 
the T cells of the donor (Wang et al. 2002), leading to eradication of the disease. 
One  of  the  limitations  of  successful  transplantation  in  advanced  malignant 
disease  is  the  relapse  rate.  Although  relapse  may  be  due  to  an  insufficient 
conditioning regime,  the absence  of a GvL  effect may  also contribute.  When 
outcomes have been compared between allogeneic and syngeneic  transplants, 
the risk of relapse was higher in the syngeneic transplant group, suggesting that 
an antileukaemic  effect is  associated  with allogeneic  marrow  (Horowitz  et al. 
1990; Ringden and Horowitz 1989).  In an attempt to reduce the incidence and 
severity  of  GvHD,  T  cell  depletion  has  been  used  to  great  success  (Hale, 
Waldmann 1994; Hale and Waldmann 1996).  However, it has been found that 
the  incidence  of  relapse  is  higher  in  recipients  of  T  cell  depleted  allogeneic 
transplants  when  compared  with  unmodified  marrow  (Apperley  et  al.  1988; 
Goldman  et  al.  1988;  Martin  et  al.  1988).  CML  in  chronic  phase  is  highly 
susceptible  to  GvL  effects  mediated  by  allogeneic  T  cells,  as  evidenced  by  a
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5.14-fold  increased  risk  of  relapse  associated  with  T  cell  depletion  of  donor 
marrow  prior  to  HLA-identical  allogeneic  bone  marrow  transplantation 
(Horowitz et al. 1990).
The most compelling evidence for a GvL effect in humans is that, in some cases, 
patients with relapsed disease can be brought back into remission through an 
infusion of donor lymphocytes post transplant (Collins Jr et al. 1997; Kolb et al. 
1990; Kolb et al. 1995).  The effector cells that mediate a GvL effect may include 
CD8+  CTL  that  recognise  tumour  antigens  in  association  with  MHC  class  I 
antigens, CD4+ T cells that recognise tumour antigens in association with MHC 
class II antigens, or NK/LAK cells that mediate an antitumour effect through 
cytokine secretion and without MHC restriction (Sosman et al. 1989).
The challenge is to induce a GvL effect while reducing the GvHD response as 
much as possible.  This has been attempted by reducing the number of CD3+ 
cells  infused  in  the  donor  lymphocyte  infusion  (DLI)  (Giralt  et  al.  1995; 
Mackinnon et al. 1995), altering post-transplant imuune suppression (Sullivan et 
al. 1989), and the use of IL-2 therapy to stimulate the likely effectors of the GvL 
effect (Soiffer et al. 1994).
Tolerance
During T cell education in the thymus,  thymocytes are deleted if they have a 
strong  affinity  for  self-MHC  (reviewed  in  Nossal  1994).  Preventing  the 
emergence  of  autoimmune  T  cells  from  the  thymus  represents  the  central 
mechanism  of  self-tolerance.  However,  this  mechanism  of  central  tolerance 
induction cannot explain the lack of response seen against antigens encountered 
in the periphery that are not expressed in the thymus.  Peripheral tolerance is 
maintained  by  mechanisms  that  act  on  mature  lymphocytes  that  encounter 
self-antigens  in  peripheral  tissues.  Some  self-antigens  may  induce  neither 
central nor peripheral tolerance but are simply ignored by the immune system. 
Such "clonal ignorance"  (Ohashi et al. 1991), may be because the self-antigen is 
physically  separated  from  immunocompetant  lymphocytes  or  because  the 
antigen is presented to lymphocytes in the absence of the second signals that are 
needed  to  trigger  effective  immune  responses.  For  an  immune  response  to
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occur, lymphocytes must usually be exposed to two types of stimulus.  The first 
signal,  an  antigen,  ensures  the  specificity  of  the  response,  second  signals 
include costimulators and cytokines, usually produced as a result of the initial 
innate  immune response to a  pathogen  (Fearon and  Locksley  1996).  Because 
self-antigens  do  not  normally  elicit  innate  immune  reactions,  they  may  be 
ignored by the immune system.
It is widely believed that self-antigen recognition without costimulation induces 
functional anergy, although it is not known which factors determine whether a 
self-antigen  is  functionally  ignored  or  induces  anergy.  The  frequently  noted 
association  between infections  and  autoimmunity  has  been  attributed  to  the 
activation  of  anergic  self-reactive  lymphocytes  by  adjacent  cells  reacting  to 
microbial  antigens  but  may  also  result  from  the  activation  of  autoreactive 
lymphocytes that have remained ignorant of the antigen until second signals are 
up-regulated  as  a  consequence  of  the  infection.  The  best  characterised 
co-stimulatory  signalling  components  are  the  B7  molecules  (CD80/CD86) 
expressed on antigen presenting cells, and their receptor, CD28, expressed on T 
cells.  Ligation of CD28 by B7 molecules or anti-CD28 antibodies co-stimulates 
the growth of niave T cells, whereas anti-B7 antibodies that inhibit the binding 
of B7 to CD28 inhibit T cell responses (de Boer et al.  1992).  Self-antigens may 
also  induce  tolerance  in  the  mature  T  lymphocyte  if  the  self-antigens  trigger 
mechanisms that actively block lymphocyte activation or induce apoptosis, for 
example,  with  CTLA-4-mediated  inhibition.  A  T  cell  co-receptor  for  B7 
molecules, called  CTLA-4,  was  shown to function primarily to  shut off T cell 
activation  (Krummel  and  Allison  1995).  CTLA-4  is  induced  on  T  cells  after 
activation, and upon binding B7 on the APC, it transduces signals that inhibit 
the  transcription of IL-2  and  the  progression  of T  cells through  the  cell  cycle 
(Krummel  and  Allison  1996).  CTLA-4  blocks  signals  transduced  by  CD28, 
suggesting  that  these  two  B7-recognising  molecules  function  as  mutual 
antagonists.
In  a  transplant  setting,  the  aim  is  to  induce  immunological  tolerance  to  the 
engrafted tissue.  This has been shown in mice where a mixed chimera has been
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achieved  post allogeneic  bone marrow transplantation, where haematopoietic 
cells from both donor and recipient locate to the thymus and hence delete both 
host-reactive  and  donor  reactive  T  cells,  resulting  in  a  peripheral  T  cell 
repertoire that is both host and donor tolerant (Manilay et al. 1998; Tomita et al. 
1994).  Due to the presence of both host and donor-derived APCs in the thymus 
of a mixed chimera, the deletion of both host and donor-reactive T cells occurs 
to  a  greater  extent  than  in  a  full  chimera  (Yoshikai  et  al  1990).  In  human 
transplantation, the risk of GvHD and relapse are great barriers to the induction 
of  a  mixed  chimera  and  other  avenues  have  required  exploration.  Animal 
models  involving  second  signal  blockade  (Adams  et  al.  2001;  Wekerle  et  al. 
2000),  have  shown  encouraging  results  that  may  be  applicable  to  allogeneic 
bone marrow transplantation in humans.
Factors affecting transplant outcome
In  unrelated  bone  marrow  transplantation,  the  most  important  factor  with 
respect to out come is HLA matching (Madrigal et al. 1997).  However, if more 
than  one  HLA  matched  donor  is  available,  other  factors  must  be  taken  into 
account to ensure the choice of donor will give the best outcome possible.  It has 
been seen  in  HLA  identical  sibling  bone  marrow  transplantation that certain 
characteristics of the recipient and donor can be associated with poor transplant 
outcome. Risk factors include age of the donor and recipient, with transplants 
performed with older donors and recipients having an increased risk of acute 
and chronic GvHD (Ochs et al. 1994; Weisdorf et al. 1991).  Also, transplantation 
of a male recipient with marrow from a female donor is thought to increase the 
risk of developing GvHD,  due  to  recognition  of male-specific  minor  antigens 
(Vogt et al.  2000).  This is especially relevant in multiparous women,  or those 
who  have  had  previous  blood  transfusions,  who  may  have  already  had 
exposure  to  a  male  antigen  (Wiesdorf  et  al.  1991).  Treatment  of  the  bone 
marrow  graft  or  the  recipients  with  T-cell-depleting  antibodies  is  thought  to 
reduce the risk of graft-versus-host disease, but can increase the risk of disease 
relapse  in  some  individuals  (Apperley  et  al.  1986;  Hale,  Waldmann  1994). 
Through  studies  carried  out  on  the  rapidly  increasing  number  of  unrelated
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transplants  performed  it  has  been  found  that  these  and  other  factors  could 
influence the outcome of allogeneic bone marrow transplantation, but still the 
most important selection criteria rested with the MHC (Madrigal et al. 1997).
Disease
Factors  to  consider  include,  type  and  subtype  of  disease,  stage  of  disease  at 
diagnosis and  transplant and  the  time  from  diagnosis  to  transplant.  Disease 
stage at time of transplant is the most important factor influencing outcome in 
all  disease  categories,  more  advanced  disease  is  associated  with  increase  in 
transplant  related  mortality  and  higher  incidence  of  relapse  (Gratwohl  and 
Hermans 2000).
Chronic Leukaemia
Chronic Myeloid Leukaemia can be separated into three stages, chronic phase 
(CP), accelerated phase (AP) and blast crisis (BC).  Characteristic of CML is the 
Philadelphia  chromosome  (Nowell  and  Hungerford  1960),  a  cytogenetic 
abnormality  present  in  the  malignant cell  population,  t(9;22),  forming fusion 
genes  p210B C R "A B L   or  pl90B C R -A B L   (Rowley  1973).  Disease  in CP,  spleen  size, 
percentage of circulating blasts, platelet count and age are the features that have 
shown prognostic  significance  (Sokal et al.  1984).  Chromosomal  abnormalities 
additional  to  Philadelphia  are  thought  to  give  a  poor  prognosis  (Sokal  et  al. 
1988), but unpredictable onset of malignant transformation means these factors 
are of little help in deciding on treatment.
Until  now,  the  main  cure  for  chronic  phase  CML  has  been  bone  marrow 
transplantation.  Therefore, this disease has been the most widely studied with 
respect to unrelated bone marrow transplantation, and has a very good success 
rate with overall survival at approximately 50%, and relapse at 15%  at 3 years 
post transplant (Beatty et al. 1989; Devergie et al. 1997; Dini et al. 1998; Marks et 
al.  1993;  Spencer  et  al.  1995).  Due  to  the  slow  progression  of  CML,  it  was 
originally thought there was no  urgency  in  finding  a  matched  donor,  giving 
more time to find an exact match.  However, potential problems associated with 
GvHD for CML patients have since shown to be offset by early transplantation,
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within first year of diagnosis,  to ensure best chance of long-term disease free 
survival.  For CML patients, factors found to have a significant adverse effect on 
survival  included  patient  age  over  50  and  long  interval  from  diagnosis  to 
transplantation  (Hansen  et  al.  1998).  It  is  thought  for  successful
transplantation in patients with a matched donor, increased cell dose should be 
considered to minimize the risk of graft failure (Petersdorf et al. 1997).  In a risk 
assessment of CML patients from the EBMT, it was found that disease stage had 
a  significant  effect  on  overall  survival  and  transplant  related  mortality 
(Gratwohl et al. 1998).  In the same study, relapse incidence was only associated 
with a stage of disease that was accelerated phase or greater.
Until  recently,  interferon-a  (IFN-a)  was  used  to  treat  patients  with  CML-CP 
who  were  not  eligible  for  allogeneic  stem  cell  transplants.  However,  a  new 
drug, Imatinib mesylate (STI571), has been developed, which inhibits the kinase 
activity  of  all  proteins  that  contain  ABL,  inhibiting  cellular  growth  and 
inducing apoptosis in CML (Deininger et al. 1997; Druker et al. 1996; le Coutre et 
al.  1999).  It  was  first  used  in  1998  to  treat  CML  patients,  and  it  induced 
complete haematologic responses in over 95% of patients with CML resistant to 
treatment with IFN-a but still in CP, and it induced major cytogenetic responses 
in  over  40%  (Druker  et  al.  2001).  Imatinib  mesylate  has  also  been  used  in 
relapsed  CML  post  transplant  with  failed  response  to  DLI,  giving  positive 
results  (Olavarria  et  al.  2002).  However,  further  research  is  required  before 
Imatinib mesylate can be considered as a replacement for allogeneic stem cell 
transplantation as a proportion of patients disease has become resistant to the 
drug (Roche-Lestienne et al. 2002).
Acute Leukaemia
Most patients with acute leukaemia have been treated successfully with various 
chemotherapeutic  regimes,  but for  a  subset  of patients  who  are  refractory  to 
treatment or where remission is not achieved, bone marrow transplantation is a 
treatment option (Biggs et al. 1992).  Reports of disease free survival at 5 years 
post transplant, for AML and ALL in second complete remission, have shown
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rates of 27%  + 11%  and 37%  + 11%  respectively (Sierra et al. 1997).  In patients 
with  acute  leukaemia,  the  stage  of  the  disease  at  the  time  of  transplant  is  a 
primary  determinant  of  overall  outcome.  For  patients  with  high-risk  acute 
leukaemia,  disease  free  survival  was  better  for  adults  in  CR.  Results  have 
shown to be improved if the patient is transplanted in remission or early first 
relapse (Kernan et al. 1993).
Acute Myeloid Leukaemia
AML  can  be  diagnosed  through  the  identification  of  >30%  leukaemic 
myeloblasts in the peripheral blood and bone marrow (reviewed in Lowenberg 
et al. 1999).  Based on morphology and chromosomal abnormalities, the disease 
is separated into subtypes M0-M7 based on the French-American-British (FAB) 
classification  scheme  (Bennett  et  al.  1985a;  Bennett  et  al  1985b).  Allogeneic 
transplantation  is  generally  an option for  patients who  have  an  intermediate 
risk  of  relapse  after  chemotherapy,  whereas  for  those  in  first  remission  it 
unnecessary as relapse is 30-40%, and high risk and older patients, do less well 
after transplantation often without benefit (Grimwade et al. 1998).  It has been 
shown in multicentre randomised trials that allogeneic stem cell transplantation 
is the most effective strategy for preventing relapse in first CR of AML (Woods 
et  al.  2001;  Zittoun  et  al.  1995).  In  adult  patients,  however,  this  does  not 
necessarily lead to improved disease free survival due to the significant level of 
transplant related mortality (Cassileth et al. 1998; Harousseau et al.  1997).  In a 
study  of 97 patients who received  allogeneic  transplants for  AML  from HLA 
identical siblings, no significant difference was seen between patients grafted in 
CR1  as  compared  with  those  engrafted  in  CR2  for  event  free  survival, 
transplant related mortality, or GvHD (Robin et al. 2003).  This is contrary to the 
reports of other studies, where long term leukaemia free survival has been seen 
in patients transplanted in first complete remission (Zittoun et al. 1995), with a 
much  reduced  leukaemia  free  survival  rate  in  patients  transplanted  in  2CR 
(Clift et al. 1998).  However, the overall survival rate of patients with refractory 
AML who undergo transplantation have been reported to be as low as 10-15% 
(Edenfield and Gore 1999; Greinix et al. 2002).
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Acute Lymphoblastic Leukaemia
In contrast to AML cells, ALL cells lack specific morphological or cytochemical 
features, so the diagnosis depends on immunophenotyping.  ALL can be of B 
lymphocyte  or  T  lymphocyte  origin  and  specific  genetic  abnormalities  are 
found in the blast cells  of 60-75%  of patients with ALL (reviewed  in Pui and 
Evans  1998).  Transplantation  is  usually  considered  for  those  who  have  no 
response  to  the  initial  induction  treatment  and  those  who  have  a  second 
remission  after  haematological  relapse  (Appelbaum  1997),  but  some  patients 
with unfavourable prognosis can be transplanted in first remission (Sebban et 
al. 1994).  The duration of CR2 in ALL has been shown to be short, e.g. Median 
<1  year in children relapsing on therapy or within 6 months of discontinuing 
therapy, so BMT must be performed rapidly to be effective (Henze et al. 1991). 
Two thirds  of the  patients  diagnosed with ALL  are children,  who  have  a  far 
better prognosis than adults where transplantation is generally the only option 
(Parker et al. 1997).  Patients who are generally candidates for allogeneic BMT 
are those with risk factors predicting treatment failure after chemotherapy, such 
as high white cell counts, age >30 years, cytogenetic abnormalities, and a long 
interval to achieve first remission (Chao et al. 1991; Sebban et al. 1994; Wingard 
et al. 1990).  The risk of relapse is a major problem in ALL, possibly due to the 
selection of patients with  high risk leukaemia,  with a  trend  for  lower  risk  of 
relapse  seen  in  patients  grafted  in  CR1-CR2,  but  not  so  in  patients  with 
advanced disease (Zikos et al. 1998).  In ALL patients, acute GvHD has shown a 
favourable effect on relapse and in turn, transplant related mortality (Doney et 
al. 1991).
Other malignant disease
Myelodysplastic  syndrome  (MDS)  refers  to  a  heterogeneous  group  of closely 
related  clonal  haematopoietic  disorders.  All  are  characterised  by  a  cellular 
marrow,  with  impaired  morphology  and  maturation  (dysmyelopoiesis),  and 
peripheral blood cytopenias, resulting from ineffective blood cell production. 
French-American-British  (FAB)  Cooperative  Group,  classified  the 
Myelodysplastic  disorders  into  5  subgroups,  differentiating  them  from  acute
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myeloid leukemia. Two subgroups of refractory anaemia characterized by 5% 
or less myeloblasts in bone marrow exist:  (1) refractory anaemia  (RA)  and (2) 
RA with ringed sideroblasts  (RARS).  Two subgroups of refractory anaemia's 
with  greater  than  5%  myeloblasts  exist:  (1)  RA  with  excess  blasts  (RAEB), 
defined as 6-20% myeloblasts, and (2) RAEB in transformation (RAEB-T), with 
21-30% myeloblasts. The higher the percentage of myeloblasts, the shorter the 
clinical  course and  the closer the disease is  to acute myelogenous leukaemia. 
The  fifth  type  of  MDS,  the  most  difficult  to  classify,  is  called  chronic 
myelomonocytic leukaemia (CMML) (Bennett et al. 1982).
Allogeneic bone marrow transplantation is the definitive therapy for MDS.  In 
patients with less advanced MDS (i.e., patients with RA or RARS),  the 3-year 
disease-free survival (DFS) rate ranged from 40% to 60%, with a relapse rate of 
10%  to 20%  and  a mortality  rate of about 30%  (Deeg et al.  2000).  Compared 
with patients with MDS who are at low risk, patients with advanced MDS who 
underwent  allogeneic  BMT  (i.e.,  those  with  RAEB  or  RAEB-T)  had  a  much 
lower DFS rate (0%  to 20%) and high relapse and mortality rate (30%  to 60%) 
(de Witte et al.  2000b).  In  MDS or  MDS-related  AML,  transplant  outcome  is 
related to disease morphology, patient age, disease duration, CMV status, blast 
count and neutrophil count (Anderson et al. 1996).
Since  the  median  age  of  MDS  is  between  60  and  70  years,  patients  who  can 
benefit from  BMT are limited  in number,  which may  explain  the higher  DFS 
and  mortality.  In addition,  elderly  patients usually  have  a  lower tolerance to 
myeloablative  treatment  and  total  body  irradiation,  although  a  recent  study 
suggested  that  allogeneic  and  syngeneic  marrow  transplantation  can  be 
successfully  carried  out  in  patients  with  MDS who  are  55  to  65  years  of age 
(Deeg et al. 2000).
Multiple  Myeloma  is  an  incurable  but  highly  treatable  form  of cancer  of  the 
blood and immune system. It is characterized by the accumulation of malignant 
plasma cells in the bone marrow and excess monoclonal immunoglobulin (Ig) 
in the serum and/or urine. The cause of Myeloma is unknown.  When B cells 
respond to an infection, they mature and change into plasma cells. Plasma cells
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produce and release immunoglobulins to attack and help kill pathogens such as 
bacteria.  When plasma cells grow out of control, they can produce a tumour. 
These  tumours  can  grow  in  several  sites,  particularly  in  the  bone  marrow. 
When  these  tumours  grow  in multiple  sites,  they  are  referred  to  as  multiple 
myeloma.
Traditional  approaches  for  treatment  of  multiple  myeloma  have  included 
systemic chemotherapy and radiation to the affected sites, however, less than 
15%  of  patients  have  survived  more  than  10  years  under  these  conditions 
(reviewed  in  Alexanian  and  Dimopoulos  1994).  High  dose  chemotherapy 
followed by allogeneic bone marrow transplantation has been shown to induce 
a graft versus tumour effect (Lokhorst et al. 1997; Tricot et al. 1996), but 5 year 
survival rates are only 25%, due to a high treatment related mortality of 40-50% 
(Bensinger  et  al.  1996;  Bjorkstrand  et  al.  1996;  Gahrton  et  al.  1995).  Stage  of 
disease,  time  from  diagnosis  to  transplant,  and  the  number  of  cycles  of 
chemotherapy the patient had received before transplant were found to be risk 
factors for poor transplant outcome (Bensinger et al. 1996).
Non-Hodgkin's lymphoma (NHL) is a malignant growth of B or T cells in the 
lymph system.  The  Non-Hodgkin's  lymphomas  encompass  over  29  types  of 
lymphoma. The distinctions are based on the type of cancer cells.  Lymphomas 
can be  grouped  by  cell  type  and  rate  of growth.  The  United  States  National 
Cancer  Institute  now  splits  lymphomas  into  aggressive  (fast  growing)  and 
indolent (slow growing) although T-Cell,  B-Cell,  Large Cell,  or Follicular Cell 
can also group them.  The main groups are low-grade NHL, intermediate-grade 
NHL,  high-grade  NHL  (immunoblastic  subtypes),  lymphoblastic  lymphoma, 
Burkitt's  lymphoma  and  Hodgkin's  disease  (Institute  1982).  In  comparison 
with autografts, allogeneic bone marrow transplants have  resulted  in a  lower 
relapse rate in the treatment of lymphoma (Copelan et al. 1990; Mandigers et al. 
1998).  However,  it  is  thought  that  the  high  treatment  related  mortality 
observed in allogeneic bone marrow transplantation for NHL might outweigh 
the benefits of a lower relapse rate (Peniket et al. 2003).
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Non-malignant diseases
The aim of transplantation for many non-malignant diseases is to replace the 
missing or malfunctioning cells of the immune system to avoid the problems of 
infection or the need for transfusion.  Non-malignant diseases including several 
immunodeficiencies, have been treated with some success with unrelated bone 
marrow  transplantation  (Buckley  et  al.  1999;  Mullen  et  al.  1993).  Factors 
important for improved transplant outcome include early diagnosis, resulting 
in healthier  patients  at  the  time  of transplantation  (Myers  et al.  2002).  Also, 
prevention  of  disease  and  transplantation  related  complications  such  as 
infection  and  GvHD.  The  main  advantage  of  allogeneic  transplantation  for 
immunodeficiencies, is that little or no myeloablation or immunosuppression is 
required,  so  engraftment  may  not  a  problem.  However,  for  some  non- 
malignant conditions such as aplastic anaemia engraftment can be a significant 
problem.
SCID, Severe  Combined  Immunodeficiency,  is  a  primary  immune  deficiency. 
The  defining  characteristic  is  a  severe  defect  in  both  the  T-  &  B-lymphocyte 
systems. This can result in the onset of one or more infections within the first 
few months  of life.  These  infections are usually  serious,  and  can  even be  life 
threatening,  they  may  include  pneumonia,  meningitis  or  bloodstream 
infections.
Immunodeficiency with Hyper-IgM (HIM) is a rare primary immunodeficiency 
characterized  by  the  production  of  normal  to  increased  amounts  of  IgM 
antibody  of  questionable  quality  and  an  inability  to  produce  sufficient 
quantities  of IgG  and  IgA.  Individuals  with HIM  are susceptible  to recurrent 
bacterial  infections and are at an increased risk of autoimmune disorders and 
cancer at an early age.  X-linked immunodeficiency with hyperimmunoglobulin 
M (XHIM) is caused by the absence of CD40 ligand (CD154), which is normally 
expressed on activated CD4+  T lymphocytes.
Wiskott-Aldrich syndrome (WAS)  is a condition with variable expression, but 
commonly includes immunoglobulin M  (IgM) deficiency.  WAS always causes 
persistent  thrombocytopenia  and,  in  its  complete  form,  also  causes  small
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platelets,  atrophy, cellular  and  humoral  immunodeficiency,  and  an increased 
risk  of autoimmune  disease  and  haematological  malignancy.  In  one  study  of 
154  patients  with  WAS,  only  30%  had  a  classic  presentation  with 
thrombocytopenia,  small  platelets,  eczema,  and  immunodeficiency;  although 
84%  had  clinical  signs  and  symptoms  of  thrombocytopenia,  20%  had  only 
haematological abnormalities, 5% had only infectious manifestations, and none 
had  eczema  exclusively.  WAS  is  an  X-linked  recessive  genetic  condition; 
therefore, this disorder is found almost exclusively in boys.
The Hurler syndrome is an autosomal recessive disease that belongs to a group 
of  diseases  called  mucopolysaccharidoses.  Storage  of  abnormal  quantities  of 
this material  (mucopolysaccharide) in different body tissues is responsible for 
the symptoms and appearance of the disease.  Bone marrow transplantation is 
the only long-term therapy known to prolong the life of patients born with the 
Hurler syndrome  (Fleming et al.  1998; Hobbs et al.  1981), who would  usually 
within the first decade  of life.  Age at the  time  of transplant is an important 
factor,  with  those  transplanted  before  the  age  of  2  years  have  an  improved 
transplant  outcome  with  marrow  from  an  unrelated  donor  than  those 
transplanted over the age of 2 (Peters et al. 1996).
CMV status
A  major  complication  of  bone  marrow  transplantation  is  infection  post 
transplant.  The  patient  has  been  treated  for  their  primary  disease  with 
therapeutic  agents,  such  as  chemotherapy,  which  results  in  immune 
suppression.  During  preparative  regimes  for  the  bone  marrow  transplant, 
immune  suppressive  drugs  and  usually  irradiation  are  given  to  further 
suppress the immune system to avoid rejection of the allogeneic graft.  Once the 
patient is immune suppressed  they can be  open to effects from latent viruses 
and infection from opportunistic pathogens.  One of the more severe infections, 
which  can  lead  to  morbidity  and  mortality  in  bone  marrow  transplant 
recipients, is cytomegalovirus  (CMV)  (Broers et al. 2000).  CMV is a virus that 
can become latent after primary infection.  It infects cells involved  in immune 
responses,  particularly  bone  marrow  progenitors,  endothelial  cells,
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polymorphonuclear leukocytes and monocytes (Taylor Wiedeman et al.  1991). 
The  human  CMV  virus  has  many  ways  of  evading  immune  recognition, 
allowing  it  to  become  a  permanent  resident  of  the  cells  of  its7   host.  Upon 
infection, host cell protein synthesis becomes dramatically reduced, and some 
CMV  genes  have  been  shown  to  prevent  the  cell-surface  expression  of  HLA 
class I (Barnes and Grundy 1992).  For example, the US6 gene binds directly to 
the TAP complex and therefore inhibits peptide translocation from the cytosol 
to the ER (Lehner et al. 1997).  Although this mechanism can evade recognition 
by T -cells it should be noted that these cells could now be putative targets for 
NK  cell  attack.  CMV  infection  has  also  shown  to  have  immunosuppressive 
effects on lymphocyte proliferative responses (Meyers et al. 1986).
Infected  healthy  individuals  show  no  symptoms  of CMV  infection,  but  viral 
DNA can be detected by PCR of known viral sequences, or the expression of the 
CMV  lower  matrix  phosphoprotein  pp65  can  be  detected  in  the  peripheral 
leukocytes  (Bacigalupo  et  al.  1995).  These  individuals  are  regarded  as  CMV 
seropositive.  When  an  individual  is  immune  suppressed,  for  example,  in  a 
bone  marrow  transplant  situation,  or  through  HIV  infection,  the  virus  is  no 
longer controlled  and  can  become  symptomatic.  For  recipients  of  allogeneic 
bone marrow transplantation, the most life threatening manifestation of CMV 
infection is interstitial pneumonitis, which inevitably results in death (Meyers et 
al. 1986).
There  is  a  poor  correlation  between  viral  titre  and  disease  severity  in  these 
patients  (Slavin  et  al.  1994),  which  has  lead  to  the  hypothesis  that  the 
pathogenesis  of  CMV  pneumonitis  involves  tissue  damage  caused  by  the 
immune system.  CMV pneumonitis has also been shown to be associated with 
the occurrence and increased severity of GvHD (Meyers et al. 1986).
If  a  seropositive  patient  is  transplanted,  or  a  seropositive  donor  is  donating 
bone marrow to a seronegative recipient, the recipient can be prophylactically 
treated with antiviral therapy,  in order to try to control any viral  reactivation 
(Goodrich et al. 1991).
The use of fluconazole for the prevention of fungal infection (Slavin et al. 1995),
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and gancyclovir given at time of engraftment or onset of CMV antigenemia for 
the prevention of CMV disease (Goodrich et al. 1991), improved the safety and 
efficacy of allogeneic grafts.
CMV seropositivity in patients has been seen as an independent risk factor for 
increase risk of GvHD and incidence of transplant related mortality  (Broers et 
al. 2000; Craddock et al. 2001).  CMV-specific T cell proliferation is significantly 
less likely to occur in recipients of unrelated BMT, who are therefore at greater 
risk  of  developing  CMV  disease  (Krause  et  al.  1997).  However,  a  CMV- 
seropositive donor has not been found as a risk factor of CMV infection in the 
recipient  post  transplant  (Miller  et  al.  1986).  The  use  of  Gancyclovir  in 
seropositive patients has been associated with increased survival (Hansen et al. 
1998).
Age
The  success  of  allogeneic  bone  marrow  transplantation  relies  partly  on  the 
ability  of  naive  progenitor  cells  of  the  donor  marrow  to  migrate  to,  and  be 
educated by, the thymus of the recipient.  It can be hypothesised  that,  due to 
involution  of the  thymus  beginning  in  teenage  years  and  culminating by  the 
age of 30 years, younger patients will have greater capacity for this education to 
occur  (Botnick  et  al.  1982).  Both  recipient  and  donor  age  can  influence  the 
transplant  outcome.  Younger  recipients  transplanted  with  stem  cells  from 
younger  donors  (less  than  30  years)  have  been  reported  to  have  the  greater 
overall  survival  rate,  which  could  be  due  to  their  higher  tolerance  level  for 
transplant related complications (Gratwohl et al. 1995).  In a study from Genoa, 
patients  over  35  had  increased  transplant  related  mortality  when  a  standard 
conditioning regimen was used (Bacigalupo 2000).
Many  haematological  malignancies  increase  in incidence with advancing  age, 
such  as  the  acute  leukaemias,  myelodysplastic  syndrome  and  non-Hodgkins 
lymphoma  (Molina  and  Storb  2000).  Also,  unfavourable  chromosomal 
abnormalities are more common in older patients (Faderl et al. 1998; Grimwade 
et al. 1998), leading to a poorer overall prognosis.  Advanced age may translate 
into  poorer  outcome  after  allogeneic  transplantation,  and  the  age  of  the
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recipient has been shown to be an independent risk factor for transplant related 
mortality  (Gratwohl  et al.  1998).  In  a  retrospective  study  carried  out by  the 
EBMT, advanced age was identified as an independent poor prognostic factor 
in AML and  ALL, but with development and changes in transplant protocols 
over time, an improvement in transplant related mortality has been observed 
(Frassoni et al.  1996).  The effect of age on the development of acute GvHD is 
controversial.  In  some  studies,  the  risk  of  developing  acute  GvHD  and  the 
severity of acute GvHD was associated with increased age of the donor (Doney 
et al.  1991),  and  the  patient  (Nash et al.  1992;  Weisdorf et al.  1991).  In  other 
studies,  however,  age  has  not  been  associated  with  increased  risk  of  acute 
GvHD (Hagglund et al. 1995; McGlave et al. 2000; Ringden et al. 1998).
Increased patient age has been observed as a risk factor in the development of 
chronic GvHD in many studies (Carlens et al. 1998; Ochs et al. 1994), including 
and excluding the previous manifestation of acute GvHD (Atkinson et al. 1990). 
This effect, however, can be reduced with increased GvHD prophylaxis, or from 
T cell depleted transplants, which can lower the incidence of GvHD and  also 
increase survival rates in older patients (Aschan and Ringden 1994).
The NMDP have shown that increased donor age was a significant risk factor 
for overall and disease-free survival,  independent of the age of the transplant 
recipient (Kollman et al. 2001).  No significant effect of donor or recipient age on 
the risk disease relapse was found in the same study.
With  the  development  of  unrelated  cord  blood  transplantation  (i.e.  the 
"youngest7  donor possible), it is now recognised that perhaps this entirely naive 
population of cells do not cause GvHD, even across HLA mismatched barriers 
(Gluckman et al. 1997).  Due to the low number of cells available in cord blood 
donations,  it was thought to  only  be possible to transplant a very  small  (and 
therefore young) individual, who would be likely to have the thymic capacity 
for education of the T-cells (Mackall et al. 1995).  The average number of CD34+  
cells in a 100ml cord blood unit is 1.2xl06, and the ideal number of CD34+ cells 
though  to  give  a  successful  transplant  outcome  is  >8x106/kg  of  patient 
(D7  Arena  et  al.  1996).  Further  work  has  now  shown  that  it  is  possible  to
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transplant an adult donor with cord blood stem cells with an acceptable level of 
GvHD post transplant, but not completely without a GvHD response (Laughlin 
etal 2001).
Gender and parity of female donors
It has been observed that female recipients of male bone marrow have a higher 
risk of graft rejection than when transplanted with bone marrow from a female 
donor (Voogt et al. 1990).  A similar effect has also been seen in the greater risk 
of developing GvHD in male recipients of female grafts.  The association of a 
gender  mismatch  with  graft  rejection  and  (GvHD)  in  bone  marrow 
transplantation  could  be  due  to  so-called,  male-specific,  minor 
histocompatibility  antigens  (mHag)  (Goulmy  et  al.  1983;  Goulmy  et al.  1996). 
These are generally HLA class I restricted peptides, derived from male-specific 
proteins, which are encoded by genes found on the Y chromosome (Meadows et 
al.  1997;  Wang  et  al.  1995).  One  such  set  of  mHag,  the  H-Y  antigens,  are 
expressed on the surface of haematopoietic cells and can be recognised by H-Y 
specific cytotoxic T-cells, in intro (Voogt et al. 1988).  In some studies, a gender 
mismatch has been shown to increase the incidence of GvHD  (Gratwohl et al.
1995), especially in male recipients receiving marrow from a female, where the 
T-cells present in the female marrow may recognise a peptide encoded by the 
male H-Y chromosome,  presented  by matched  HLA  class  I  molecules  on  the 
recipient cells (Vogt et al.  2000; Wang et al. 1995).  The presence of these HLA 
class  I-presented  peptides  in a  sex-mismatched  transplant has been shown to 
induce  a  graft-versus-host  disease  response  (Goulmy  et  al.  1996;  Rufer  et  al. 
1998).  The parity of female donors and sex of donor and recipient have been 
shown  as  significant  risk  factors  for  de  novo  chronic  GvHD,  with  the 
combination of the parous female donor and male recipient having the highest 
risk for chronic GvHD development (Wagner et al. 2000).  In a study of donor 
characteristics  affecting  transplant  outcome,  the  NMDP  found  no  significant 
association between donor sex and parity of female donors with relapse.  The 
sex of the donor had no effect on overall or disease free survival, regardless of 
the effect of the recipient (Kollman et al. 2001).  In an EBMT  study  of sibling
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transplants  from  female  donors,  male  recipients  showed  an  increase  in 
transplant related mortality (Gratwohl et al. 2001).
For  the  aforementioned  reasons,  a  young  male  donor  is  highly  sought  after. 
However,  currently,  only  30%  of  potential  donors  on  the  Anthony  Nolan 
Register  are  male.  This  could  be  due  to  recruitment strategies;  the  fact  that 
some  women  may  have  more  time  for  donation;  or  that  women  feel  more 
comfortable about needles or being in a clinical environment.
Conditioning and GvHD prophylaxis
Conventional conditioning regimens result in an almost complete elimination of 
patient lympho-haematopoietic tissue.  The aim of conventional conditioning is 
tumour  ablation  and  rejection  prophylaxis,  and  it  was  originally  believed 
ablation  of  the  marrow  was  required  to  create  space  for  the  donor  cells, 
although  it is  now  realised  donor cells  can clear  recipient cells  for  the  space 
needed (Storb et al. 1997).  However, the side effects of this treatment are severe, 
including:  nausea  and  alopecia,  organ  damage,  severe  immunodeficiency, 
infertility,  growth  retardation  and  secondary  malignancy  (reviewed  in 
Vindelov  2001).  The primary  means  of conditioning is total  body  irradiation 
(TBI)  along  with  chemotherapy  agent,  Cyclophosphamide  (CY),  which  is 
immunosuppressive  but  not  myeloablative.  It  has  been  shown  in  canine 
experiments that the TBI dose required for stable engraftment could be reduced 
from the myeloablative dose of 9.2 Gy to the non-myeloablative dose of 2.0 Gy 
(McSweeney and Storb 1999), and in human studies, a fractionated dose of TBI 
compared with a single dose has improved event free survival in AML patients 
(Deeg et al. 1986; Thomas et al. 1982).  Alkylating agents such as Busulphan or 
Melphalan  can  be  used  in  combination  with  one  another  and  other 
chemotherapy agents as an alternative to TBI for myeloablation, although there 
are  still  many  side  effects.  There  is  evidence  in  animals  that  stable  donor 
chimerism can be achieved with sublethal doses of TBI and drugs (Storb et al. 
1997).  A  reduced  intensity  conditioning  regimen  needs  to  be  sufficient  for 
engraftment, but retain sufficient of the patient's lympho-haematopoietic tissue 
to support a mixed chimerism and be protective in the short term (McSweeney,
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Storb  1999).  A  mixed  chimerism  results  in  a  state  of  bi-directional 
(donor/patient) tolerance, while at the same time reactivity against third party 
antigens  remains  intact.  A  combination  of  reduced  intensity  conditioned 
transplant  followed  by  donor  lymphocyte  infusions  has  shown  this  to  be  an 
alternative to the conventional conditioning regimen (Massenkeil et al. 2003).
One of the most widely used methods for the  depletion of T-cells from bone 
marrow for the prevention of GvHD and  graft rejection is through the use of 
CAMPATH-1  antibodies.  CAMPATH-1M  and  -1G  antibodies  are  specific  for 
CD52,  a cell  surface  marker expressed  on all  human lymphocytes  which  is  a 
good target for cell lysis by antibody with human complement (Hale et al. 1983; 
Hale et al. 1998). CAMPATH-1 antibodies have been used either ex-vivo ("in the 
bag")  or  in-vivo  (treating  the  recipient),  in  the  attempt  to  control  GvHD  and 
prevent  rejection  following  allogeneic  bone  marrow  transplantation,  by 
removing alloreactive T-cells (Hale, Waldmann 1994).  It is thought that these 
effector  T-cells  in  the  graft  have  been  educated  on  the  histocompatibility 
background of the donor and will therefore recognise any mismatches of minor 
or major histocompatibility antigens between the donor and recipient, leading 
to graft versus host disease.  As well  as being associated  with a  reduction in 
acute and chronic GvHD  (Kernan et al.  1993;  McGlave  1993), T cell  depletion 
appears to be linked with reduced post transplantation complications such as 
hepatic  veno-occlusive  disease  and  pulmonary  dysfunction  (Ho  et  al.  2001; 
Moscardo et al. 2001; Soiffer et al. 2001), and has been associated with delayed 
neutrophil  engraftment  (Hale,  Waldmann  1994).  T  cell  depleted  transplants 
also  leave  the  patient  susceptible  to  opportunistic  infection  post  transplant 
(Pirsch and Maki 1986).
The  main  disadvantage  of  T  cell  depletion  is  its  interference  with  the  graft 
versus  leukaemia  (GVL)  mechanism,  leading  to  an  increased  relapse  rate  in 
leukaemia patients (Marmont et al. 1991).  In a single centre study, comparing T 
cell  depleted  transplants  with  T  cell  replete  transplants,  the  overall  survival 
rates were not significantly  different between the  two patient groups,  despite 
the higher risk or relapse (Schots et al. 2001).  Transplant related mortality was
35C hapter 1
lower in the T cell depleted transplant group in the same study.  T cell depletion 
of the graft, therefore, can reduce the risk of developing GvHD, but can increase 
the risk of relapse.  This can be overcome to some extent by the introduction of 
donor lymphocyte infusions post transplant,  in an effort to introduce enough 
lymphocytes to control  or eradicate  disease, without inducing a  GvHD  effect 
(Bacigalupo et al. 1997; Collins Jr et al. 1997; Dazzi et al. 2000; Giralt et al. 1995; 
Guglielmi et al. 2002; Kolb et al. 1995).
The History of the Major Histocompatibility Complex
Both  B  and  T  lymphocytes  recognise  antigens  through  their  cell  surface
receptors.  B cells, however, can capture free antigen via their immunoglobulin 
receptors, whereas T cells are only able to recognise antigens on a cell surface, 
in association with Major Histocompatibility Complex (MHC) molecules.  The 
phenomenon  of  the  MHC  molecule  restriction  of  T  cell  recognition  was 
published  by  Nobel  Prize  winners,  Doherty  and  Zinkernagel,  in  1974 
(Zinkernagel  and  Doherty  1974b),  however  the  road  to  the  discovery  of  this 
system began many years before with the work of Gorer, Snell and Medawar in 
rodents and rabbits.
Discovery of Murine MHC (H-2)
Peter Gorer, working at the  Lister Institute in London,  discovered  the  mouse 
MHC  H-2  system,  when  attempting  to  identify  blood  groups  in  inbred  mice 
(Gorer,  1936).  By  immunising  rabbits  with  mouse  blood  cells,  he  produced 
antibodies specific for antigens he called I, II, III and IV.  Through studies with 
mouse tumours transplanted between the same and different strains of mice, it 
was  discovered  that  a  difference  of  antigen  II  was  responsible  for  the  rapid 
rejection of allogeneic skin and tumour grafts (Gorer 1937a; Gorer 1937b; Gorer 
1938).  George  Snell,  who  at  the  same  time  was  also  working  with  mice  in 
Maine,  USA,  tried  to  isolate  these  'histocompatibility  antigens',  by  producing 
congenic pairs of inbred mouse strains (which have a small genetic region from 
another strain, but which are otherwise identical to the original inbred strain.
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Congenic strains are derived by backcrossing to a parental inbred strain for at 
least ten generations while  selecting for heterozygosity  at a  particular  locus). 
Each  pair  should  differ  by  an  individual  allele,  and  when  a  tumour  was 
transplanted from one to the other,  the rejection episode was directed  at this 
allele  expressed  by  the  tumour  (Snell  1948).  The  rejection  episodes  could  be 
distinguished  as  strong  or  weak,  and  this  led  to  the  definition  of  'major'  or 
'minor' histocompatibility antigens.  The major antigen described by Snell was 
identical to the "antigen II" described by Gorer around the same time, and they 
finally combined their work (Gorer et al. 1948), and named what they thought 
was a single antigen in the mouse, H-2 (Snell 1948).  Gorer continued to study 
the  gene  and  found  that  it was  actually  a  cluster  that could  be  divided  into 
several serological specificities, with antibodies from the sera of one individual 
able to agglutinate the leukocytes of another (Gorer and Mikulska 1954; Gorer 
and Mikulska 1959).
Discovery of Human MHC (Human Leukocyte Antigen)
The first human MHC antigens were reported by Jean Dausset (Dausset 1954;
Dausset  and  Nenna  1952),  and  named  MAC  (Dausset  1958).  He  found 
antibodies that agglutinated donor white cells in the sera of leukopenic patients 
who  had  received  many  blood  transfusions  (Dausset,  Nenna  1952).  Similar 
work was also being carried  out by Rose Payne, at Stanford University, USA, 
and  Jon  van  Rood  in  Leiden,  The  Netherlands,  where  both  found  that 
pregnancy had immunised mothers against leukocyte antigens inherited by the 
child from the father (Payne and Rolfs 1958, van Rood, 1958 #292; van Rood et 
al.  1958).  Van  Rood  named  these  antigens  4a  and  4b  (van  Rood  and  van 
Leeuwen 1963), and Payne christened the system of three specificities she had 
found, LA (Payne et al. 1964).
Nomenclature of Human MHC and the history of Tissue typing
As  many  investigators  were  reporting  different  tissue  specific  antigens,  and
methods of testing them, a forum was needed for them to compare their data.
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To  this  end,  the first International  Histocompatibility  Workshop  (IHWS)  was 
established.  It  was  held  in  Washington,  in  1964,  and  organised  by  Bernard 
Amos.  Alarmingly, none of the data collected correlated between the groups! 
Workshops were subsequently held in 1965 in the Netherlands, where reagents 
and a cell panel were formed, which could be used by all participants and in 
1967 in Italy.  Finally, by the third workshop, it was established that there was a 
single  major  complex  of  genes  encoding  all  these  human  leukocyte  specific 
antigens.  It took a year for the workshop nomenclature committee to agree on a 
name for the complex, which was "Human Leukocyte locus A" (HL-A) and was 
later  changed  to  "Human  Leukocyte  Antigen"  (HLA)  (Curtoni,  1967)  (Klein 
1986).  The  serological  methods  used  to  distinguish  these  HLA  antigens 
demonstrated antibody-mediated immunity, however, a test was needed which 
would define the cellular response to histocompatibility.
It  was  with  the  development  of  the  Mixed  Lymphocyte  Culture  (MLC) 
technique (Bach and Hirschhorn 1964; Bach and Voynow 1966) that the MHC 
class II  antigens were discovered.  The reactivity  seen when peripheral blood 
mononuclear cells from individuals were mixed, was seen to be induced by a 
locus  closely  related  to  the  class  I  loci  (Amos  and  Bach  1968).  Using 
homozygous cells in the MLC test led to the discovery of several new antigens 
termed  MLC,  LD  and  eventually  HLA-D  at  the  1975  Histocompatibility 
Workshop (Bradley et al. 1973; Dupont et al. 1973; Mattiuz et al. 1975; Mempel et 
al.  1973;  van  den  Tweel  et  al.  1973).  Some  further  identification  of  class  II 
molecules was carried out using cells that were P-2-microglobulin deficient, and 
therefore  could  not  express  HLA  class  I  molecules.  These  were  originally 
named  DC1  and  DC2  and  were  found  to  be  in  strong  linkage  with  HLA-D 
antigens already found  (Tosi et al.  1978).  Sera from multiparous  women was 
again utilised to determine specificity of HLA-DR, and using these,  the MLC, 
and  other  in  house  tests,  the  class  II  locus  HLA-DQ  was  also  discovered 
(Ceppellini et al. 1971; Duquesnoy et al. 1979; Park et al. 1978).  Finally, HLA-DP 
was  discovered  using  a  secondary  MLC,  the  Primed  Lymphocyte  Test  (PLT) 
(Shaw et al. 1980; Termijtelen et al. 1980).
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Serology
Until  the fourth Histocompatibility  Workshop,  histocompatibility  laboratories 
had  been  identifying  different  HLA  antigens  using  their  own  antisera,  and 
subsequently, using the complement dependant cytotoxicity reaction (van Rood 
et al.  1975).  At the fourth histocompatibility workshop,  held  in Los  Angeles, 
January  1970,  Paul  Terasaki  introduced  the  first  standard  tissue  typing 
technique, the lympho-micro-cytotoxicity assay (Mittal et al. 1968; Terasaki and 
McClelland 1964; Terasaki et al.  1966).  In this cell cytotoxicity assay,  selected 
allo-antisera  and  late  monoclonal  antibodies  were  mixed  with  viable 
lymphocytes. Specific antibodies bound to the polymorphic  protein moiety  of 
the  HLA  molecule  expressed  on  the  cell  surface.  Exogenous  complement 
(usually rabbit) was added to the well which resulted in lysis of cells to which 
antibody  had  bound.  The  damaged  cells  could  then  take  up  a  vital  or 
fluorescent  dye,  and  be  identified  through  inverted  phase  contrast  or 
fluorescent microscopy.
Antisera for the typing trays had to be selected with the greatest of care, and 
sera  from  pregnant women were  the  predominant  source.  The  trays  had  to 
contain antibodies to all antigens common in the population to be tested, with 
preferably  one  antigen  being  recognized  by  at  least  two  antisera.  If  no 
monospecific  antisera  were  available,  a  combination  of  sera,  with  different 
cross-reactivity patterns were used, meaning different patterns could be picked 
out  to  identify  certain  HLA  specificity.  Controls  were  used  to  confirm  the 
presence of known epitopes, for example in HLA-B typing, all B locus antigens 
carry  either  the  Bw4  or  Bw6  determinant,  encoded  by  aa77-83  on  the  al 
domain of the class I heavy chain (Bjorkman et al. 1987a).
Antibodies detect amino acid differences on the surface of the HLA molecule, 
distal  from  the  cell  membrane.  Serological  specificities,  therefore,  are  not 
homologous  to  all  allele  types,  meaning  many  molecular  subtypes  cannot be 
detected by serology (Middleton et al. 1988).  For example, 3 HLA-A2 antigens 
can be detected using serological methods, but at least 78 HLA-A2 alleles have 
been detected using molecular typing methods (Robinson et al. 2000; Robinson
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et al. 2003).
The microcytotoxicity assay was found to be most useful in the determination 
of  HLA-A  and  -B  antigens,  but  did  not  give  very  reproducible  results  with 
HLA-C.  Anti-C  sera  were  scarce  and  many  C  locus  alleles  may  not  have 
serological equivalents (Bunce and Welsh 1994).  HLA class II specificities could 
only  be  identified  on  B-lymphocytes.  To  obtain  a  B  lymphocyte  enriched 
population from PBLs it was necessary to deplete the T cells.  This was carried 
out through sheep red blood cell agglutination, using nylon wool separation, or 
using magnetic beads loaded with B or T cell specific antibodies for example. 
HLA  class  II  typing  was  further  complicated  by  the  expression  of  varying 
numbers of gene products that can be expressed at the cell surface.  An HLA- 
DR  haplotype  can  express  one  or  two  -DR  molecules  depending  on  the 
specificity (Svensson et al. 1996).  Also, due to the high linkage disequilibrium 
between  HLA-DR  and  -DQ,  some  antisera  were  directed  against  class  II 
haplotypes instead of specific antigens (Carlsson et al. 1987).  The development 
of monoclonal antibodies against the class II antigens has made class II typing 
by serological methods easier, but cross reactivity, due to shared epitopes, still 
hampers the method.
Cellular Assays
The majority of cellular assays to detect the minor and major histocompatibility 
difference  between  individuals  have  been  derived  from  the  observation  that 
lymphocytes from two unrelated individuals could stimulate each other when 
cultured in vitro for a period of time (Bain et al. 1964).  The stimulation seen was 
primarily  due  to  differences  in  HLA-DR  antigens,  resulting  in  cellular 
activation and blast transformation  (Al-Daccak et al.  1990b;  Baxter-Lowe et al. 
1992).  The technique developed to identify the determinants involved became 
known  as  the  mixed  lymphocyte  culture  (MLC)  or  reaction  (MLR)  (Bach, 
Hirschhorn 1964; Bain et al. 1964).  When patient and donor cells were mixed in 
the MLC, CD4+  T cells proliferated and cytotoxic CD8+  T cells were generated, 
meaning that responses within the assay could either be measured through cell 
expansion  or  killing.  It  was  recognized  that  these  different  populations  of
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lymphocytes were  stimulated  by  various  MHC  differences  (Bach et al.  1973). 
Cell proliferation can be measured through the incorporation of 3H-Thymidine 
into the DNA of dividing cells, or by identifying and measuring the cytokines 
secreted by the activated cells.  Cytotoxicity can be measured by the amount of 
Chromium released by the lysed cells.
For a standard "one-way" MLR assay, three cell samples were used, stimulator, 
responder and  third  party  (of known HLA  type).  To  emulate  a  graft versus 
host response,  the  patient cells would  be  the  stimulators  and  the  donor cells 
would be the responders.  Each set of cells was divided into two aliquots, one of 
each of which was irradiated with 3000 rads, to prevent them from responding 
(Bach,  Voynow  1966).  Experiments  were  set  up  using  combinations  of 
irradiated and non-irradiated  stimulators and  responders,  including the  third 
party cells and responder cells as a positive and negative control respectively. 
Cells were  harvested  and  the  amount  of thymidine  uptake  measured  by  a  p 
counter.  If the test response of the responder against the irradiated stimulators 
was  significantly  greater  than  the reactivity  of responder  cells  alone,  the  test 
was considered positive.
HLA-DR mismatches predominate in the MLR (Al-Daccak et al. 1990a; Baxter- 
Lowe et al. 1992), along with HLA-DQ mismatches (Clay et al. 1989).  However, 
positive MLRs can occur in HLA-DR and -DQ matched pairs, suggesting roles 
for  other  loci  such  as  HLA-DP  (Clay  et  al.  1989),  and  HLA-A  and  -B 
(Termijtelen and van Rood 1981a).  The effect of HLA-DP mismatch on the MLR 
was at first controversial (Pawelec et al. 1982; Termijtelen and van Rood 1981b), 
but  it  was  later  determined  that  some  HLA-DP  mismatches  could  induce 
proliferation (Al-Daccak et al. 1990b; Cesbron et al. 1990; Olerup et al. 1990). 
Although the MLR has been used in the selection of donors for bone marrow 
transplantation, it is now accepted that it does not predict GVHD and clinical 
outcome after BMT from unrelated donors (Al-Daccak et al. 1990b; Hows et al. 
1986; Mickelson et al.  1993; Segall et al.  1996).  This may be because  the  MLR 
mainly  detects  CD4+   lymphocytes  and  CD8+   lymphocytes  to  a  lesser  extent, 
which are an important effector cell population in the GVHD response.  It has
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been suggested that the MLR be used in the selection of donors alongside other 
tissue typing techniques in order to exclude known mismatched donors before 
the MLR stage (Clay et al. 1989).
The CTLp (Cytotoxic T lymphocyte precursor) assay was used as a quantitative 
HLA matching test that confirms HLA  identity between donor and recipient. 
An alloreactive CTLp is a naive T cell that has the potential to differentiate into 
a mature CTL after encountering the specific alloantigen recognized by its T cell 
receptor.  The CTLp assay is dominated by alloreactive CD8+  CTLs recognizing 
HLA  class  I  differences  on  the  foreign  stimulators  cells,  with  a  minor 
contribution from CD4+   CTLs  (Kabelitz  et al.  1985;  Moretta et al.  1983).  The 
CTLp is an example of a limiting dilution assay  (LDA),  meaning the limiting 
factor  must  be  the  number  of  mononuclear  cells  added  which  contain  the 
precursor.  PBMCs from patient (stimulator), donor (responder) and third party 
of known HLA type (control) were split and irradiated.  Responder cells were 
diluted into varying concentrations and mixed with irradiated stimulator cells. 
At the same time, fresh stimulator and control cells were plated separately, and 
stimulated with phytohaemagglutinin (PHA) as targets for the responders.  On 
the  day  of  assay,  these  PHA  blasts  were  incubated  with  Sodium  chromate 
(51Cr).  On addition of the PHA blasts to the cytotoxicity assay plate, they were 
killed by any specific cytotoxic T lymphocytes.  This killing was measured by 
the release of chromium from the target cells.
The CTLp could define HLA differences between donor and patient that were 
indistinguishable by serological methods (Rufer et al. 1993).  For example, HLA- 
B44.1  and  B44.2 were indistinguishable by  serology, but CTLs specific for the 
mismatched antigen could be detected in a CTLp assay. This mismatch involves 
a  single  amino  acid  difference  at  position  156,  and  it  has  been  shown  that 
transplants  involving  this  mismatch  have  resulted  in  GvHD  and  rejection 
(Fleischhauer et al. 1990; Keever et al. 1994).  High CTLp frequency was shown 
to  predict  severe  acute  GvHD  post  HLA-matched  unrelated  donor  BMT  in 
some cases (Kaminski et al. 1989; Roosnek et al. 1993), but not others (Fussell et 
al. 1994; Montagna et al. 1996).  Due to these mixed findings, the CTLp was still
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used in donor selection, but thought to be most useful in cases where more than 
one matched unrelated donor was available.
Another LDA, the HTLp (Helper T lymphocyte precursor) assay, has been used 
to identify the frequency of IL-2 secreting alloreactive T helper cells  (Vie and 
Miller  1986).  The  HTLp  response  has  been  attributed  to  alloreactive  CD4+ 
HTLs recognising HLA class II differences, and also a significant contribution of 
CD8+  HTLs  recognizing  HLA  class  I  (Jooss  et  al.  1989;  Schwarer  et  al.  1994; 
Theobald and Bunjes 1993).  The HTLp has been shown to correlate with acute 
GvHD  after  unrelated  donor  BMT  (Schwarer  et  al.  1994).  Although  these 
cellular assays were found to be useful in demonstrating an in vivo response in 
vitro,  in  some  cases,  they  were  not  ideal  as  actual  tissue  typing  techniques. 
They were labour-intensive and time-consuming to perform and the numbers 
of donor and recipient cells available were limited.  They are now thought to be 
more useful  tools  in the final  stages  of donor selection,  when more  than one 
unrelated  donor  is  available  for transplant,  in  the  hope  that an unfavourable 
response can be detected.
Biochemical Techniques
Along with cellular assays, the application of biochemical techniques,  such as 
one-  and  two-dimensional  isoelectric  focusing  (IEF)  in  polyacrylamide  gels 
helped to identify some of the serologically undetectable subtypes (Yang et al. 
1985; Yang et al. 1984).  IEF works on the principle that, for any protein there is a 
characteristic pH, called  the  isoelectric point,  at which the protein has  no net 
charge  and  therefore  will  not  move  in  an  electric  field.  Proteins  are 
electrophoresed in polyacrylamide gel in which a pH gradient is established by 
a mixture of special buffers.  Each protein moves to a point in the gradient that 
corresponds  to  its  isoelectric  point  and  stays  there  (Dale  and  Latner  1968). 
Complex mixtures of proteins cannot be resolved well on one-dimensional gels, 
but  two-dimensional  gel  electrophoresis,  combining  two  different  separation 
methods,  can  be  used  to  resolve  proteins  in  a  two-dimensional  protein  map 
(Kenrick and Margolis 1970).  In the first step, native proteins are separated in a 
gel on the basis of their intrinsic charge using isoelectric focusing.  In the second
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step, this gel is placed on top of a gel slab and the proteins are subjected to SDS- 
PAGE in a direction perpendicular to that used in the first step.  Each protein 
migrates to form a discrete spot.  As with the cellular assays, however,  these 
techniques were cumbersome for routine operation, and difficult to standardise. 
Also,  some HLA  antigens were found  to be  difficult to  separate  due  to  their 
similar IEF patterns (Levine and Yang 1995; Vega et al. 1985).
The  serological,  cellular  and  biochemical  techniques  mentioned  could  not 
definitively  identify HLA alleles, meaning it was not possible to  evaluate the 
effect of HLA matching at the allelic level, or determine which incompatibilities 
may  not  affect  outcome.  DNA  based  techniques  for  the  detection  of  allelic 
differences  have  provided  the  ability  to  investigate  the  relationship  between 
HLA sequence disparity and transplant outcome.
DNA based HLA typing methods 
Restriction Fragment Length Polymorphism (RFLP)
RFLP relies  on  the behaviour  of restriction  endonucleases,  enzymes  that  cleave 
DNA  molecules  at specific  nucleotide  sequences  depending  on  the  particular 
enzyme  used.  Following  digestion  of  the  DNA  template,  the  fragments 
produced were separated by agarose gel electrophoresis.  Following transfer to 
a  membrane,  fragments  could  be  identified  through  hybridization  with  a 
homologous  probe,  usually  labeled  with  32P.  RFLP  was  first  used  for  the 
analysis  of  HLA  sequences  in  1982  (Wake  et al.  1982),  and  was  a  successful 
method  of  typing  HLA  class  II  alleles  that  could  not  be  determined  using 
serological  techniques  (Paulsen  et  al.  1985).  Isolation  of  sufficient  DNA  for 
RFLP  analysis  was  time-consuming  and  labor  intensive.  However,  the 
development of the polymerase chain reaction (PCR) (Mullis et al. 1986), meant 
small amounts of DNA template could be amplified to the levels required for 
RFLP  analysis  (Higuchi  et  al.  1988).  When  the  PCR  step  was  included,  the 
product was used as a template for endonuclease digestion, the fragments were 
separated  by  agarose  gel  electrophoresis  and  visualized  through  ethidium
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bromide staining.  This process was called PCR-RFLP and was applied to both 
HLA class I and class II typing (Al-Daccak et al. 1990b; Tatari et al. 1995).  The 
specificity of the technique could be developed by the use of a greater number 
of endonucleases, or through a number of secondary amplifications with group 
specific primers (Nomura et al. 1991; Ota et al. 1991).
For RFLP analysis to be performed successfully, some idea of the sequence of 
the  allele  is  required.  Also,  some  combinations  of  alleles  in  heterozygous 
individuals cannot be distinguished (Olerup 1990).
Sequence specific primer extension (SSP)
Using PCR,  it became  possible to make many copies of a  specific  area  of the 
gene  of  interest,  rendering  the  number  of  copies  produced  sufficient  to  be 
visualized on a gel.  Sequence specific primers (SSP), for HLA typing (Wu et al 
1989),  were  developed,  which  were  complimentary  to  an  allele,  or  group  of 
alleles specific for a serologically defined antigen.  The terminal 3' nucleotide of 
the primers matched the target DNA sequence, meaning it could be amplified 
with  Taq  polymerase.  If  the  primers  were  not  complimentary  to  the  DNA 
sequence, amplification would not be successful.  Following amplification, the 
PCR products could be visualized as specifically sized bands on an agarose gel 
with Ethidium Bromide incorporation.  As the result of the reaction is either "a 
PCR product" or "no PCR product", an internal positive control was added to 
each reaction.  This constituted a primer pair specific for a "housekeeping" gene 
(Olerup  and  Zetterquist,  1992),  which  was  a  gene  that  should  be  present  in 
every  sample, for example,  p-actin.  Therefore, regardless of whether the SSP 
reaction  was  positive  or  negative,  the  control  should  always  amplify.  If  no 
positive control band was seen, the SSP reaction had failed.  In PCR-SSP, many 
of these PCR reactions were performed on a single sample simultaneously, and 
the pattern of alleles amplified corresponded to the genotype for a single locus, 
or  many  loci  depending  on  the  number  of  reactions  employed.  One  of  the 
biggest  challenges  in  highly  polymorphic  genes  was  to  locate  a  sufficient 
number of allele-specific sites to provide the necessary specificity for the PCR-
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SSP reactions,  meaning combinations  of sequence-specific  primer  mixes  must 
be used (Bunce et al. 1995).  To obtain a high resolution typing, many PCR-SSP 
reactions must be employed, which can be arduous.  Some laboratories use a 
two-step approach, using a low-resolution method for typing beforehand (Yu et 
al.  1997).  The  method  is  limited,  in  that  it  identifies  only  known 
polymorphisms that are utilized to predict the entire sequence.  If an unknown 
allele is present, it may be missed.
Sequence specific oligonucleotide probes (SSOP)
The specificity of SSOP (sequence specific oligonucleotide probes) was initiated 
through the detection system and not the initial amplification as with PCR-SSP, 
described in the previous section.  In this method, a generic PCR amplification 
was performed, specific only for a given HLA locus.  A battery of probes was 
then used, determining an allele-specific pattern of sequence motifs (Saiki et al. 
1986).  Each probe had a DNA sequence complimentary to a small area of the 
gene that showed  differences between alleles.  The  probes were labeled  with 
digoxigenin  (DIG)  at  the  5'  end,  for  detection  with  an  enzyme-linked  anti- 
digoxigenin  antibody,  and  subsequently  an  enzyme-specific  fluorescent 
substrate.  The PCR reaction was performed and the product for each patient 
sample was dot blotted onto a nitrocellulose membrane, each membrane being 
specific for a different probe.  The membranes were then exposed to UV light to 
denature  the  double-stranded  template,  and  incubated  with  the  DIG-labelled 
probes.  After any excess probe was washed off, the membranes were incubated 
with the anti-DIG antibody, which bound to the DIG on any probes bound to 
the DNA in the membrane.  Following another washing step, the substrate was 
added and the films exposed to X-ray film.  Once developed, the patterns of the 
dots seen were compared to the known patterns for each allele.
PCR-SSOP was found to be cheap to run and gave a high throughput, meaning 
many samples could be processed at the same time.  However, the technique is 
quite complex, in that the number of alleles to be detected, and the presence of 
heterozygous combinations can make interpretation difficult.  To resolve these
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issues, many probes are required, making the technique more cumbersome and 
analysis  of the  results  problematical.  Because  the  probes  used  are  based  on 
known polymorphisms, reagents need to be constantly updated, and unknown 
polymorphism could remain unidentified.
Conformational analysis of DNA
The  principle  of  conformation-based  methods  relies  on  the  study  of  the 
behaviour  of  DNA  fragments  in  polyacrylamide  gel,  under  electrophoresis 
(PAGE).  The mobility  of the  DNA fragment in PAGE  depends  upon its  size 
and sequence.
SSCP
The single strand conformation polymorphism (SSCP) method takes advantage 
of the defined secondary  structure  of single stranded  DNA.  The  structure  is 
sequence-specific  in  solution,  and  under  certain  conditions  can  be  separated 
and defined (Orita et al. 1989).  Through differences in the mobility of the single 
stranded  DNA  in  non-denaturing  PAGE,  it  is  possible  to  identify  different 
sequences.
The method involves group specific amplification by PCR, melting of the PCR 
products  and  analysis  of  the  single  strands  on  non-denaturing  PAGE. 
Separation  depends  on  the  nucleotide  sequence  and  length  of  the  DNA 
fragments and also the optimization of electrophoretic conditions to maximize 
the  differential  migration  between  different  single-stranded  fragments.  The 
resolution of the technique can be improved by the addition of glycerol to the 
gel,  reduction of temperature,  lengthening of the  gel  and  the use  of different 
polyacrylamide matrices (Dean and Gerrard 1991).
SSCP has been used as a donor selection tool for matching with patient (Clay et 
al. 1995; Pursall et al.  1996), and also as a typing tool in combination with SSP 
(Lo et al. 1992).  SSCP analysis has also been used in the detection of novel HLA 
alleles (Blasczyk et al. 1995a; Blasczyk et al. 1995b; Blasczyk et al. 1995c).
SSCP is simple and inexpensive, complex instrumentation is not required and
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high sample throughput can be achieved  (Hoshino et al. 1992).  However, the 
use of SSCP for HLA analysis has its drawbacks, for example, the optimal size 
fragment for analysis is only 150-200 bp, although larger fragments can be used 
when detection of all  potential  single nucleotide substitutions is not essential 
for the analysis (Sheffield et al. 1993).  Also, there is the potential for one DNA 
fragment  to  adopt  several  different  stable  conformations  under  the  same 
conditions, resulting in complex banding patterns.  Banding patterns can also 
be confusing due to inter- and intra-gel variability that could be due to changes 
in electrophoretic conditions, gel temperature, running time or gel composition.
Heteroduplexing
DNA  heteroduplexes  are  formed  mainly  during  the  final  stages  of  the  PCR 
reaction, between co-amplified alleles of a particular locus, or between loci due 
to primer cross-reactivity at sites with similar sequences (Wood et al. 1991).  The 
resulting  double-stranded  molecules  contain  regions  where  some  of  the 
nucleotide sequences on each strand are complimentary to one another, and in 
some  areas  the  strands  are  mismatched,  forming  loops  or  bulges  along  the 
DNA, see figure 1-1.
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Figure  1-1.  Cartoon  of a  DNA  homoduplex  and  heteroduplex.  A homoduplex is  formed between 
complimentary  strands  of  DNA.  When  strands  are  non-complimentary,  under  certain  conditions, 
mismatches occur forming loops and bulges.
AG   CAGACAGAG  CAGACAG 
CAG  C   G   C   CAG  C   G   C
n _  
A G   A   G   C  C   C
C   C  A   G   G   AG
y -
These  mismatches  along  the  length  of  the  DNA  fragment  cause  it  to  kink, 
producing a  "drag"  effect when the  molecule  is  subjected  to  non-denaturing 
PAGE.  The homoduplexes formed are more streamlined and can travel quickly 
through the gel, whereas the heteroduplexes travel more slowly.  This not only 
allows separation between the homoduplex and heteroduplex, but also between 
heteroduplexes  with  different  base  pair  mismatches  and  hence  different 
conformations.
The banding pattern produced was originally used in an HLA setting to match 
donors  and  recipient  in  a  crossmatch  test.  DNA  samples  from  patient  and
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donor  were  mixed  and  amplified  together  in  the  same  PCR  reaction.  The 
resulting band pattern was compared to those obtained when each patient or 
donor sample was amplified alone under the same conditions.  Matching bands 
indicated HLA identity, whereas mismatched bands or the production of any 
new heteroduplexes would indicate a mismatch.  The heteroduplexes would be 
formed between the sense and antisense strands of an allele of donor origin and 
a different allele of patient origin.  To enhance the sensitivity of the method, the 
PCR product from an HLA allele that is not represented in the tissue type of 
that patient or donor was added after the sample amplification, but before the 
annealing stage.  This induced the formation of new heteroduplexes,  giving a 
more complex, but informative band pattern (Clay et al. 1991).  The analysis of 
multiple duplexes can be simplified by the incorporation of a label, such as a 
radioisotope or biotin,  to one strand  of a known PCR product.  This process, 
directed heteroduplex analysis (DHA), has been used in typing HLA-DQ alleles 
(Zimmerman et al. 1993).
Heteroduplexing has been used in the analysis of both HLA class I and class II 
genes (Clay et al. 1994; Martinelli et al. 1996a; Martinelli et al. 1996b; Savage et al. 
1996; Savage et al. 1995; Sorrentino et al. 1991; Zimmerman et al. 1993).  For some 
HLA  loci,  where  locus  specific  amplification  is  used,  heteroduplexes  may  be 
formed  between  the  gene  of  interest  and  divergent  or  pseudogenes,  for 
example, in HLA-DRB, heteroduplexes are formed due to the hybridization of 
divergent DRB genes on all DR haplotypes except DR8 (Wood et al. 1991).
The  use  of  the  heteroduplexing  method  was  greatly  improved  with  the 
development of the universal heteroduplex generator (UHG) (Clay et al. 1994), 
This  synthetic  sequence  mimics  the  genomic  DNA  sequence  but  contains 
controlled  nucleotide  substitutions,  deletions,  or  insertions  at  nucleotide 
positions  opposite  to,  and  contiguous  with,  known  mutation  sites  within  the 
genomic  DNA.  This  controlled  variation  in  the  UHG  greatly  enhances 
electrophoretic sorting of single-base substitutions in the samples and increases 
the  resolution  between  homoduplex  and  heteroduplex  DNA.  The  UHG  has 
been successfully utilized in heteroduplex analysis screening for the selection of
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unrelated  donors  (Bidwell  and  Hui  1990;  Clay  et  al.  1991),  and  also  in 
conjunction with SSCP for HLA-A, -B and -C allotype matching (Pursall et al.
1996).
Heteroduplex  analysis  is  a  rapid,  safe  and  cost-effective  method  that  can  be 
used  in  any  routine  laboratory,  with  the  only  post-PCR  manipulation  being 
polyacrylamide  electrophoresis.  The  main  advantages  heteroduplex  analysis 
has  over  SSCP  are  that  each  double-stranded  duplex  adopts  a  unique 
conformation under constant conditions, meaning only one band is detected for 
each, and longer fragments can be analysed.  However, if a heteroduplex differs 
by  only  one  or  two  bases  from  the  homoduplex,  the  heteroduplex  signal  is 
difficult to  distinguish  due to  the  greater intensity  of the  homoduplex  signal 
when analysed by PAGE.
Reference strand mediated conformation analysis (RSCA), is a heteroduplexing 
technique  also  including  a  second  DNA  sample  for  the  introduction  of extra 
duplexes.  This DNA molecule is fluorescently labelled (the FLR) and allows the 
detection  of only  those  duplexes  that contain  the  labelled  strand  of the  FLR. 
The principles of the RSCA method will be discussed in more detail later.
Denaturing and temperature gradient gel electrophoresis
Denaturing  gradient  gel  electrophoresis  (DGGE)  has  been  shown  to  detect 
differences in the melting behavior of small DNA fragments (200-700 bp) that 
differ by as little as a single base substitution (Fischer and Lerman 1979; Fischer 
and  Lerman  1980).  When  a  DNA  fragment  is  subjected  to  an  increasingly 
denaturing  physical  environment,  it  partially  melts.  As  the  denaturing 
conditions  become  more  extreme,  the  partially  melted  fragment  completely 
dissociates  into single  strands.  Rather than partially  melting  in a  continuous 
zipper-like  manner,  most  fragments  melt  in  a  step-wise  process.  Discrete 
portions or domains of the fragment suddenly become single-stranded within a 
very  narrow  range  of  denaturing  conditions.  The  rate  of  mobility  of  DNA 
fragments in acrylamide gels changes as a consequence of the physical shape of 
the  fragment.  Partially  melted  fragments  migrate  much more  slowly  during 
electrophoresis  through  the  polyacrylamide  matrix  than  completely  double­
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stranded fragments (Fischer, Lerman 1980).  When a double-stranded fragment 
is  electrophoresed  into  a  gradient  of  increasingly  denaturing  conditions,  it 
partially melts and undergoes a sharp reduction in mobility because it changes 
shape.  In practice,  the denaturants  used  are heat  (a  constant temperature  of 
60°C) and a fixed ratio of formamide (ranging from 0-40%) and urea (ranging 
from 0-7 M).
When the fragment completely denatures, its mobility again becomes a function 
of size.  Complete strand separation can be prevented by the presence of a high 
melting domain, which is usually artificially created at one end of the molecule 
by incorporation of a GC clamp. This is accomplished during PCR amplification 
using a PCR primer with a 5' tail consisting of a sequence of 40 GC (Myers et al. 
1985).  The position in the gradient where a domain of a DNA fragment melts 
and thus nearly stops migrating is dependent on the nucleotide sequence in the 
melted  region.  Sequence  differences  in  otherwise  identical  fragments  often 
cause them to partially melt at different positions in the gradient and therefore 
'stop' at different positions in the gel.  By comparing the melting behavior of the 
polymorphic  DNA  fragments  side-by  side  on  denaturing  gradient  gels,  it  is 
possible to detect fragments that have mutations in the first melting domain. 
DGGE  has  been  rarely  used  in  HLA  typing,  usually  after  group-specific 
amplification,  or  in  conjunction  with  another  method  (Knapp  et  al.  1997; 
Tamouza et al. 1997).
DGGE requires specific conditions to be maintained  for the particular system 
under  investigation  and  it  may  be  difficult  to  reproduce  these  conditions 
between gel runs.  Also, two alleles that have a different sequence, but similar 
melting  points,  may  not  be  resolved  as  they  may  produce  identical  gel 
retardation and resulting band pattern.
Sequence Based Typing
Many methods have been developed for sequence based typing (SBT), but the 
one  mainly  in use  in  histocompatibility  laboratories  is  the  dideoxy-mediated 
chain  termination  method,  utilizing  chain-terminating  dideoxynucleotide 
triphosphates  (ddNTPs)  (Sanger et al,  1977).  A  generic  PCR was  performed,
52C hapter 1
specific  for  the  locus  of  interest,  and  the  PCR  product  denatured,  through 
heating,  to  produce  single  stranded  DNA.  A  sequencing  primer  was  then 
annealed to the single stranded DNA in a PCR reaction with ddNTPs.  When 
the  chain  of nucleotides  extended  in  the  5'  to  3'  direction,  a  ddNTP became 
incorporated instead of a regular dNTP, meaning the sequence was terminated. 
Each  ddNTP  was  labelled  with  a  different  fluorescent  dye;  meaning  four 
separate  sets  of  chain-terminated  fragments  were  produced.  As  each  chain- 
terminated  fragment  was  still  bound  to  it's  single  stranded  DNA  template, 
heating was required to separate them.  The chain terminated fragments were 
then  separated  by  polyacrylamide  gel  electrophoresis  (PAGE)  using  an 
automated sequencing machine, which would assign each base depending on 
the  fluorescent  labeled  dye,  and  produce  a  matching  sequence.  With  the 
development of sequence analysis software, it was then possible to match the 
sequences produced to a database, containing all known sequences to date of 
each HLA allele (Lefranc 2002; Robinson et al. 2000).
As  this method  determines  the actual  sequence  of nucleotides  in  the  gene  of 
interest, theoretically it should give the highest resolution typing.  However, the 
main problem facing this technique in HLA typing is the existence  of a  large 
number of identical sequence motifs that are present in different alleles.  The 
computer  software  and  analysis  methods  are  limited  in  that  they  cannot 
determine the cis or trans orientations of the nucleotide sequences.  Therefore, 
heterozygous ambiguities  are  an increasing  problem  for  direct  sequencing  of 
HLA  genes,  where  many  combinations  of  some  groups  of  alleles  cannot  be 
resolved,  even  when  group-specific  amplification  is  used  (Rozemuller  and 
Tilanus  1996).  To  resolve  these  ambiguities,  other  techniques,  or  additional 
steps are required, making this procedure difficult to perform on a routine basis 
(Voorter et al. 1998).
Genetic Organisation of HLA
The  Major  Histocompatibility  Complex  (MHC)  situated  on  the  short  arm  of 
chromosome  six  (6p21.3)  (Lamm  et  al.  1974)  encodes  the  Human  Leukocyte 
Antigen  (HLA)  genes  in  humans.  The  MHC  consists  of  three  major
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Histocompatibility gene clusters, HLA class I, II and III (Trowsdale et al. 1991). 
HLA class I and class II antigens are classical transplantation antigens, whereas 
the  class  III  region  encodes  for  genes  such  as  complement  components  and 
clotting factor B (Carroll et al 1984), cytochrome P-450 and the 21  hydroxylase 
genes (Carroll et al. 1985).  A simplified map of the human MHC can be seen in 
Figure 1-2.
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Figure 1-2.  Simplified map of the MHC.  HLA class I genes are shown in red, with HLA class Ii genes 
in blue.  MHC class I  associated genes are highlighted  in yellow.  Adapted from  Immunobiology,  the 
Immune System in Health and Disease (Janeway et al. 1999).
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The class I region of the human MHC contains three 'classical' loci, HLA-A, -B 
and -C and the class I-like genes, which encode class I molecules such as HLA- 
E, -F and -G.  These non-classical class I genes exhibit far fewer alleles than the 
classical  genes,  and  the function is  less  well  defined  compared  with classical 
class I molecules.  It is thought the non-classical class I antigens may be targets 
for Natural Killer (NK) cell inhibitory receptors, for example, HLA-G which is 
expressed on the surface of trophoblasts and may prevent foetal attack by NK 
cells  (Houlihan  et  al.  1995;  Munz  et  al.  1997).  HLA-E,  for  example,  binds 
peptides encoded by the leader sequences of HLA-A, -B, -C and -G, but not its 
own  leader  sequence,  and  is  recognised  by  NKG2A  and  NKG2B  inhibitory 
receptors, and NKG2C non-inhibitory receptors expressed on NK cells (Braud et 
al 1998; Long 1998).
The class II region of the MHC encodes both the a and p chains of HLA-DM, - 
DO, -DP, -DQ and  -DR.  The genes encoding a chains are designated  A and 
those encoding the p chains designated B.  The most complex part of the HLA 
class II region is that which encodes the HLA-DR molecules.  There are several 
functional  p-chains, as well as pseudogenes, and the different arrangement of 
these  P-chains  can  result  in  the  formation  of  different  HLA-DR  haplotypes 
(Svensson et al. 1996).
Structure of HLA class I
HLA  class  I  molecules  are  made  up  of  an  MHC  encoded  heavy  chain,  non- 
covalently associated with a non-polymorphic light chain, Beta-2-microglobulin 
(p2m), which is not encoded within the MHC, and a peptide of between 9 and 
12 amino acids in length. The first HLA molecular structure to be determined 
was that of HLA-A2, using X-ray crystallography (Bjorkman et al. 1987b).  The 
al and a2 domains of the heavy chain form a groove for binding the peptide, 
the domains are each divided  into an a helix and 4 p-strands, which together 
form  the  peptide-binding  groove.  The  a3  domain  is  associated  with  p2m, 
positioned beneath the peptide-binding groove (see Figurel-3).
The class I gene is made up of 7 or 8 exons; the first constitutes a 5' untranslated 
extracellular domains, al, a2 and a3, which protrude from the cell surface. The
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a3 domain of class I, encoded by exon 4, has a conserved sequence, required for 
its interactions with p2m and the TCR co-receptor, CD8 (Salter et al. 1989).  The 
fifth exon encodes the transmembrane region, which anchors the molecule into 
the plasma membrane of the cell.  This then extends into exons 6-7 (or in some 
circumstances 8) which encode the cytoplasmic tail (Strachan 1987).  A cartoon 
of the class I HLA molecule can be seen in figure 1-3.
Figure l-3a.  Ribbon diagram of an HLA class I molecule.  HLA class I molecules are composed of a 
heavy chain consisting of the al, a2 and a3 regions, transmembrane region and cytoplasmic tail, and p2- 
microglobulin as a light chain.  N and C refer to the amino and carboxy termini of the polypeptide chains 
respectively (adapted from Janeway et al. 1999)
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Figure l-3b. Schematic diagram of the HLA class I molecule.  The correspondence between exons of 
genes  and  domains  of proteins.  E = exon,  TM  = transmembrane  region,  UTR =  untranslated  region 
(adapted from Klein and Horejsi 1997)
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Structure of HLA class II
HLA class II genes are slightly more complex than class I as they are made up 
of  two  potentially  polymorphic  heavy  chains  as  opposed  to  one.  There  are 
three class II genes, HLA-DR, -DQ and -DP.  The a and p chains of these loci are 
all  polymorphic  apart from  HLA-DRa,  and  in  addition,  there  are  other  DRp 
chains  (DRp3, 4, and 5),  each of which can bind  the a chain to give a  second 
HLA-DR  "allele"  expressed  on the cell  surface.  Additional  a  and  p  chains  of 
HLA-DQ  also  exist,  but  are  pseudogenes  and  are  not  expressed  on  the  cell 
surface (Charron et al. 1984).
The  class  II  molecules  are  expressed  on  the  cell  surface  as  heterodimeric 
glycoproteins, consisting of two chains (a and p) joined by non-covalent bonds. 
Each chain has five regions, two extracellular domains (al and a2, pi and p2), a 
connecting  segment,  a  transmembrane  region  and  a  cytoplasmic  region 
(Kaufman et al. 1980).  The class II genes are made up of between 4 and 6 exons, 
exon 1  codes  for  the  leader  sequence,  exons  2  and  3  encode  the  extracellular 
domain, and exons 4-6 encode the connecting segment, and the transmembrane 
and  cytoplasmic  regions.  The  a  and  p  chains  of the  HLA  class  II  molecules 
show similar structure to HLA class  I,  although they are associated  with one 
another rather than with P2m (Fremont et al. 1996).  The peptide binding groove 
is shaped slightly differently to that of HLA class I, with open-ends rather than 
those which are closed off, giving less restriction to the size of peptide which 
can be accommodated  (Rammensee 1995).  A schematic  representation  of the 
HLA class II molecule can be seen in figure 1-4.
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Figure  l-4a.  Ribbon diagram of an HLA class II  molecule.  HLA class II molecules consist of an a 
and  p  chain.  N  and C refer to the amino and carboxy termini  of the polypeptide chains respectively 
(adapted from Jane  way et al. 1999).
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Figure l-4b. Schematic diagram of the HLA class II  molecule.  The correspondence between exons of 
genes  and  domains  of proteins.  E = exon,  TM  = transmembrane  region,  UTR =  untranslated  region 
(adapted from Klein, Horejsi 1997)
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Polymorphism of HLA
The  HLA  genes  are  extremely  polymorphic,  with  over 1700  alleles  currently 
sequenced  (Robinson et al.  2003).  The  number  of sequenced  alleles  for  each 
locus is described in table 1-1.
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Table 1-1.  The number of HLA alleles currently sequenced (Robinson et al. 2003) 
HLA class I Alleles
HLA-A 303
HLA-B 559
HLA-C 150
HLA-E 6
HLA-F 2
HLA-G 15
HLA class II Alleles
HLA-DRA 3
HLA-DRB 439 HLA-DRB1 362
HLA-DQA1 25 HLA-DRB2 1
HLA-DQB1 56 HLA-DRB3 40
HLA-DPA1 20 HLA-DRB4 12
HLA-DPB1 107 HLA-DRB5 17
HLA-DMA 4 HLA-DRB6 3
HLA-DMB 6 HLA-DRB7 2
HLA-DOA 8 HLA-DRB8 1
The polymorphism of the HLA genes comes about through genetic exchange, 
recombination,  and  point  mutation.  Genetic  exchange  can  be  seen  at  the 
chromosome level, between alleles of different, but homologous, loci, a process 
called gene conversion.  It can also be seen at the allelic level, between alleles of 
the  same  locus,  allele  conversion  (Madrigal  et  al.  1992;  Parham  et  al.  1988). 
Recombination can occur through the cross over of two alleles, for example, the 
HLA-A*6901  allele  structure  suggests  that  it  was  formed  through  the 
recombination  of exons  1  and  2  of  HLA-A*6801  and  the  remainder  of  HLA- 
A*0201 (Holmes and Parham 1985).
One  hypothesis  for  the  polymorphic  nature  of  the  HLA  molecules  is  their 
specific function.  The role of the HLA molecule is to be able to specifically bind
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as many pathogen peptides as possible in order to present them to a cytotoxic T 
cell, which will in turn eliminate the infected cell (Zinkernagel, Doherty 1974b). 
It is also important for the HLA molecule to bind non-pathogenic peptides for 
thymic education and the development of the T-cell repertoire (Ignatowicz et ah 
1996).  The peptides bind to the HLA molecule using specific anchor residues 
that  fit  into  "pockets"  within  the  peptide  binding  site,  therefore  the 
polymorphism  of  the  binding  groove  pockets  determine  which  peptides 
residues can bind to which HLA molecule (Bjorkman et al. 1987b).  Most of the 
polymorphism observed in the HLA system is targeted in the peptide-binding 
groove,  affecting  the  peptide  binding  specificity  of  the  molecule  (Saper  et  al.
1991).  This polymorphism allows the HLA molecules to bind a large repertoire 
of  peptides.  These  are  then  presented  to,  and  recognised  by,  specific  T  cell 
receptors. Due to the polymorphic nature of the HLA genes, most individuals 
will  be  heterozygous for  a  given locus.  One  set  of  genes,  or  a  haplotype,  is 
inherited from each parent, therefore giving the possibility of any one of four 
possible  haplotype combinations  in  one  offspring.  This,  as we will  see  later, 
makes the possibility of finding a sibling donor for HLA identical bone marrow 
transplantation rather complicated.
Linkage Disequilibrium
As previously mentioned, HLA alleles are inherited as haplotypes, and there is 
variation  between  the  frequencies  of  alleles  present  in  different  populations. 
This  occurs  through  natural  selection  over  time,  where  populations  are 
subjected  to  various  diseases  and  only  a  section  of  the  population  has  HLA 
molecules, which are capable of binding and presenting the appropriate peptide 
from  the  pathogen.  These  individuals  would  eradicate  the  pathogen  and 
survive, whereas those without the appropriate HLA molecule would not (Hill 
et al. 1991; Hughes and Nei 1988).
When the frequency  of particular haplotypes  is studied,  it can be  seen  that  a 
given  haplotype  occurs at a  higher  frequency  than  expected  when compared 
with the gene frequency of the separate alleles (Grange et al. 1981).  This is due 
to  genetic  linkage  disequilibrium,  which  depends  on  the  amount  of  possible
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recombination between loci,  i.e.  cross  over  can  occur between  chromosomes. 
There is generally more opportunity for cross over to occur between two loci 
which  are  separated  by  a  large  distance  on  the  chromosome  compared  with 
those which are situated close to one another (Hiller et al. 1978).  There are also 
regions known as recombinatorial hotspots present on the chromosome, which 
allow cross over even thought the two loci may be close to one another (Baisch 
and Capra 1993).  Linkage disequilibrium within the MHC is most prevalent for 
genes found close together, for example the HLA-B and -C, or HLA-DR and - 
DQ genes.  Also, this haplotype may have been "advantageous" at some time, 
which may account for its higher frequency (Proust et al. 1982).
A common haplotype in the Caucasoid population is HLA-A1 (allele frequency 
15%), -B8  (allele frequency 13.7%)  and  DRB1*03  (allele frequency  12.4%) with 
the  expected  haplotype  frequency  being  0.25%  (Kimura  and  Sasazuki  1992). 
The actual frequency of this haplotype in the Caucasoid population is 6.4%, due 
to the lack of recombination between these loci.
This phenomenon is not true for all HLA loci, or all haplotypes, however; HLA- 
DPB1  is  situated  on  the  chromosome  close  to  DQB1,  but  there  is  a 
recombinatorial  hotspot situated  between them,  leading to  a  large amount of 
crossover (Baisch, Capra 1993; Howell et al. 1993).  This means it is very rare to 
find a common haplotype, which includes an HLA-DPB1 allele.  Thus, HLA-DP 
is usually excluded when looking for an HLA matched unrelated donor as it is 
almost impossible  to find  one  with the  same  HLA-DBP1  alongside  matching 
haplotypes for the other HLA alleles.
For  many  years,  the  high  level  of linkage  between  HLA-B  and  -C  suggested 
there  was  no  need  to  type  the  C  locus,  as  if the  B  locus  were  matched,  this 
would  be  too.  However,  as  HLA  typing  techniques  became  of  increased 
specificity it was found that more than one HLA-C allele can be in linkage with 
the  same  HLA-B  allele,  so  now  typing  for  both  loci  has  become  more 
commonplace (Prasad et al. 1999).
Function of HLA molecules
HLA molecules are found on the surface of all nucleated cells and their natural
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function  is  to  act  as  a  restriction  element  for  the  recognition  of  pathogenic 
antigens by T cells for the distinction of normal 'healthy'  tissue from infected 
tissue  (Zinkernagel  and  Doherty  1974a).  As  mentioned  previously,  the HLA 
molecules  expressed  on  the  cell  surface  can  also  act  as  targets  for 
allorecognition (Schendel et al. 1992; Termijtelen 1990).
The function of the HLA molecules is to bind peptide fragments derived from 
pathogens  and  transport  them  to  the  cell  surface  for  presentation  to  T-cells. 
HLA  class  I  molecules  present  pathogenic  peptides  on  the  surface  of  cells 
infected with virus or bacteria, whose replication cycle occurs within the host 
cell  (Friih  and  Yang  1999;  Knittler  et  al.  1998;  Pamer  and  Cresswell  1998; 
Roosnek  et  al.  1988;  van  Endert  1999).  These  HLA:peptide  complexes  are 
recognised by cytotoxic T-cells expressing CD8 (McMichael et al. 1986).  Infected 
cells are killed, preventing the formation of new viral particles, or eliminating 
further  infection  from  cytosolic  bacteria.  HLA  class  I  molecules  can  also  be 
bound by receptors on NK cells.
HLA class  II  molecules  bind  and  present  peptides  from  pathogens  and  their 
products,  which  have  been  internalised,  or  are  present  in  vesicular  cell 
compartments (Barlow et al.  1998; Machamer and Cresswell 1982; Malcherek et 
al.  1998;  Panina-Bordignon  et  al.  1991).  These  pathogens  are  internalised  by 
phagocytosis  or  endocytosis  depending  on  the  type  of  pathogen. 
Macrophages,  for  example,  have  intracellular  vesicles  where  some  classes  of 
pathogen, such as mycobacteria and Leishmania spp. can replicate. On activation 
of the macrophage, the proteins of these pathogens are degraded by proteases 
to form peptides, which are presented on the cell surface, bound to HLA class II 
molecules.  This will initiate a response from Thl  type CD4-expressing T-cells 
that will release cytokines to induce the macrophage to destroy the pathogen.  B 
cells  can  internalise  pathogens  through  receptor-mediated  endocytosis,  and 
again  peptides from  these  pathogens  are  transported  and  presented  by  HLA 
class II molecules on the cells surface.  Th2 type CD4-expressing T cells bind to 
these  HLA-peptide  complexes  and  activate  the  B  cell  to  produce  antigen- 
specific antibodies to neutralise or destroy the pathogens.  CD4+  cells are also
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important in providing help to CD8+  cells, there are 2 different mechanisms for 
activating a CD8 T cell.  In one model, there is a CD4 cell that sees Ag on the 
surface  of  an  APC.  The  CD4  cell  is  then  triggered  to  express  CD40L,  which 
activates  CD40  on  the  APC.  The  APC  then  upregulates  expression  of  CD80 
(B7.1)  or CD86  (B7.2)  that stimulate the CD4 T cell  through CD28.  The T cell 
then produces IL-2. This IL-2 can activate a CD8 T cell by providing a second, 
costimulatory  signal,  assuming  the  CD8  cell  is  already  interacting  with 
Ag/MHCI  complex  on  an  APC.  This  process  occurs  in  the  lymph  nodes. 
Following activation, the CD8 cell leaves the lymph node and migrates to the 
tissue where it can carry out its effector functions.
The Discovery of HLA Function
Doherty  and  Zinkernagel  identified  restriction  of  T  cell  recognition,  by  the 
MHC, in 1974 (Zinkernagel, Doherty 1974b).  Two different mouse strains were 
innoculated with lymphocytic choriomeningitis virus (LCMV) and the immune 
lymphocytes of the infected mice were then cultured with 51Cr-labelled LCMV- 
infected  target cells,  and  cell  lysis  measured  by  the  amount  of 51Cr  released. 
The target cells used were from the 'L'  cell line derived from an H-2k mouse. 
The L cells were killed by the cytotoxic T cells (CTL) of the mouse strain CBA 
(H-2k) and the FI  offspring of this mouse e.g. (CBA x C57BL/6)F1, but not the 
strains BALB/c  (H-2d)  or C57BL/6 (H-2b).  All  strains infected with the virus 
died,  therefore  there  was  no  problem  with  the  infectivity  of  the  virus. 
Zinkernagel  and  Doherty  gave  two  hypotheses  for  this  finding,  either  some 
strains  did  not  produce  CTL,  or  all  strains  produced  CTL,  but  the  cells  only 
killed H-2 compatible targets.  Further tests revealed the latter to be true.  Thus, 
the  conclusion  was  drawn  that  T  cells  were  capable  of  recognising  viral 
antigens (non-self) and MHC molecules on stimulating/target cells (self).
HLA class I antigen processing and presentation
HLA class I molecules usually bind peptides from intracellularly derived self or 
viral  proteins,  whereas  HLA  class  II  molecules  bind  peptides  from 
extracellularly derived proteins.  Proteins that come from infecting viruses are
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processed, and presented on the cell surface in the same way as self-peptides, as 
the  virus  takes  over  the  cell's  normal  biosynthetic  pathway  to  make  its  own 
proteins (Lwoff 1966).  The proteins formed in the cytosol are broken down by 
proteases present in a complex called the proteosome.  This structure is made 
up  of  28  subunits,  three  of  which  are  known  as  LMP2,  LMP7  and  MECL-1. 
LMP2 and LMP7 are encoded within the MHC, and their expression, along with 
that of HLA, is regulated by the cytokine, interferon-gamma (IFNy), as is that of 
MECL-1  which is encoded  on chromosome 16  (Larsen et al.  1993).  When the 
expression  of LMP2,  LMP7  and  MECL-1  is  up  regulated,  they  substitute  for 
their  homologous  subunits  of  the  proteosome,  y,  MBI  and  Z  respectively 
(Eluteri  et  al.  1997).  These  substitutions  seem  to  alter  the  specificity  of  the 
proteosome,  which results  in the cleavage  of peptides  after hydrophobic  and 
basic residues, producing peptides with carboxy-terminal residues optimal for 
binding  HLA  class  I  molecules  (Bouvier  and  Wiley  1994).  The  peptides  are 
transported  into  the  endoplasmic  reticulum  (ER)  in  order  to  bind  the  HLA 
molecules.  This occurs via the transporter associated with antigen processing 
(TAP).  This  heterodimer  is  made  up  of  two  molecules  (TAP-1  and  TAP-2, 
which  are  encoded  within  the  MHC),  each  of  which  has  a  hydrophobic 
transmembrane  domain,  which  protrudes  into  the  lumen  of the  endoplasmic 
reticulum,  and  an  ATP-binding  cassette  domain,  which  lies  within  the 
cytoplasm.  This  TAP  complex  forms  a  channel  through  which  the  peptides 
enter the lumen of the endoplasmic reticulum where they will be bound to HLA 
class I molecules. The newly synthesised HLA class I molecules in the ER are 
bound to a chaperone protein, calnexin, which maintains their correct structure 
(Suh et al. 1996).  Beta-2-microglobulin (P2m) is also present in the ER and binds 
to  the  folded  HLA  molecule.  The  calnexin  molecule  is  displaced  and  the 
complex  binds  calreticulin,  another  chaperone  protein  (Solheim  et  al.  1997). 
Tapasin, a protein associated with TAP-1, connects the HLA:P2m complex with 
TAP, making it easily accessible for the peptides entering the ER (Elliott 1997). 
Once  an  appropriate  peptide  has  bound,  the  HLA:p2m:peptide  complex  is 
released from its chaperone proteins and leaves the ER, to be transported to the
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cell surface.  HLA molecules not bound to a peptide cannot leave the ER, as the 
peptide is needed to stabilise the complex, which would dissociate quickly on 
reaching the cell surface, were the peptide not present.
HLA class II antigen processing and presentation
Peptides  presented  by  HLA  class  II  molecules  are  formed  in  a  less  specific 
manner,  as  the  size  and  characteristics  of  the  peptide  do  not  seem  to  be  as 
strictly defined as those required for binding HLA class I molecules (Siklodi et 
al.  1998).  These  class  II  binding  peptides  originate  from  proteins  present 
extracellularly.  The antigen presenting cell (APC) internalises the pathogen or 
extracellular  protein  into  an  intracellular  vesicle  known  as  an  endosome 
(Chapman  1998).  As  this  vesicle  migrates  further  inside  the  cell,  it becomes 
more acidic, inducing the activation of proteases such as cathepsins B, D, S and 
L, which eventually break the protein down into peptides (Mizuochi et al.  1994; 
Riese et al.  1996).  HLA class II molecules are present in the ER alongside the 
HLA class I molecules.  This poses a potential problem, as the smaller peptides 
destined  for  class  I  binding,  or  newly  formed  larger  proteins  could  possibly 
bind to the empty class II molecules non-specifically.  This is prevented by the 
binding of the invariant chain (Ii), part of which blocks the HLA class II peptide 
binding groove,  preventing binding of any  peptides  present in the  ER  (Hitzel 
and Koch  1996; Machamer, Cresswell 1982).  As well as preventing the binding 
of spurious peptides, Ii also helps target delivery of the HLA class II molecules 
to the endosomes, where they can be loaded with peptide (Malcherek et al.  1998; 
Xu  et  al.  1995).  The  vesicle  containing  the  HLA  class  II  molecules  and  the 
endosome  fuse,  and  proteases  in  the  low  pH endosome  cleave  fractions  of Ii 
away from the HLA class II molecule, leaving one small fragment in the peptide 
binding  groove,  known  as  CLIP  (class  II  associated  invariant  chain  peptide) 
(Machamer,  Cresswell  1982;  Wu  and  Gorski  1996).  These  events  occur  in  the 
MIIC  (MHC  class  II  compartment),  where  there  is  a  class  II-like  molecule 
present called  HLA-DM  (Ferrari  et  al.  1997).  HLA-DM  differs  from  the  other 
class  II  molecules  in  that  it  is  not expressed  at  the  cell  surface  and  does  not 
require  a  peptide  for  stabilisation.  HLA-DM  acts  as  a  catalyst  for  exchange
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between CLIP and peptides present in the endosome, into the peptide binding 
groove of HLA class  II  (Sherman  et al.  1995).  It also helps  in the  selection of 
peptides for each class II molecule, binding to separate HLAipeptide complexes, 
and removing peptides which have a low binding efficiency,  and exchanging 
them for those which bind in a more stable manner.  Once the peptide with the 
best binding affinity for the class II HLA molecule is bound, the molecule can 
travel to, and be stabilised on, the cell surface.
T cell development and education
HLA  class  I  complexes  are  recognised  by  T  cells  which  express  the  CD8  co­
receptor, and HLA class II complexes are recognised by T cells which express 
the CD4 co-receptor.  The haematopoietic stem cell, formed in the bone marrow, 
may form committed thymic progenitors, which then migrate to the thymus to 
mature.  Progenitor  cells  enter  the  cortex  of  the  thymus  with  very  few  cell 
surface markers and no T cell receptor rearrangement.  There were originally 
two  models  predicting  how  thymocytes  develop  into  a:p  or  y:8  receptor 
expressing  T  cells.  The  first  states  that  TCR-y  and  TCR-5  genes  rearrange 
preferentially or at the same time as D-JP gene segments, and only those which 
produce compatible y and 5 chains terminate gene rearrangement and become 
y:8  T  cells  (Livak  et  al.  1995).  The  second  model  denotes  successful 
rearrangement  of  TCR-p  chain  as  the  deciding  factor,  which  gives  signals 
through  the  pTa:p  complex,  initiating  a  rearrangement  and  deleting  the  8- 
chain.
The end-point of the maturation pathway for a:p T cells is to express CD4 or 
CD8  and  be  specific  for  immunogenic  peptides  presented  by  self  HLA,  but 
unreactive  toward  self  peptides  presented  by  self  HLA.  The  immature 
progenitors, which express no T cell surface markers are therefore, at this stage, 
known  as  'double  negative'  (DN)  thymocytes  as  they  do  not express  CD4  or 
CD8  (Petrie et al.  1990).  The DN  thymocytes interact with the thymic  stroma 
and undergo differentiation and proliferation.  The DN thymocytes then begin 
to express some cell surface markers as they proceed through the thymic cortex,
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firstly CD44, an adhesion molecule, and later CD25, which is the a chain of the 
interleukin-2 receptor (IL-2R) (Shortman and Wu 1996).  As the DN thymocytes
develop from CD44low to CD25  , rearrangement of the T cell receptor (TCR) p- 
chain  occurs.  These  p-chains  then  go  on  to  pair  with  the  surrogate  a-chain, 
pTa, which allows the formation of a pre-TCR.  The thymocyte loses expression 
of CD44 and CD25 at this stage and the pre-TCR joins with CD3 that is present 
in the ER and this complex is transported to the cell surface via the cis-  Golgi. 
Once  the  pre-TCR  and  CD3  reach  the  cell  surface,  this  stops  further  p-chain 
gene rearrangement and induces the cell  surface expression of both CD4  and 
CD8.  The thymocyte is now double positive (DP), and needs to interact with 
APCs present in the cortex to allow only those cells restricted by self HLA but 
unreactive with self peptide, to enter the periphery.  The first stage is to exclude 
all  those  cells  which  cannot  recognise  self  HLA,  'positive  selection'  (von 
Boehmer 1994).  Only those cells which can recognise self HLA get through to 
the  next  stage  and  the  remaining  die.  These  successfully  positively  selected 
cells then rearrange their a-chain genes which eventually replaces the pre-TCR 
forming the a:p TCR (Petrie et al. 1993).  They also undergo 'negative selection', 
eliminating  the  cells  which  respond  too  strongly  to  self  peptideiself  HLA 
complexes (reviewed in Nossal 1994).  Finally, depending on whether the TCR 
is specific for HLA class I or class II, the thymocyte loses the expression of CD4 
or  CD8,  emerging  into  the  thymic  medulla  and  out  into  the  periphery  as  a 
single positive T cell, with a CD8 co-receptor if it is specific for HLA class I and 
a CD4 co-receptor if specific for class II.  There are two main theories for how 
this  occurs,  the  instructive  model  and  the  stochastic  or selection model.  The 
instructive model, states that a signal through a class II specific T cell receptor 
and CD4 shuts of CD8 expression and vice versa (Bommhardt et al. 1997).  The 
stochastic model states that the CD4 or CD8 expression is generated randomly, 
and  the  thymocytes  only  pass  through  negative  selection  and  become  single 
positive when the co-receptor is matched for the class I or class II specificity of 
the T cell receptor (Fowlkes and Schweighoffer, 1995).
In  the  periphery,  CD8+   T-cells  recognise  intracellularly-derived  peptides
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presented by HLA class I molecules, and CD4+  T-cells recognise extracellularly- 
derived peptides presented by HLA class II molecules as previously discussed. 
In the allogeneic bone marrow transplant situation, HLA:peptide complexes are 
recognised  in  the  same  manner,  which  can  lead  to  cell  death  if  the  HLA 
molecule, peptide, or both are recognised as foreign.
NK cell recognition of HLA
When CTL's bind HLA:peptide complexes, an activatory signal is received by 
the T cell, which causes it to kill the APC, however, when an inhibitory receptor 
expressed  on the surface of the  NK cell  binds HLA molecules, killing can be 
prevented, depending on which activatory and inhibitory receptors participate 
in the signalling  (Moretta et al.  1995).  This  inhibitory  phenomenon was  first 
discovered  in  experiments  by  Karre  et al  (Ljunggren  and  Karre  1985),  where 
murine NK cells showed greater killing of tumour cells which had lost their cell 
surface HLA expression, than those which bore HLA molecules - this is known 
as the "missing-self"  theory.  The loss of HLA expression can occur in virally 
infected  cells  as  well  as  tumour  cells,  as  a  means  of  escape  from  T  cell 
recognition.
NK  cells  express  two  types  of  receptors  on  their  surface,  inhibitory  and 
activatory (Moretta et al. 1995). The receptors can be divided into two groups. 
The first are C-type (Ca2+-dependant)-lectin-like receptors, which in humans are 
heterodimers  consisting  of CD94  and  NKG2,  both  type  2  integral  membrane 
proteins  (Lanier  et  al.  1994).  The  second  group  of  inhibitory  receptors  are 
immunoglobulin-type  monomers  consisting  of  type  1  integral  membrane 
proteins  known  as  KIRs  (killer  immunoglobulin-like  receptors).  The  KIRs 
recognise  certain  epitopes  expressed  by  HLA-B  and  -C  molecules,  and  some 
HLA-A also (Colonna and Samaridis 1995), whereas the CD94:NKG2-A, and -B 
inhibitory  receptors,  and  NKG2-C  activatory  receptor  recognise  HLA-E 
molecules which bind peptides from the signal sequences of HLA-A, -B and -C 
(Braud  et  al.  1998).  Inhibitory  KIRs  which  have  two  immunoglobulin  (Ig) 
domains can recognise HLA-C molecules,  dependent on whether they have  a 
Serine and a Asparagine, or an Asparagine and a Lysine at amino acid positions
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77 and  80  in  their  a l  helix  (Colonna  et  al.  1993).  Those  containing  three  Ig 
domains  recognise  HLA-B  antigens  which  have  the  Bw4  sequence  motif  at 
positions 77-83 of the al helix (Gumperz et al. 1995).
For a receptor to be able to transmit an inhibitory signal, it needs to have two 
immune receptor tyrosine-based inhibitory motifs (ITIM).  Crosslinking of the 
receptor  induces  tyrosine  phosphorylation  of  the  ITIM,  which  then  recruits 
tyrosine  phosphatase  SHP-1.  In  contrast,  activatory  receptors  have  IT AMs 
(immune  receptor  tyrosine-based  activatory  motifs),  that  can  bind  lck  and 
adaptor  molecule  pp36,  which  becomes  intensely  phosphorylated  when 
activatory receptors are engaged.  However, when the inhibitory KIR engages 
HLA class I, and SHP-1 becomes activated, this is thought to then prevent the 
phosphorylation  of  pp36.  Failure  to  phosphorylate  pp36  prevents  complex 
formation  with  phosphorylated  PLC-y  and  Grb2,  an  essential  event  for  IP3 
generation  and  the  calcium  cascade,  which  leads  to  the  release  of  cytotoxic 
granules onto the target cell (Valiante et al. 1996).
Each individual should express at least one NK cell inhibitory receptor, which 
is specific for their own HLA molecules, to prevent lysis of their own cells.  In 
an allogeneic transplant situation, it is possible that one of the class I molecules 
which are recognised by  the receptors is mismatched,  and  the  HLA molecule 
expressed will not be recognised by the NK receptor, resulting in lysis of the 
allogeneic cell.  This could be important in both rejection and graft versus host 
responses.  A study by  Velardi's  group has shown, in mice,  an NK-mediated 
graft  versus  leukaemia  response  without  GvHD  if  NK  cells  were  transfused 
before T cell depleted marrow (Ruggeri et al. 2002).
HLA class I-like genes
Along with HLA, there are also some "class I-like"  genes that map within the 
HLA, such as the MIC (MHC class I chain related) genes (Groh et al. 1996).  The 
MIC genes (MICA and MICB) were found during a search of the HLA-B region 
of the HLA, for other genes encoding expressed proteins (Bahram et al.  1994), 
and  are  situated  between the  major histocompatibility  loci  HLA-B  and  HLA- 
DR.  The MIC genes have a similar structure to that of HLA class I, with an al,
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a2 and a3 external domains, a transmembrane region and a carboxyl-terminal 
cytoplasmic  tail,  including  two  pairs  of  cysteines  in  the  a2  and  a3  domains 
which  form  intradomain  disulphide  loops.  In  comparison  with  class  I, 
however, the intron separating the leader sequence and the exon encoding a l is 
much larger in the MIC genes, and the cytoplasmic tail and untranslated region 
are  encoded  within  a  single  exon.  MICA  has  been  shown  to  have  15-21% 
sequence homology with the al domain, 32-36% homology with the a2 domain 
and 32-36% homology with the a3 domain of class I (Bahram et al. 1994).  The 
MIC  genes  also  show  some  polymorphism,  although  the  function  for  this 
polymorphism is not clear, as the recognition by T cell and NK cell receptors so 
far investigated has been shown to be broad, and unable to distinguish between 
different  allele  products  (Bauer  et  al.  1999).  When  the  MICA  structure  is 
superimposed  onto that of an HLA  class  I  molecule,  the variable  residues  in 
MICA are positioned on the edge of where the peptide binding groove would 
be (Bahram et al. 1996).
MICA  has  been  crystallised,  indicating  a  somewhat  distorted  structure  in 
comparison with that of HLA class  I  antigens  (Bjorkman et al.  1987b;  Li et al. 
1999).  There  is  no  peptide-binding  groove,  instead  a  shallow  platform  is 
present, with a loop comprised of the residues that would generally form the a2 
helix in HLA class I.  There is no evidence that these proteins can bind peptide, 
they also do not associate with P2m (Groh et al. 1996).  The reason for the lack of 
p2m binding could be due to a number of factors:  Binding of oligosaccharides 
instead of p2m, steric clashes with the side chains of residues present in MICA 
that  are  different  to  those  in  HLA  class  I  and  residues  of  p2m,  or  steric 
hindrance  of  p2m  due  to  salt  bridges  formed  between  some  MIC  residues. 
Although MICA does not need to bind P2m to refold correctly, it is still not clear 
how it maintains a stable structure.
MIC antigens are recognised by T cells expressing the y:5 receptor, and not the 
a:p  receptor,  which recognise  HLA  molecules  (Groh et al.  1998).  Due  to  the 
discovery  of  y:8  T-cells  in  the  intestinal  endothelium,  where  MICA  is 
constitutively expressed, it was originally thought that it was this receptor that
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bound MICA (Groh et al. 1998), however, it was later discovered that these cells, 
along with NK cells, express another activatory receptor, NKG2:DAP10 (Bauer 
et al. 1999; Wu et al. 1999).  If both these receptors were bound to MICA, it may 
lead to a stronger response (Hagmann 1999), however, it has since been found 
that only the NKG2 receptor is specific for MICA (Steinle et al. 2001).
The MIC antigens are upregulated when the cell is put under stress, in a similar 
way to some other proteins encoded by genes found within the MHC, such as 
heat shock protein 70 (hsp70) (Milner and Campbell 1990), due to their common 
promoter regions.  Upregulation may occur when the cell is damaged, infected 
or proliferating.  MICA and MICB have been found expressed on the surface of 
epithelial cells, and transcription has been seen in endothelial cells, but not B 
cells, T cells or monocytes.  The nature of this expression could implicate MIC 
molecule  upregulation  on  leukaemic  or  virally  infected  cells,  and  could  be 
utilised as a useful target in immunotherapy.  The polymorphic nature of the 
MIC antigens could mean that they are relevant as GvHD or rejection targets in 
allogeneic transplantation.
MHC and Allorecognition
Direct  allorecognition  occurs  when  the  APC  and  the  T  cell  are  of  different 
origins.  In  the  unnatural  setting  of  allogeneic  bone  marrow  transplantation, 
this system can introduce problems in the form of graft rejection or graft versus 
host disease (GvHD).  Graft rejection can occur in any transplant situation when 
the cells of the patient react against the cells in the transplanted tissue.  Graft 
versus host disease only occurs when the transplanted tissue itself is capable of 
an immune response (Barnes et al. 1956).  Studies on precursor frequencies for T 
cells capable of recognizing foreign MHC molecules have shown they can be 10- 
100 times higher than T cells which can recognize a peptide in the context of a 
self-MHC molecule (Ford and Burger 1983; Ford and  Atkins 1973).  There are 
two ways in which foreign MHC molecules can be recognized by T cells in a 
transplant  situation;  through  direct  and  indirect  allorecognition.  Direct 
allorecognition  describes  the  process  where  T  cells  bind  intact  foreign  MHC 
molecules and bound  peptide on the cell surface, recognising different amino
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acids  present  on  both  the  endogenous  peptide  and  the  MHC  molecule 
(Lombardi et al. 1989).  Alternatively, antigens may be shed from the foreign cell 
surface and processed and presented by self antigen presenting cells, with the T 
cells recognizing the amino acids of the presented peptide only (Sherwood et al. 
1986).  Indirect  allorecognition  can  elicit  both  acute  and  chronic  rejection 
episodes (Fluck et al. 1999), however, it is thought that direct allorecognition is 
the dominant process in acute organ rejection (Larsen et al. 1990a; Larsen et al. 
1990b).
This phenomenon may be explained as a result of the T cell thymic education 
process.  During thymic selection, all T cells are educated to self and non-self as 
thymocytes.  Thymocytes  that  have  too  strong  an  affinity  for  self-MHC  are 
deleted (negative selection), whilst those immature T cells with the ideal affinity 
for self MHC are allowed to continue through the education process (positive 
selection).  Since the developing T cell repertoire has no a priori knowledge of 
self-MHC, T cells must be capable of relatively high affinity interactions with all 
potential MHC molecules.  Under natural circumstances, where T cells would 
interact  only  with  self-MHC  molecules,  T  cells  with high  affinity  are  deleted 
through negative selection.  However,  in allogeneic  transplantation,  mature T 
cells  encounter  non-self  MHC  and  the  T  cells  with  high  affinity  for  such 
molecules  have  not  been  deleted  in  the  thymus,  accounting  for  the  high 
frequency and affinity of allogeneic T cells.
HLA matching in allogeneic bone marrow transplantation
Transplant from an HLA-matched  related  donor is the primary  technique for
allogeneic  transplantation,  however,  only  40%  of  otherwise  eligible  patients 
have a suitably histocompatible or closely HLA-matched related donor (Beatty 
et  al.  1985).  The  probability  of  finding  an
HLA-A/B/Cw/DRB1/DRB3/DRB5/DQB1  compatible  unrelated  donor  has 
also been shown as 38.4% (Tiercy et al. 2000).  It is therefore important not only 
to identify HLA mismatches between donor and recipient, but also to determine 
whether one type of mismatch has a greater detrimental effect when compared 
with  another.  As  knowledge  of  the  MHC  has  increased,  and  tissue  typing
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methods  have  improved,  HLA  mismatching  in  allogeneic  bone  marrow 
transplantation has been investigated in a number of ways.  Investigations into 
the  effect  of  HLA  mismatches  on  the  outcome  of  unrelated  bone  marrow 
transplantation  have  been  carried  out  retrospectively,  as  higher  resolution 
typing  technology,  and  the  discovery  of  new  HLA  antigens  and  alleles  have 
come  about  (Scott  et  al.  1998).  Various  different  ways  of  examining  HLA 
mismatching in unrelated bone marrow transplantation include the comparison 
of HLA class  I  and  class  II  effects,  the  effect of individual  locus  mismatches, 
antigenic or allelic mismatches and the effect of cumulative HLA mismatches.
HLA class I vs class II mismatches
It has been shown in related transplants that when mismatching for one HLA 
antigen,  the  risk  of  GvHD  is  greater  with  and  HLA-DR  mismatch  than  for 
HLA-A  or  -B  (Servida  et  al.  1996).  Also,  that  the  risk  of  acute  GvHD  is 
increased with the presence of multiple mismatches (Beatty et al. 1985).  Initial 
reports in unrelated transplantation focused on HLA-DR matching, showing an 
increased risk of acute GvHD and decreased survival in patients who received 
an HLA-DR mismatched transplant (Petersdorf et al. 1995).  It was later found 
that matching for both HLA-DRB1 and -DQB1 reduced the risk of acute GvHD 
and improved survival after unrelated BMT (Petersdorf et al. 1996).  However, 
when compared  with HLA  identical  sibling  donors,  the  risk  of acute  GvHD, 
graft failure and mortality was still  greater than with unrelated  donors when 
matched by serology and MLC (Beatty et al. 1991; Davies et al. 1995; Hows et al. 
1986; Kernan et al. 1993), therefore, it was thought that HLA class I mismatches 
may also play a role.
Following the demonstration that a patient mismatched for HLA-B44 exhibited 
acute GvHD (Keever et al. 1994), further investigations were carried out into the 
detection  and  effect  of  an  HLA  class  I  mismatch  on  transplant  outcome 
(Petersdorf et al. 2001b; Rufer et al. 1993; Sasazuki et al.  1998; Scott et al.  1998). 
Graft failure was shown to be primarily associated with HLA class I disparity, 
especially  where  2  or  more  alleles  were  mismatched  (Petersdorf  et  al.  1998; 
Petersdorf et al. 1997).  Also, HLA-A and -C mismatches have been shown to be
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risk factors for acute GvHD (Sasazuki et al. 1998).
Petersdorf  determined  that  HLA  class  I  determinants  governed  graft 
acceptance, whereas class II determinants played a role in GvHD (Petersdorf et 
al  1998).  The  presence  of  multiple  class  I  disparities  was  associated  with 
increased  risk  of  graft  failure,  and  the  presence  of  class  II  disparities  was 
associated  with  an  increased  risk  of GvHD.  These  finding  were  contrary  to 
what was  seen in a similar study  carried  out on transplants for the Japanese 
Marrow  Donor  Program,  where  severe  acute  GvHD  was  seen  with  a  class  I 
mismatch,  and class II  matching did not significantly effect the occurrence  of 
GvHD (Sasazuki et al. 1998).  These findings indicate that the roles of individual 
HLA  loci  may  differ  according  to  ethnic  background,  and  the  types  of 
mismatches  found  were  different  due  to  HLA  differences  in  the  two 
populations.
HLA allele versus HLA antigen mismatches
In a cohort of 548 patients with CML who underwent unrelated bone marrow 
transplantation,  Petersdorf  investigated  the  effect  of  antigenic  versus  allelic 
mismatches  for  HLA  class  I  loci  on  graft failure  (Petersdorf et al.  2001b).  A 
greater number of nonsynonymous amino acid substitutions were found in the 
antigenic mismatches when compared with allelic mismatches.  The allele and 
antigen mismatches also differed in the location of the mismatched amino acids 
in the ai  and  ot2 domains.  Mismatching involving a  single  HLA-A,  -B  or  -C 
allele was not associated with graft failure, but mismatching involving a single 
antigen  mismatch  or  multiple  HLA  class  I  allele  or  antigen  mismatches  was 
associated with an increased risk of graft failure.  Homozygosity of the recipient 
for  mismatched  alleles  or  antigens  was  identified  as  a  risk  factor  for  graft 
failure, and Petersdorf postulates that if donor mismatches cannot be avoided, 
then the preferred HLA-A, -B or -C antigen or allele mismatch should be at a 
locus for which the recipient is heterozygous.  This would ensure a concomitant 
recipient  mismatch  to  counterbalance  the  donor  mismatch  (Petersdorf  et  al. 
2001b).
This approach has been criticized because 86% of the patients in the study also
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had  a class  II  mismatch (Cooper et al.  2002), which has been  associated  with 
GvHD (Petersdorf et al. 1998).
Individual locus mismatches
Many  studies  have  been carried  out to  determine  the  effect of a  single  HLA 
locus mismatch on the outcome of unrelated transplantation (Bishara et al. 1995; 
Moreau  and  Cesbron  1994;  Petersdorf  et  al.  1997;  Petersdorf  et  al.  1995; 
Petersdorf et al. 1996; Petersdorf et al. 1993b).  However, due to the high level of 
linkage disequilibrium within the MHC (Baisch, Capra 1993; Hiller et al. 1978), 
it is unusual to find a single allele mismatch between donor and recipient.  A 
number of the studies carried out have relied on serological matching for loci 
other than the locus of interest for each study (Beatty et al. 1993; Petersdorf et al. 
1995), meaning there could be allelic mismatches between other loci (Scott et al. 
1998),  that  were  not  considered  in  the  study,  that  could  have  an  effect  on 
transplant outcome.
Now  that  it  is  possible  to  carry  out  high  resolution  typing  to  identify  allelic 
mismatches for all HLA loci, a true mismatch for a single locus can be defined 
on  a  completely  matched  background.  However,  as  stated  previously,  it  is 
difficult to find a single mismatch due to linkage  disequilibrium between the 
HLA  loci  (Sasazuki  et  al.  1998).  This  linkage  does  not  extend  to  HLA-DP 
(Baisch, Capra 1993), making it an ideal candidate to study the effect of a single 
locus  mismatch  (Varney  et  al.  1999).  In  unrelated  transplants,  HLA-DP 
mismatches  have  been  reported  in  75-89%  of  cases  (Hurley  et  al.  2000; 
Petersdorf  et  al.  2001a;  Varney  et  al.  1999).  It  has  been  determined  that  a 
mismatch for HLA-DPB1  in unrelated bone marrow transplantation can result 
in acute GvHD (Petersdorf et al. 2001a; Varney et al. 1999), but these studies had 
conflicting results with regard to the effect on patient survival.  To look at the 
effect of mismatches  of other  individual  loci  on the  background  of otherwise 
HLA  allele  matched  pairs,  very  large  studies  need  to  be  undertaken.  Two 
groups  have  investigated  the  effect  of  individual  locus  mismatches  on  an 
otherwise  HLA  matched  background  in  440  and  300  unrelated  transplants
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(Petersdorf et al. 1998; Sasazuki et al. 1998).  Sasazuki found HLA-A and HLA-C 
mismatches to be strong risk factors for the development of severe acute GvHD 
(Sasazuki et al. 1998), whereas Petersdorf found the numbers of single HLA-A, - 
B and -C mismatches to be too small for meaningful comparison (Petersdorf et 
al.  1998).  Sasazuki also found that matching for HLA-C increased the risk of 
leukaemic relapse and HLA-A mismatching significantly affected the survival 
rate  (Sasazuki et al.  1998),  but the  effect of HLA  class  II  mismatches  did  not 
appear  to  have  a  significant  effect  on  outcome.  It  was  suggested  that  the 
reduced risk of relapse with an HLA-C mismatch indicated a role for NK cells 
in  a  graft  versus  leukaemia  response,  implying  that  donor  NK  cells  killed 
patient leukaemia cells which did not express the necessary HLA-C ligand to 
bind the NK receptor and inhibit killing (Sasazuki et al. 1998).
Cumulative HLA mismatches
The effect of linkage disequilibrium means there may be multiple HLA class I 
and  II  mismatches between serologically  matched  patients  and  donors  when 
typed retrospectively at high resolution (Grundschober et al. 1997; Petersdorf et 
al. 2001b; Petersdorf et al. 1995; Rufer et al. 1995; Santamaria et al. 1994; Tiercy et 
al.  1991).  The  risk  of  acute  GvHD  is  greater  in  the  presence  of  multiple 
mismatches  (Beatty  et al.  1985),  and  severe  acute  GvHD  is  a  greater  risk  for 
patients  with  class  I  plus  class  II  mismatches  when  compared  with  single 
mismatches at any of the class I loci (Petersdorf et al. 1998).  Also, patients with 
multiple class I mismatches and those with both class I and class II mismatches 
show significantly lower survival than matched patients (Petersdorf et al. 1998). 
A single class I or class II mismatch had little demonstrable effect on survival 
(Petersdorf et al. 1998).  Disparity for 2 or more HLA class I alleles is associated 
with graft failure (Petersdorf et al.  1998), as is a mismatch for both class I and 
class II alleles (Petersdorf et al. 1997).
Qualitative mismatches
Now  that  it  is  possible  to  identify  an  allelic  mismatch  at  any  given  locus,  it 
should be possible to identify the impact of different mismatches, or find which
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mismatches  are  "permissive".  Due  to  the  low  number  of  genotypically 
matched unrelated  donors available  to a  single patient, the goal should be to 
establish  minimal  matching  criteria  that  enables  transplantation  to  be 
conducted  safely  without  excluding  donors  for  patients  who  have  no  other 
therapeutic option.  This means comparing the effect of mismatches at different 
loci in a qualitative rather than quantitative manner.  This hierarchical effect of 
mismatches at different loci has been successfully demonstrated in the risk of 
graft failure of kidney transplantation (Gilks et al.  1987).  This model allowed 
the relative risk of each mismatch combination to be estimated independently 
by assessing the effect of 0,1 or 2 mismatches at each locus, which in this case 
showed that mismatching for HLA-DR had a greater effect than mismatching 
for HLA-B, which in turn was greater than HLA-A.
Minor histocompatibility antigens
T cells recognise MHC molecules complexed with specific peptides.  There are 
thought  to  be  three  main  ways  this  recognition  occurs,  the  T  cell  either 
recognises epitopes on the peptide alone, the MHC molecule alone, or both the 
peptide and the MHC molecule together.  The correct peptide is still required to 
be bound to a specific MHC molecule, even if it is not directly recognised by the 
T cell, because the binding of the peptide can alter the shape of the part of the 
MHC molecule  exposed  to  the  T cell,  and  different  amino  acids  can  be  seen 
depending  on  its  orientation  (Bjorkman  et  al.  1987b).  When  the  donor  and 
recipient  are  completely  matched  for  all  their  HLA  molecules,  the  proteins 
present  in  the  cells  of  each  individual  will  still  be  different  and  can  be 
recognised as foreign peptides restricted by self HLA molecules, when the cell 
is actually  of host origin,  resulting in cell  killing.  Any  HLA  mismatches can 
also be recognised directly, or as peptides presented by self-HLA molecules on 
the donors own cells.
Minor histocompatibility antigens (mHag) are peptide components of proteins 
which differ between individuals.  In the case of mHags, the peptide alone is 
recognised,  because  the  HLA  molecule  presenting  the  peptide  is  usually 
matched  between  the  patient  and  donor  (Goulmy  et  al.  1996).  With  high
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resolution  HLA  typing  and  matching  techniques  now  available  for  any 
polymorphic  gene  (Argiiello  et  al.  1998b),  it  may  be  possible  to  completely 
match  individuals  for  all  polymorphic  HLA  genes.  In  a  completely  HLA 
matched situation, mHag mismatching may become more of a problem, as has 
been shown in HLA identical sibling transplantation (Goulmy et al. 1996).
The first evidence of responses against minor histocompatibility antigens was 
described in mouse experiments, where individuals transplanted with tumours 
matched for their MHC had a rejection episode, though less acute than those 
with known MHC mismatches (Counce et al. 1956; Snell 1948).  In humans, the 
first defined mHags were male-specific, since found to be encoded by genes on 
the Y-chromosome (Goulmy et al. 1978; Goulmy et al. 1983; Goulmy et al. 1976; 
Goulmy et al. 1977; Wang et al. 1995).  Peptides from these, such as H-Y, can be 
recognised when presented by a few different HLA antigens, namely HLA-A1, 
-A2,  -B7 and  -B60  and  is expressed  on a  broad  range  of cell  lineages  of both 
haematopoietic and non-haematopoietic origin (Goulmy 1997).
The  presence  of  a  further  set  of  autosomal  mHAgs  has  been  described  by 
Goulmy  et al,  and  called  HA-1,  HA-2,  HA-3,  HA-4  and  HA-5  (Van  Els  et al.
1992).  HA-1, HA-2 and HA-3 were found to occur at a frequency of 69-95% in a 
healthy  population,  while  HA-4  and  HA-5  were  only  present  in  7-16%  of 
individuals  tested  (Van  Els  et  al.  1992).  A  mismatch  for  the  diallelic,  HLA- 
A*0201-restricted, HA-1 has been shown to induce a graft-versus-host response 
in HLA-A*0201 matched transplants.
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Hypotheses for the project
That an information database could be established, for the Anthony Nolan Bone 
Marrow Trust, to store demographic and clinical information pertaining to each 
unrelated  transplant  performed  for  later  statistical  analysis  with  a  view  to 
analyse factors affecting the outcome of transplants from donors provided by 
the Trust.
That  a  novel  HLA  matching  and  typing  tool,  Reference  Strand  mediated 
Conformation Analysis, could be used to determine the level of matching at 6 
HLA loci, between donor and recipient and the effect of this matching analysed 
with respect to outcome in the form of overall  survival,  disease free survival, 
transplant  related  mortality,  relapse  incidence  and  occurrence  of  acute  and 
chronic GvHD.
The ultimate aim is to use the processes and the database developed to collect 
DNA, PBMCs and plasma samples and clinical information on all patients who 
undergo a transplant with a  donor provided  by  the  Anthony  Nolan  Registry 
from 1996  onwards.  The data collected can then be  used  for more  definitive 
studies.  The  information  gained  from  this  primary  analysis  will  be  used  to 
calculate the number of samples required for the next study.
81C hapter 2
Chapter 2
Materials and Methods
Sample collection
Two  25ml  aliquots  of  whole  blood  were  collected  from  both  recipients  and 
donors originally in Heparin as an anticoagulant.  Later a second medium was 
used;  RPMI  1640  (BioWhittaker),  containing 0.5mM  p-mercaptoethanol,  and 
0.6%  Tri-sodium  citrate.  These  samples  were  used  for  the  isolation  of 
Peripheral  Blood  Mononuclear  Cells  (PBMC).  A  further  10ml  sample  was 
collected  in  EDTA  (1.6  mg/ml  of blood)  for  DNA  extraction.  Samples  were 
transported by post, or courier, depending on the location of the transplant or 
harvest  centre,  with  the  aim  of  having  the  samples  arrive  in  the  laboratory 
within 2 days.
Processing and storage of samples
PBMCs  were  isolated  from  Heparinised  or  Sodium  Citrated  blood  using  the 
Lymphoprep™ gradient cell separation system.  The heparinised samples were 
diluted  1:1  with  RPMI  1640  and  10-15ml  layered  onto  each  10ml  of 
Lymphoprep™,  centrifuged  at  974g  (without  brake)  for  22  minutes  and  the 
layer of PBMCs transferred into 20ml fresh RPMI.  The cells were then washed 
in a total volume of 50ml RPMI 1640 and pelleted by centrifugation at 652g for 
10 minutes and were then given two further washes in 50ml fresh RPMI 1640. 
Samples collected  in Sodium Citrate which were  less  than 24 hours  old  were 
treated  as  above.  Samples  collected  in  Sodium  Citrate,  which  had  been  in
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transit for more than 24 hours, were defibrinated.  lOOjil 1M Calcium Chloride 
was added per 5ml of blood and the samples were transferred to sterile glass 
conical flasks containing glass beads.  The flasks were shaken manually until a 
clot formed  between  the  platelets,  red  blood  cells  and  beads.  The  remaining 
liquid phase containing the PBMCs was layered onto Lymphoprep and treated 
as previously described.  The PBMCs were stored in liquid nitrogen (N2) at a 
density  of  lOxlO6  cells/ml  in  foetal  calf  serum  (FCS,  Serum  Supreme™, 
BioWhittaker) with 10% DMSO (BDH) for later use.  The whole blood collected 
in EDTA was separated in two.  One fraction of whole blood was stored at - 
70°C.  The  remainder  was  separated  into  buffy  coat  and  plasma  by 
centrifugation at 515g for 5 minutes, and stored at -70°C for DNA extraction and 
functional analyses respectively.
DNA Extraction
DNA was extracted from the blood sample collected in EDTA using a salting- 
out technique (Miller et al. 1988).  Between 1 and 2ml of whole blood was mixed 
with 13-14ml of Red Cell Lysis Buffer (RCLB, lOmM Tris pH 8.0, 5mM MgCL2, 
ImM NaCl) in a 15ml tube (Falcon) and incubated at room temperature for 10 
minutes.  The  cell  lysate was  then centrifuged  for  10 minutes  at 2500g.  The 
supernatant  was  carefully  discarded,  leaving  approximately  0.5ml,  and  the 
pellet released into suspension by vortex.  This process was repeated until all 
red blood cells were lysed, indicated by a clear supernatant and white cell pellet 
after  centrifugation.  Distilled  water  (240pl)  and  80pl  Enzyme  Buffer  (lOmM 
Tris,  lOmM  EDTA,  50mM  NaCl)  was  added  and  the  cell  pellet  dissociated 
through  manipulation  using  a  lOOOpl  Gilson  pipette.  Thirty  microlitres  of 
10mg/ml  Proteinase  K  (Flowgen)  was  added  along with 20pl  10%  SDS.  The 
tube  was  incubated  in  a  water  bath  at 55°C  for  55  minutes.  The  lysate  was 
transferred to a sterile 1.5ml microcentrifuge tube.  Fifty microlitres of 5M NaCl 
was added and the tube vortexed at high speed for 15 seconds.  The solution 
was centrifuged at 1500g for 10 minutes.  The supernatant was then transferred 
to a new sterile 1.5ml  microcentrifuge tube containing 750pl 99%  Ethanol,  on
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ice.  The solution was gently mixed until strands of genomic DNA were seen to 
precipitate.  This DNA was extracted from the tube by spooling onto a sealed 
glass pasteur pipette and washed with lml of 70% Ethanol before being allowed 
to air dry.  Once DNA strands appeared clear, indicative of thorough drying, 
the DNA was dissolved  in 50-1 OOpl  of  1M Tris pH  8.0, 0.5M EDTA  and  the 
optical  density  measured  at  260nm  and  280nm  to  determine  purity  and 
concentration.  Ideal  purity  was  given by OD260nm:OD280nm  =  1.6 - 1.8 and  an 
ideal concentration of more than 500ng/pl.  Samples of acceptable purity and 
concentration were stored at -20°C  until  use, when an aliquot was  diluted  in 
sterile distilled water to 200ng/pl and stored at 4°C.  Samples which did not 
yield  sufficient purity  or concentration were concentrated  and  purified  using 
GFX™ columns (Pharmacia Biotech™).
Purification using GFX™ columns
GFX™ purification (Pharmacia Biotech) uses an ion exchange technique for the 
purification of genomic DNA.  At high salt concentration the nucleic acid binds 
to the glass fibre matrix in the GFX™ column.  The DNA was washed with an 
ethanol-based  solution  to  dissolve  impurities,  but not  the  bound  DNA.  The 
DNA  is  then  eluted  in  the  buffer  of  choice,  which  due  to  its  reduced  salt 
concentration will  allow release  of the  DNA  from  the  matrix.  DNA  or PCR 
products were purified following manufacturer's protocols.  Briefly, one GFX™ 
column was used per sample to be purified, this was placed into a labelled 2ml 
waste  collection  tube.  500(4.1  of chaotropic  Capture  Buffer  was  added  to  the 
column  and  100|d  of the  sample  to  be  purified  was  added  and  mixed.  The 
column with tube were centrifuged at 12000g for 30 seconds, and the liquid in 
the collection tube discarded.  500|il of ethanol-based Wash Buffer was added to 
the column and it was centrifuged as before.  The column was then transferred 
to a labelled 1.5ml microcentrifuge tube and 50|iil  (or less,  depending on final 
concentration required) elution buffer (1M Tris pH 8.0, 0.5M EDTA for DNA, 
IX PCR buffer for PCR product) was added and the column incubated at room 
temperature  for  one  minute.  The  column  and  microcentrifuge  tube  were
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centrifuged for a further minute, the eluted DNA/PCR product collected in the 
microcentrifuge  tube  and  the  column  discarded.  DNA  was  stored  in 
concentrated form at -20°C until diluted for use.
Reference Strand mediated Conformation Analysis
RSCA  is  a  DNA  based  technique  that was  developed  at  the  Anthony  Nolan
Research Institute, allowing the detection of polymorphisms in gene sequences, 
and has been mainly applied for high resolution HLA class I and class II typing 
(Argiiello et al. 1998b).  RSCA is a heteroduplexing technique, which relies on 
the  behaviour  of  double  stranded  DNA,  in  polyacrylamide  gel,  for  the 
separation of different base pair sequences.  A heteroduplex is formed between 
a  fluorescently-labelled  "known"  single  stranded  DNA  fragment,  and  an 
unlabelled  "unknown"  single  stranded  DNA  fragment.  Any  mismatches 
between  the  two  fragments  in  the  heteroduplex  will  cause  loops  and  bulges 
where the bases are uncomplimentary, whereas completely matched fragments 
will form a smooth, streamlined homoduplex.  The mismatched fragments will 
run slowly through the gel,  due to their uneven shape, whereas the  matched 
homoduplex  will  travel  uninhibited  through  the  gel.  This  means  the 
homoduplex would run faster through the gel than the heteroduplexes.  Due to 
the  specific  flurochrome  labelling,  only  the  duplexes  containing  the  labelled 
strand  of  the  FLR  were  detectable  with  laser  excitation  of  the  Cy5  on 
ALFexpress DNA sequencing apparatus, see figure 2-1.
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Fig 2-1.  Schematic of Reference Strand mediated Conformation Analysis.  This figure was adapted 
from ArgUello et al (ArgUello et al. 1998a).  Homozygous FLR was hybridised to unlabelled sample PCR 
product and the resulting duplexes separated by PAGE on the ALFexpress automated sequencer 
(Pharmacia Biotech)
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The first step in the RSCA process is to amplify a specific area of the gene of 
interest  using PCR.  This  area  is  identified  through  the  analysis  of  sequence 
data and  sequence  specific  primers  are  designed  to  sit either side.  For HLA 
class I analysis, locus specific primers positioned within intron 1  and intron 3 
allowed the PCR amplification of an amplicon encompassing exons 2 and 3 of 
the individual HLA-A, -B and -C loci (Cereb et al. 1995).  Similarly, HLA class II 
analysis of HLA-DRB1, -DQB1 and -DPB1 was facilitated by the generation of a 
PCR fragment encompassing the informative polymorphisms of exon 2 for each 
locus (Kimura, Sasazuki 1992).  The HLA allele nomenclature used throughout 
is that defined at the time of analysis.
Generation of locus specific PCR product
Three  alternative  protocols  were  utilised  for  the  amplification  of  these 
fragments, as described in Table 2-1.
Table 2-1.  PCR protocols for HLA class I and II amplifications.
Reagent HLA-A and -B HLA-C HLA class II
(NH4)2S04 13.3mM 13.3mM 16mM
MgCh 0.84mM 0.42mM 1.5mM
dNTP 74|iM 74pM 200|iM
each primer 25 pmol 25 pmol 25 pmol
Taq polymerase 1.25 units 1.25 units 0.75 units
DNA 200-500ng 200-500ng 200-500ng
Primers  used  for  HLA-DPB1  and  -DQB1  amplification  were  described  in  the 
11th Histocompatibility Workshop (Kimura, Sasazuki 1992), along with other - 
DQB1  specific  primers  designed  in  house.  Generic  primers,  designed  by  Pel- 
Freez™,  were  used  for HLA-DRB1  amplification.  Flanking HLA-DRB1  group 
specific primers were designed in house and were used in conjunction with the 
generic  primers  in  a  nested  PCR  to  avoid  amplification  of  other  HLA-DRB
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genes and to give a PCR product of the correct size for use in RSCA.  Sequences 
of all primers are described in the Appendix I.
PCR cycling was carried out in a PTC-200 Peltier Thermocycler (MJ Research, 
Watertown,  Massachusetts,  USA).  To  confirm  the  presence  of  amplification 
product, 3pl from each 25pl PCR reaction was run on a 1.5% agarose gel in IX 
TBE, at 120 volts for 45 minutes (see fig 2-2).  PCR products were visualised by 
including 0.5ng/ml Ethidium Bromide  in the  agarose  gel  and  viewing  under 
ultra-violet light on a transilluminator.  Size of PCR product was determined by 
the inclusion of a molecular weight marker (XIV, Boehringer Mannheim) with 
products ranging from 100 bp to over 2KB, each band separated by 100 bp (see 
figure 2-2).
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HLA-A  HLA-B  HLA-C
Figure 2-2.  Successful  PCR am plification.  HLA-A, -B and -C PCR products had an expected length of 
979 bp, 940 bp and 909 bp respectively (lanes marked 1   and 2 in each gel shown).  The DNA molecular 
weight marker used in all agarose gels was 100 bp marker XIV (Boehringer Mannheim, L), with 
fragments of 100 bp -  1500 bp, at 100 bp intervals, with a larger band at the top of the marker of 2642 bp.
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Formation of FLR (fluorescent labelled reference)
The  FLR  is  a  locus  specific  DNA  fragment,  generated  by  PCR  from  a
homozygous  B  lymphoblastoid  cell  line  (B-LCL)  DNA,  or  plasmid-cloned 
template  (obtained  from  collaborators  at  Pel-Freez™  Inc.  USA),  using  a  Cy5 
labelled sense primer (Pharmacia™).  The primer pair used to amplify the FLR 
PCR  product were  identical  to  those  used  to  amplify  the sample  DNA  to be 
tested, with either the sense or anti-sense primer having a Cy5 label on the 5' 
end  (see  Table  2-2).  DNA  was  extracted  from  B-LCL  described  in  the  12th 
International  Histocompatibility  Workshop cell  line  panel  (Marsh et al  1998), 
and others obtained locally.
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Table 2-2.  B-LCL’s used for the formation of FLRs
Locus Template FLR Cy5 label (5')
HLA-A B-LCL STEINLIN A*0101 sense strand
Plasmid Template A*0102 sense strand
B-LCL AMALA A*0217 sense strand
Plasmid Template A*0205 sense strand
HLA-B SP0010 B*4402 sense strand
RSH B*4201 sense strand
JBUSH B*3801 sense strand
HLA-C BOB B*51011 sense strand
WJR076 B*5701 sense strand
BM92 B*5701 antisense strand
HOM-2a B*27052 antisense strand
AMALA Cw*0303 sense strand
STEINLIN Cw*0701 sense strand
HLA-DRB1 KAS116 DRB1*0101 sense strand
SPL DRB1*08021 sense strand
REN DRB1*1001 sense strand
PLH DRB1*0701 sense strand
HLA-DQB1 AMALA DQB1*03011 antisense strand
BTB DQB1*0402 sense strand
BTB DQB1*0402 antisense strand
HLA-DPB1 QBL DPB1*0202 sense strand
PLH DPB1*1501 sense strand
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Formation of duplexes
For PCR positive samples, 3-5pl of amplification product was hybridised to lpl 
FLR.  The mixture of PCR product and FLR was heated to 95°C for 5 minutes 
which denatures the double stranded DNA, then cooled to 55°C for 5 minutes 
which allows non-specific re-annealing of the sense and antisense strands of the 
sample PCR and FLR fragments, forming multiple duplexes.  The samples were 
then cooled to 15°C for 5 minutes.  Homoduplexes formed between the sense 
and  antisense  strands  of  the  original  DNA  amplification  products,  and 
heteroduplexes formed between the sense strands of the FLR and the antisense 
strands  of  the  samples,  and  vice  versa.  However,  due  to  the  specific 
flurochrome labelling, only the duplexes containing the labelled  strand  of the 
FLR  were  detectable  with  laser  excitation  of  the  Cy5  on  ALFexpress  DNA 
sequencing apparatus.
Electrophoresis
Between  ljul  and  2pl  of  appropriate  loading  buffer  was  added  to  each 
hybridisation product and 2pl of this mixture was loaded onto non-denaturing 
polyacrylamide gel.  For HLA class I analysis a 6% gel was optimal: 9.6ml Long 
Ranger  gel  solution  (FMC  BioProducts),  8ml  10X  TBE  buffer  (BioWhittaker), 
48pl  TEMED  (Amersham  Pharmacia  Biotech)  and  480pl  10%  Ammonium 
persulphate  (Amersham  Pharmacia  Biotech)  in  a  total  volume  of  80ml.  For 
HLA class II analysis MDSequagel™ (National Diagnostics) was used at 0.5X: 
20ml, 8ml 10X TBE buffer (BioWhittaker), 48pl TEMED (Amersham Pharmacia 
Biotech)  and  480pl  10%  Ammonium  persulphate  (Amersham  Pharmacia 
Biotech) in a total volume of 80ml.  Gel length was 21cm to laser detection and 
gel  thickness  was  0.5mm.  RSCA  was  performed  using  the  ALFexpress 
Automated  Sequencer  (Amersham  Pharmacia  Biotech).  For  each  transplant 
pair,  the  recipient  sample  was  loaded  in  the  first  of  three  lanes,  the  donor 
sample in the second lane and a pool of the two in the third lane.  Using this 
loading method it was possible to distinguish a real mismatch, as an extra peak 
appears in the mixture lane.  This allows elimination of artefacts due to lane-to-
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lane  variability.  Electrophoretic  conditions  were  30  W  constant  power  at  a 
temperature of 40°C maintained with an external  cooling system,  for 400-580 
minutes, depending on the mobility times of the duplexes.  Gels could be re­
used  up  to five times on addition of fresh running buffer  (IX TBE)  to buffer 
reservoirs.  As the fluorescently labelled duplexes crossed the fixed laser in the 
Sequencer, the Cy5 fluorescent label was excited.  A signal was detected by the 
sequencer,  and  recorded  in  a  software-generated  results  file  where  it  was 
represented as a peak in the electropherogram (see Figure 2-1).
Formation of top and bottom markers
The  problems  usually  associated  with  heteroduplex  techniques  effecting 
difficulties in direct sample-to-sample comparison include intra- and inter-gel 
variability,  and  resolution  of  DNA  fragments  of  similar  mobility.  These 
problems have been overcome  using RSCA.  Inter  and  intra  gel variability  is 
avoided by using markers in every lane, and locus specific ladders in each gel. 
Where  necessary,  internal  markers  are  formed  from  duplexes  which,  due  to 
conformational  differences,  run faster  than  the  homoduplex  and  slower  than 
the  slowest  running  heteroduplex  observed.  They  are  added  to  the  loading 
buffer (15% Ficoll + 1.2%  dextran blue) and therefore can be included in every 
lane.
HLA-A markers
For HLA-A, the top and bottom marker are the heteroduplex and homoduplex 
(respectively) of the hybridisation of a hybrid HLA-A*2501  exon 2 and Patr-A 
exon 3 chimp MHC molecule, created by overlap extension (Pel-Freez™, patent 
pending) unlabelled PCR product and a short A*0102 Cy5 sense strand labelled 
PCR  product.  Initially  PCR  products  were  obtained  using  a  nested  PCR 
protocol  as  the  primers  sit  inside  those  used  for  sample  and  standard  FLR 
amplification (5AInl-46 and 3A36L).  Pel-Freez™ have now generated plasmid 
cloned  template  for  both  these  amplicons.  The  template  for  the  top  marker 
allele  was  provided  already  dilute  from  Pel-Freez™  and  this  was  amplified 
using the same set of primers,  unlabelled.  40pl  of Cy5 labelled  short  A*0102
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PCR was hybridised to 120pl top marker allele PCR product. 10pl of Cy5 sense 
labelled  short  A*0102  product  was  added  post  hybridisation  to  increase  the 
intensity of the bottom marker as most will have been used in the hybridisation, 
and  this was  diluted  1:1  with Ficoll  loading buffer  (15%  Ficoll,  1.2%  dextran 
blue).  For use, 2pl was added to 4pl of test product/FLR hybrid and 2pl loaded 
on the gel.
HLA-B markers
For HLA-B, the top and bottom marker are the heteroduplex and homoduplex 
of  a  hybridisation  of  short  HLA-B*4501  unlabelled  PCR  product  and  short 
HLA-B*4201 Cy5 sense strand labelled PCR product.  These PCR products were 
generated using a nested PCR protocol as the primers sit inside those used for 
sample and  standard  FLR amplification  (5Binl:41-62  and  3BIn3-12L).  The  B- 
LCL RSH (HLA-B*4201) was amplified using standard B locus primers and the 
product  checked  on  agarose  gel.  A  1:100  dilution  was  made  and  used  as  a 
template for a nested PCR using Cy5 sense labelled 5B short and unlabelled 3B 
short  primers,  giving  a  Cy5  sense  labelled  short  B*4201  PCR  product.  The 
template  for  the  HLA-B*4501  top  marker  allele  was  provided  already  dilute 
from  Pel-Freez™  and  this  was  amplified  using  the  same  set  of  primers 
unlabelled.  40pl of Cy5 labelled short B*4201  PCR product was hybridised to 
120pl top marker allele PCR product.  lOpl of Cy5 sense labelled  short B*4201 
product was added to the hybridisation product to increase the intensity of the 
bottom marker as most will have been used in the hybridisation, and this was 
diluted 1:1 with Ficoll loading buffer (15% Ficoll, 1.2%  dextran blue).  For use, 
2pl were added to 4pl of test product/FLR hybrid and 2pl loaded on the gel.
HLA-C markers
For HLA-C the top and bottom marker are the heteroduplex and homoduplex 
of  a  hybridisation  of Cw*1601  unlabelled  PCR  product  and  long  B*5701  Cy5 
sense strand labelled PCR product.  DNA from B-LCL PF97387 (HLA-Cw*1601) 
was amplified using HLA-C specific  primers 5Cinl-61  (Cereb et  al.  1995)  and
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3Cin3-12L.  This PCR product was performed as a 200pl reaction and purified 
and concentrated on a GFX™ column to a final volume of lOOpl.  After PCR and 
GFX™ purification, l-3pl of product was checked using an agarose gel to show 
successful  PCR  and  purification.  DNA  from  B-LCL WJR076  (HLA-Cw*5701) 
was amplified using HLA-B specific primers Cy5 sense labelled  5Binl-62 and 
3Bin3:37-84.  Before hybridisation to  the Cw*1601  PCR product, the FLR was 
run  in  a  Long  Ranger  polyacrylamide  gel  in  the  ALFexpress  to  ensure  no 
contamination was present.  6pl of the B*5701 FLR was hybridised to 18pl of the 
concentrated Cw*1601 PCR product and the resulting duplexes tested by PAGE 
on the ALFexpress.  To form the HLA-C specific loading buffer, hybridisation 
product and Ficoll loading buffer were combined 1:1, with 1.5pl  extra  B*5701 
FLR added  to  increase  the  intensity  of the bottom marker  as  most will  have 
been used in the hybridisation.  2pl was added to each sample to be tested.
External Standard Ladders
For HLA-A and -B, external ladders were prepared for each of the 5 FLRs used 
(2 for HLA-A and 3 for -B).  After amplification of well-defined control cell line 
DNA, exhibiting alleles of known gel mobility, hybrids were generated with the 
relevant locus-specific references.  These hybrids were  pooled  and  stored at - 
20°C  until  required.  After  addition  of  the  relevant  internal  marker  loading 
buffer,  the  ladders  could  then  be  loaded  into  at  least  two  gel  lanes  prior  to 
electrophoresis.  The  heteroduplex  peaks  of  defined  mobility  present  in  the 
external  standard ladder,  in combination with specialised computer  software, 
allowed  the calculation of a standard curve to evaluate test product duplexes 
hybridised  to  the  same  FLR.  For  HLA-C,  a  ladder  utilising  only  one  FLR 
hybridised to HLA-C allele PCR product was used; to be run alongside all the 
FLRs.
HLA-A ladder
For HLA-A analysis, one ladder was used for each different FLR - HLA-A*0102 
from the B-LCL DAUDI and HLA-A*0205 from the B-LCL AM.  PCR products
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were  amplified  using  standard  HLA-A  primers  (unlabelled  5AInl-46  and 
3A36L)  from  B-LCL  WT100BIS  (A*1101),  DEM  (A*0201)  and  TERESAKI  995 
(A*2402), for the A*0102 ladder, and AMAI (A*6802), LWAGS (A*3301), LBUF 
(A*3001)  and  TERASAKI  995  (A*2402)  for  the  A*0205  ladder.  Each  PCR 
product was purified and concentrated using a GFX™ column as before.  The 
PCR  products  were  hybridised  individually  (3:1)  with  the  A*0102  or  A*0205 
FLR and mixed after checking their purity and mobility values on Long Ranger 
gel using RSCA on the ALFexpress.
HLA-B ladder
For HLA-B analysis, one ladder was used for each different FLR - HLA-B*4201 
from  the  B-LCL  RSH,  HLA-B*4402 from  the  B-LCL  SP0010  and  HLA-B*3801 
from the B-LCL JAP-NF.  Ladder components were amplified using standard 
HLA-B  primers  (unlabelled  5Binl:41-62  and  3Bin3-12L)  from  B-LCL  PF04015 
(B*0801), EA (B*0702), CALOGERO (B*4002), PLH (B*4701), PITOUT (B*44031), 
AKIBA  (B*52011)  and  DOP-ND  (B*44031  and  B*1516),  for  the  B*4201  ladder, 
PITOUT (B*44031), PLH (B*4701), LK707 (B*52011 and B*7301), BM21  (B*4101), 
EJ32B  (B*1801),  EA  (B*0702)  AND  OMW  (B*4501)  for  the  B*4402  ladder  and 
AMAI  (B*5301),  LK707  (B*52011  and  7301),  CALOGERO  (B*4002),  IBW9 
(B*1402),  EA  (B*0702),  OMW  (B*4501)  and  BOLETH  (B*1501)  for  the  B*3801 
ladder.  Each PCR product was purified and concentrated using a gfx™ column 
as  before.  The  PCR  products  were  hybridised  individually  (3:1)  with  the 
B*4201,  B*4402  or  B*3801  FLR  and  mixed  after  checking  their  purity  and 
mobility values on Long Ranger gel using RSCA on the ALFexpress.
HLA-C ladder
For HLA-C analysis, a single ladder was used for all FLRs.  The FLR used in the 
formation of the ladder was  B*5101  from the  B-LCL BOB amplified with Cy5 
sense  labelled  5Binl:41-62  and  3Cin3-12L.  This  was  then  hybridised  (1:3)  to 
PCR  products  from  B-LCLs  HOM  2a  (Cw*0102),  RSH  (Cw*1701),  DEM 
(Cw*0602), CJO A (Cw*0401), PF97387 (Cw*1601) and BOB (Cw*1502) in turn,
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which were  amplified  using unlabelled  5Cinl-61  and  3Cin3-12L  primers  and 
purified and concentrated using GFX™ columns.  The hybridisation products 
were tested by PAGE in the ALFexpress and then pooled.  For analysis, 4pl of 
ladder was added to 2pl of ficoll loading buffer with 2pl loaded on the gel.
HLA-DPB1 ladder
Three ladders for each FLR were generated by Daniel Ramon, at the Anthony 
Nolan  Research  Institute  (Ramon  et  al.  1998).  This  number  of  ladders  was 
required as no top and bottom markers were available  for HLA-DP analysis. 
The DPB1*0202 and DPB1*1501  FLRs were generated as previously described. 
The  DPB1*0202  FLR was  hybridised  (1:3)  to  PCR  products  from  DPB1*0401, 
DPB1*02012,  DPB1*0402,  DPB1H901,  DPB1*0601  and  DPB1*1401,  to  make 
ladder  1,  DPB1*1601,  DPB1*2101,  DPB1*0301,  DPB1*0901  and  DPB1*1501  to 
make  ladder  2,  and  DPB1*01011,  DPB1*0501,  DPB1*2001,  DPB1*1701, 
DPB1H001  and  DPB1*1401  to  make  ladder  3.  The  DPB1H501  FLR  was 
hybridised (1:3) to PCR products from DPB1* 2001, DPB1* 02012, DPB1* 0301, 
DPB1* 0501, DPB1* 0401 and DPB1* 1901 to make ladder 4, DPB1* 0402, DPB1* 
01011, DPB1* 0601, DPB1* 1701  and DPB1* 0202 to make ladder 5 and  DPB1* 
2301,  DPB1*  1301,  DPB1*  0901,  DPB1*  1001,  DPB1*  2101  and  DPB1*  1401  to 
make ladder 5.  For analysis, 4pl  of ladder was added to 2pl  of ficoll loading 
buffer with 2pl loaded on the gel.
Assignment of a mobility scale
Gels  were  analysed  using  Allelelinks™  fragment  analysis  software  on  the 
ALFexpress.  The  migration  of  the  different  duplexes  were  measured  as  the 
time taken for each to travel from the well until traversing the laser.  As with all 
gel systems there could be variability in the gel, meaning two identical duplexes 
in different lanes could have slightly different time values.  This problem was 
overcome by utilising a part of the software, which allows the assignation of an 
arbitrary value to certain peaks, allowing complete alignment of the gel.
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For analysis, the bottom marker was given a value of 1000 and the top marker 
was given a value of 2000.  As these markers appeared in every lane, the gel 
could then be aligned and analysed using these arbitrary values instead of time, 
giving  a  scale  of  mobility.  Further  alignment  of  the  HLA  class  I  gels  was 
achieved using the ladders, which were ideally loaded either side of the area of 
the  gel  containing the  matching FLR.  Each component of the  ladders  had  a 
known mobility, and these could be assigned in the same way as the values for 
the markers were, allowing even more accurate alignment of the gel, for more 
comprehensive analysis.  The alignment of the gel with markers and ladders is 
represented in figure 2-3.
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Figure 2-3.  A lignm ent o f the gel using  m arkers and  ladders
(a) Lanes are aligned by the assignation of an arbitrary value of 1000 to the bottom marker and 
2000 to the top marker.
(b) Lanes can be further aligned by adjusting the position of the ladders to a standard value, 
which is automatically applied to the rest of the gel, therefore avoiding gel to gel variation.
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For HLA class II, the peak created by the labelled primer in the FLR PCR was 
given an arbitrary value of 1  and the homoduplex peak an arbitrary value of 
1000  and  the  top  marker  an  arbitrary  value  of  2000.  As  the  technique  was 
developed,  the  need  for  running  ladders  in  every  gel  became  less  as  more 
known HLA alleles were assigned a specific value.  Therefore, ladders were not 
required for the analysis of HLA-DRB1 and HLA-DQB1 gels.
MICA Analysis
Primers  were  designed  to  amplify  exons  2-5  of the  MICA  gene,  and  specific 
probes  were  developed  at  the  Anthony  Nolan  Research  Institute  to  be  used 
with the SSO technique (Mendoza-Rincon et al. 1999).  Exon 5 of the MICA gene 
was analysed using RSCA and the results combined.
Amplification of exons 2-5 of MICA
PCR  conditions  for  exons  2-5  employed  the  Expand  Long  Template  Kit 
(Boehringer Mannheim)  using  Buffer  1  included  in  the  kit,  with 3.5mM  each 
dNTP, 35pmol  of each primer  and 7.5 units of Expand Long  Tnqmix  in lOOpl 
reaction  volume.  Exon  5  was  amplified  separately  using  16mM  NH4(S0 4 )2  
buffer  (Bioline),  3mM  MgCh,  200|iM  each  dNTP,  12.5pmol  each  primer,  0.75 
units  of  BioTaq  (Bioline)  in  a  25pl  reaction.  To  confirm  the  presence  of 
amplification product, 3pl from each PCR reaction was run on a 1.5%  agarose 
gel in IX TBE, at 120 volts for 45 minutes.
Labelling of probes
A Di-digoxygenin (DIG) labelling kit was used (Boehringer Mannheim), to label 
each oligonucleotide probe.  lOOpmol of oligo was added to 5X Tailing buffer, 
25mM C0CI2, ImM DIG/ddUTP, and 50 units of T.  Transferase all supplied in 
the kit.  This mix was incubated at 37°C for 20 minutes and then the reaction 
stopped with 2pl of a mixture of lpl Glycogen solution (supplied in the kit) and 
200jil 0.2M EDTA (pH7.8 - 8.0).  The oligo was precipitated with 2.5pl 4M LiCl 
and 75(0.1100% Ethanol, and incubated at -70°C for 30 minutes.  The oligo was 
removed by centrifugation at 12,000g for 15 minutes and air-dried.  The oligo 
was resuspended in lOOpl dH20 ready for use.
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Positive controls for oligotyping
Through  previous  sequencing  of  various  B-LCL  DNA  for  MICA,  positive 
controls were available for most probes.  For those where positive controls were 
not  available,  pseudo  controls  were  formed.  This  involved  amplification  of 
DNA  from  the  B-LCL JY  using  the  probe  as  a  sense  primer  and  the  closest 
intronic antisense primer in a PCR reaction,  the conditions for which were as 
described for the amplification of MICA exon 5.
Sequence specific  oligotyping of MICA exons 2-4
PCR  products were  denatured  at 95°C and  rapidly  cooled  on  ice.  Using the 
HYDRA 96  (Robbins Scientific), 2pl  of each PCR product was  dotted  onto 25 
labelled  nylon  positively  charged  membranes  (Boehringer  Manheim),  along 
with  controls  for  each  probe.  The  PCR  products  were  hybridised  to  the 
membrane using ultraviolet light.  Each membrane was blocked with a solution 
of  4X  SSPE,  0.1%  Lauroylsarcosite  and  1%  Blocking  solution  (Boehringer 
Manheim),  then  exposed  to  one  of  25  DIG-labelled  oligonucleotide  probes 
specific  for  MICA  nucleotide  motifs  at a concentration  of lOpmol  in  5ml  3M 
Tetramethylammonium,  20mM  Tris  pH  8.0  and  2mM  EDTA  (TMAC).  The 
membranes were washed  thoroughly  with 2X SSPE  and  1%  SDS  and  TMAC 
solution at specific temperatures of 58°C or 60°C to remove excess probe.  After 
washing, filters were neutralised  with IX  Neutralisation Solution  (Boehringer 
Manheim). Membranes were incubated at 37°C for 40 minutes in 0.1M Tris pH 
7.5, 0.15M NaCl, 1%  Blocking reagent (Boehringer Manheim) and  an anti-DIG 
Fab  antibody  fragment,  labelled  with  Alkaline  Phosphatase  (Boehringer 
Manheim).  After  washing  with  IX  Neutralisation  Solution  (Boehringer 
Manheim)  and,  0.1M  Tris  pH  7.5,  0.15M  NaCl  and  50mM  MgCh  The 
membranes  were  exposed  to  a  chemiluminescent  substrate,  Disodium3-(4- 
methoxyspiro[l,2-dioxetane-3,2/-(5,-chloro)tricyclo(3.3.1.13'7)decan]-4-yl)phenyl 
phosphate (CSPD) (Boehringer Mannheim).  Membranes were then exposed to 
Kodak  X-ray  film  for  5-20  minutes.  The  film  was  developed  and  results 
analysed  manually  and  using  the  Typetool™  computer  package  (LabScan 
Systems Inc. USA).
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RSCA analysis of MICA exon 5
Two FLRs were used in the analysis of MICA exon 5, (called 5A and 5D).  These 
were  formed  from  B-LCLs  EJ32B  and  PF97387  DNA  respectively  by  exon  5 
amplification with sense Cy5 labelled primers Amplification and hybridisation 
were  carried  out  as  previously  described.  Ladders  were  formed  containing 
heteroduplexes,  which  represented  the  six  expected  positions  in  RSCA  for 
MICA  exon  5.  Each  position  was  given  a  reference  (5A,  5D  etc)  which 
corresponded to a "probe"  on the Typetool™ analysis carried out on the SSO 
results of MICA exons 2-4.  With this additional information it was possible to 
assign a MICA type to each sample using the Typetool™ software.
Sequence specific PCR detection of HA-1
For  HA-1  analysis a  kit developed  by  Olerup  SSP™  (Robbins  Scientific)  was 
used.  It contained primers developed by Professor Els Goulmy's group in The 
Netherlands, which had been previously published  (Wilke et al.  1998).  Thirty 
nanograms of DNA was added to the PCR Master Mix, provided with the kit, 
which contained nucleotides, buffer, glycerol and cresol red.  Ten microlitres of 
this  mix  was  then  added  to  two  PCR  tubes,  each  containing  a  primer  pair 
specific for the HA-1H or HA-1R  allele (to give a PCR product of 210 bp) and a 
control primer pair matching non-allelic sequences  (to give a PCR product of 
515 bp and 430 bp respectively).  After amplification,  the entire PCR product 
was loaded on a 2% agarose gel and run for 45 minutes at 150 volts (see figure 
3-5, Chapter 3).
Detection of HA-1 specific T cells
Phycoerythrin-labelled  HLA-A*0201/HA-1H  tetramers were  made  in  order  to 
detect whether HA-1 specific T cells were present in patients with Graft versus 
Host Disease (GvHD). Tetramers can be used for the detection of specific T cells 
in  a  heterogeneous  sample.  A  tetramer  is  formed  from  4  monomers  (HLA 
heavy  chain  -  specific  peptide  -  P2m)  bonded  via  Biotin  to  a  Streptavidin 
molecule fluorescently labelled with Phycoerythrin.  Specific T cells bind to the 
HLA/peptide  molecules  and  can  be  detected  in  conjunction  with  specific
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surface  markers  by  flow  cytometry  on  a  Fluorescence  Activated  Cell  Sorter 
(FACS).
HLA-A*0201/HA-1H  Tetramer formation 
Cloning ofHLA-A*0201 and ffrm
This work was carried out by Geraldine Aubert and Christina Zamoyska at the 
Anthony  Nolan  Research  Institute.  Exons  1-3  of  HLA-A*0201  cDNA  were 
amplified with primers containing restriction sequences for the Nco I and  Bam 
HI  restriction  enzymes  and  cloned  into  a  PCR2.1  plasmid  (Invitrogen).  The 
HLA-A*0201 was then cut from the plasmid with Nco I and Bam HI restriction 
enzymes  (Gibco)  and  subcloned  into  an  inducible  expression  vector,  peT3d 
(Novagen), containing a C-terminal sequence coding for a biotinylation target. 
This  vector  was  then  transfected  into  pLysS  Escherichia  Coli  (E.Coli)  for 
expression of the protein.
The  P2m gene,  cloned  in another expression vector  was a  generous  gift from 
Professor Don Wiley, Harvard University, USA, which was also transfected into 
E. Coli XL1 Blue (Promega).
The  HA-1H  peptide  was  synthesised  by  Applied  Biosystems  using  standard 
Fmoc chemistry.
Expression of proteins
Stocks  of  E.  Coli  pLysS  containing  HLA-A*0201:Bsp2  and  p2m  expression 
vectors were streaked  onto 1.2%  agar  (Gibco)  2XYT  (16g Tryptone,  lOg Yeast 
Extract, 5g NaCl in 1L H2O) culture plates, with chloramphenicol (34fig/ml in 
ethanol)/  ampicillin  (50jrg/ml)  and  ampicillin  (50^ig/ml)  antibiotics, 
respectively.  The A*0201:Bsp2 vector and the p2m vector contained resistance 
genes for ampicillin, and the E.  Coli pLysS had resistance for chloramphenicol. 
The plates were incubated at 37°C overnight.
One  isolated  colony  from  each  plate  was  added  to  5mls  2XYT  medium  in  a 
sterile  15ml  centrifuge  tube  containing  the  appropriate  antibiotics  and 
incubated  for  six  hours  at  37°C  in  a  shaking  incubator.  These  E.  coli  pLysS
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suspensions were then expanded into one litre in a sterile 2L conical flask under 
the  same  conditions,  until  an  optical  density  of  OD500  =  0.4  was  reached 
(approximately 4 hours).  When this stage of growth (mid-exponential growth 
phase)  was  reached,  lOOmg  Isopropyl  p-D-Thiogalactopyranoside  (IPTG)  was 
added  to induce protein expression and  the culture  incubated  for  a further 4 
hours.
Induction of protein expression was checked using a Sodium dodecyl sulphate 
(SDS) polyacrylamide gel.
SDS -PAGE
For protein separation, stacking SDS-PAGE was used.  This consists of a double 
layer gel with the top layer having a lower acrylamide concentration than the 
bottom.  The lower gel was 15% acrylamide (Protogel™, National Diagnostics) 
with  0.5%  SDS  and  1.5M  Tris  buffer  pH  8.0,  and  the  upper  gel  was  4.5% 
acrylamide  with  0.4%  SDS  and  0.5M  Tris  buffer  pH  8.0.  Once  the  gel  was 
polymerised,  proteins  to  be  tested  were  mixed  with  SDS  loading  buffer 
(0.0625M Tris pH 8.0, 2% SDS, 10%  glycerol, 5%  p-mercaptoethanol and 0.01% 
bromophenol blue) and denatured at 100°C for 5 minutes before loading.  The 
gel was run for 60 minutes at 30 kV in 0.025M Tris buffer with 0.192M Glycine 
and 0.1% SDS, and then removed from the glass plates and stained with 0.25% 
Coomassie  Brilliant  Blue,  45%  Methanol,  10%  Acetic  acid,  followed  by  de- 
staining in 10% Methanol with 7%  Acetic acid.  The results of this analysis are 
shown in figure 2-4.
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Fig 2-4.  D etection o f the induction o f protein  expression  by SD S-P A G E .  The first two lanes show the 
lysed E.  Coli before and after expression of the HLA-A*0201:bsp protein and the second two lanes show 
the lysed E.  Coli before and after expression of the (32m, with IPTG.  The areas of interest can be seen in 
the yellow boxes, where a strong band is present in the lanes where the protein has been expressed.  The 
final lane contains a molecular weight marker to ensure that the proteins are the expected size.
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Harvesting proteins
The  E.  coli were pelleted by centrifugation at 4,000g for 10 minutes and  then 
lysis initiated with 50mM Tris-HCl pH 8.0, 25%  Sucrose and ImM EDTA pH 
8.0.  The cells were lysed by the addition of 25mg Lysosyme and incubated on 
ice for 30  minutes.  Magnesium Chloride  (lOmM),  MnCh  (ImM)  and  DNase 
(lOpg/ml)  were  added  and  the  lysate  incubated  at  room  temperature  for  30 
minutes.  10ml Detergent buffer was added (0.2M NaCl, 1%  Deoxycholic acid, 
1% Nonidet P40, 20mM Tris-HCl, 2mM EDTA) and incubation was carried out 
at room temperature for a further 10 minutes.  The lysate was  sonicated  and 
then centrifuged at 10,000g for 20 minutes at 4°C.  The pellet was washed with
0.5% Triton X100, 50mM Tris-HCl, lOOmM NaCl and ImM EDTA, then finally 
resuspended in 50mM Tris pH 8.0, 5mM EDTA and 2mM Dithiothreitol (Alexis 
Biochemicals).
Protein Refolding
30mg  of  HLA-A*0201:bsp2  and  25mg  p2m  were  separately  dissolved  in  8M 
Urea  and  then  mixed,  aggregates  were  removed  by  centrifugation.  Ten 
milligrams  of HA-1H  peptide was  dissolved  in 50%  DMSO and  added  to  the 
other proteins.  This protein solution was then added to 200ml of 4°C refolding 
buffer  (lOOmM  Tris-HCl  pH  8.0,  400mM  L-arginine-HCl,  2mM  EDTA,  5mM 
reduced  Glutathione,  0.5mM  oxidised  Glutathione  and  0.5mM 
Phenylmethlysulfonyl fluoride (PMSF) and incubated, with continuous stirring 
at 4°C for 24 hours.
A  further  15mg  HLA-A*0201:bsp2  was  added  and  incubation  continued, 
stirring for 24 - 48 hours.  Correct refolding was tested using specific antibodies 
in a dot blot technique after FPLC purification.
The monomer solution was filtered first through a 0.2 micron filter to remove 
any  large  aggregates  and  then  vacuum  filtered  using  an  Amicon™  stir  cell 
through a YM10 microfiltration membrane with a molecular weight cut off of 
10,000  (Millipore).  A Vivaspin 20ml  concentration column  (Vivascience)  was 
then  used  to  concentrate  the  monomers  to  lml,  by  centrifugation.  This
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concentrate  was  again  filtered  with  a  0.2  micron  Vivaspin  0.5ml  filtration 
column (Vivascience) to remove any aggregates which may have formed, and 
purified on a fast protein liquid chromatography (FPLC) gel filtration column in 
lOmM Tris pH 8.0, 5mM NaCl, and the monomer fractions collected (the FPLC 
trace can be seen in figure 2-5).  The fractions in each peak were then pooled 
and concentrated using Vivaspin 0.5ml concentrator columns, to a final volume 
of 200pl.  Each fraction was analysed with a  dot blot technique to  determine 
correct refolding.
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Figure 2-5.  FPLC  Purification o f m onom ers.  Each fraction was collected and those contained in the 
same peak were pooled.  A 200pl sample was taken for dot blotting and the remaining fractions were 
concentrated ready for biotinylation.
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Dot blotting  for the detection of correctly folded proteins
Twenty microlitres of the concentrated fractions collected from the FPLC were 
dotted  onto  a  0.45p  nitrocellulose  Hybond  C™  membrane  (Amersham  Life 
Science), which was blocked 4°C overnight in PBS, 5% BSA (Sigma) and washed 
in PBS with 0.05% Tween 20 (BDH), prior to incubation with antibodies in the 
same solution.  The membranes were exposed to various conformation-specific 
mouse  anti  human monoclonal  antibodies.  Antibodies  used  for  detection  of 
correct refolding were; W6/32 (HLA class I conformation specific), BB7.2 (HLA- 
A2  specific)  and  BBM1  (human  p2m  specific).  All  antibodies  used  were 
produced in house from hybridoma culture supernatants.  Each antibody was 
used for staining at a concentration of lpg/m l.  After washing with PBS 0.05% 
Tween  20,  a  secondary  goat  anti  mouse  antibody  labelled  with  Horseradish 
peroxidase was added.  After washing, the membranes were treated with the 
ECL™ chemiluminescent substrate solution (Amersham Life Science), and then 
exposed to Kodak film.  See figure 2-6.
109Chapter 2
Figure 2-6.  C onfirm ation  o f correct  refolding  by dot  blot.  Twenty microlitres of the pooled fractions 
that  represented  a  peak  in  the  FPLC  purification  (see  figure  2-5)  were  dotted  onto  a  nitrocellulose 
membrane.  Specific  monoclonal  antibodies  were  added,  with  a  secondary,  Peroxidase-labelloed 
antibody, and after addition of luminescent substrate, the membranes were exposed to X-ray film.
HLA class I  HLA-A*2  (^m specific 
specific  specific  BBM1
W6/32  BB7.2
^ -------FPLC fraction 7
^ -------FPLC fractions 8 and 9
^ -------FPLC fractions 13 and 14
M-------FPLC fractions 17 and 18
A*0201 positive B-LCL lysate
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Biotinylation and Tetramerisation
A kit was used for Biotinylation of the monomers (Avidity LLC).  Bir A enzyme 
(Biotin protein ligase) and kit components Biomix A and Biomix B, were mixed 
with protease inhibitors (Pepstatin A 5pg/pl, Benzamidine 5mM, E64 lOpM and 
Elastatinal  10pg/ml)  and  incubated  at  30°C  overnight.  Biotinylation  was 
detected  by  dot  blot  with  Horseradish  Peroxidase-labelled  Streptavidin,  the 
results of which can be seen in figure 2-6.  After biotinylation, the monomers 
were filtered and purified by FPLC, in a running buffer of 150mM NaCl, lOmM 
Tris  pH  8.0.  The  monomers  were  concentrated  using  a  Vivaspin  column  to 
2mg/ml,  measured  by  OD280.  As  each  Streptavidin  has  four  Biotin  binding 
sites,  the  Tetramerisation  mixture  must  have  4  Biotin  molecules  for  each 
Streptavidin.  For each milligram of monomer, 0.375mg Phycoerythrin-labelled 
Streptavidin was added at a rate of 10pl every 5 minutes over approximately 
two hours, on ice.
After biotinylation, any non-biotinylated product or free Biotin was separated 
by FPLC as before.
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Figure 2-7.  Separation o f free biotin.  Biotin, which had not been attached to any of the monomers with 
the BirA enzyme, was removed by FPLC.  The peaks containing biotinylated product were collected and 
pooled ready for tetramerisation.
FPLC fractions 8, 9 and 10 
FPLC fraction 6
Figure  2-8.  D etection  o f  B iotinylation  w ith  Streptavidin  -  Peroxidase.  Fractions  of the  monomer 
before and after biotinylation were dotted on the Hybond C membrane as before (with blocking carried 
out in Marvel™ instead of BSA) and probed with Horseradish Peroxidase labelled Streptavidin to detect 
biotinylated monomers.  The membranes were then exposed to X-ray film.
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Detection of HLA-A*0201:HA-1H  specific CTLs 
Staining cells with tetramer
Information regarding HLA-A*0201 positive patients undergoing Bone Marrow 
Transplantation at the Hammersmith Hospital was kindly provided by Linda 
Casey and Paul Brookes.  Post transplant blood samples were provided weekly 
and PBMCs separated using techniques previously described.  Between 5 x 105 
and 1 x 106 cells were washed and aliquoted into each of 5 wells of a 96 well V- 
bottomed plate, in staining buffer (lOOjil RPMI 1640, 5% FCS and 5mM NaNs). 
One well of cells was stained with lpl of tetramer at 37°C for 30 minutes.  Cells 
were pelleted by centrifugation at 1600 rpm for 3 minutes, washed once with 
staining buffer, and resuspended in the same buffer.  lOpl of mouse anti human 
CD3-PerCP  and  CD8-FITC  monoclonal  antibody  (Beckton  Dickinson)  was 
added to various wells to give a final staining of Tetramer, anti-CD3 and anti- 
CD8; anti-CD3 and anti-CD8;  anti-CD3 alone;  anti-CD8 alone;  and no staining 
(as a negative control).  The cells were incubated with the antibodies at 4°C for 
30 minutes and washed twice in staining buffer.  The cells were fixed with lOOpl 
RPMI  1640,  1%  formaldehyde  to  prevent  internalisation  of  antibodies  and 
tetramer.
Analysis of Tetramer-stained cells by flow cytometry
The  detectors  on  the  Becton  Dickinson  FACScan™  flow  cytometer  were  set 
using  the  unstained  fraction  of  cells.  The  fluorescence  detection  was 
compensated  with  the  samples  stained  with  single  fluorescently  labelled 
antibodies.  For  each  analysis,  200,000  cells  were  acquired  and  analysis  of 
tetramer  positive  cells  carried  out  on  CD8+   positive  cells,  which  were 
previously gated on CD3.
Formation of HA-1 specific CTL
In order to test the efficacy of the HLA-A*0201/HA-1H specific tetramers it was 
essential  to  have  a  positive  control,  in  the  order  of  an  HLA-A*0201/HA-1H 
specific  cell  line.  Antigen  presenting  cells  were  required,  in  the  order  of 
potential dendritic cells from an HLA-A*0201/HA-1H negative individual (HA-
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1R homozygous) which could be pulsed with HA-1H peptide and present the 
peptide to T cells of the same individual in an autologous manner.
Formation of potential dendritic cells
PBMCs were  obtained  from  the  peripheral  blood  of  A*0201/HA-1H  positive 
individuals as previously  described.  Potential  dendritic  cells were  generated 
following  a  protocol  described  in  a  current  study  being  undertaken  by  the 
European Union Concerted Action on Peptide Sensitisation (EUCAPS).  On day 
-7,  Twenty  million  cells  per  well  in  3ml  of  Ex-Vivo  medium  (BioWhittaker) 
were plated in a six well plate, and incubated for 2 hours at 37°C at 5% CO2.  All 
non-adherant  cells  were  removed  by  washing  and  retained  for  later  use  as 
responder  cells.  Cells  were  maintained  in  2.5ml  Ex-Vivo  medium  with  800 
U/ml GM-CSF (R&D Systems) and 500 U/ml IL-4 (R&D Systems).  On day -5, 
2.5  ml  Ex-Vivo  medium  with  1600  U/ml  GM-CSF  and  1000  U/ml  IL-4  was 
added.  On day  -3,  2.5ml  medium was  removed  and  replaced  with medium 
containing the same cytokine cocktail.  On day 0,  the potential  dendritic cells 
were harvested and resuspended by washing with Ex-Vivo medium.  It would 
have  been  ideal  to  have  tested  the  phenotype  of  these  cells,  however,  the 
number of cells available was insufficient to carry out this analysis.
T cell stimulation
The  potential  dendritic  cells  were  resuspended  in  1ml  Aim-V  medium 
(BioWhittaker)  and pulsed with 50pg/ ml HA-1H peptide overnight at 37°C in 
5%  CO2.  One millilitre of RPMI with 10%  autologous serum, lU /m l IL-2 and 
lU /m l IL-12, and 10 x 106 autologous PBMCs was added.  On day +5, lOU/ml 
IL-2 was added.  On day +7, autologous monocytes were procured from 10 x 
106 PBMC's layered for 2 hours, harvested and pulsed for 2 hours with peptide, 
then added to the culture.  This series of events was repeated until enough T 
lymphocyte-like cells were available for staining with tetramer.
114C hapter 2
Statistical analysis
Calculation of Kaplan-Meier Survival Curves
All survival data was calculated by the Kaplan-Meier method, using the SPSS™, 
version  10.0  (SPSS  Inc.,  Chicago,  IL,  USA)  statistical  analysis  program.  The 
equation used for this analysis was:
P[T > ti ]  =  ini=l [1 - di / ni]
Where P[T > U] is the probability of survival to a specific time, T.
Where iJT^i [1 - di /  ni] is the cumulative product of the conditional probabilities 
of survival at each time point.
Where d is the number of events which occur at a particular time point and n is 
the risk of these events occurring at that time point, t.
Basically,  the  equation is worked  out in stages.  Initially,  the  time  points  are 
calculated at which an event occurred and put in chronological order, with the 
number of events, and censored points occurring at this each time point.
The  number  of  patients  at  risk  of  the  event  occurring  at  that  time  point  is 
calculated by the total number of patients  (at the first time point at which an 
event  occurs)  minus  the  number  of  censored  patients  at  that  time  plus  the 
number of patients for which an event occurred.  The probable survival at each 
time point is then calculated by one minus the number of events  occurring at 
that  time  point  over  the  number  of  patients  calculated  to  be  at  risk.  The 
probable survival  is then added  in a  cumulative  manner and  plotted  against 
each time point to give a survival curve.  Confidence intervals were calculated 
at one year for most outcomes.
Significance Testing using the Log Rank Test
To test whether there was a significant difference between the variables tested 
and  transplant  outcome,  the  non-parametric  Log  Rank  Test  was  utilised.
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Ninety-five  percent confidence  intervals  were  used,  meaning  that  if  p  <0.05, 
there  was  a  significant  difference  on  outcome  between  the  variables.  Those 
calculations  involving  HLA  matching were  tested  in  a  pairwise  fashion  with 
HLA matched individuals.
Regression Model
The Cox proportional hazards model was used to determine the independent 
effects  of  factors  on  the  outcome  of  unrelated  bone  marrow  transplantation. 
This was calculated using the SPSS™, version 10.0 (SPSS Inc., Chicago, IL, USA) 
statistical analysis program.  The equation used was:
h(t)  =  A,o(£)exp{PiXi + p2x2 +.... + pnxn}
Where  Xi(t)  is  the  hazard  for  individual  i  at  time  t,  and  Xo(t)  is  an  arbitrary 
baseline hazard.
Where  x\  xn  are  the  variables  in  the  model  and  pi  pn  are  the
corresponding coefficients.
The relative hazard is assumed to be constant over time in this model and by 
measuring the covariant against log(time) it is possible to determine whether it 
has a significant effect on outcome.
Estimating sample size
Estimating sample size is important in the design of a study, and the quality of 
the estimate ultimately depends on the quality of the information used to derive 
it.  The information used in calculating the sample size should reflect as closely 
as possible the type of data that will be gathered from the study in question. 
Ideally, studies should be large enough to detect reliably the smallest possible 
differences in the primary outcome.  Sample size must be planned carefully to 
ensure that the research time, effort and support costs invested in any study are 
not wasted.
Power  increases  with  sample  size,  therefore,  a  larger  sample  has  a  greater
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ability than a small sample to detect a clinically important effect if it exists.  A 
balance is required between sample size and the factors that affect it.  In order 
to calculate the sample size required it is necessary to have an idea of the results 
expected  in  the  study.  The  larger  the  sample  size,  the  smaller  the  sampling 
error.
The statistical  null  hypothesis  (Ho)  is the  opposite  to  what you  believe  to be 
true.
Using statistical theory, it is necessary to show from the data collected that Ho is 
false and  should  be rejected.  This is know as  Reject Support testing, because 
rejecting the null hypothesis supports the findings.
Result agrees with Ho = correct acceptance 
Result disagrees with Ho = correct rejection
The type 1 error rate (a) must be <0.05 and Type 2 error rate must be <0.2 (p). 
Statistical  power  should  be  at  least  0.8  (1  -  Type  2  error  rate)  to  detect  a 
reasonable departure from the null hypothesis.  As will  be seen in  this study, 
the sample size was too low and the experiments carried out lack the precision 
to  provide  reliable  answers  to  some  the  questions  it  is  investigating.  The 
probability of accepting HO is 1-a.  The probability of incorrectly rejecting HO is 
p.  The probability of correctly rejecting Ho is 1-p.
State of the World
HO HI
Decision
Ho
Correct
Acceptance
Type II Error
p
H,
Type I error 
a
Correct
Rejection
The minimum information needed to calculate sample size for a study in which 
a specific event is being counted  includes the power,  the level  of significance, 
the underlying event rate in the population under investigation and the size of 
the effect sought.
The number of participants required in each intervention group, m, is given by:
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m = 2 x [z(i-a/2) + z(i-p)] 2 
A2
where z(i- a /2) and z(i- p) represent percentage points of the normal distribution 
for statistical significance level and power, respectively  (1.96 and 0.8416), and 
A represents the standardised  difference  (i.e.  the treatment difference  divided 
by its standard deviation) (Rosner, 1990;  Altman, 1990;  Juszczak, 2003)
The  power  of  a  study  is  its  ability  to  detect  a  true  difference  in  outcome 
between the standard or control group (eg. matched) and the group including 
the factor to be studied (eg. mismatched). This is usually chosen to be 80%. By 
definition, a study power set at 80% accepts a likelihood of one in five (that is, 
20%) of missing such a real difference.
The chosen level of significance sets the likelihood of detecting a variable effect 
when no effect exists (leading to a so-called  "false-positive" result) and defines 
the threshold "p value". Results with a p value above the threshold lead to the 
conclusion that an observed difference may be due to chance alone, while those 
with a p value below the threshold lead to rejecting chance and concluding that 
the factor has a real effect. The level of significance is most commonly set at 5% 
(that is, p = 0.05). This means the investigator is prepared to accept a 5% chance 
of erroneously reporting a significant effect.
The effect of the factor in the study can be expressed as an absolute difference. 
That is, the difference between the rate of the event (eg. death)  in the control 
group (eg. HLA matched) and the rate in the variable group (eg. HLA class I 
mismatched), or as a relative reduction, that is, the proportional change in the 
event rate with the variable. If the rate in the control group is 63% and the rate 
in  the  variable  group  is  42%,  the  absolute  difference  is  21%;  the  relative 
reduction with the variable is 21%/63%, or 33%.
118C hapter 2
Checklist for determining sample size for a definitive study
1.  Estimate  the  event  rate  in  the  control  group  by  extrapolating  from  a 
population similar to the population expected in the study.
2.  Determine, for the primary outcome, the smallest difference that will be 
of clinical importance.
3.  Determine the clinically justifiable power for the particular study (80%).
4.  Determine the significance level or probability of a "false positive" result 
that is scientifically acceptable (p = 0.05).
The  data  produced  in  this  pilot  study  may  be  used  in  a  sample  size  power 
calculation in order to estimate the number of samples required for definative 
studies.
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Chapter 3
Method Development
Introduction
In  order  to  detect  the  factors  that  affected  the  outcome  of  unrelated  bone 
marrow transplantation, a system was required for the collection, storage and 
processing of the samples.  Also, when using techniques for analysis of these 
samples, some modifications were required in order to obtain ultimate results. 
This  chapter  describes  some  of  the  problems  found  in  the  initiation  and 
progression of the study, and how they were overcome.
Sample Collection and Storage 
Project initiation
Blood  samples  were  collected  pre-  unrelated  donor  bone  marrow  transplant 
from transplant recipients and their unrelated donors.  It was established which 
transplant centres had carried out transplants using unrelated donors provided 
by the Anthony Nolan Bone Marrow Trust Register over the previous two years 
(1994  -1996),  by  studying  transplant  records  on  the  Anthony  Nolan  Bone 
Marrow  Trust  (ANBMT)  database.  The  Consultant  Haematologist  of  each 
Transplant Centre and Harvest Centre was contacted  (see Appendix  II, Letter 
1),  given  details  of  the  study  and  asked  whether  they  would  be  willing  to 
participate.  The Consultant was asked to nominate an internal contact that had 
direct  interaction  with  the  recipient  or  donor  and  was  able  to  take  a  blood 
sample, this was usually the Bone Marrow Transplant Co-ordinator.
A project proposal (see Appendix III), and copies of all letters, and forms, were 
approved by the Royal Postgraduate Medical School and Royal Free Hospital
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Ethics Committees. The responsibility lay with the transplant centre to explain 
the details of the study to the recipient. An Ethically Approved Consent Form, 
which gave a brief explanation to the patient was enclosed with each sample 
collection box  to be signed by  the  patient or donor  and  the  phlebotomist,  to 
verify informed consent (see Appendix IV).
Sample Collection
Collaboration  was  established  between  the  ANBMT  Operations  Department 
and  the  Research  Institute.  Details  of  transplants  between  donors  and 
recipients  resident  in  the  UK  were  then  routinely  forwarded  from  the 
Operations  Department  to  the  Research  Institute.  Blood  samples  were 
requested from the harvest centre by the Operations Department at the time of 
donor medical  examination,  usually  14  days before harvest.  Patient  samples 
were requested by letter from myself and obtained from the transplant centre 
when  the  patient  was  admitted  to  begin  their  pre-transplant  conditioning 
regimen.  Transport boxes with pre-paid return envelopes,  the relevant forms 
described,  and  blood  sample  collection  tubes  containing  anticoagulant  were 
sent with the sample request.
All blood samples were originally collected with Sodium-Heparin (10 units per 
ml  of  blood);  however,  it  was  discovered  that  the  cells  sent  by  post  in  this 
anticoagulant  had  a  poor  viability.  On  investigation  of  other  research 
organisations that had attempted sample collection by post, it was found that 
the  Imperial  Cancer  Research  Institute  had  seen  similar  problems,  and  had 
developed  a  more  suitable  transport  medium  (Marsh  1996).  Subsequently, 
blood  samples  were  collected  in  this  transport  medium  (Tri-sodium  citrate 
(0.6%)  in  RPMI  1640  (BioWhittaker),  with  0.5mM  (3-mercaptoethanol),  which 
was prepared at the Anthony Nolan Research Institute under sterile conditions. 
Use of this medium resulted in greater cell viability, although sample-to-sample 
variation was still inevitable.  To further avoid the deterioration of the sample 
during transit a courier system was  introduced  for those  hospitals  providing 
the most samples.
Samples collected with Heparin as an anticoagulant also gave poor quality PCR
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product,  due  to  the  inhibition  of  Taq  polymerase,  even  with  the  use  of 
Heparinase (Sigma) in the PCR, used to denature the Heparin.  Blood to be used 
for  DNA  extraction  was  subsequently  collected  in  EDTA  (1.6  mg  per  ml  of 
blood)  as  an  anticoagulant  which,  at  low  concentrations,  did  not  inhibit  Taq 
polymerase, and gave improved PCR results.
Establishment of the database of clinical information 
Data Collection and Storage
The  fields  created  in  the  Filemaker  Pro™  (FileMaker  Inc,  Santa  Clara,  CA 
database) reflected those of the Bone Marrow donor recruitment form (figure 
3-1),  the  transplant  form  (figure  3-2),  the  prescription  for  marrow  collection 
(figures 3-3, 3-4 and 3-5)  provided  to each transplant centre to follow up  the 
patients who had received a transplant from a donor provided by the Anthony 
Nolan Registry.  An example of the main database page for each transplant can 
be seen in figure 3-6.
Fields duplicated from the "Formal recruitment of a bone marrow donor" form 
(figure 3-1), included details about the patient's name, date of birth, transplant 
centre ID number, CMV status, blood group, weight, disease status (including 
diagnosis)  and  number  of days  conditioning.  Fields  were  also  made  for  the 
original HLA typing data of the patient and the donor (see figure 3-6).
Fields were made for details of the transplant centre and transplant coordinator 
contact  details  in  a  linked  database,  with  the  link  based  on  the  Transplant 
Centre field (figure 3-6).  A field was made for the result of any CTLp analysis 
carried  out,  but was  rarely  used  as  not  many  centres  requested  this  type  of 
analysis.
Fields duplicated from the transplant form (figure 3-2) included  donor name, 
donor  number  (from  the  Anthony  Nolan  register),  whether  the  donor  had 
previous  pregnancies,  live  births  or  blood  transfusions  and  the  harvest  date 
(figure 3-6).
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Figure 3-1. Bone marrow donor recruitment form.
PATIENT DATA:
THE ANTHONY NOLAN  BONE MARROW TRUST 
THE  ROYAL FREE HOSPITAL.   
 
 
FORMAL  RECRUITMENT OF A  BONE MARROW  DONOR
Patient name: Oaie of birth: Sex:
Patient  ID  t: Blood group: CMV:
Registry: Height: Weight  (kg):
(Diagnosis:
Serology  / 
DNA Typing:
B
Current disease status:
DR DR
DRB1
DR81
DRB 3/4/5 
ORB 3/4/5
DQB1
DQB1
DO  DQ
DPB1
DPB1
TRANSPLANT CENTRE:
Hospital: Contact  name:
Address: Fax no:
Phone no:
Preferred harvest  date:
Alternative dates:  (1) (2l
Number of days of  conditioning  prior  to transplant:
(Conditioning of patient should not be undertaken until the registry has confirmed the donor to be medically
fit and the results of all screening tests are known and have been reported to the transplant centre).
DONOR DATA:
Donor  ID#:  Typing date:
Serology  A A  B  B  C  C  DR  DR  DQ  DQ
DNA Typing:
A B C DRB1 DRB 3/4/5 DQB1 DPB1
A B C DRBl DR8 3/4/5 DQB1 DPB1
CELLULAR ASSAY RESULTS:
Signature: Date:
MLC  •  Not  performed: MLC  •  performed: GvH HvG RR  % Date:
CTLp HTLP Other
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Figure 3-2.  Transplant form.
TRANSPLANT FORM
DONOR PATIENT/DONEE:
Name: Reference A
Date of Birth: Reference B
Address: Diagnosis:
Tel. Day: Status (= coded age)
Tel. Home: Conditioning:
Donor No.
Occupation: Marrow Request:  As attached
Pregnancies: Live Births:
Previous Blood Transfusions:
Smoker:
GP:
Address:
Tel:
HARVEST CENTRE: TRANSPLANT CENTRE:
Doctor:
Hospital: Hospital.
Tel:
Date of Harvest: Invoice No.
Date of Admittance: Invoice Date:
Pick Up/Delivery Arrangements: 
To be advised
Signed:
Date:
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The  pages  of  the  database  that  contained  follow-up  information,  were 
duplicates of all the fields in the follow-up forms (figures 3-3 to 3-5).  Each form 
had a box linked to the main database page  (figure 3-6), which contained the 
survival status of the patient.  This allowed knowledge of whether the patient 
was alive or not without needing to scroll through each update sheet.
Extra  fields  were  added  to  the  main  database  page  in  order  to  track  the 
collection  of  samples  and  consent,  and  also  information  about  the  samples 
when they had been processed (figure 3-6).  Information regarding the weight 
of the  donor,  CMV status  and blood  type were collected  from records  at the 
Anthony Nolan Trust, or by approaching the harvest centre directly.
125FOLLOW-UP  OF  RECIPIENT  HAVING  RECEIVED  DONE  MARROW  FROM  AN  UNRELATED  DONOR  PROVIDED THROUGH
THE  ANTHONY  NOLAN  RESEARCH  CENTRE  (ANRC)
SIX  WEEKS POST TRANSPLANTATION
RECIPIENT  LAST  NAME: RECIPIENT  FIRST  NAME: ANRC  REF:
RECIPIENT  LOCAL  REF. TRANSPLANT  CENTRE: PHYSICIAN:
PRIMARY  DIAGNOSIS: TRANSPLANT  DATE:
DAY/MONTI I/YEAR
ANRC  DONOR  REF:
Please  provide  the  following  information:
1.  Is  the  recipient  alive? YES/NO  If DECEASED  please  stale:
(iii) contributory cause(s)  of death:  ...............................................................................
2.  What  was  the  disease  status  at  the  time
3.  Did  ihe  marrow  engraft? YES/NO  If YES,  please  give  date  of engraftincnt:
(3rd  day  of 3  consecutive  readings  of  NTS  >   0.5  x  10'VL)
DAY/MONTH/YEAR
4.  Has  the  recipient  received  a  further bone  marrow  transplant  or YES/NO  If  YES,  please  specify  source  of marrow  or
lymphocyte  infusion  (autologous or otherwise)? lymphocytes:  ..............
.  .  DATE:...........................
DAY/MONTH/YEAR
FORM  COMPLETED  BY DATE (DAY/MONTI 1/YEAR)
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Figure 3-4.  Patient update form -  3 months post transplant.
(page  I) FOLLOW-UP OF  RECIPIENT  HAVING  RECEIVED  BONE MARROW  FROM  AN  UNRELATED  DONOR  PROVIDED THROUGH 
THE  ANTHONY  NOLAN  RESEARCH  CENTRE (ANRC)
THREE MONTHS OR 100 DAYS POST TRANSPLANTATION
RECIPIENT  I ..AST  NAME: RECIPIENT  FIRST  NAME: ANRC  REF:
RECIPIENT  LOCAL  REF: TRANSPLANT  CENTRE: PHYSICIAN:
PRIMARY  DIAGNOSIS: TRANSPLANT  DATE:
DAY/MONTH/YEAR
ANRC  DONOR  REF:
’lease provide the following mlormation:
1.  Is  the recipient alive? YES/NO  If DECEASED  please stale:
(ii)  principal cause of d e a th :........................................................................
(iii) contributor)’ causc(s) o f death:  ..............................................................
2.  Please give brief details of conditioning: Chemotherapy:
Radiotherapy:  Dose of TBI  .  .
R a te ................
No.  of fractions
Additional:  (e.g.  Campath IgG or ATG)
If YES,  please  state: 3.  Was the bone marrow T-cell depleted? YES/NO
(i)  method    ...................................
(ii) approximate no.  of T-cells rcmovcd/Kg
4.  What post transplant immunosuppression was used?
(Pip: 2) THREE MONTHS OR  100 DAYS POST TRANSPLANTATION (continued)
5.  Did the marrow engraft? YES/NO  If YES,  please give date of engraftnicnt:
(3rd day of 3 consecutive readings of NTS  >  0.5  x  lO'/l.)
DAY/MONTH/YEAR
6.  Has recipient experienced recurrence of the original disease? YES/NO/NOT APPLICABLE  If YES,  please give date:
DAY/MONTH/YEAR
7.  Has the recipient experienced acute GvHD? YES/NO  If YES,  to what extent?  (pleaic grade aeeordiag u> uble)
8.  Has  the recipient experienced serious infections?
(e.g.  htcr&titinl pneumonia, Cerbral tox.oplaiincKis,  Invasive  fungal infection)
YES/NO  If YES,  please specify:  (and uEeihtr ongoing or rcKilvcd)
9.  i)  Is this the recipient’s first bone marrow transplant? YES/NO  If NO,  please specify:  ................................................
ii)  Has’ the recipient  received a  further bone marrow 
transplant or lymphocyte infusion?
YES/NO  If YES,  please  specify source of marrow or
lymphocytes (autologous or otherwise):  ...........
11.  Please state Kamofsky/Lansky rating:
12.  Is patient hospitalized? YES/NO  If out-patient please state date of patient's
Last v isit................................  Next v is it................
FORM  COMPLETED  BY 
(DAY/MONTH/YEAR)
DATE
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Figure 3-5. Patient update form -  6 months post transplant.
(|>«£c I) FOLLOW-UP OF  RECIPIENT  HAVING  RECEIVED  BONE  MARROW  FROM  AN  UNRELATED  DONOR  PROVIDED THROUGH 
THE ANTHONY  NOLAN  RESEARCH  CENTRE  (ANRC)
SIX MONTHS POST TRANSPLANTATION
RECIPIENT  I A ST  NAME: RECIPIENT  FIRST NAME: ANRC  REF:
RECIPIENT  LOCAL REE: TRANSPLANT  CENTRE: PHYSICIAN:
PRIMARY  DIAGNOSIS: TRANSPLANT  DATE:
DAY/MONT It/YEAX
ANRC  DONOR  REF:
Please provide the lollowing tnlormation:
|  I.  Is the recipient alive? YES/NO  If DECEASED  please  slate:
(iii) contributory causc(s) of death:  ............................................................1
2.  Has recipient experienced graft failure? YES/NO  If YES,  please  give dale:
DAY/MONTH/YEAR
3.  I his recipient relapsed? YES/NO/NOT APPLICABLE  If YES,  please give date:
DAY/MONTH/Y EAR
4.  Has the recipient experienced chronic 
GvHD?
____
(Page 2)
YES/NO  If YES,  to what extent?
SIX MONTHS POST TRANSPLANTATION (continued)
5.  Has recipient experienced any infections since the 3-month report?  YES/NO  If YES,  please specify:  (and whether ongoing or resolved)
6.  Has the recipient received a further bone marrow transplant or 
lymphocyte infusion (autologous or otherwise)?
YES/NO  If YES,  please specify source of marrow or 
lymphocytes:
DATE:
DAY/MONTH/YEAR
--------  -------— ■  ■
7.  Pleas.- state Kamofsky/Lansky  rating:
8.  Is patient hospitalized? YES/NO  If NO,  please state date of patient’s:
Last visit........................Next v is it.......................
FORM COMPLETED  BY D A TE.........................(DAY)MONTIPYEAR)
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Figure 3-6.  Main database page completed for each transplant.
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The  original  follow  up  form  was  sent  to  the  transplant  centre  6  weeks  post 
transplant (figure 3-3), and different forms sent at 3 months (figure 3-4) and 6 
months (figure 3-5) post transplant, then every following 6 months with similar 
forms.  Once the hard copy forms were returned, by fax or mail, the information 
provided  was  entered  into  the  relevant  fields  in  the  database.  It  was  soon 
found,  however,  that  the  information  given  on  these  forms  was  sometimes 
incomplete, and the consecutive forms did not always agree.  To this end, once 
RSCA analysis had been completed, a further single form that encompassed the 
information required for analysis, was sent to the transplant centres for the 138 
transplants to be included in this study (figure 3-7).  This form was created as a 
page  in  the  database  where  all  the  most  up  to  date  information  could  be 
accessed  without  having  to  look  at  many  different  pages.  From  the  fields 
present in the  main  database  page  (figure  3-6)  and  the  Clinical  data  request 
form (figure 3-7), data was extracted electronically into the computer program 
SPSS™, version 10.0 (SPSS Inc., Chicago, IL, USA) for statistical analysis.
The  clinical  data  request  form  was  a  page  made  in  the  database  to  try  and 
collect all the missing data required at the time of study close (figure 3-7).
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Figure 3-7. Clinical data request form.
THE ANTHONY NOLAN BONE MARROW TRUST
For the purpose of a research project, looking at molecular typing of donor-recipient 
pairs, being undertaken at the Anthony Nolan Bone Marrow Trust by Professor 
Alejandro Madrigal, the following information is needed.
Please fill in the blank spaces and return as soon as possible to:
Senior Lecturer in Haematology
Royal Free Hospital
Fax: 
p DNA number
Patient  name 
Hospital
Contact
Diagnosis
Radiotherapy  conditioning
Chemotherapy  conditioning
Date  of  engraftment  or  days  to  engraftment 
(day  neutrophils  >0.5)
Acute  GVHD
date  of  graft 
rejection
Chronic  GVHD 
and  extent
Grade
'  date  of 
relapse, 
molecular  and 
cytogenetic
Patient  number 
BMT  Date
Disease  stage
Additional  conditioning
T  cell  depletion  of  graft
details  of  infections
Is  recipient  alive? 
date  and  cause  of  death
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Methods used to validate and maintain quality of the data
The  clinical  data  collected  for  the  final  set  of  138  patients  was  manually 
validated  when  first  entered  into  the  FileMaker  Pro  database,  which  was 
possible as the data set was relatively small.  Data was deemed to be correct if 
the information was obtained in writing from the transplant centre.  A sanity 
check was carried out to ensure dates were consecutive, for example, birth date 
occurred before transplant date, and date of last follow up or relapse occurred 
after the transplant date.  Also, that the age of the donor was greater that 18 and 
any categorical data was coded correctly.  All  data manually entered into the 
database was checked by a second person.  Once the data was transferred into 
SPSS  for  analysis,  electronic  validation  was  carried  out,  some  examples  of 
which are described in table 3-1.
132Table 3-1.  Examples of electronic validation of data in SPSS database.
Field Definition Data Type Validation Rule
PATIENTID Unique patient number Number Must  be  a whole  number and UNIQUE  per patient forming  a 
primary KEY
DONORID Unique donor number Number Data Type set to number to ensure numeric values are entered
HARVEST Harvest Date Date/Time DateDiff("D",  [HARVEST],  [Date_DEAj >0,  this  explicitly 
ensures that the date within the HARVEST field is greater than 
that of the DATE  DEA.  The algorithm calculates the number 
of  days  for  HARVEST  and  DATE  DEA  and  ensures  that 
HARVEST  is  greater  than  that  of  the  DATE  DEA,  thus 
allowing valid entries.
DOBP Date of birth of patient Date/Time Where  (DOBP  >  18)  AND  (DOBP  <  HARVEST) 
Format([dobp], DDMMYYYY)
PATAGE Age of patient at transplant Number Data Type set to number to ensure numeric values  are entered. 
DateDiff("Y",[DOBP],[ HARVEST]) calculates the difference in 
years between DOBP and the bone marrow transplant date.
PAT <>27 If patient was greater or less than 
mean age at transplant
Number Populated  with  1  OR  0.  If  [PATAGE]  <=27  then 
[PATRANGE] = 0 Else [PATRANGE] = 1.
DOBD Date of birth of donor Date/Time Where [DOBD]  >=18 years before [HARVEST] AND [DOBD] 
< [HARVEST].
DONAGE Age of donor at transplant Number Data Type set to number to ensure numeric values  are entered. 
DateDiff  ("Y",[DOBD],[  HARVEST])  calculates  the  difference 
in years between DOBD and the bone marrow transplant date.
DON 0 3 6 If donor was greater or less than 
mean age at transplant
Number Populated  with  1  OR  0.  If  [DONAGE]  <=36  then 
[DONRANGE] = 0 Else [DONRANGE] = 1.
DATE_ENG Date of engraftment Date/Time Where  [DATE  ENG]  > [HARVEST] AND  [DATE  ENG]  < 
[DATE  DEA]1
3
4
Table 3-1 continued...
ENGRAFTD Number if days from BMT to 
engraftment
Number DateDiff("D",[HARVEST],[Date_ENG]) >0,  this  explicitly 
ensures  that the  date  within the  HARVEST field is  greater than 
that of the DATE  ENG.  The algorithm calculates the number of 
days  for  HARVEST  and  DATE  ENG  and  ensures  that 
HARVEST is greater than that of the DATE  ENG, thus allowing 
valid entries.
DATE_AGV Date of acute GvHD diagnosis Date/Time Where  [DATE  AGV]  >  [HARVEST]  AND 
DateDiffC'D",[HARVEST],[Date  AGV]) <=100
DAYS2AGV Days from BMT to acute GvHD 
diagnosis
Number DateDiff("D",[HARVEST],[Date_AGVj,  this  explicitly  ensures 
that the date within the HARVEST field is greater than that of the 
DATE  AGV.  The  algorithm  calculates  the  number  of  days 
difference between fields.
DATE_CGV Date of chronic GvHD diagnosis Number DateDiff("D",[HARVEST],[Date  CGV]),  this  explicitly  ensures 
that the date within the HARVEST field is greater than that of the 
DATE  CGV.  The  algorithm  calculates  the  number  of  days 
difference between fields.
DAYS2CGV Days from BMT to chronic GvHD 
diagnosis
Number Where  [DATE  CGV]  >  [HARVEST]  AND 
DateDiff(M D M ,[HARVEST],[Date  CGV]) >100
RELAPSE Date of relapse Date/Time Where  [RELAPSE]  >  [HARVEST]  AND  [RELAPSE]  < 
[DATE  DLI]
DAYS2REL Days from BMT to relapse Number DateDiff("D",[HARVEST],[RELAPSE])  determines  the  number 
of days to relapse.
DEATHSTA Is patient alive? Text List box created to ensure only values of; "0";’T"; where 0  = alive 
and 1 = dead; regarding patient status.
DATE  DEA Date of last follow up Date/Time Where [DATE  DEA]  > [HARVEST]
T1MEDEAT Days from BMT to last follow up Number DateDiff("D",[HARVEST],[DATE_DEA]) determines the 
number of days to follow up.C hapter 3
One of the main problems with collecting clinical data in this manner was that it 
required  the  transplant  clinician  to  have  instant  access  to  the  data, 
retrospectively.  As  most  transplant  centres  do  not  have  a  Data  Manager 
employed, to research this information would mean returning to the patient's 
notes, and some clinicians were not able to do this (even with repeated requests 
from Dr Mike Potter, Haematology Consultant at the Royal Free Hospital), as 
they  were  so  busy.  The  collection  of clinical  data  is  a  major  problem  in  all 
studies of this nature.  Due to these problems the information returned was still 
not as detailed as required from most transplant centres.  The ideal  situation 
would be if I could have gone to the centre and access the notes myself, but as I 
am not a  qualified  clinician,  I  was  not allowed  to  access  clinical  data  in this 
manner.  To  avoid  this  problem  in  the  future,  this  project  has  now  been 
undertaken  by  a  Haematology  Registrar  employed  at  the  Anthony  Nolan 
Research Institute.  However,  problems accessing clinical  data are ongoing as 
some transplant centres do not allow access to their patient files.
Experimental Method Development 
DNA extraction
Most of the analyses carried out during this project involved the use of genomic 
DNA extracted from donor and recipient whole blood samples.  Due to the high 
throughput of samples expected it was originally thought that too much time 
would be taken in using standard  methods,  and various DNA extraction kits 
were  employed.  Kits  used  were  advertised  to  give  high  yield,  good  quality 
DNA  from  whole  blood,  these  included  QIAmp  DNA  Blood  Mini  Kit™ 
(Qiagen)  and  Generation  Capture  Column™  (Flowgen).  Both  kits  used  a 
column  system  where  0.2ml  blood  sample  was  loaded  into  the  top  of  the 
column in a high salt solution which lysed cells and optimised binding of the 
nucleic  acids  to  the  matrix  in  the  column.  Washing  was  carried  out  with 
ethanol based solutions and then the sample eluted in sterile distilled water.
The DNA obtained from some patient samples using both kits was of low yield 
and  quality  (determined  by  optical  density  at  OD260  and  OD280,  Chapter  2),
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although experiments with fresh and frozen samples from healthy donors gave 
good quality results with a high yield.  The samples that gave the lowest quality 
DNA were those that had been in transit for more than 24 hours, which was 
unavoidable.  Experiments were carried out comparing extraction of the same 
samples with the kits and the long "salting-out" technique described in Chapter 
2 (Miller et al.  1988).  It was found that using the longer,  in house technique 
gave better results than either of the kits for problem samples.  This was due to 
the flexibility of the "salting-out"  technique, where the quality of the product 
can  be  assessed  after  every  stage  and  steps  taken  to  improve  quality.  For, 
example, during transit some of the red blood cells in the sample adhered to the 
mononuclear cells.  Using the kits, these residues were probably not removed as 
the white cell and red cell lysis occurred at the same time.  Using the "salting- 
out" technique, the red cell residues were removed thoroughly with lysis buffer 
(see Chapter 2) before the white cells were lysed, giving a cleaner product.  For 
samples  that  still  had  some  contamination  with  protein,  purification  was 
carried out using GFX columns (Pharmacia Biotech).
PCR troubleshooting
HLA class I  typing using RSCA required PCR amplification of genomic DNA 
extracted from donor and recipient blood samples.  The expected length of the 
PCR products were 979, 940 and 909 respectively.  During the development of 
the  RSCA  technique  we  had  used  HLA  class I  locus  specific  primers  for  the 
amplification of genomic DNA (Cereb et al. 1995), with great success.  The DNA 
used  in  the  standardisation  of  the  technique  was  extracted  from  many  B 
lymphocyte  cell  lines  provided  by  the  12th  International  Histocompatibility 
Workshop  of  the  World  Health  Organisation  (Marsh  et  al.  1998).  However, 
when the same amplification protocol was used with DNA extracted from the 
whole blood of recipients and  donors in this study,  the results were variable, 
even  though  the  DNA  was  of reasonable  quality.  Various  parameters  of the 
PCR were tested, including salt concentration, amount of dNTP and brand and 
quantity  of  Taq  polymerase.  But,  none  of  these  parameters  gave  consistently 
improved results for recipient and donor samples.  I studied the sequence of the
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primers used  in the HLA class  I  amplifications with the hope of lengthening 
one of the primers to improve annealing in the PCR reaction.  In the primers 
described (Cereb et al. 1995), specificity is dictated mainly by the sense primer, 
therefore, the antisense primer was chosen as a vehicle for the extra nucleotides 
to be added.  In order to maintain the promiscuity of the locus-specific primers, 
only  a  small  number  of  nucleotides  could  be  added,  without  specifically 
excluding some alleles (see figure 3-8).  The sequences of these primers can be 
seen in Appendix I.
137Figure 3-8.  Position  o f extended antisense  prim ers for  H LA class  I  PCR.  The antisense primers for the group specific PCR of HLA-A, -B and -C were extended at 
the 3’ end to aid annealing during the PCR reaction.  In this figure, the original primer position can be seen in yellow and the extension in pink.  Primer sequences are 
listed in Appendix I.
C o n se n su s
A *0101
A *2301
A *2901
A *3001
A *8001
C o n se n su s
B *0702
B *1302
B *40011
GTACCAGGGGCCACGGGGCGCCTCCCTGATCGCCTGTAGATCTCCCGGGCTGGCCTCCCACAAC GAGGGGAGACAAT T GGGAC CAACACTAGAATATCGCCCTCCCTCTGGTCCTGAGGGAGAGGAATCC
----------------------------------------- T--------------------------------------------------- -------- *-------A------------------- C----------------------------------
1  10  20  30
GTACCAGGGGCCACGGGG. CGCCTCCCTGATCI
------------------- AGT--------- A------------ CC---- 1
------------------- AGT--------- A-------T— CC----1
------------------- AGT--------- A-------G— CC---- 1
40  50  60  70  80  90  100  110  120  130
|G................TAGATCT. . . CCCGG. GCTGGCCTCCCACAAGGAGGGGAGACAATTGGGACCAACACTAGAATATCGC. CCTCCCTCTGGTCCTGA
|A .................— -G — G. .  . — G------ A------------------- G— A— A------GA— A--------- T --G -G ------------ G--------. ------------------------ ------
    G—G. . . G-G-------A------------------- G— A— A------GA— A---------T— G-G------------G--------.-----------------------------
    G—G.. .G-G------- A  G------------ G—A— A------GA— A--------- T— G-G------------G------- . -----------------------------
C o n se n su s
Cw*0102
Cw*0401
Cw*0701
10  20  30  40  50  60  70  80  90  100  110  120  130
TACCAGG^BCACGGGG. CGCCTCCCTGATCGCCTG................TAGATCT. . . CCCGG. GCTGGCCTCCCACAAGGAGGGGAGACAATTGGGACCAACACTAGAATATCGC. CCTCCCTCTGGTCCTGA
------------H aGT----------A----- T --C C ----- T - -C -........................   . . . ----- CA-------------------G----------------- G A --A------- T --G -G ------------------------. ----------- ------------ — -
------------L— AGT----------A----- T— CC  T— C-.................................. .  . -------------A--------------------G------------------G A --A-------- T— G-G-----------------------. -----------------------------
------------n GT----------A----- T— CC— T----- A ................................. . . -------------- A-------------------G----------------- GA— A------- T— G-------- G-----------------. ------------   —
W
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HA-1 Analysis
HA-1 is a peptide presented by HLA-A*0201 molecules and is a minor antigenic 
target in Graft versus Host Disease  (den Haan et al.  1998).  Sequence Specific 
PCR  was  carried  out  on  all  HLA-A*0201  positive  patients  and  their  HLA 
identical donors.  Three protocols were developed in order to type for the two 
alleles of HA-1.
Multiplex PCR analysis of HA-1
Firstly an in house method based on that described (Wilke et al. 1998).  Two sets 
of primers were available for the genomic  detection of the HA-1  alleles, both 
giving  PCR  products  of  different  sizes.  It  would  therefore  ultimately  be 
possible to carry out a multiplex PCR with each band being a positive control 
for  the  other.  First  experiments  were  carried  out  with  each  set  of  primers 
individually.  200-500ng of DNA was amplified in IX KC1 buffer (Qiagen), 1.25 
jd  each  primer,  ImM  each  dNTP,  1.25mM  MgCb  and  0.025  units  of  Taq 
polymerase (Qiagen).  PCRs were successful when using B-LCL DNA controls 
(see  figure  3-9),  but  found  not  to  be  reproducible  when  using  DNA  from 
individuals in the laboratory as controls.
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1   2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  L
400 bp 
200 bp
Figure 3-9.  Amplification of samples with  in  house HA-1  specific  primers.  Lanes  1,  5,  9 and  13
contain amplified DNA from B-LCL KAS011  (HA-1h, HA-1h), lanes 2, 6,  10 and  14 contain amplified 
DNA from B-LCL BTB (HA-1R , HA-1R) and lanes 3, 7,  11 and  15 contain amplified DNA from B-LCL 
AMALA (HA-1h, HA-1r).  Lanes 4, 8, 12 and 16 contain distilled water as a negative control.
HF + CR 
HA-1H 
specific 
5’ primer
CF + HR 
HA-1H 
specific 
3’ primer
RF + CR 
HA-1R 
specific 
5’ primer
CF + RR 
HA-1R 
specific 
3’ primer
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Detection of HA-1 with a restriction enzyme
The  second  protocol  employed  a  restriction  enzyme,  from  Chlorella  virus- 
infected green algae, CviRl (Megabase Research Products).  The restriction site 
for  the enzyme  (TGCA)  was  present  in the HA-1H  allele  and  not the HA-1R  
allele,  meaning  a  different  pattern  would  be  seen  depending  on  the 
combination of alleles present (see Figures 3-10 and 3-11).
Figure 3-10.  The use of CvlRl restriction enzyme for the detection of HA-1.  The CviRl restriction 
enzyme specific cutting motif is present in the sequence of the HA-1h allele, but not the HA-1R allele, 
therefore it was expected that the HA-1h allele would be cut and the HA-1R  allele would not.
CUT
HA-1H
^   GTGCTGCATGAGC 
HA-1R   ^  GTGTTGCGTGACG
TG v  CA 
AC  GT
X
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Figure 3-11.  Expected  cutting  pattern  of the CviRl restriction  enzyme when  generic  HA-1  PCR 
product was used as a target,  (a) cutting of the genomic DNA sequence and (b) the expected pattern 
seen when DNA homozygous for HA-1R  and HA-1h were cut and when a heterozygous sample was cut.
(a)
GTGCTGCCTCCTGG A C A CTGGGCCGG A GCCA CCGGA GCCCA CTGA C A 
GCCGCCA GCCCGGGCG A GCTGCCC A CCGA GGGTGCCGGCCCGG  A CGTC 
GTCGA GG  A C A TCTCCCA TCTGCTGGCGG A CGT GGCCCGCTTCGCT G A G 
GGCCTTG  A G A A A CTTA A GGA  gtgagagccacgggg
acaccgaggcctgggtggaagacagagccagacccaagggaggatggagggagggacttggggaggctcagaa 
gggagggaggctcagatggcagggagggctgtgtggaagaggccatgacagctaaggctctgagggatgtgtag 
gagtttggtgggggagtccctgagcgtcactggctcaagagggtgcccactttattttttttaaaggatctgatggcaa 
ttaggagggaaaB
(b)
R/R  H/H  H/R
487 bp - uncut PCR product
280 bp - second part of PCR product
173 bp - first part of PCR product
34 bp - final part of PCR product
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Generic  amplification  of  the  HA-1  alleles  utilised  generic  primers  capable  of 
amplifying both HA-1 alleles.  Two hundred nanograms of DNA was amplified 
with  IX  Qiagen  KC1  buffer,  12.5pmol  each  primer,  200pM  each  dNTP,  4mM 
MgCh and 0.75 units of Taq polymerase (Qiagen).  To confirm the presence of 
amplification  product,  3pl  from  each  25pl  PCR  reaction  was  run  on  a  1.5% 
agarose  gel  in IX TBE,  at 120 volts  for 45  minutes.  lOpl  PCR  product,  1.5pl 
enzyme buffer (lOmM Tris-HCl, 150mM KC1, lOmM MgCh, lOOpg/ml BSA, pH 
7.8) and 10 units of CviRl were incubated at 37°C for 4 hours and then loaded 
onto a 2% agarose gel and run at 150 volts for 45 minutes.  Although in theory, 
this  protocol  seemed  comprehensive,  in  practice  it  was  found  that  cutting 
efficiency of the enzyme was not 100% in our hands and it would therefore be 
difficult to detect a HA-1H homozygous sample.
Sequence specific PCR detection of HA-1
The final protocol utilised a kit developed by Olerup SSP™ (Robbins Scientific) 
containing  the  same  primers  previously  mentioned  (Wilke  et  al.  1998).  This 
method is described in Chapter 2.  As this method was shown to be the most 
robust of the three tested, it was utilised for all HA-1 typing performed in this 
study (see figure 3-12).
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Figure 3-12.  Sequence specific PCR of the HA-1  alleles.  Represented are a molecular size marker (L), 
a sample homozygous for HA-1h, a sample homozygous for HA-1R  and a heterozygous sample.
internal control bands
HA-1 specific band
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C h ap ter 4
The use of the database of clinical information to examine 
the effect of patient, donor and transplant variables on 
outcome
A  clinical  database  was  established  for  the  storage  of  patient  and  donor 
demographic  data  and  clinical  data  corresponding  to  the  transplant.  The 
database  was  designed  to  contain  data  to  be  used  for  the  analysis  of  the 
outcome  of  unrelated  transplants  performed  with  donors  from  the  Anthony 
Nolan Register.  Presented here is a primary analysis to demonstrate the type of 
statistical investigations that can be carried out with the data collected.  There 
are limitations to the conclusions that can be drawn from the data due to the 
small number of transplants involved (n = 138) and for this reason it can only be 
considered an exploratory analysis.
Transplant and sample details
The number of transplants carried out with Anthony Nolan donors for patients 
located in the UK over the study time period (8 June 1996 - 3 September 2000) 
was  608.  For  576  of  these  transplants,  information  was  entered  into  the 
database.  The remaining 32 transplants carried out were at transplant centers 
that had not yet agreed to  participate in the study  at the time that transplant 
was to take place, meaning a sample was not requested.  361 of the donors gave 
informed consent to participate in the study (see Appendix IV - Consent Form) 
and provided a 50ml blood sample at their medical examination before the bone 
marrow  harvest  (at  the  London  Clinic,  University  College  or  Royal  Free 
Hospital harvest centres - see Appendix V).  344 of the patients gave informed
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consent and provided a blood sample at a hospital visit prior to the start of their 
conditioning regimen.  All samples were processed, giving PBMCs, plasma and 
DNA for later analysis.  For 59 patients and 129 donors, blood  samples were 
provided with no Consent Form.  These samples were processed and the DNA, 
plasma and PBMCs stored with a view to obtaining consent at a later date.  If 
consent was not received, RSCA analysis was not carried out and the samples 
were not used in the study.  At the time of the analysis, both donor and patient 
had given informed consent and a blood sample for 235 transplants. Of these, 
138 were finally included in the study.  The number of transplants provided per 
transplant centre can be seen in table 4-1.
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Table 4-1.  The number of transplants, included in the study, carried out at each transplant centre.
Transplant Centre
Transplants recorded in 
database
Transplants used in 
study
Addenbrooke’s Hospital 4 0
Birmingham Children’s Hospital 18 3
Birmingham Heartlands Hospital 7 2
Bristol Royal Hospital for Sick Children 67 7
Christie’s Hospital 13 3
Glasgow Royal Hospital for Sick Children 8 3
Glasgow Royal Infirmary 10 5
Great Ormond Street Hospital 33 5
Hammersmith Hospital 67 50
]ohn Radcliffe Hospital 8 1
Kings College Hospital 31 4
Leicester Royal Infirmary 8 4
Manchester Royal Infirmary 13 5
Newcasde General Hospital 16 6
Nottingham City Hospital 40 6
Our Lady’s Hospital for Sick Children 2 0
Poole Hospital 1 1
Queen Elizabeth Hospital 9 1
Royal Bournemouth Hospital 1 0
Royal Free Hospital 22 3
Royal Liverpool Childrens Hospital 5 0
Royal Liverpool Hospital 13 2
Royal London Hospital 5 1
Royal Manchester Childrens Hospital 28 4
Royal Marsden Hospital 36 6
Royal Victoria In firman7 12 2
Sheffield Childrens Hospital 8 2
St Bartholemew’s Hospital 3 0
St George’s Hospital Medical School 4 0
St James’ University Hospital 22 3
University College Hospital 58 7
University7  Hospital of Wales 4 2
Total 576 138
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Reasons for attrition with respect to the study
The  main  reasons  for  sample  attrition  from  the  study  were  poor  quality  of 
patient DNA, and lack of clinical information.  DNA and cells collected at the 
beginning of the study were of poor quality, especially from whole blood that 
spent longer in transit due to the location of the transplant centre.  This led to a 
large amount of red and white cell lysis, giving poor quality of samples by the 
time they were processed.  Most patient samples were sent by first class mail, 
and could take up to 5 days, and be exposed to varying ambient temperatures 
depending on the time of year.  These cells showed poor viability, of <80% and 
the DNA extracted had a purity of <1.6 (as measured by the ratio of absorbance, 
OD260nm:OD280nm),  and  a  low  concentration,  making  it  difficult  to  amplify  for 
some  loci,  despite  attempts  at  purification  (as  described  previously).  These 
problems were overcome somewhat by the introduction of courier services to 
some  facilities  and  the  use  of transport medium  as  described  in  the  Method 
Development chapter.  Samples were processed for PBMCs, plasma and DNA, 
but RSCA analysis was not carried out on patient and donor samples collected 
after 26 November 1999 due to time constraints.
Only  those  samples  with  PCR  products  available  for  analysis  for  all  six  loci 
tested (HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1) were included in the study. 
For the 138 transplant pairs that had complete RSCA analysis, the Clinical data 
request  form  was  sent  out  to  the  transplant  centres  to  try  and  obtain  any 
missing follow-up data.  All data was considered valid when it was received in 
writing from the transplant center on the Clinical data request form (figure 3-8). 
Unfortunately, one of the main problems found during the study was that the 
transplant teams at many of the centres changed with time, and it might take 
one  or  two  rounds  of  follow-up  with  no  response  to  find  the  contact  had 
changed.  Many times, the study would have to be explained to the new study 
nurse or transplant coordinator and they were not always as familiar with the 
project  as  the  original  contact,  meaning  some  follow-up  data,  and  original 
details of the transplant were unavailable.  Despite persistent letters, telephone 
calls and faxes, patients had to be included with some clinical details missing.
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One of the biggest omissions was the actual date of the diagnosis of acute or 
chronic  GvHD.  Only  22  of  71  patients  with  acute  GvHD  and  37  of 55  with 
chronic GvHD had a date of diagnosis, therefore, analysis was carried out using 
binary logistic regression where acute or chronic GvHD either did or did not 
occur.  Thirty-one  patients  died  before  day  100,  and  4  patients  were  not 
followed up after 100 days and were therefore not available for chronic GvHD 
analysis.  Another omission that affected the analysis of the data was the CMV 
status  of  the  patient  and  the  donor.  Eighteen  donors  and  39  patients  were 
missing their CMV status.  When interaction term analysis was carried out to 
assess the effect of the donor and patient CMV status combined on the outcome 
of transplant, this limited the number of transplants that could be analysed to 
99.  As  data  was  being  collected  retrospectively,  information  such  as  CMV 
status may only have been available in the patient or donor notes, which may 
not  have  been  immediately  accessible.  The  8  patients  with  non-malignant 
disease were excluded from any evaluations involving disease relapse, as this 
was  not  relevant  to  their  condition.  In  another  twelve  patients,  the  date  of 
disease relapse was not given, and in these cases, the date of last follow-up was 
used as the relapse date and treated as unvalidated  data.  For one donor, the 
actual  date  of  birth  was  in  question;  there  was  a  difference  between  the 
information stored on the register and that provided by the harvest centre.  The 
age of the donor was >36 years in both cases so the data could be used although 
it was unvalidated.
Patient, donor and transplant characteristics
The patient and donor demographic information and transplants characteristics 
are listed in table 4-2.
149Table 4-2.  Demographics and transplant characteristics.
Total Match
(HLA-A, -B, -C, DRB1,  -DQB1 & -DPB1)
Class I mismatch only
(HLA-A, -B & -C)
Class II mismatch only
(HLA-DRB1  &  -DQB1)
Mismatch at class I and II
(HLA-A, -B or -C & HLA-DRB1,  or DQB1 )
Number of transplants 1 3 8 6 0 4 8 19 11
Disease
CML 7 2 3 3 2 2 1 0 7
AML 2 2 11 7 3 1
ALL 2 4 10 10 1 3
Other malignant disease 12 6 3 3 0
Other non-malignant disease 8 0 6 2 0
Age (donor/patient)
< = 3 6  years/<= 2 7  years 3 0 11 12 4 3
< = 3 6  years/>27 years 3 8 2 2 9 4 3
> 3 6  years/<= 27 years 3 2 9 13 7 3
> 3 6  years/> 2 7  years 3 8 18 14 4 2
CMV status# (donor/patient)
seronegative/seronegative 51 2 9 15 5 2
seronegative/seropositive 15 4 7 3 1
seropositive/seronegative 19 8 7 3 1
seropositive/seropositive 14 5 6 2 1
Gender (donor/patient)
male/male 6 0 2 6 2 2 10 2
male/female 31 13 11 6 1
female/male 2 5 9 11 2 3
female/female 2 2 12 4 1 5
T cell depletion
T cell depleted 101 4 7 3 5 14 5
T cell replete 3 7 13 13 5 6
#CMV status of 18 donors and 39 patients missingChapter 4
Patient's age ranged from 5 months to 52 years old  (mean 27 and median 29 
years)  and  donors  ranged  from  21  to  54  years  old  (mean 36  and  median  37 
years).  The mean of each group was used in the statistical analyses.  Seventy- 
two patients had CML, 65 in chronic phase, 4 in accelerated phase and 3 in blast 
crisis.  Twenty-two  patients  had  AML,  of  whom  7  were  in  first  complete 
remission (CR), 14 in second CR and  one transplanted with relapsed  disease. 
There were 24 patients with ALL, 4 in first CR, 17 in second CR, 2 in fourth CR 
and one with relapsed disease.  Twelve patients had other malignant diseases, 9 
with MDS, 2 with NHL and one with Myeloma.  Of the remaining 8 patients in 
the non-malignant disease group, 3 had SCID, 2 had Hyper IgM syndrome, 2 
had  Hurler  syndrome  and  one  had  Wiskott-Aldrich  syndrome.  All  HLA 
matching results presented were determined using RSCA.
The longest time to follow-up  was  1286  days,  with the  shortest time being 5 
days (median 217 days).  Data was available on 74% of patients after 100 days, 
59%  of  patients  after  200  days  and  43%  of  patients  after  1  year.  Nineteen 
percent of patients were followed up at 2 years and 3% at 3 years.
Sixty-nine  of the  138  patients  (50%)  were  alive  at  the  time  of  last  follow-up. 
Cause of death for each patient that died is listed in table 4-3.
Table 4-3. Cause of death of patients in the study
Cause Number of patients (%)
Regimen-related toxicity 3(2)
GvHD 6(4)
Organ failure 8(6)
Relapse 24 (17)
Infections 28 (20)
Statistical Analyses
Outcome variables investigated included overall survival, disease free survival, 
transplant  related  mortality,  relapse  incidence  and  occurrence  of  acute  and 
chronic GvHD.  Overall survival was determined as the survival  status of the 
patient,  where  death  was  considered  an  event,  and  if  the  patient  was  last 
known to be alive, the patient event was censored at the date of last follow-up.
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In the calculation of disease free survival, the patient was considered to have an 
event if they either had a relapse or they died.  All other patients were censored 
at the date that they were last known to be alive and disease-free.  Therefore, 
disease free survival was considered to be a combined endpoint, with both the 
time to relapse or death counting as events.
Transplant related mortality was defined as the occurrence of death as a result 
of the transplant procedure.  Patients that died from any cause except relapse 
were considered to have transplant related mortality.  Patients who died from 
relapse were censored at the date of death.  Causes of death are listed in table 
4-3.
A patient was considered to have relapsed if molecular or cytogenetic relapse 
was  diagnosed.  When  the  date  of  relapse  diagnosis  was  unknown,  it  was 
considered to have occurred at the date of last follow-up.  Patients who did not 
relapse were included until the date of final follow-up and then censored. 
Incidences  of  acute  and  chronic  GvHD  were  assessed  as  a  binary  outcome. 
Grade 0 or I acute GvHD were scored as negative (ie. that acute GvHD had not 
occurred) and  grades  >11  were scored as positive.  Any  occurrence of chronic 
GvHD  was  scored  as  positive,  independent  of  extent.  Overall  survival, 
leukaemia free survival, transplant related mortality and relapse incidence were 
calculated using standard survival methods, including Kaplan-Meier plots, log 
rank  test  and  Cox  proportional  hazards  regression.  Incidences  of  acute  and 
chronic  GvHD  were  assessed  using chi-squared  tests  and  logistics  regression 
models.  These  statistical  analyses  were  carried  out  using  the  computer 
program SPSS, version 10.0 (SPSS Inc., Chicago, IL, USA).
The  factors  included  in  the  analyses  were  as  follows;  type  of  disease,  donor 
CMV status, patient CMV status, donor age, patient age, donor gender, patient 
gender,  whether  transplant  was  T-cell  depleted  or  not  and  HLA  matching 
status.  Where  appropriate,  the  occurrence  of acute,  and  chronic  GvHD  were 
also included.  For these primary analyses, HLA-DPB1 matching was excluded 
to  provide  data  more  representative  of  the  majority  of  this  type  of  study. 
Analysis  of  HLA  matching  including  HLA-DP  was  investigated  and  will  be
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discussed  separately  in  the  next  chapter.  All  HLA  matching  data  was 
determined using RSCA.
Outcome analysis for all patients in the study
To  give  an  indication  of  the  overall  outcome  of  all  patients  included  in  the 
study, Kaplan Meier analysis was performed for each outcome variable.
Figure 4-1.  Probability o f overall survival in  all  patients.  A Kaplan-Meier plot showing 
percentage overall survival against time in days for all patients in the study (green, censored 
events in red).
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As  shown  in  table 4-3,  69  patients  died  during  the  course  of the  study.  As 
demonstrated in figure 4-1, the estimated probability of overall survival for all 
patients in the study at 1 year was 54% (95% Cl, 46-63%), at 2 years it was 47% 
(95% Cl, 37-56%) and at 3 years it was 43% (95% Cl, 33-54%).
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Figure 4-2. Probability o f disease free survival in all  patients.  A Kaplan-Meier plot showing 
percentage disease free survival against time in days for all patients in the study (green, 
censored events in red).
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Figure  4-2  shows  the  estimated  probability  of  disease  free  survival  for  all 
patients  at risk from disease  relapse  (n  =  130).  The  probability  of surviving 
without disease relapse at 1  year was 23%  (95%  Cl, 16-31%) and at 2 years it 
was 17% (95% Cl, 10-24%), with the final event occurred at 632 days.  Overall, 
105  of  130  patients  with  data  available  for  analysis  either  relapsed  or  died 
during the course of the study.
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Figure 4-3.  Probability of transplant related mortality of all patients.  A Kaplan-Meier plot 
showing cumulative incidence of transplant related mortality against time in days for all 
patients in the study (green, censored events in red).
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As shown in figure 4-3, the estimated probability of transplant related mortality 
at 1 year was 33% (95% Cl, 25-42%) and at 2 years it was 38% (95% Cl, 29-48%), 
with the final event occurring at 700 days.  The number of transplant related 
deaths totalled 45 (see table 4-3).
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Figure 4-4 shows the probability of relapse incidence for all patients at risk from 
recurring disease (n = 130).
Figure 4-4.  Probability of relapse incidence of all patients. A Kaplan-Meier plot showing cumulative 
incidence of relapse against time in days for all patients at risk of relapse in the study (green, censored 
events in red).
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The estimated probability of disease relapse in the study population was 64% 
(95% Cl, 54-74%) at 1 year and 71% (95% Cl, 62-81%) at 2 years (figure 4-4).  The 
final event occurred at 619 days.  Overall, 68 patients had disease relapse.
The total number of patients who developed grade II-IV acute GvHD was 71 
(51%).  Fifty-five (53%) of the 103 patients available for analysis after 100 days 
developed chronic GvHD.
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Analysis of the effect of patient, donor and transplant 
characteristics on outcome
As previously discussed in chapter 1, many factors can influence the outcome of 
unrelated bone marrow transplants.  In this pilot study the data collected in the 
clinical database was used to investigate the effect of some of the variables that 
prior studies have suggested a  possible  prognostic value,  on overall  survival, 
disease  free survival,  transplant related  mortality  and  relapse  incidence.  We 
also assessed the effect of these factors on the development of acute and chronic 
GvHD and whether the incidence of GvHD also had an effect on the outcome of 
transplant.
Graft versus host disease
Of the 71 patients with grade II-IV acute GvHD, 60 had grade II, 5 had grade III 
and  6 had  grade IV.  Of the  remaining 67 patients, 36  did not develop  acute 
GvHD  and  31  had  grade  I  acute  GvHD.  Uni  variable  and  multivariable 
analysis, using binary logistic regression, was carried out to assess the effect of 
the patient,  donor  and  transplant characteristics  in  the  development  of acute 
GvHD (table 4-4).
157Table 4-4.  Analysis of variables that may affect the development of acute GvHD.  Binary logistic regression was used in univariable and multivariable 
analysis to find which factors had an independent effect on acute GvHD.
Factor
Univariable Result Multivariable Result
Odds Ratio 95% Confidence Interval P Odds Ratio 95% Confidence Interval P
Disease CML 1.00 - 0.04 1.00 _ 0.53
AML 0.39 0.15  ,  1.04 0.55 0.14  ,  2.07
ALL 0.28 0.11  ,  0.75 0.28 0.06  ,  1.30
malignant 0.57 0.17  ,  1.93 0.44 0.09  ,  2.06
non-malignant 0.19 0.04  ,  1.00 0.37 0.03  ,  3.95
CMV status (donor/patient) seronegative/seronegative 1.00 -   )  - 0.10 1.00 -   (  - 0.10
seropositive/seropositive 0.21 0.05  ,  0.83 0.18 0.04  ,  0.83
seropositive/seronegative 0.68 0.24  ,  1.97 0.71 0.21  ,  2.45
seronegative/seropositive 1.52 0.45  ,  5.08 1.66 0.41  ,  6.79
Age (donor/patient) >36 years/> 27 years 1.00 - 0.79 1.00 -   t  - 0.50
<=36 years/<= 27 years 1.03 0.39  ,  2.68 2.12 0.39  ,  11.55
>36 years/<= 27 years 0.70 0.27  ,  1.80 1.22 0.25  ,  5.89
<=36 years/>27 years 1.11 0.45  ,  2.74 0.65 0.41  ,  6.79
Gender (donor/patient) male/male 1.00 _ 0.43 1.00 -   t  - 0.19
female/female 0.50 0.18  ,  1.37 0.26 0.06  ,  1.17
male/female 0.93 0.39  ,  2.22 0.83 0.22  ,  3.20
female/male 1.31 0.51  ,  3.39 1.81 0.42  ,  7.79
T cell depletion T-cell depletion 1.00 - 0.43 1.00 -  ,  - 0.10
no T-cell depletion 1.35 0.64  ,  2.88 3.38 0.80  ,  14.27
HLA-A,  -B,  -C, -DRB1, -DQB1  matching matched 1.00 - 0.62 1.00 -  ,  - 0.35
Class I   mismatch 0.64 0.30  ,  1.37 0.34 0.11  ,  1.12
Class II  mismatch 1.13 0.40  ,3.19 0.80 0.15  ,  4.25
Class I and II mismatch 1.22 0.27  ,  3.57 0.58 0.06  ,  5.86Chapter 4
In univariable  analysis,  disease was  the  only variable  significantly  associated 
with  the  development  of  acute  GvHD  at  the  5%  level  (p  =  0.04,  table  4-4). 
Compared  to  CML  patients,  those  with  AML  had  a  61%  reduced  odds  of 
developing acute GvHD  (Odds Ratio (OR)  = 0.39; 95%  Cl 0.15, 1.04).  Those 
with ALL had a 72%  reduced chance (OR = 0.28; 95% Cl 0.11, 0.75) and those 
with malignant disease had a 43% reduced chance (OR = 0.57; 95% Cl 0.17,1.93) 
compared with CML patients. Patients with non-malignant disease had an 81% 
reduced odds of developing acute GvHD (OR = 0.19; 95% Cl 0.04,1.00).  This 
relationship association became non-significant in the multivariable analysis (p 
= 0.53, table 4-4).
As  there was  some  evidence  of a  relationship  between  disease  type  and  the 
occurrence  of  acute  GvHD,  this  was  explored  further.  Table  4-5  shows  the 
percentage of patients who had acute GvHD according to disease type.  It can 
be seen that a higher percentage of those patients with CML developed acute 
GvHD (64%) compared with the other disease types.
Table 4-5. The effect of disease type on the development of acute GvHD.
Disease
CML AML ALL Malignant Non-malignant Total
no aGVHD 26 (36%) 13 (60%) 16 (67%) 6 (50%) 6 (75%) 67
aGVHD 46 (64%) 9 (40%) 8 (33%) 6 (50%) 2 (25%) 71
Total 72 22 24 12 8 138
159Table 4-6. Analysis of variables that may effect the development of chronic GvHD.  Binary logistic regression was used in univariable and multivariable 
analysis to find which factors had an independent effect on chronic GvHD.
Univariable Result Multivariable Result
Factor Odds Ratio 95% Confidence Interval P Odds Ratio 95% Confidence Interval P
Disease CML 1.00 0.08 1.00 "  »   " 0.32
AML 0.76 0.24  ,  2.35 0.85 0.16  ,  4.49
ALL 0.18 0.05  ,  0.63 0.24 0.03  ,  1.89
malignant 0.39 0.10  ,  1.56 0.64 0.11  ,  3.78
non-malignant 1.18 0.20  ,  7.01 5.59 0.30  ,  102.64
CMV status (donor/patient) seronegative/seronegative 1.00 j  " 0.05 1.00 0.04
seropositive/seropositive 0.31 0.07  ,  1.41 0.25 0.04  ,  1.52
seropositive/seronegative 0.15 0.04  ,  0.63 0.11 0.02  ,  0.55
seronegative/seropositive 0.49 0.12  ,  2.11 0.49 0.07  ,3.17
Age (donor/patient) >36 years/> 27 years 1.00 ”  t  “ 0.97 1.00 "  j  ~ 0.63
<=36 years/<= 27 years 1.15 0.39  ,  3.44 2.02 0.26  ,  15.74
>36 years/<= 27 years 0.92 0.30  ,  2.83 3.52 0.49  ,  25.30
<=36 years/>27 years 1.15 0.39  ,  3.44 2.14 0.43  ,  10.62
Gender (donor/patient) male/male 1.00 “  i  ~ 0.42 1.00 " "   j  “ 0.24
female/female 1.46 0.47  ,  4.58 1.97 0.39  ,  9.83
male/female 2.44 0.84  ,  7.06 6.37 1.06  ,  38.39
female/male 1.14 0.38  ,  3.37 1.72 0.29  ,  10.14
T cell depletion no T-cell depletion 1.00 ”  i  ” 0.07 1.00 0.68
T-cell depletion 0.41 0.16  ,  1.06 1.44 0.25  ,  8.27
HLA-A, -B, -C, -DRB1, -DQB1  matching matched 1.00 «  i  “ 0.35 1.00 "  »   " 0.69
Class I mismatch 0.71 0.30  ,  1.69 0.46 0.12  ,  1.80
Class II mismatch 2.19 0.60  ,  8.01 1.02 0.10  ,  10.38
Class I and II mismatch 1.75 0.29  ,  10.54 0.47 0.02  ,  12.15Chapter 4
In the analysis of variables associated with the development of chronic GvHD 
(table 4-6), the effect of patient and donor CMV status was significant at the 5% 
level (p = 0.046).  Compared with CMV seronegative patients transplanted with 
stem cells from seronegative donors, seropositive patients had a 51%  reduced 
odds  of  developing  chronic  GvHD  when  transplanted  with  stem  cells  from 
seronegative donors (OR = 0.49; 95%  Cl 0.12, 2.11), and a 69% reduced chance 
when transplanted with stem cells from seropositive donors (OR = 0.31; 95% Cl 
0.07,1.41).  Seronegative donors transplanted with stem calls from seropositive 
donors had an 85% reduced odds of developing chronic GvHD (OR = 0.15; 95% 
Cl 0.04, 0.63). Chi squared analysis (table 4-7) shows that 62%  of seronegative 
patients  transplanted  with  stem  cells  from  a  seronegative  donor  developed 
chronic GvHD,  whereas  all  the  other  combinations  of CMV status  of patient 
and donor had a higher percentage of patients without chronic GvHD.
Table 4-7.  The effect of CMV status of patient and donor on the development of chronic GvHD.
CMV status of donor and patient
+/+ +/- -/+ -/- Total
no cGVHD 6 (66%) 12 (80%) 5 (56%) 16 (38%) 39
cGVHD 3 (33%) 3 (20%) 4 (44%) 26 (62%) 36
Total 9 15 9 42 75
Table 4-6 shows that multivariable analysis confirmed that the CMV status of 
the donor and patient was independently associated with the development of 
chronic GvHD (p = 0.04), showing the same relationship as univariable analysis. 
The  analysis  was  repeated  to  include  acute  GvHD  as  a  factor  potentially 
affecting the development of chronic GvHD (table 4-8).
161Table 4-8. Analysis of variables that may effect the development of chronic GvHD, including acute GvHD.  Binary logistic regression was used in 
univariable and multivariable analysis to find which factors had an independent effect on chronic GvHD.
Factor
Univariable Result Multivariable Result
Odds Ratio 95% Confidence Interval P Odds Ratio 95% Confidence Interval P
Disease CML 1.00
_ 0.08 1.00 - - 0.49
AML 0.76 0.24 ,  2.35 0.84 0.14 ,  5.10
ALL 0.18 0.05 ,  0.63 0.57 0.06 ,  5.47
malignant 0.39 0.10 ,  1.56 1.02 0.14 ,  7.52
non-malignant 1.18 0.20 ,  7.01 11.27 0.44 ,  289.22
CMV status (donor/patient) seronegative/seronegative 1.00 - - 0.05 1.00 - - 0.08
seropositive/seropositive 0.31 0.07 ,  1.41 0.57 0.07 ,  4.55
seropositive/seronegative 0.15 0.04 ,  0.63 0.11 0.02 ,  0.58
seronegative/seropositive 0.49 0.12 ,  2.11 0.43 0.06 ,  3.30
Age (donor/patient) >36 years/> 27 years 1.00 - - 0.97 1.00 - - 0.72
<=36 years/<= 27 years 1.15 0.39 ,  3.44 1.55 0.16 ,  14.94
>36 years/<= 27 years 0.92 0.30 ,  2.83 2.47 0.31 ,  19.49
<=36 years/>27 years 1.15 0.39 ,  3.44 2.41 0.44 ,  13.09
Gender (donor/patient) male/male 1.00 _ 0.42 1.00 _ - 0.18
female/female 1.46 0.47 ,  4.58 3.05 0.49 ,  18.98
male/female 2.44 0.84 ,  7.06 8.42 1.18 ,  60.24
female/male 1.14 0.38 ,  3.37 1.68 0.25 ,  11.39
T cell depletion no T-cell depletion 1.00 - - 0.07 1.00 - - 0.74
T-cell depletion 0.41 0.16 ,  1.06 1.35 0.23 ,  8.14
HLA-A, -B, -C, -DRB1, -DQB1  matching matched 1.00 - - 0.35 1.00 - - 0.89
Class I mismatch 0.71 0.30 ,  1.69 0.60 0.13 ,  2.76
Class II mismatch 2.19 0.60 ,  8.01 1.15 0.10 ,  13.86
Class I  and I I  mismatch 1.75 0.29 ,  10.54 0.43 0.01 ,  13.48
GVHD no acute GvHD 1.00 - _ <0.01 1.00 - . 0.01
acute GVHD 3.73 1.65 ,  8.44 6.07 1.52 ,  24.23Chapter 4
When  the  analysis  was  repeated  to  include  acute  GvHD  as  a  variable 
potentially  affecting  the  development  of  chronic  GvHD,  the  development  of 
acute  GvHD  was  found  to  have  a  significant  effect  on  the  development  of 
chronic  GvHD  in  both  univariable  (p  =  <0.01)  and  multivariable  (p  =  0.01) 
analyses (table 4-8).  Univariable  analysis showed patients with acute GvHD 
had  an  increased  chance  of  developing  chronic  GvHD,  3.73  times  that  of  a 
patient  who  had  not  had  acute  GvHD  (OR  =  3.73;  95%  Cl  1.65,  8.44). 
Multivariable  analysis  showed  a  similar  relationship,  with  the  acute  GvHD 
patients having 6 times the risk of developing chronic GvHD compared with 
patients who did not have acute GvHD (OR = 6.07; 95%  Cl 1.52, 24.23).  No 
other variables analysed in were shown to be independently associated with the 
development  of  chronic  GvHD,  when  the  incidence  of  acute  GvHD  was 
included as a variable.
Overall survival
Univariable and multivariable analysis was carried out using Cox Regression to 
investigate the effect of all factors on the overall survival of the patients in the 
study (table 4-9).
In univariable analysis, disease type, CMV status of donor and patient and lack 
of  chronic  GvHD  were  the  factors  found  to  be  significantly  associated  with 
estimated reduced overall survival (p = 0.047, p = 0.04 and p = 0.01 respectively, 
table 4-9).
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Table 4-9. Analysis of variables that may affect overall survival.  Cox regression was used in univariable and multivariable analysis to find which factors
had an independent effect on overall survival.
Factor
Univariable Result Multivariable Result
Hazard Ratio 95% Confidence Interval P Hazard Ratio 95% Confidence Interval P
Disease CML 1.00 - _ 0.05 1.00 _ <0.01
AML 2.38 1.28 ,  4.41 10.03 2.84 ,  35.40
ALL 1.63 0.87 ,  3.05 0.14 0.01 ,  1.54
malignant 1.53 0.67 ,  3.50 3.51 0.76 ,  16.27
non-malignant 0.57 0.14 ,  2.38 0.00 0.00 ,  0.10
CMV status (donor/patient) seronegative/seronegative 1.00 - - 0.04 1.00 - - 0.88
seropositive/seropositive 2.39 1.16 ,  4.92 1.37 0.37 ,  5.04
seropositive/seronegative 1.26 0.60 ,  2.67 1.76 0.40 ,  7.69
seronegative/seropositive 2.32 1.10 ,  4.91 1.09 0.22 ,  5.39
Age (donor/patient) >36 years/> 27 years 1.00 - *   " 0.15 1.00 - - 0.61
<=36 years/<= 27 years 0.62 0.30 ,  1.29 1.00 0.18 ,  5.44
>36 years/<= 27 years 1.42 0.75 ,  2.66 2.45 0.59 ,  9.94
<=36 years/>27 years 0.95 0.49 ,  1.83 1.36 0.30 ,  6.14
Gender (donor/patient) male/male 1.00 - - 0.57 1.00 _ . 0.01
female/female 1.04 0.52 ,  2.09 7.51 1.86 ,  30.43
male/female 1.00 0.53 ,  1.90 0.35 0.09 ,  1.41
female/male 1.51 0.81 ,  2.80 0.56 0.11 .  2.83
T cell depletion no T-cell depletion 1.00 _ i  ” 0.08 1.00 - - 0.68
T-cell depletion 1.74 0.93 ,  3.25 1.47 0.23 ,  9.38
HLA-A, -B, -C, -DRB1, -DQB1 matching matched 1.00 _ - 0.18 1.00 _ . <0.01
Class I mismatch 1.53 0.88 ,  2.66 11.75 3.57 ,  38.66
Class II mismatch 1.51 0.74 ,  3.08 3.03 0.71 ,  13.01
Class I  and II mismatch 2.39 1.02 ,  5.57 650.61 31.27 ,  13535.93
GVHD no acute GvHD 1.00 - *   ” 0.54 1.00 - - 0.02
acute GVHD 1.16 0.72 ,  1.88 5.34 1.35 ,  21.10
no chronic GvHD 1.00 - - 0.01 1.00 - ,  - 0.01
chronic GvHD 0.40 0.20 ,  0.79 0.20 0.06 ,  0.70Chapter 4
A patient with AML was estimated to have more than twice the risk of dying as 
someone with CML (Hazard ratio  (HR)  = 2.38; 95%  Cl 1.28, 4.41), those with 
ALL or another malignant disease were estimated to have over a 50%  greater 
chance of dying (HR = 1.63; 95% Cl 0.87, 3.05 and HR = 1.53; 95% Cl 0.67, 3.50 
respectively)  Those  with  non-malignant  disease  had  a  43%  reduced  risk  of 
death compared with  CML patients (HR = 0.57; 95% Cl 0.14,2.38).
The estimated probability of overall survival at 1 year for AML patient, using 
Kaplan-Meier methods, was 25% (95% Cl, 6-44%), CML patients was 64% (95% 
Cl,  52-76%),  ALL  patients  50%  (95%  Cl,  30-70%),  patients  with  malignant 
disease 50%  (95% Cl, 22-78%) and those with non-malignant disease 75% (95% 
Cl, 45-100%).  The estimated probability of overall survival at 1 year for CML 
patients with acute  phase  disease was  25%  (95%  Cl,  0-67%), blast crisis  33% 
(95% Cl, 0-87%) and chronic phase 68% (95% Cl, 56-80%).
The CMV status of the patient and the donor was also found to be a significant 
factor associated with overall survival in univariable analysis  (p  = 0.04, table 
4-9).  CMV  seropositive  patients,  regardless  of  the  CMV  status  of  the  donor, 
were estimated to be over 2.3 times at risk of dying than seronegative patients 
with a seronegative  donor  (HR  =  2.39;  95%  Cl  1.16, 4.92 with a  seropositive 
donor  and  HR  =  2.32;  95%  Cl  1.10,  4.91  with  as  seronegative  donor).  CMV 
seronegative patients with a seropositive donor had a 26% greater risk of death 
than those with a seronegative donor (HR = 1.26; 95% Cl 0.60, 2.67).
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The estimated probability of overall survival at 1  year, calculated by Kaplan- 
Meier methods, for a CMV seropositive donor and patient, was 36%  (95%  Cl, 
11-61%), a seronegative patient with a seropositive donor was 47% (95% Cl, 25- 
70%), a seropositive patient with a seronegative donor was 30% (95% Cl, 5-55%) 
and a seronegative patient and donor was 62% (95% Cl, 48-75%).
When entered into a multivariable analysis model, disease (p = <0.01), gender 
of patient and donor (p = 0.01), HLA matching (p = <0.01) and the incidence of 
acute (p = 0.02) and chronic GvHD (p = 0.01) were shown to be independently 
associated with reduced overall survival (table 4-9).  A patient with AML had a 
risk of dying 10 times that of a CML patient (HR = 10.03; 95% Cl 2.84, 35.40), 
and a patient with malignant disease had 3.5 times the risk (HR = 3.51; 95% Cl 
0.76,16.27).  Those patients non-malignant disease had a greatly reduced risk of 
dying compared to those with CML (HR = 0.00; 95% Cl 0.00, 0.10 respectively). 
Interestingly,  ALL  patients  had  a  greater  risk  of  dying  compared  with CML 
patients in the univariable analysis (HR = 1.63; 95% Cl 0.87, 3.05; p = 0.05), but 
the multivariable analysis showed a reduced risk (HR = 0.14; 95% Cl 0.01,1.54). 
This may mean that other factors had more of an effect on overall survival than 
disease in this case.
Female patients transplanted with stem cells from female donors had 7.5 times 
the risk of death compared with male patients with male donors  (HR =  7.51; 
95% Cl 1.86, 30.43).  Female patients with male donors had a 65% reduced risk 
of  death  (HR  =  0.35;  95%  Cl  0.09,  1.41)  compared  to  male  patients.  Male 
patients with female donors had a 44% reduced risk of death compared to those 
with male donors (HR = 0.56; 95% Cl 0.11, 2.83).
Patients who were mismatched with their donor at one or more class I and class 
II loci were at a far greater risk of dying than those who were matched at all loci 
(HR = 650.61; 95% Cl 31.27,13535.93).  Those with a class I mismatch only were 
almost 12 times more at risk of death than matched patients (HR = 11.75; 95% 
Cl 3.57, 38.66).  A class II mismatch only led to a 3 times greater risk of dying 
compared to matched patients (HR = 3.03; 95% Cl 0.71,13.01).
Patients  who  developed  acute GvHD had  over 5  times  greater risk  of dying
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than those that did not develop acute GvHD (HR = 5.34; 95% Cl 1.35, 21.10). 
Disease free survival
Univariable and multivariable analysis was carried out using Cox Regression to 
investigate the effect of all variables on the disease free survival of the patients 
in the study (table 4-10).
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Table 4-10. Analysis of variables that may affect disease free survival.  Cox regression was used in univariable and multivariable analysis to find which
factors had an independent effect on disease free survival.
Factor
Uni  variable Result Multivariable Result
Hazard Ratio 95% Confidence Interval P Hazard Ratio 95% Confidence Interval P
Disease CML 1.00 - _ 0.07 1.00 _ . 0.001
AML 0.91 0.54 1.53 1.07 0.48 2.42
ALL 0.55 0.32 0.96 0.08 0.02 0.41
malignant 0.46 0.21 1.01 0.18 0.05 0.63
CMV status (donor/patient) seronegative/seronegative 1.00 - - 0.09 1.00 - . 0.23
seropositive/seropositive 1.52 0.79 2.93 0.91 0.35 2.34
seropositive/seronegative 0.96 0.49 1.88 1.01 0.38 2.69
seronegative/seropositive 2.18 1.12 4.22 3.45 1.01 11.73
Age (donor/patient) >36 years/> 27 years 1.00 - - 0.73 1.00 - - 0.38
<=36 years/<= 27 years 0.73 0.41 1.30 1.25 0.36 4.32
>36 years/<= 27 years 0.55 0.55 1.56 2.46 0.88 6.88
<=36 years/>27 years 0.59 0.59 1.61 1.31 0.52 3.28
Gender (donor/patient) male/male 1.00 . . 0.96 1.00 . . 0.02
female/female 0.91 0.51 1.61 2.07 0.66 6.51
male/female 0.92 0.56 1.50 0.42 0.17 1.02
female/male 1.05 0.62 1.79 0.31 0.12 0.81
T cell depletion no T-cell depletion 1.00 - . 0.71 1.00 - - 0.30
T-cell depletion 1.09 0.69 1.71 1.98 0.54 7.32
HLA-A, -B, -C, -DRB1, -DQB1  matching matched 1.00 . _ 0.01 1.00 . - <0.01
Class I  mismatch 1.77 1.14 2.77 5.22 2.28 11.97
Class II mismatch 1.19 0.65 2.17 1.11 0.38 3.24
Class I and II mismatch 2.78 1.41 5.47 59.23 7.97 439.99
GVHD no acute GvHD 1.00 . . 0.12 1.00 - - 0.19
acute GVHD 1.36 0.92 2.01 1.81 0.75 4.36
no chronic GvHD 1.00 - - 0.16 1.00 - - 0.91
chronic GvHD 1.40 0.87 2.23 1.05 0.47 2.32Chapter 4
HLA  matching  (for  HLA-A,  -B,  -C,  -DRB1  and  -DQB1  loci)  was  the  only 
variable in the model that was estimated to have a significant effect on disease 
free  survival  in  the  univariable  analysis  (p  =  0.01,  table  4-10).  A  patient 
transplanted  with  a  class  II  mismatch  only  was  estimated  to  have  a  19% 
increased risk of death or relapse compared to a patient who had a matched 
transplant (HR = 1.19; 95% Cl 0.65, 2.17), a patient transplanted with a class I 
mismatch only was estimated to have a 77% greater risk of death or relapse (HR 
= 1.77; 95% Cl 1.14, 2.77) and a patient transplanted with an HLA class I and a 
class II mismatch was estimated to be 2.8 times more likely to die or relapse (HR 
= 2.78; 95% Cl 1.41,5.47).
The estimated  probability  of  disease  free  survival  at 1  year,  calculated  using 
Kaplan-Meier methods,  for patients with HLA matched  transplants was 34% 
(95% Cl, 22-46%).  For HLA class II mismatched transplants it was 24% (95% Cl, 
3^44%), for HLA class I mismatched transplants was 14%  (95% Cl, 4-25%) and 
those with transplants mismatched at both a class I and a class II locus had all 
died or relapsed by one year (last event 287 days).
Multivariable  analysis  of  the  effect  of  the  different  factors  on  disease  free 
survival  showed  that  HLA  matching  was  independently  associated  with 
disease free survival (p = <0.01), as were the disease (p = <0.01) and gender of 
donor and recipient (p = 0.02, table 4-10).
Patient who were mismatched with their donor for both a class I and a class II 
locus  had  the  greatest risk  of  death  or  relapse  compared  with  patients  who 
were HLA matched with their donor (HR = 59.23; 95% Cl 7.97, 439.99), patients 
with a class I mismatch only had over 5 times the risk of death or relapse (HR = 
5.22; 95%  Cl 2.28, 11.97) and those with a class II mismatch only had an 11% 
increased risk (HR = 1.11; 95% Cl 0.38, 3.24).
Patients with AML had a similar risk of dying or relapse as those with CML 
(HR = 1.07; 95%  Cl 0.48, 2.42), patients with other malignant diseases had an 
82%  reduced risk compared with CML patients (HR = 0.18; 95%  Cl 0.05, 0.63) 
and ALL patients had a 92% reduced risk (HR = 0.08; 95% Cl 0.02, 0.41).
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Female patients with female donors had twice the risk of death or relapse when 
compared with male patients  transplanted with stem cells from male  donors 
(HR = 2.07; 95% Cl 0.66, 6.51).  Transplants with a gender mismatch seemed to 
do  better  than  those  that  were  of  the  same  sex,  female  patients  with  male 
donors had a 58% reduced risk of death or relapse (HR = 0.42; 95% Cl 0.17,1.02) 
compared to male patients with male  donors,  and male patients with female 
donors had a 69% reduced risk (HR = 0.31; 05% Cl 0.12,0.81).
Transplant related mortality
Univariable and multivariable analysis was carried out using Cox Regression to 
investigate the effect of all variables on the transplant related mortality of the 
patients in the study (table 4-11).
170Table 4-11. Analysis of variables that may affect transplant related mortality.  Cox regression was used in univariable and multivariable analysis to find 
which factors had an independent effect on transplant related mortality.
Univariable Result Multivariable Result
Factor Hazard Ratio 95% Confidence Interval P Hazard Ratio 95% Confidence Interval P
Disease CML 1.00 _ 0.11 1.00 "  »   * 0.07
AML 2.43 1.14  ,  5.15 12.91 1.98  ,  83.40
ALL 1.88 0.89  ,  3.98 1.04 0.04  ,  27.14
malignant 1.37 0.46  ,  4.05 6.68 0.82  ,  54.23
non-malignant 0.45 0.06  ,  3.38 0.00 0.00  ,  0.00
CMV status (donor/patient) seronegative/seronegative 1.00 -  _   - 0.05 1.00 ~   i  " 0.58
seropositive/seropositive 2.34 0.94  ,  5.82 1.70 0.26  ,  11.01
seropositive/seronegative 1.79 0.77  ,413 3.56 0.56  ,  22.59
seronegative/seropositive 3.08 1.33  ,  7.16 2.02 0.26  ,  15.83
Age (donor/patient) >36 years/> 27 years 1.00 "  »   " 0.61 1.00 "  »   “ 0.94
<=36 years/<= 27 years 0.61 0.25  ,  1.47 0.76 0.05  ,  10.78
>36 years/<= 27 years 1.10 0.50  ,  2.41 1.25 0.18  ,  8.47
<=36 years/>27 years 0.88 0.40  ,  1.94 1.47 0.19  ,  11.57
Gender (donor/patient) male/male 1.00 "  »   " 0.75 1.00 “  i  * * 0.56
female/female 0.90 0.36  ,  2.26 2.72 0.36  ,  20.61
male/female 0.58 0.58  ,  2.60 0.45 0.08  ,  2.53
female/male 0.66 0.66  ,  3.10 0.59 0.08  ,  8.54
T cell depletion no T-cell depletion 1.00 ”  t  * * 0.05 1.00 "  i  * 0.92
T-cell depletion 2.39 1.01  ,  5.65 1.15 0.07  ,  18.11
HLA-A, -B, -C, -DRB1, -DQB1 matching matched 1.00 ”  t  “ 0.39 1.00 "  i  * 0.01
Class I mismatch 1.43 0.72  ,  2.83 14.72 2.54  ,  85.31
Class II mismatch 1.44 0.59  ,  3.50 4.79 0.85  ,  27.07
Class I and II mismatch 2.34 0.85  ,  6.42 210.61 5.51  ,  8055.58
GVHD no acute GvHD 1.00 "  »   " 0.70 1.00 ”  i  * 0.01
acute GVHD 1.13 0.62  ,  2.01 9.47 1.69  ,  53.16
no chronic GvHD 1.00 "  »   ~ 0.08 1.00 *  i  * 0.08
chronic GvHD 0.42 0.19  ,  1.10 0.25 0.05  ,  1.19Chapter 4
Univariable analysis shows CMV status  (p  = 0.049) and T cell depletion (p  = 
0.047,  table  4-11)  were  associated  with  increased  risk  of  transplant  related 
mortality.  A  CMV  seropositive  patient  with  a  seronegative  donor  was 
estimated to be 3 times at risk of transplant related mortality as a seronegative 
patient  with  a  seronegative  donor  (HR  =  3.08;  95%  Cl  1.33,  7.16),  and  a 
seropositive patient with a seropositive donor was 2.3 times as likely to be at 
risk of transplant related mortality (HR = 2.34; 95% Cl 0.94, 5.82).
The  estimated  risk  of  transplant  related  mortality  at  1  year  for  a  CMV 
seropositive  donor  and  patient  was  46%  (95%  Cl,  19-73%),  a  seronegative 
patient with  a  seropositive  donor  was  48%  (95%  Cl,  25-71%),  a  seropositive 
patient with a seronegative donor was 60% (95% Cl, 35-85%) and a seronegative 
patient and donor was 27% (95% Cl, 14-40%).
Univariable analysis shows a patient with a T cell depleted transplant had a 2.4 
times greater estimated risk of transplant related mortality than a patient who 
received a T cell replete transplant (HR =  2.39; 95%  Cl  1.01, 5.65, table 4-11). 
Figure 4-5 shows the cumulative incidence of transplant related mortality for T 
cell replete transplants at 1 year was 9% (95% Cl, 0-18%) and for T cell depleted 
transplants it was 41% (95% Cl, 31-51%).
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Figure 4-5.  Kaplan-Meier analysis of the effect of T cell depletion on the risk of transplant related 
mortality.  The risk of transplant related mortality of a patient who underwent a T cell replete 
transplant (green, censored events in red), was compared with that of a patient who underwent 
a T cell depleted transplant (pink, censored events in blue).
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In  multivariable  analysis,  increased  risk  of  transplant  related  mortality  was 
closely associated with HLA matching of donor and patient (p = 0.01, table 4-8) 
and incidence of acute GvHD (p = 0.01).
The  greatest  risk  of  transplant  related  mortality  was  seen  for  patients 
mismatched with their donors at both an HLA class I and a class II locus.  These 
patients were estimated to have an increased risk of 210.6 times compared with 
patients who underwent an HLA matched transplant (HR = 210.61; 95% Cl 5.51, 
8055.58).  Patients with a class I mismatch only had a 14.7 times increased risk 
of transplant related mortality compared  with matched  patients  (HR =  14.72; 
95%  Cl 2.54, 85.31), and  patients with only a class II  mismatch had 4.8  times 
increased risk (HR = 4.79; 95% Cl 0.85, 27.07).
The  incidence  of acute GvHD  was  independently  associated  with  transplant 
related mortality, with a 9.5 times increased risk compared to patients who did 
not develop acute GvHD (HR 9.47; 95% Cl 1.69, 53.16).
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Relapse incidence
Univariable and multivariable analysis was carried out to investigate the effect 
of all variables on the incidence of relapse of the patients in the study (table 4- 
12).
174Table 4-12. Analysis of variables that may affect the incidence of disease relapse.  Cox regression was used in univariable and multivariable analysis to 
find which factors had an independent effect on relapse incidence.
Factor
Univariable Result Multivariable Result
Hazard Ratio 95% Confidence Interval P Hazard Ratio 95% Confidence Interval P
Disease CML 1.00 - <0.01 1.00 _ _ <0.01
AML 0.50 0.24 ,  1.06 0.58 0.21 1.56
ALL 0.24 0.10 ,  0.57 0.05 0.01 0.36
malignant 0.23 0.07 ,  0.74 0.04 0.01 0.38
CMV status (donor/patient) seronegative/seronegative 1.00 - i  " 0.56 1.00 - - 0.29
seropositive/seropositive 1.19 0.49 ,  2.91 0.84 0.28 2.54
seropositive/seronegative 0.52 0.18 ,  1.48 0.65 0.17 2.44
seronegative/seropositive 1.20 1.20 ,  3.47 3.41 0.81 14.28
Age (donor/patient) >36 years/> 27 years 1.00 - i  “ 0.84 1.00 - - 0.54
<=36 years/<= 27 years 0.87 0.43 ,  1.76 1.42 0.33 6.06
>36 years/<= 27 years 0.93 0.47 ,  1.83 2.50 0.73 8.57
<=36 years/>27 years 1.17 0.63 ,  2.18 1.25 0.43 3.59
Gender (donor/patient) male/male 1.00 . i  " 0.89 1.00 . _ 0.02
female/female 1.01 0.51 ,  1.97 3.05 0.88 10.54
male/female 0.85 0.46 ,  1.57 0.49 0.17 1.38
female/male 0.79 0.38 ,  1.61 0.28 0.09 0.92
T cell depletion no T-cell depletion 1.00 . 0.22 1.00 . - 0.45
T-cell depletion 0.73 0.44 ,  1.21 1.78 0.39 8.00
HLA-A, -B, -C, -DRB1, -DQB1 matching matched 1.00 . i  " 0.02 1.00 . <0.01
Class I mismatch 1.90 1.08 ,  3.34 3.33 1.30 8.52
Class II mismatch 1.50 0.74 ,  3.02 1.17 0.32 4.22
Class I and II mismatch 3.52 1.50 ,  8.27 68.00 6.07 761.88
GVHD no acute GvHD 1.00 _ »   " 0.08 1.00 - - 0.62
acute GVHD 1.56 0.95 ,  2.54 1.31 0.45 3.81
no chronic GvHD 1.00 - > 0.01 1.00 - - 0.72
chronic GvHD 2.02 1.16 ,  3.50 1.20 0.45 3.20Chapter 4
Table 4-12 shows that disease  (p  =  <0.01),  HLA matching  (p  =  0.02)  and  the 
presence of chronic GvHD  (p = 0.01) were associated with the risk of disease 
relapse.  Of the  68  patients  who  had  recurrence  of their  original  disease,  28 
received  a  donor  lymphocyte  infusion.  Univariable  analysis  showed  CML 
patients had the greatest estimated probability  of disease relapse  (table 4-12), 
twice that of AML patients (HR = 0.50; 95% Cl 0.24, 1.06).  Patients with ALL 
and those with other malignant diseases had a  >75%  reduced risk of relapse 
compared to CML patients (HR = 0.24; 95% Cl 0.10, 0.57 and HR = 0.23; 95% Cl 
0.07,0.74, respectively).
The  1  year  cumulative  incidence  of relapse  for  patients  with CML was  76% 
(95% Cl, 65-87%), AML was 70% (95% Cl, 42-98%), ALL was 39%  (95% Cl, 14- 
63%) and other malignant disease was 40% (95% Cl, 1-59%).  Two cases of acute 
phase CML and all 3 cases of CML in blast crisis relapsed within 6 months of 
transplant, and the cumulative incidence of relapse for CML in chronic phase at 
1 year was 75% (95% Cl, 63-87%, p = <0.01, data not shown).
Patients with an HLA class I and a class II mismatch had a 3.5 times greater risk 
of disease relapse compared to those matched with their donor for HLA-A, -B, 
-C, -DRB1  and  -DQB1  (HR  =  3.52;  95%  Cl  1.50,  8.27).  Those with a class  II 
mismatch only had a 50% greater risk of relapse (HR = 1.50; 95% Cl 0.74, 3.02) 
and a class I mismatch only meant the patient had a 1.9 times greater risk of 
relapse (HR = 1.9; 95% Cl 1.08,3.34).
The  1  year cumulative  incidence  of relapse,  as calculated with Kaplan-Meier 
methods, for patients transplanted with stem cells from an HLA matched donor 
was 51% (95% Cl, 36-65%), with a class I mismatch was 74%  (95% Cl, 57-91%), 
class II mismatch was 73% (95% Cl, 51-95%) and with a mismatch at HLA class I 
and class II was 81% (95% Cl, 49-100%, last event occurred at 287 days).
Patients who developed chronic GvHD were estimated to have twice the risk of 
relapse as those who did not have chronic GvHD (HR = 2.02; 95% Cl 1.16, 3.50). 
Figure  4-6  shows  the  effect  of  having  chronic  GvHD  on  the  cumulative 
incidence of relapse.
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Figure 4-6.  Kaplan-Meier analysis of the effect of developing chronic GvHD on  the risk of disease 
relapse.  The relapse incidence of patients who did not develop chronic GvHD (green, censored 
events in red) was compared with that for patients who had developed chronic GvHD (pink, 
censored events in blue).
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The  1  year  cumulative  incidence  of  relapse  was  46%  (95%  Cl,  29-63%)  for 
patients who had not developed chronic GvHD and 71%  (95% Cl, 54-88%) for 
patients who had developed chronic GvHD (figure 4-6).
Multivariate  analysis  shows  that  disease  (p  =  <0.01,  table  4-12),  gender 
matching between donor and patient (p = 0.02) and HLA matching (p = <0.01), 
were all independently associated with the risk of relapse.
AML patients had a 42% reduced risk of relapse compared with CML patients 
(HR  =  0.58;  95%  Cl  0.21,  1.56),  with  ALL  patients  and  those  with  other 
malignant diseases showing a 95% reduced risk of relapse (HR = 0.05; 95% Cl 
0.01, 0.36 and HR = 0.04; 95% Cl 0.01, 0.38 respectively).
Female  patients transplanted  with stem cells from female  donors  had  over 3 
times the risk of relapse compared with male patients transplanted from male
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donors (HR = 3.05; 95% Cl 0.88,10.54).  Female patients with male donors had a 
51% reduced risk (HR = 0.49; 95% Cl 0.17,1.38) and male patients with female 
donors had a 72% reduced risk (HR = 0.28; 95% Cl 0.09,0.92).
Patients mismatched with their donors at HLA class I and class II had 68 times 
the risk of relapse as those matched with their donors for the loci tested (HR = 
68.00; 95% Cl 6.07, 761.88).  Those with a class I mismatch showed 3 times the 
risk (HR = 3.33; 95% Cl 1.30, 8.52) and those with a class II mismatch had a 17% 
increased risk compared with matched patients (HR = 1.17; 95% Cl 0.32,4.22).
Discussion of the analysis of the effect of chosen factors on 
transplant outcome.
This  pilot  study  consisted  of  138  transplants,  a  small  number  compared  to 
similar studies usually carried out by bone marrow registries.  For example, a 
study  from  the  European  Group  for  Blood  and  Marrow  Transplantation 
examining different types of transplants and the effect of donor, recipient and 
transplant characteristics on outcome contained 1378 transplants (de Witte et al. 
2000a), a study looking at the significance of HLA compatibility from the Japan 
Marrow Donor Program included 1298 transplants (Morishima et al. 2002) and a 
study  of  factors  determining  long  term  survival  by  the  International  Bone 
Marrow Transplant Registry included 6691 transplants (Socie et al. 1999).
The analyses presented were carried out in order to give a model for the type of 
analysis that can be done on the data collected in this ongoing investigation. 
The results presented here could be used in sample size calculations to find the 
number  of transplants  required  to  give  a  definitive  study.  The  results  from 
larger  studies  may  then  be  used  in  the  attempt  to  improve  the  outcome  of 
unrelated  stem  cell  transplants  through  informed  donor  selection.  In  this 
section,  the  results  of  the  preliminary  analysis  are  discussed  and  it  is 
understood,  that  due  to  the  small  number  of transplants  studied,  some  data 
may be not be precise as determined by the wide confidence intervals presented 
in some cases.
HLA matching
HLA  matching  for  the  HLA-A,  -B,  -C,  -DRB1  and  -DQB1  loci  was
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independently  associated  with reduced  risk of relapse  (table 4-12),  increased 
disease free survival  (table 4-10),  reduced risk  of transplant related mortality 
(table 4-11)  and increased  overall survival  (table 4-9).  In all cases,  the worst 
outcome was associated with a mismatch at both class I and class II loci, which 
agrees with the results of a similar study by Petersdorf et al  (Petersdorf et al. 
1998), followed by a mismatch at class I only, which has also been cited as a risk 
factor for reduced survival (Sasazuki et al. 1998).  Patients matched for HLA-A, 
-B, -C, -DRB1 and -DQB1 had the least risk of all outcomes, also found in the 
study by Petersdorf (Petersdorf et al. 1998).  Interestingly, the mismatches found 
were not associated with the risk of developing acute and chronic GvHD in this 
study, whereas HLA mismatches are a known risk factor for the development 
of acute and chronic GvHD (Petersdorf et al. 1999; Sasazuki et al. 1998; Szydlo et 
al. 1997). As seen in the next chapter, many of the HLA mismatches seen were 
known  pre-transplant  and  this  may  have  affected  the  way  the  patient  and 
transplant were conditioned, to reduce a potential graft-versus-host response.
Disease
Disease  type  was  found  to  be  independently  associated  with  risk  of relapse 
(table 4-12),  disease free  survival  (table 4-10)  and  overall  survival  (table 4-9). 
CML  patients  had  the  greatest  risk  of  disease  relapse,  followed  by  AML 
patients.  However, AML patients had the greatest risk of dying from relapse as 
reflected  in  the  overall  survival  and  disease  free  survival  analyses.  AML 
patients were twice as likely to die as those with CML in univariable analysis, 
and ten times at risk when entered into the multivariable model. This may be 
due to 15 of the 22 AML patients being at a late stage of disease (2nd complete 
remission) or relapsed at the time of transplant, which has shown to result in 
reduced overall survival (Greinix et al. 2002).  This could also be due to CML 
patients being given a donor lymphocyte infusion to rescue them from disease 
relapse  (Bacigalupo  et  al.  1997;  Dazzi  et  al.  2000).  In  univariable  analysis, 
disease  was  associated  with  increased  risk  of  developing  acute  GvHD,  with 
CML patients having the greatest risk.
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Multivariable  analysis  was  carried  out  including  only  patients  with CML  in 
chronic phase, to correct for any influence of disease type or stage.  However, 
none of the analyses performed gave a significant result, most likely due to the 
small number of patients in the analysis (n = 65).
CMV status
CMV  status  of  the  patient  and  donor  was  only  found  to  be  associated  with 
outcome in univariable analyses and no independent association was seen.  The 
greatest risk of developing chronic GvHD was seen in the group where both 
donor  and  recipient  were  CMV  negative  (table  4-6).  In  other  studies,  a 
seronegative  donor  with  a  seronegative  patient  has  been  associated  with  a 
lower rate of chronic GvHD (Kollman et al. 2001).  In the groups where CMV 
was  present,  seropositive  patients  with  seronegative  donors  had  the  greatest 
risk  of  developing  chronic  GvHD,  followed  by  seropositive  patients  with 
seropositive  donors,  indicating  the  positive  CMV  status  of  the  patient  to  be 
more important with respect to the development of chronic GvHD compared 
with that of the donor.  CMV seropositive patients were twice as likely to die as 
seronegative patients, regardless of the CMV status of the donor.  A low level of 
overall survival of CMV positive patients,  independent of donor CMV status 
has  been  reported  (Broers  et  al.  2000),  thought  to  be  due  to  a  high  level  of 
transplant  related  mortality  in  these  patients.  More  recent  investigations, 
however,  indicate  a  CMV  seropositive  donor  may  be  beneficial  for  a  CMV 
seropositive patient in the hope of a transfer of specific immunity against CMV 
infection (Ljungman et al. 2003).
Age
Interestingly, although increased donor and recipient age have been shown to 
adversely  affect  outcome  in  various  registry  studies  (Greinix  et  al.  2002; 
Kollman et al. 2001; Remberger et al.  2002; Socie et al. 1999), age of donor and 
recipient did not appear to be a risk factor for any of the outcomes tested in this 
study.  This may have been because the cohort studied was relatively young 
(median patient age 29  years and median donor age 37 years).
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Gender
The  gender  of  the  donor  and  recipient  was  independently  associated  with 
relapse (table 4-12) and disease free survival (table 4-10).  Female patients with 
female donors had the greatest risk of relapse and the lowest risk of disease free 
survival followed by male patients with male donors.  This may be due to a lack 
of graft-versus-leukaemia response directed at the H-Y antigen (Gratwohl et al. 
2001).  The group with the lowest risk were male patients with female donors. 
As previously mentioned, it has been observed that female recipients of male 
bone marrow have a higher risk of graft rejection than when transplanted with 
bone marrow from a female donor (Voogt et al. 1990).  A similar effect has also 
been seen in the greater risk of developing GvHD in male recipients of female 
grafts  and  female  recipients  of  male  grafts  have  lower  disease  free  survival 
(Barrett et al. 1989).
T cell depletion
In univariable analysis, patients who received T cell depleted transplants had a 
greater risk of transplant related mortality than those who had a T cell replete 
transplant (table 4-11).  The greatest difference in cause of death between T cell 
depleted  and  T  cell  replete  transplant  groups  was  death  from  infection. 
Twenty-three  percent  of  patients  died  from  infection  in  the  T  cell  depleted 
group, compared with 8%  in the T cell replete group.  The three patients who 
died from regimen related  toxicity  were  all  in the T  cell  depleted  transplant 
group.  Due to delayed immune reconstitution seen after T cell depleted stem 
cell  transplantation,  patients  remain  susceptible  to  opportunistic  infections 
(Novitzky and Rouskova 2001).
GvHD
The  presence  of  acute  GvHD  was  independently  associated  with  reduced 
overall survival.  It was also associated with increased risk of transplant related 
mortality  (table  4-11)  in  univariable  analysis.  The  only  factor  to  be 
independently  associated  with  the  development  of  chronic  GvHD  was  the 
presence  of acute  GvHD  (table 4-8).  This  result was  expected  and  has  been 
shown in many larger  studies  of both related  and  unrelated  allogeneic  bone
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marrow transplants (Atkinson et al. 1990; Castro-Malaspina et al. 2002; Ochs et 
al. 1994; Remberger et al. 2002).
The  absence  of  chronic  GvHD  was  independently  associated  with  reduced 
overall survival (table 4-9), and in univariable analysis, the presence of chronic 
GvHD was associated with increase risk of disease relapse (table 4-12).  In other 
studies  it  has  been  shown  that  patients  with  chronic  GvHD  have  a  lower 
incidence  of  relapse  and  better  disease  free  survival  than  do  those  without 
chronic GvHD (Horowitz et al. 1990; Weiden et al. 1979).  However, the presence 
of  moderate  or  severe  chronic  GvHD  also  implies  an  increased 
immunosuppressive  state  leading  to  a  higher  risk  of  infection  and  reduced 
function  of  the  affected  organs  (Remberger  et  al.  2002).  In  our  study,  the 
presence of chronic GvHD was not significantly associated with better disease 
free survival and patients with chronic GvHD were twice as likely to relapse as 
those without (table 4-12), in univariable analysis.  One explanation could be 
that the immunosuppressive state mentioned may be affecting the graft versus 
leukaemia effect.  In conclusion, further study is required with larger numbers 
of patients to find if the effects seen here are true.
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Chapter 5
RSCA analysis and the effects of HLA allele compatibility
Reference  strand  mediated  conformation  analysis  was  used  to  identify  HLA 
allele mismatches between donor and patient for HLA-A, -B, -C, -DRB1, -DQB1 
and  -DPB1 in 138 bone marrow transplant pairs.  Any results discrepant with 
previously established methodologies were identified and the effects  of HLA 
compatibility for all six loci were analysed, focusing on the role of HLA-DPB1 
as a transplantation antigen.
RSCA analysis of all transplant pairs
DNA  samples  from  both  patient  and  donor  were  amplified  by  PCR  and 
subjected to RSCA  as  described  (Chapter 2).  Mismatches were  identified by 
running patient and donor separately in two lanes of the  gel and mixed in a 
third lane.  HLA types were assigned based on the position of the band in the 
gel, once alignment had been carried  out as described.  All HLA typing was 
carried out blind to the original typing results.  Results are shown in table 5-1.
183Table 5-1.  RSCA typing results.  Mismatches are highlighted in yellow, with turquoise for those homozygous versus heterozygous loci matched in a GvH direction.
HLA-A HLA-B HLA-C HLA-DRB1 HLA-DQB1 HLA-DPB1
Patient 5 2902 3001 1302 4501 0602 - 0401 0701 0301 0201/02 0 2 0 1 2 -
Donor 6 2902 3001 1302 4501 0602 - 0401 0701 0301 0201/02 0 4 0 1 1 701
Patient 15 0201/09 2402 4001 5701 0303/04 0602 0701 1302 03032 0604 0 4 0 1 0 3 0 1
Donor 16 0201/09 2402 4001 5701 0303/04 0602 0701 1302 03032 0604 0 4 0 1 0 2 0 1 2
Patient 17 0101 2402 0801 1501 0303 0701/05/06 0401 1501 0302 0602 1 1 0 1 1 4 6 0 1
Donor 18 0101 2402 0801 1501 0303 0701/05/06 0401 1501 0302 0602 1901 4 6 0 1
Patient 33 0101 0201/09 0702 - 0702 - 1302 1501 0602 0604 0 4 0 1 0 6 0 1
Donor 34 0101 0201/09 0702 - 0702 - 1302 1501 0602 0604 0 3 0 1 0 4 0 1
Patient 35 0205 - 1501 5001 0303/04 0602 0701 1301 0201/02 0603 1401 1301
Donor 36 0201/09 0205 1501 5001 0303/04 0602 0701 1301 0201/02 0603 0 4 0 2 0 3 0 1
Patient 37 3 3 0 1 3 0 0 1 1302 1402 0602 0802 0 1 0 1 1501 0501 0601 0 4 0 1 0 4 0 2
Donor 38 3 3 0 1 3 2 0 1 1302 1402 0602 0802 0 1 0 1 1 5 0 2 0501 0601 0 3 0 1 0 2 0 1 2
Patient 39 0 2 0 1 /0 9 0 2 0 5 27052 4001 0102 0302 0401 1501 0 3 0 1 0 6 0 1 0401 -
Donor 40 0 2 0 1 /0 9 - 27052 4001 0102 0302 0401 1501 0 3 0 2 0 6 0 1 0401 0301
Patient 43 0101 3001 0801 1302 0602 0701/05/06 0301 0701 0201/02 - 0 4 0 1 0 4 0 2
Donor 44 0101 3001 0801 1302 0602 0701/05/06 0301 0701 0201/02 - 0 4 0 1 1301
Patient 47 0101 - 0801 5701 0602 0701/05/06 0 3 0 1 0 7 0 1 0303 0201 0 4 0 1 1301
Donor 48 0101 - 0801 5701 0602 0701/05/06 0 3 0 2 0 7 0 1 0303 0201* 0 4 0 2 2 0 0 1
Patient 55 0101 2902 0801 4403 0701/05/06 1601/02 0301 0701 0201/02 - 0401 11011
Donor 56 0101 2902 0801 4403 0701/05/06 1601/02 0301 0701 0201/02 - 0401 11011
Patient 71 0201/09 2902 1401 44031 0802 0501 0701 - 0201/02 - 0 4 0 1 1 1 0 1 1
Donor 72 0201/09 2902 1401 44031 0802 0501 0701 - 0201/02 - 0 3 0 1 0 4 0 1
Patient 73 0201/09 0302 0702 1501 0 3 0 3 0 7 0 2 1101 1501 0301 0602 0401 -
Donor 74 0201/09 0302 0702 1501 0 2 0 2 0 7 0 2 1101 1501 0301 0602 02012 0401
Patient 75 0101 - 5701 - 0602 - 0701 - 0303 - 0401 -
Donor 76 0101 > 5701 - 0602 - 0701 - 0303 - 0401 -
Patient 79 2 9 0 2 6 8 0 1 44031 5201 1202 1501 0701 1502 0201 0601 0401 -
Donor 80 3 3 0 1 6 8 0 1 44032 5201 1202 1501 0701 1502 0201 0601 0401 1301
* unusual linkage - expect DRB1*0302-DQB 1*0402Table 5-1 continued.
HLA-A HLA-B HLA-C HLA-DRB1 HLA-DQB1 HLA-DPB1
Patient 87 0101 2601 0801 1401 0701/05/06 0802 0301 0701 0201/02 - 0 4 0 2 -
Donor 88 0101 2601 0801 1401 0701/05/06 0802 0301 0701 0201/02 - 0 1 0 1 1 0 2 0 1 2
Patient 89 0 1 0 1 0 2 0 1 /0 9 0702 0801 0701/05/06 0702 0301 0404 0201/02 0302/05 0 2 0 1 2 0 4 0 1
Donor 90 0 1 0 1 0 2 0 5 0702 0801 0701/05/06 0702 0301 0404 0201/02 0302/05 0 3 0 1 0 5 0 1
Patient 93 0 2 0 1 /0 9 2 4 0 2 0702 1501 0702 0304 0301 1102 0 2 0 1 /0 2 0 3 0 1 02012 -
Donor 94 0 2 0 1 /0 9 2 3 0 1 0702 1501 0702 0304 0301 1102 0 6 0 2 0 3 0 1 02012 0401
Patient 101 0201/09 1101 0801 52011 0701/05/06 1202 0301 1502 0 2 0 1 /0 2 0 6 0 1 11011 -
Donor 102 0201/09 1101 0801 52011 0701/05/06 1202 0301 1502 0 6 0 2 0 6 0 1 0401 11011
Patient 103 0301 2402 1501 3503 0303/4 0401 0 1 0 1 13 0 1 0501 0603 0 2 0 1 2 1 1 0 1 1
Donor 104 0301 2402 1501 3503 0303/4 0401 0 1 0 2 13 0 1 0501 0603 13 0 1 190 1
Patient 111 0102 2902 44031 5701 0602 1601 0701 - 0201/02 0303 1 1 0 1 1 2 3 0 1
Donor 112 0102 2902 44031 5701 0602 1601 0701 - 0201/02 0303 2 3 0 1 -
Patient 113 0 1 0 1 2 9 0 1 0801 1302 0602 0701/05/06 0301 1301 0201 0603 0 1 0 1 1 0 4 0 2
Donor 114 0 1 0 1 0 2 0 1 /0 9 0801 1302 0602 0701/05/06 0301 1301 0201 0603 0 4 0 2 -
Patient 117 0201/09 - 4001 4402 0302/04 0501 0101 0401 0301 0501 2 3 0 1 2 8 0 1
Donor 118 0201/09 - 4001 4402 0302/04 0501 0101 0401 0301 0501 2 3 0 1 -
Patient 119 0201/09 0301 0702 3502 0 4 0 1 0 7 0 2 0101 1101 0301 0501 0401 2301
Donor 120 0201/09 0301 0702 3502 0 4 0 1 1 5 0 5 0101 1101 0301 0501 0401 2301
Patient 123 0201/09 1101 0801 4402 0 2 0 2 # 0 7 0 2 0301 - 0201/02 - 0 4 0 1 2 3 0 1
Donor 124 0201/09 1101 0801 4402 0 5 0 1 0 7 0 2 0301 - 0201/02 - 0 1 0 1 1 1 1 0 1 1
Patient 125 0101 0201/09 1801 27052 0 2 0 1 2 0 7 0 1 /0 5 /0 6 0101 1301 0501 0603 13 0 1 3 8 0 1
Donor 126 0101 0201/09 1801 27052 0 2 0 1 2 1 2 0 3 0101 1301 0501 0603 1 7 0 2 2 3 0 1
Patient 131 0101 68012 0801 51011 0 7 0 1 /0 5 /0 6 1 4 0 2 0301 0701 0201/02 - 0 6 0 1 140 1
Donor 132 0101 68012 0801 51011 0 7 0 1 /0 5 /0 6 1 5 0 2 0301 0701 0201/02 - 0 4 0 1 1 1 0 1 1
Patient 133 0201/09 2501 1801 4402 0501 1202/03 03011 0401 0201 0301 0401 0402
Donor 134 0201/09 2501 1801 4402 0501 1202/03 03011 0401 0201 0301 0401 0402
Patient 135 0201/09 2402 1402 4402 0 2 0 2 0 5 0 1 0102 0401 0301 0501 0 4 0 1 0 9 0 1
Donor 136 0201/09 2402 1402 4402 0 5 0 1 0 8 0 2 /0 3 0102 0401 0301 0501 0 2 0 1 2 0 4 0 1
#unusual B-C association - expect B*4405 - Cw*0202Table 5-1 continued.
HLA-A HLA-B HLA-C HLA-DRB1 HLA-DQB1 HLA-DPB1
Patient 141 0201/09 1101 4402 5101 0302/04A 1502 0402 1301 0603 0302 0301 0401
Donor 142 0201/09 1101 4005 5101 0302/04 1502 0402 1301 0603 0302 0301 0401
Patient 143 0201/09 0301 0702 4402 0501 0702 0401 1501 0301 0602 0401 1401
Donor 144 0201/09 0301 0702 4402 0501 0702 0401 1501 0301 0602 0401 1901
Patient 153 0201/09 2402 0702 4402 0501 0702 1501 0901 03032 0602 0301 0401
Donor 154 0201/09 2402 0702 4402 0501 0702 1501 0901 03032 0602 0301 0401
Patient 155 2301 2402 0702 44031 0401 0702 0701 1501 0202 0602 0301 0401
Donor 156 2301 - 0702 44031 0401 0702 0701 1501 0202 0602 0401 02012
Patient 157 0201/09 - 0702 - 0702 - 0407 1501 0301 0602 02012 0401
Donor 158 0201/09 - 0702 - 0702 - 0407 1501 0301 0602 0401 -
Patient 163 2402 6901 1402 3508 0401 0802/03 0403 0701 0201/02 0302 02012 0401
Donor 164 2402 0201/09 1402 3508 0401 0802/03 0403 0701 0201/02 0302 02012 -
Patient 175 0201/09 3002 4402 1302 0501 0602 0701 - 0201/02 - 0401 -
Donor 176 0201/09 3001 4403£ 1302 0501 0602 0701 - 0201/02 - 0401 -
Patient 181 1101 - 0702 4402 0102 0702 0401/16 1501 0301 0602 0401 -
Donor 182 1101 - 0702 4402 0102 0702 0401/16 1501 0301 0602 0401 -
Patient 189 0201/09 68011 0802 1801 0701/05/06 - 0301 0404 0201/02 0302 0401 2801
Donor 190 0101 68012 0802 1801 0701/05/06 0501 0301 0404 0201/02 0302 0401 -
Patient 201 0101 0201/09 4402 3502 0401 0501 0101 1501 0501 0602 0401 0402
Donor 202 0101 0201/09 4402 3502 0401 0501 0101 1501 0501 0602 0401 0402
Patient 203 0101 0301 44031 5701 0602 1601 0701 - 03032 0201/02 01011 0301
Donor 204 0101 0301 44031 5701 0602 1601 0701 - 03032 0201/02 02012 -
Patient 207 0101 - 0801 - 0701/05/06 - 0701 - 0201/02 0303 01011 11011
Donor 208 0101 - 0801 - 0701/05/06 - 0701 0301 0201/02 0303 01011 01011
Patient 209 0201/09 2301 3801 4402 0501 1203 0401 1301 0301 0603 0401 2101
Donor 210 0201/09 2301 3801 4402 0501 1203 0401 1301 0301 0603 0401 2101
Patient 211 0101 0201/09 0702 0801 0701/05/06 0702 0101 0301 0201 0501 0401 -
Donor 212 0101 0201/09 0702 0801 0701/05/06 0702 0101 0301 0201 0501 01011 0601
Aunusual B-C association - expect B*4005 - Cw*0302  £unusual B-C association - expect B*4402 - Cw*0501Table 5-1 continued...
HLA-A HLA-B HLA-C HLA-DRB1 HLA-DQB1 HLA-DPB1
Patient 215 0201/09 - 0702 1501 0304 0702 0301 1501 0201/02 0602 1301 2001
Donor 216 0201/09 - 0702 1501 0304 0702 0301 1502' 0201/02 0602 0301 0401
Patient 217 0301 1101 0702 51011 0702 1502 0701 1501 0201/02 0602 02012 0401
Donor 218 0301 1101 0702 51011 0702 1502 0701 1501 0201/02 0602 0401 4601
Patient 221 0101 0201/09 1401 4001 0303/04 0801 0701 1302 0201/02 0604/08 0301 0401
Donor 222 0101 0201/09 1401 4001 0303/04 0801 0701 1302 0201/02 0604/08 0402 1401
Patient 223 0201/09 1101 3501 4402 0401 0501 0401 1301 0301 0603/07 0301 1501
Donor 224 0201/09 1101 3501 4402 0401 0501 0407 1301 0301 0603/07 0301 0901
Patient 233 0201/09 68011 3503 4001 0304 1203 0401 0801 0301 0402 0401 0901
Donor 234 0201/09 - 3503 4001 0304 0401 0401 0801 0301 0402 0401 02012
Patient 239 0102 0201/09 4402 5001 0501 0602 0401 0701 0202/02 0301 0301 0401
Donor 240 0101 0201/09 4402 5001 0501 0602 0401 0701 0202/02 0301 0301 0401
Patient 241 0102 2402 0801 44031 0701/05/06 0401 0701 0301/05 0201/02 - 0301 0401
Donor 242 0102 2402 0801 44031 0701/05/06 1601 0701 0301/05 0201/02 - 0401 0601
Patient 253 0201/09 2402/03 0702 39062 0702 0702 0404 0801 0302 0402 0401 1001
Donor 254 0201/09 2402/03 0702 39062 0702 0702 0404 0801 0302 0402 0402 -
Patient 257 0201/09 - 4402 4901 0501 0701/05/06 0103 0401/16 0301 - 0301 0401
Donor 258 0201/09 - 4402 4901 0501 0701/05/06 0101/04" 0401/16 0301 - 0401 -
Patient 259 0101 0301 0801 4001 0202 0701/05/06 0301 0701 0201/02 - 0301 02012
Donor 260 0101 0301 0801 4001 0302 0701/05/06 0301 0701 0201/02 - 02012 0401
Patient 263 0101 2501 4402 - 0501 - 0101 0401 0301 0501 0301 2001
Donor 264 0101 2501 4402 - 0501 - 0101 0401 0302 0501 0401 0401
Patient 267 2301 - 44031 4901 04011 0701/05/06 0701 1101 0201/02 0301 0301 0401
Donor 268 2301 - 44031 4901 16011 0701/05/06 0701 1101 0201/02 0301 0401 11011
Patient 269 0101 2902 0801 44031 0701/05/06 1601/02 0301 0701 0201/02 - 01011 0202
Donor 270 0101 2902 0801 44031 0701/05/06 1601/02 0301 0701 0201/02 - 0401 11011
Patient 273 2402 3201 3503/13 51012 0401 1601/02 1501 1101 0301 0602 0401 -
Donor 274 2402 3201 3503/13 51012 0401 1601/02 1501 1101 0301 0602 1401 1701
'Unusual DRB1  - DQB1  association - expect DRB1*1501 - DQB1*0602  "unusual DRB1-DQB1  association - expect DRB1*0101  - DQB1*0501Table 5-1 continued...
HLA-A HLA-B HLA-C HLA-DRB1 HLA-DQB1 HLA-DPB1
Patient 277 0101 0301 0702 5701 0602 0702 0701 1401 0301 03032 0202 0401
Donor 278 0101 0301 0702 5701 0602 0702 0701 1401 03032 05031 01011 1001
Patient 295 0301 3201 0702 44031 0501 0702 0101 1101 0301 0501 1701 2701
Donor 296 0301 3201 0702 44031 0501 0702 0101 1101 0301 0501 0401 1701
Patient 313 0201/09 - 1501 4001 0401 - 0101 0801 0401/02 0501 0401 0402
Donor 314 0201/09 - 1501 4001 0202 - 0101 0801 0401/02 0501 02012 02012
Patient 317 0201/09 - 1501 4402 0304 0501 0401 - 0301 0302 0401 2001
Donor 318 0201/09 - 1501 4402 0304 0501 0401 - 0301 0302 0401 02012
Patient 319 3001 6802 1302 1402 0602 0802/04 0701 1303 0201/02 0301 2101 1401
Donor 320 3001 6802 1302 1402 0602 0802/04 0701 1303 0201/02 0301 2101 1401
Patient 321 0201/09 - 1302 51011 0602 1502 0401 1101 0301 0302 0401 -
Donor 322 0201/09 - 1302 51011 0602 1502 0401 1101 0301 0302 0401 -
Patient 333 0201/09 2402 5101 3501 0401 02021 1101 1104 0301 - 0401 0402
Donor 334 0201/09 2402 5101 3501 0401 1502 1101 1104 0301 - 0401 -
Patient 337 0201/09 31012 4001 5001 0303 0602 0404 0701 0201/02 0302 0401 0601
Donor 338 0205 31012 4001 5001 0303 0602 0404 0701 0201/02 0302 0401 0601
Patient 341 0205 1101 0702 1501 0401 0702 0401 - 0301 0302 0401 -
Donor 342 0201/09 1101 0702 1501 0401 0702 0401 - 0301 0302 0401 2301
Patient 349 0101 2902 0801 44031 0701/05/06 1601 03011 0701 0201/02 - 0401 01011
Donor 350 0101 2902 0801 44031 0701/05/06 1601 03011 0701 0201/02 - 11011 01011
Patient 351 0201 2902 3501 44031 0401 0501 0701 1201 0201/02 0301 0401 0402
Donor 352 0201/09 2902 3503 44031 0401 0501 0701 1201 0201/02 0301 0401 11011
Patient 355 6801 0302 0703 44031 0702 1601 1501 0301 0201/02 0602 0401 -
Donor 356 6802 0302 0702 44031 0702 1601 1501 0301 0201/02 0602 0301 0401
Patient 365 0102 1101 0702 0801 0702 0701/05/06 1501 - 0602 0603 0401 -
Donor 366 0102 1101 0702 0801 0702 0701/05/06 1501 - 0602 - 0401 -
Patient 367 0101 0201/09 0801 4001 0302/04 0701/05/061/06 0301 1302 0201/02 0604/08 0301 0401
Donor 368 0101 0201/09 0801 4001 0302/04 0701/05/061/06 0301 1302 0201/02 0604/08 0301 0401Table 5-1 continued...
HLA-A HLA-B HLA-C HLA-DRB1 HLA-DQB1 HLA-DPB1
Patient 381 0205 0301 0801 5001 0602 0701/05/06 0701 0301 0201/02 0602 0401 02012
Donor 382 0205 0301 0801 5001 0602 0701/05/06 0701 0301 0202/02 - 01011 1701
Patient 385 2402 0201/09 0702 3501 0401 0702 0101 01021 0501 - 2801 -
Donor 386 2402 0201/09 0702 3501 0401 0702 0101 01021 0501 - 0401 2801
Patient 387 0101 6801 0702 3501 04011 0702 0401 1501 0302 0602 0402 02012
Donor 388 0101 6802 0702 3501 04011 0702 0401 1501 0301 0602 0401 -
Patient 389 2402 - 0702 1501 0303 0702 0101 1301 0501 0603 0402 3801
Donor 390 2402 - 0702 1501 0303 0602 0101 1301 0504 0603 0301 0401
Patient 393 2601 - 3503 3801 0401 1203 0402 - 0302 - 0401 -
Donor 394 2601 - 3503 3801 0401 1203 0402 - 0302 - 0401 -
Patient 407 0201/09 31012 4402 2705 0202 0501 0401 1301 0301 0603 0401 -
Donor 408 0201/09 31012 4402 2705 0202 0501 0401 1301 0301 0603 0401 -
Patient 411 0201/09 2902 1302 4501 0602 - 0401 1501 0301 0602 0401 0901
Donor 412 0201/09 2902 1302 4501 0602 - 0401 1501 0301 0602 0401 0601
Patient 427 0101 0201/09 0702 0801 0701/05/06 0702 0301 1501 0201/02 0602 0601 -
Donor 428 0101 0201/09 0702 0801 0701/05/06 0702 0301 1501 0201/02 0602 0401 -
Patient 447 0201/09 2402 2705 5001 0202 0602 0701 1101 0201/02 0301 02012 2701
Donor 448 0205 2402 2705 5001 0202 0602 0701 1101 0201/02 0301 02012 2701
Patient 449 0201/09 2901 0705 5701 0602 1502 0701 - 03032 0201/02 0601 1401
Donor 450 0201 2901 0705 5701 0602 1502 0701 - 03032 0201/02 0202 2801
Patient 455 0101 - 0801 5701 0602 0701/05/061/06 0301 0701 0201 0303 0401 1301
Donor 456 0101 - 0801 5701 0602 0701/05/061/06 0301 0701 0201 0303 0401 0301
Patient 475 0201/09 - 1501 4402 0304 0501 0401 1501 0302 0602 0401 -
Donor 476 0201/09 - 1501 4402 0304 0501 0401 1501 0302 0602 0401 -
Patient 509 0301 2601 0702 3801 0702 1203 1301 1501 0602 0603 0402 0401
Donor 510 0301 2601 0702 3801 0702 1203 1301 1501 0602 0603 0401 3801
Patient 519 68011 2402 0801 39062 0702 0701/05/06 0301 0401 0201/02 0301 0401 0402
Donor 520 68011 2501 0801 39013 0701/05/06 1203 0301 0401 0201/02 0301 0401 110111
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Table 5-1 continued...
HLA-A HLA-B HLA-C HLA-DRB 1 HLA-DQB1 HLA-DPB 1
Patient 535 1101 0302 0702 3501 0401 0704$ 1201 1501 0301 0601/02 0401 -
Donor 536 1101 0301 0702 3501 0401 0702 1201 1501 0301 0601/02 0401 1301
Patient 545 0101 - 0801 1501 0303 0701/05/06 0301 1301 0603 0201/02 0401 0402
Donor 546 0101 - 0801 1501 0303 0701/05/06 0301 1301 0603 0201/02 0401 01011
Patient 549 0101 - 0801 - 0701/05/06 - 0301 1201 0201 0603 0401 02012
Donor 550 0101 - 0801 - 0701/05/06 - 0301 1201 0201 0301 0401 1401
Patient 551 0301 - 0702 1801 0701/05/06/03 0702 09012 1501 0602 0303 0401 02012
Donor 552 0301 - 0702 1801 0701/05/06 0702 09012 1501 0602 0303 02012 -
Patient 557 0102 0301 0702 4402 0704 0702 0101 1501 0501 0602 0401 -
Donor 558 0102 0301 0702 4402 1602 0702 0101 1501 0501 0602 0402 0202
Patient 563 0101 0301 0702 3501 0401 0702 0101 0103 0301 0501 0401 0402
Donor 564 0101 0301 0702 3503 0401 0702 0101 0103 0301 0501 0401 0402
Patient 577 0101 0301 0801 1402 0701/05/06/06 0802 0301 1302 0609 0201 0401 0501
Donor 578 0101 - 0801 1402 0701/05/06/06 0802 0301 1302 0609 0201 0402 01011
Patient 579 0201/09 68011 1401 4402 0704 0802 0101/04 0701 0501 0201 0402 0202
Donor 580 0201/09 68011 1401 4402 0704 0802 0101/04 0701 0501 0201 0402 -
Patient 583 0201/09 0101 0801 0702 0701/05/06 0702 0301 1502'’ 0201/02 0602 0401 02012
Donor 584 0201/09 0101 0804 0702 0701/05/06 0702 0301 1501 0201/02 0602 0402 1401
Patient 585 0101 0301 27052 1401 0202 0802 1401 0701 0201/02 05031 0402 0301
Donor 586 0101 0301 27052 4001 0304 0102 1401 0701 0201/02 05031 0401 1501
Patient 589 2301 3301 44031 5801 0602 1601 0701 - 0201/02 - 0402 02012
Donor 590 2301 2902 44031 5802 0602 1601 0701 - 0201/02 - 1101 0402
Patient 619 0301 - 0702 3501 0401 0702 0101 0102 0504 0501 0401 0402
Donor 620 0301 - 0702 3501 0401 0702 0101 0102 0504 0501 0401 02012
Patient 637 0102 0201/09 4002 4402 0302/04 0501 0404 1101 0301 0302 0401 -
Donor 638 0102 0201/09 4002 4402 0302/04 0501 0404 1101 0301 0302 0401 1601
Patient 653 0301 3001 1302 3503 04011 0602 0701 07 0201 0303 0402 1701
Donor 654 0301 3001 1302 3503 04011 0602 0701 0701 0201 0303 0402 11011
$unusual B-C association - expect B*0702 - Cw*0702  '’Unusual DRB1 - DQB1 association - expect DRB1*1501  - DQB1*0602Table 5-1 continued.
HLA-A HLA-B HLA-C HLA-DRB 1 HLA-DQB1 HLA-DPB 1
Patient 667 0101 0201/09 0702 5701 0602 0702 0301 0701 0201/02 0303 0401 02012
Donor 668 0101 0201/09 0702 5701 0602 0702 0301 0701 0201/02 0303 0901 2301
Patient 681 0101 - 0801 - 0701/05/061 - 0301 - 0201/02 - 01011 -
Donor 682 0101 - 0801 - 0701/05/061 - 0301 - 0201/02 - 02012 -
Patient 687 0101 2402 0801 1801 0701/05/061/06 - 1104 0301/05 0201/02 0301 0401 0402
Donor 688 0101 2402 0801 1801 0701/05/061/06 - 1104 0301/05 0201/02 0301 11011 11011
Patient 1129 0201/09 - 4006 4402 0702 1203 0401 1501 0302 0602 0401 4601
Donor 1130 0201/09 - 4006 4402 0702 1203 0401 1501 0301 0602 0401 02012
Patient 1131 0201/09 - 0702 2705 0702 1203 1302 0405 0301 0604 0401 -
Donor 1132 0201/09 - 0702 4102 1701 - 1302 0404 0302 0604 0401 -
Patient 1133 0201/09 0301 0702 39062 0702 - 0101 1501 0501 0602 0401 0301
Donor 1134 0201/09 0301 0702 39062 0702 - 0101 1501 0501 0602 0401 0601
Patient 1135 0201/09 6802 51011 5301 04011 1502 1302 0403 0302 0604 0301 06011
Donor 1136 0201/09 6802 51011 5301 04011 1502 1302 0405 0302 0604 0401 0402
Patient 1137 0301 2501 0702 4402 0501 0702 1501 - 0602 - 0401 0402
Donor 1138 0301 2501 0702 4402 0501 0702 1501 - 0602 - 0401 -
Patient 1139 0101 2402 0702 0801 0701/05/061 0702 1501 0103 0501 0602 0401 -
Donor 1140 0101 2402 0702 0801 0701/05/061 0702 1501 0101 0501 0602 0401 -
Patient 1141 0102 - 4402 - 0501 - 0101 0404 0302 0501 0402 0301
Donor 1142 0102 - 4402 - 0501 - 0101 0404 0302 0501 0402 0301
Patient 1145 2501 2902 44031 1501 "0701/05/061 1601 0701 1401 0201/02 05031 0202 -
Donor 1146 2501 2902 44031 0801 0701/05/061 1601 0701 1401 0201/02 05031 0301 0501
Patient 1147 0201/09 6601 4102 5701 1701 0602 1303 1601 0301 0502 0401 1001
Donor 1148 0201/09 6601 4102 - 0501 - 1303 1601 0301 0502 0401 02012
Patient 1149 0101 2402 0801 4002 02022 0701/05/061 0301 0701 0201/02 - 11011 -
Donor 1150 0101 2402 0801 4002 02022 0701/05/061 0301 0701 0201/02 - 11011 0401
Patient 1151 0201/09 2601 0702 0801 0701/05/061 0702 0301 1501 0201/02 0602 0401 -
Donor 1152 0201/09 2601 0702 0801 0701/05/061 0702 0301 1501 0201/02 0602 0401 -
zunusual B -C  association - expect B*0801 - Cw*0701Table 5-1 continued.
HLA-A HLA-B HLA-C HLA-DRB 1 HLA-DQB1 HLA-DPB 1
Patient 1153 0101 31012 0801 1524 0302 0701/05/061 0403 1302 0302 0604 0401 0402
Donor 1154 0101 31012 0801 1501 0302 0701/05/061 0401 1302 0302 0604 0401 -
Patient 1155 0201/09 0301 0702 1402 0802 0702 0102 1501/2 0501 0601 0401 -
Donor 1156 0201/09 0301 0702 1402 0802 0702 0102 1501/2 0501 0601 0401 1901
Patient 1157 0201/09 0202 4402 5801 04011 0701/05/061 0401 0301 0201 0301 0401 0402
Donor 1158 0201 0202 4402 5801 0701/05/061 0302 0401 0301 0201 0301 0401 -
Patient 1159 0301 2301 0702 44031 04011 0702 0301 0701 0201/02 03032 0301 02012
Donor 1160 0301 2301 0702 4402 04011 0702 0301 0701 0201/02 03032 02012 1301
Patient 1161 2301 2902 1501 44031 0303 1601 1501/2 0701 0201/02 0602 0401 0301
Donor 1162 2301 2902 1501 44031 0304 04011 1501/2 0701 0201/02 0602 0401 0402
Patient 1163 0101 0201/09 0702 0801 0701/05/061 0702 0301 1501 0201/02 0602 0401 0501
Donor 1164 0101 0201/09 0702 0801 0701/05/061 0702 0301 1502 0201/02 0602 0401 0601
Patient 1165 0201/09 2402 0702 4402 0702 0501 1101 1401 0301 05031 0401 0402
Donor 1166 0201/09 2402 0702 44031 0702 1601 1101 1401 0301 05031 0202 -
Patient 1167 0201/09 2501 0801 5703 0701/05/061 - 0301 1303 0201 0301 0401 2001
Donor 1168 0201/09 2501 0801 5701 0701/05/061 - 0301 1303 0201 0301 01011 2801
Patient 1169 0201 0301 0702 4402 0501 0702 1501 - 0602 - 0401 -
Donor 1170 0201 0301 0702 4402 0501 0702 1501 - 0602 - 0401 0901
Patient 1171 1101 0101 0702 0801 0701/05/061 0702 0301 1501 0201/02 0602 1701 -
Donor 1172 1101 0101 0702 0801 0701/05/061 0702 0301 1501 0201/02 0602 0401 0301
Patient 1173 0201 31012 4402 - 0501 - 1501 1201 0301 0602 0401 -
Donor 1174 0201 31012 4402 - 0501 - 1501 1201 0301 0602 0401 0402
Patient 1175 0101 0301 0801 3505 04011 0701/05/061 0404 0301 0201 0302 0401 0601
Donor 1176 0101 0301 0801 4001 0304 0701/05/062 0404 0301 0201 0302 0301 02012
Patient 1177 0201 3201 15 52011 0303 12022 0401 1502 0302 0601 0401 0402
Donor 1178 0201 3201 1501 52011 04011 12022 0401 1502 0302 0601 0401 -
Patient 1179 2902 3301 44031 1402 0102 0701/05/061 0102 0701 0201/02 0501 0401 1401
Donor 1180a 0201 0301 4001 5601 0302/04 - 0102 0701 0201/02 0501 02012 1001
aRetrospective analysis indicates that this sample may not have been from donor 1180Table 5-1 continued...
HLA-A HLA-B HLA-C HLA-DRB 1 HLA-DQB1 HLA-DPB 1
Patient 1181 0201 - 0702 4402 0702 1601/2 0404 1301 0302 0603 02012 0601
Donor 1182 0201 - 0702 4402 0702 1601/2 0404 1301 0302 0603 0401 1902
Patient 1183 0301 3201 3501 52011 04011 12022 0407 1502 0301 0601 0402 0301
Donor 1184 0301 3201 3501 52011 04011 12022 0403 1502 0302 0601 0401 02012
Patient 1185 0101 1101 1801 52011 1203 12022 1502 0701 0201/02 0301 0401 02012
Donor 1186 0101 1101 1801 52011 12022 0202 1502 0701 0201/02 0301 0401 01011
Patient 1187 0101 2501 1801 3501 1203 0401 1101 - 0602 0301 0401 02012
Donor 1188 0101 2501 1801 3501 1203 0401 1104 - 0301 - 0401 02012
Patient 1189 1101 0302 27052 3501 0102 04011 0101 1101 0301 0501 0402 -
Donor 1190 1101 0301 27052 3501 0102 04011 0101 1101 0301 0501 02012 -
Patient 1191 0201 - 27052 1801 0501 0202 0101 - 0501 - 0401 -
Donor 1192 0201 - 27052 1801 0102 0701/05/061 0101 - 0501 - 0401 0601
Patient 1193 0201/09 3201 0702 1524 0701/05/061 - 0101 1202 0501 0301 0401 0601
Donor 1194 0201/09 - 0702 1501 0701/05/061 - 0101 1201 0501 0301 0402 -
Patient 1195 0201 3201 52011 5001 0602 12022 1104 0701 0201/02 0301 0401 -
Donor 1196 0201 3201 52011 5001 0501 12022 1101 0701 0201/02 0301 0402 02012
Patient 1197 0101 3301 2702 1402 0202 - 0102 0403 0302 0501 11011 0401
Donor 1198 0101 0205 27052 1402 0102 0802 0101 0403 0301 0504 01011 0601
Patient 1199 0101 0201/09 0801 - 0701/05/061 - 0301 - 0201/02 - 01011 0601
Donor 1200 0101 0201/09 0801 - 0701/05/061 - 0301 - 0201/02 - 0401 -
Patient 1201 1101 0201 1501 5501 0303 0304 0401 1401 0302 0503 0401 0301
Donor 1202 1101 0201 1501 5501 0303 0304 0401 1401 0302 0503 0401 -
Patient 1203 0101 - 0801 4001 0302 0701 0401 0301 0201/02 0302 02012 2301
Donor 1204 0101 0102 0801 4002 0302 0701 0401 0301 0201/02 0302 0401 -
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The total number of pairs with a mismatch for HLA-A was 27  (2 considered 
matched  in  the  GVHD  direction),  HLA-B  was  22  (with  no  mismatches 
considered matched in the GVH direction), HLA-C was 30 (with 1 considered 
matched  in  the  GVHD  direction),  HLA-DRB1  was  19  (with  1  considered 
matched  in  the  GVHD  direction),  HLA-DQB1  was  15  (with  no  mismatches 
considered matched in the GVH direction) and for HLA-DPB1,112 pairs had a 
mismatch (with 15 of these considered matched in the GVHD direction).
RSCA discrepant results
Where  HLA  typing  was  available  by  another  method,  the  results  were 
compared with those for RSCA.  Any difference in type can be seen in table 5-2.
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Table 5-2.  Comparison of RSCA assigned types with original typing
Sample Locus RSCA Typing Original Typing
1180 HLA-A 0201/09 29
189 HLA-A 0201/09 31
1198 HLA-A 0205 33
1180 HLA-A 0301 33
113 HLA-A 2901 2
1193 HLA-A 3201 2
1194 HLA-B 1501 63
1145 HLA-B 1501 8
1131 HLA-B 2705 41
1175 HLA-B 3505 60
1180 HLA-B 4001 44
1180 HLA-B 5601 65
1148 HLA-B 4402 57
233 HLA-C 1203 0401/02
104 HLA-DRB 1 0102 0101
257 HLA-DRB 1 0103 0101
48 HLA-DRB 1 0302 0301
224 HLA-DRB1 0407 04
223 HLA-DRB 1 0401 0407
207 HLA-DRB1 0701 0301
1187 HLA-DRB1 1101 1104
1188 II  LA-D  RBI 1104 1101
1193 HLA-DRB 1 1202 1203
38 HLA-DRB1 1502 1501
216 HLA-DRB 1 1502 1501
583 HLA-DRB1 1502 1501
1164 HLA-DRB 1 1502 1501
1183 HLA-D  RBI 1502 1501
1184 HI A-DRBI 1502 1501
277 HLA-DQB1 0301 5
1198 HLA-DQB1 0301 8
390 HLA-DQB1 0504 0501
94 HLA-DQB1 0602 0201/02
102 HLA-DQB1 0602 0201/02
381 HLA-DQB1 0602 2
1187 HLA-DQBl 0602 7
549 hla-d q bi 0603 0301
114 HLA-DQBl 0603 0602
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Mismatches  were  determined  by  running  the  donor  and  patient  samples  in 
adjacent  lanes  using  RSCA,  and  a  mixture  of  the  patient  and  donor 
hybridisation products in a third lane.  If an additional peak was seen in the 
third lane, the donor and recipient were mismatched at that HLA locus.  These 
mismatches were used for the analysis of outcome later and in chapter 4.
The positions of the peaks in the gel, after correction, were used to assign HLA 
types based on the values of known samples run before.  Cases where the RSCA 
type differed from the original typing can be seen in table 5-2. The HLA-A, -B, - 
DRB1  and -DQB1  type was available for all samples  (patient and donor, n = 
276), with the HLA-C type available for 53 samples from original typing.  The 
total  number  of allele  +  antigen  types  known for  all  loci  was  2314  (276  x  2 
alleles/antigens per locus for HLA-A, -B, -DRB1 and -DQB1  + 53 x 2 HLA-C 
alleles/antigens).  From table 5-2 it can be seen the number of alleles called by 
RSCA that were different from the original typing totalled 38.  Of the total, 1.6% 
of alleles typed were miscalled.
These differences would  ideally  have been investigated further using a third 
method, for example, a sequence based typing technique.  Unfortunately, as all 
the RSCA analysis was carried out in a blinded manner, any difference with the 
original type was only identified at the end of the study.  This meant that due to 
time constraints the additional analysis was not carried out.  This extra step has 
been  built  into  the  continuation  of  the  project  and  is  being  carried  out  in 
conjunction with the team continually developing the RSCA method.
The reason for these miscalls may have been that the peak seen was for an allele 
other than that called, but an example of that allele had not yet been run on 
RSCA  and  therefore,  not  assigned  a  value.  The  nearest  known  value  was 
assigned to the peak and used in table 5-1.  The RSCA method was validated, 
and the allele positions assigned using DNA samples from B-LCL samples that 
had been well classified in the 12th International Histocompatibility Workshop 
(Marsh et al. 1998).  The main difference seen between the B-LCL hybridisation 
products and those from donors and patients was the width of the RSCA peak. 
In some samples the RSCA peak was wider than had been seen previously and
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the tip of the peak had to be assigned manually, in order for the software to 
automatically allocate a numerical value. The manual assignment of peak tip 
position may have lead to a miss call of allele.
The  most common  example  of  RSCA  calling  a  different  type  to  the  original 
method was for DRB1*1502 where the original type had been called DRB1*1501. 
DRB1*1501  ran at position 1444.3  ± 0.2 with FLR DRB1*1001  and DRB1*1502 
ran at position 1433.7 ± 0.3.  DRB1*1501  ran at position 1542.4 ± 0.2 with FLR 
DRB1*08021 and DRB1*1502 ran at position 1529.8 ± 0.5.  From these values we 
can  assume  that  the  peak  for  DRB1*1501  cannot  easily  be  confused  with 
DRB1*1502.  This is especially clear in cases such as patient 1163  (DRB1*0301, 
1501)  with  donor  1164  (DRB1*0301,  1502),  where  both  a  DRB1*1501  and
DRB1*1502 are present,  as three  peaks were  present in the third lane  (figure 
5-1).
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Figure  5-1.  C artoon  exam ple  o f the  R SC A   trace  o f patient  1163  (D R B 1*0301,  1501)  with  donor 
1164  (D R B 1*0301,1502).  Lane 1   shows the RSCA trace for patient 1163, lane 2 shows the RSCA trace 
for donor 1164 and lane 3 shows the trace of the two hybridisation products mixed.  Peaks highlighted in 
blue represent the bottom and top markers used to align the gel with arbitrary values of 1000 and 2000 
respectively.
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Mismatches identified by RSCA
As  seen  in  figure  5-1,  a  mismatch  in  the  sequence  of  two  samples  is  easily 
identifiable  using  the  RSCA  method  and  mixing  the  patient  and  donor 
hybridisation products.  Because many of the samples studied had  only been 
HLA-typed  to  the  antigen  level,  it  was  possible  to  distinguish  allelic 
mismatches that were unknown at the time of transplant.  These are listed in
table 5-3.
Table 5-3.  Previously  unknow n  m ism atches identified  by  RSCA.
Locus Sample ID Method Allele/Antigen Locus Sample ID Method Allele/Antigen
Patient 39
Serology 2
Patient 175
Serology 44
HLA-A
RSCA 0205
HLA-B RSCA 4402
Donor 40
RSCA 0201
Donor 176
RSCA 4403
Serology 2 Serology 44
Patient 175
Serology 30
Patient 355
Serology 7
HLA-A
RSCA 3002
HLA-B RSCA 0703
Donor 176
RSCA 3001
Donor 356
RSCA 0702
Serology 30 Serology 7
Patient 337
Serology 2
Patient 1153
Serology 62
HLA-A RSCA 0201/09
HLA-B RSCA 1524
Donor 338
RSCA 0205
Donor 1154 RSCA 1501
Serology 0202/05 Serology 62
Patient 341
Serology 2
Patient 1159
Serology 44
HLA-A
RSCA 0205
HLA-B
RSCA 44031
Donor 342
RSCA 0201/09
Donor 1160 RSCA 4402
Serology 2 Serology 44
Patient 355
Serology 28
Patient 1165
Serology 44
HLA-A RSCA 6801
HLA-B RSCA 4402
Donor 356
RSCA 6802
Donor 1166 RSCA 44031
Serology 28 Serology 44
Patient 447
Serology 2
Patient 1167
Serology 57
HLA-A RSCA 0201/09
HLA-B RSCA 5703
Donor 448
RSCA 0205
Donor 1168 RSCA 5701
Serology 2 Serology 57
Patient 535
Serology 3
Patient 1177
Serology 62
HLA-A RSCA 0302
HLA-B RSCA 15
Donor 536 RSCA 0301
Donor 1178
RSCA 1501
Serology 3 Serology 62
Patient 1189
Serology 3
Patient 1193
Serology 62
HLA-A RSCA 0302
HLA-B RSCA 1524
Donor 1190 RSCA 0301
Donor 1194 RSCA 1501
Serology 3 Serology 62
Of the 138 donor/ patient sample pairs that were originally typed to the antigen 
level, 14 had allelic mismatches detected by RSCA.  Six pairs were mismatched
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for HLA-A, 6 for HLA-B and 2 for both HLA-A and HLA-B (table 5-3).
The  patient,  donor  and  transplant  characteristics  including  typing  for  HLA- 
DPB1  are  shown  in  table  5-4.  Once  HLA-DPB1  typing  was  included  in 
matching for HLA class I, the number of samples in the HLA matched group 
reduced from 60 to 15, and the number in the class I mismatch group from 40 to 
7 (tables 4-2 and 5-4).  Forty-five of the samples in the HLA-A, -B, -C, DRB1, - 
DQB1 matched group in the previous chapter had a mismatch for HLA-DPB1, 
meaning these transplants were now in the class II mismatch group.  Forty-one 
of the HLA-A, -B, -C matched transplants from the previous chapter had now 
moved to the class I and class II mismatch group as they had an HLA-DPB1 
mismatch.  As  both  the  matched  and  class  I  mismatch  groups  were  now 
relatively  small,  they  were  combined  into  a  single  group  for  the  statistical 
calculations in this chapter, in an attempt to increase the power of the analyses. 
The exclusion of those pairs with HLA-DP mismatches from this group resulted 
in  a  difference  in  the  distribution  of  disease  type,  meaning  the  HLA 
matched/class I mismatch group now contained no patients with ALL or other 
malignant disease, and only one patient with non-malignant disease.  Based on 
the results seen in the previous chapter, this may be likely to bias the analyses 
for this  group,  increasing the risk  of developing acute GvHD,  increasing the 
risk  of  reduced  overall  and  disease  free  survival  and  increasing  the  risk  of 
relapse.  Also,  no  seropositive  patients  who  received  stem  cells  from  a 
seronegative donor were now included in this group.  The exclusion of these 
patients may mean this group is biased towards an increased risk of developing 
chronic GvHD, but a reduced risk of transplant related mortality.  The effect of 
HLA matching, including HLA DPB1, on the development of acute and chronic 
GvHD, overall survival, disease free survival, transplant related mortality and 
relapse incidence was analysed by regression analysis to find if the inclusion for 
HLA-DPB1 matching made a difference to the effects seen with HLA matching 
excluding HLA-DP shown in the  previous chapter.  The factors  included  in 
multivariable  analyses  were  as  follows;  type  of  disease,  donor  CMV  status, 
patient  CMV  status,  donor  age,  patient  age,  donor  gender,  patient  gender,
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whether  transplant  was  T-cell  depleted  or  not,  the  occurrence  of  acute  and 
chronic GvHD and HLA matching status.
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Table 5-4.  Demographics and transplant characteristics, with HLA typing including HLA-DPB1
Total Match
(HLA-A, -B, -C, DRB1,  -DQB1  & -DPB1)
Class I mismatch only
(HLA-A, -B&-C)
Class II mismatch only
(HLA-DRB1,  -DQB1  & -DPB1)
Mismatch at class I and II
(HLA-A, -B or -C & HLA-DRB1,  -DQB1 or -DPB1)
Number of transplants 138 15 7 64 52
Disease
CML 72 13 4 30 25
AML 23 2 2 12 6
ALL 24 0 0 11 13
Other malignant disease 12 0 0 9 3
Other non-malignant disease 8 0 1 2 5
Age (donor/patient)
<=36 years/<= 27 years 30 1 1 14 14
<=36 years/>27 years 38 5 0 21 12
>36 years/<= 27 years 32 3 2 13 14
>36 years/> 27 years 38 6 4 16 12
CMV status# (donor/patient)
seronegative/seronegative 51 10 1 24 16
seronegative/seropositive 15 0 0 7 8
seropositive/seronegative 19 2 3 9 5
seropositive/seropositive 14 2 2 5 5
Gender (donor/patient)
male/male 60 6 3 30 21
male/female 31 2 1 17 11
female/male 25 4 2 7 12
female/female 22 3 1 10 8
T cell depletion
T cell depleted 101 12 5 49 35
T cell replete 37 3 2 15 17CHAPTER 5
Effect of HLA matching including HLA-DPB1 on transplant 
outcome
Univariable and multivariable analysis was carried out as described previously 
(Chapter  2),  with  any  HLA-DPB1  mismatches  included  with  all  other 
mismatches  for  HLA  class  II  (HLA-DRB1  and  -DQB1),  and  HLA  class  I 
mismatches  grouped  with  matched  transplants.  This  chapter  presents  the 
results for the HLA typing variable, as the association between the other factors 
and the outcome measures were presented in the previous section.  The effect of 
the  new  definition  of  HLA  matching  in  the  multivariable  models  did  not 
substantially alter the results shown in Chapter 4.
Graft versus host disease
Univariable  and  multivariable  analysis,  using  binary  logistic  regression,  was 
carried  out to  assess  the  effect  of  HLA  matching for HLA-A,  -B,  -C,  -DRB1, 
-DQB1 and -DPB1 on the development of acute GvHD (table 5-5).
As can be  seen in table  5-5,  HLA  matching for  all  loci  was  not  significantly 
associated with the development of acute GvHD in univariable or multivariable 
analysis.  Although  there  was  no  significant  relationship  between  HLA 
matching and  acute GvHD,  after adjusting for  other factors,  there  was  some 
evidence that those with a class II mismatch could have as much as 2.5 times 
chance  of  developing  acute  GvHD  (OR  =  2.50;  95%  Cl  0.67,  9.30;  p  =  0.26). 
There was less evidence that having a mismatch at class I and II increased the 
risk of developing acute GvHD, as the odds ratio was 1.03 (95% Cl 0.26, 4.03; p 
= 0.26), so the estimated of increase in risk is 3%, when compared with that for 
an HLA class I mismatch alone, or a matched patient.
Univariable  and  multivariable  analysis,  using  binary  logistic  regression,  was 
also carried out to assess the effect of HLA matching for HLA-A, -B, -C, -DRB1, 
-DQB1 and -DPB1 on the development of chronic GvHD (table 5-6).
In both univariable and multivariable analysis, the odds of developing chronic 
GvHD with a class II mismatch alone were over 3 times that of patients who 
were matched or had a class I mismatch with their donor (OR = 3.18; 95%  Cl
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1.16/  8.67  and  OR  =  3.32;  95%  Cl  0.55,  20.09  respectively).  However,  these 
findings were not significant at the 5% level (p = 0.06 and p = 0.37).
204Table 5-5.  Univariable and multivariable analysis of the effect of HLA matching for all loci on the development of acute GvHD.
Factor Odds Ratio 95% Confidence Interval P Odds Ratio 95% Confidence Interval P
All HLA loci matched or class 1  mismatch 1.00 0.65 1.00 “  »   “ 0.26
Class II mismatch 1.43 0.61  ,  3.33 2.50 0.67  ,  9.30
Class 1  and II mismatch 1.08 0.44  ,  2.63 1.03 0.26  ,  4.03
Table 5-6. Univariable and multivariable analysis of the effect of HLA matching for all loci on the development of chronic GvHD.
Factor
Univariable Result Multivariable Result
Odds Ratio 95% Confidence Interval P Odds Ratio 95% Confidence Interval P
All HLA loci matched or class I mismatch 1.00 _ 0.06 1.00 0.37
Class II mismatch 3.18 1.16  ,  8.67 3.32 0.55  ,  20.09
Class I and II mismatch 2.92 1.01  ,  8.49 1.20 0.19  ,  7.57
The above analyses were adjusted for type of disease, donor CMV status, patient CMV status, donor age, patient age, donor gender, patient 
gender, whether transplant was T-cell depleted or not and the occurrence of acute and chronic GvHD.CHAPTER 5
Overall survival
Univariable and multivariable analysis was carried out to investigate the effect 
of HLA matching, including HLA-DPB1, on the overall survival of the patients 
in the study (table 5-7).
HLA  matching  for  all  loci  was  not  associated  with  reduced  overall  survival 
when subjected to univariable analysis.  In a multivariable model, compared to 
patients who had a class I mismatch or were matched with their donor, those 
with a class I and class II mismatch had a 2.4 increased risk of death (HR = 2.37; 
95% Cl 0.64,8.69; p=0.20) and those with a class II mismatch had a 45% reduced 
risk of dying (HR = 0.55; 95% Cl 0.13, 2.32; p=0.41). However, the global p-value 
for HLA matching was significant at the 5% level (p=0.02).
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Table 5-7.  Univariable and multivariable analysis of the effect of HLA matching, including HLA-DPB1, on overall survival
Factor
Univariable Result Multivariable Result
Hazard Ratio 95% Confidence Interval P Hazard Ratio 95% Confidence Interval P
All HLA loci matched or class 1  mismatch 1.00 0.41 1.00
- 0.02
Class II mismatch 1.10 0.54  ,  2.26 0.55 0.13  ,  2.32
Class 1  and II mismatch 1.49 0.72  ,  3.06 2.37 0.64  ,  8.69
Table 5-8. Univariable and multivariable analysis of the effect of HLA matching, including HLA-DPB1, on disease free survival.
Factor
Univariable Result Multivariable Result
Hazard Ratio 95% Confidence Interval P Hazard Ratio 95% Confidence Interval P
HLA all loci matched or class I mismatch 1.00 <0.01 1.00 <0.01
Class II mismatch 0.54 0.32  ,  0.93 0.21 0.08  ,  0.56
Class I and II mismatch 1.17 0.69  ,  2.00 1.58 0.63  ,  3.98
The above analyses were adjusted for type of disease, donor CMV status, patient CMV status, donor age, patient age, donor gender, patient 
gender, whether transplant was T-cell depleted or not and the occurrence of acute and chronic GvHDChapter 5
Disease free survival
Table 5-8 shows the results of univariable and multivariable analysis carried out 
to investigate the effect of HLA matching, including HLA-DPB1, on the disease 
free survival of the patients in the study.  Both univariable and multivariable 
analysis showed HLA matching for all loci to be significantly associated with 
disease free survival at the 5% level (p = <0.01).
Univariable analysis showed  patients who only had a class II mismatch with 
their donor had a 46%  reduced risk of relapse or death compared with those 
mismatched  for  class  I  or  matched  (HR  =  0.54;  95%  Cl  0.32,  0.93).  Patients 
mismatched for class I and class II had an increased risk of 17% (HR = 1.17; 95% 
Cl 0.69,2.00).
The  relationship  remained  in  multivariable  analysis,  with patients  who  only 
had a class II mismatch with their donor having a 79% reduced risk of relapse 
or death compared with those mismatched for class I or matched  (HR = 0.21; 
95% Cl 0.08, 0.56).  Patients mismatched for class I and class II had an increased 
risk of 58% (HR = 1.17; 95% Cl 0.63,3.98).
Transplant related mortality
Univariable and multivariable analysis was carried out to investigate the effect 
of HLA matching, including HLA-DPB1, on the transplant related mortality of 
the patients in the study (table 5-9).
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Table 5-9.  Univariable and multivariable analysis of the effect of HLA matching, including HLA-DPB1, on transplant related mortality
Factor
Univariable Result Multivariable Result
Hazard Ratio 95% Confidence Interval P Hazard Ratio 95% Confidence Interval P
All HLA loci matched or class 1  mismatch 1.00
. 0.81 1.00 0.27
Class II mismatch 1.04 0.44  ,  2.46 0.37 0.06  ,  2.22
Class 1  and II mismatch 1.25 0.52  ,  2.99 1.05 0.19  ,  5.88
Table 5-10. Univariable and multivariable analysis of the effect of HLA matching, including HLA-DPB1, on relapse incidence.
Factor
Univariable Result Multivariable Result
Hazard Ratio 95% Confidence Interval P Hazard Ratio 95% Confidence Interval P
All HLA loci matched or class I mismatch 1.00 ~   i  " 0.002 1.00 <0.01
Class II mismatch 0.49 0.25  ,  0.96 0.25 0.08  ,  0.77
Class I and II mismatch 1.29 0.67  ,  2.48 1.85 0.63  ,  5.43
The above analyses were adjusted for type of disease, donor CMV status, patient CMV status, donor age, patient age, donor gender, patient 
gender, whether transplant was T-cell depleted or not and the occurrence of acute and chronic GvHD.CHAPTER 5
Table 5-9 shows that HLA matching for all loci was not significantly associated 
with transplant related mortality.  However, the Hazard Ratio for patients with 
a class  II  mismatch indicates  there  may  be  an association between a class  II 
mismatch and decreased risk of transplant related mortality compared with the 
other groups assessed (HR = 0.37; 95% Cl 0.06,2.22).
Relapse incidence
Univariable and multivariable analysis was carried out to investigate the effect 
of  HLA  matching,  including  HLA-DPB1,  on  the  relapse  incidence  of  the 
patients in the study (table 5-10).
HLA  matching  for  all  loci  was  found  to  have  a  significant  effect  on  the 
incidence  of  relapse  in  both  univariable  (p  =  <0.01)  and  multivariable  (p  = 
<0.01) analysis (table 5-10).  Univariable analysis showed patient mismatched 
for class I and II with their donor had a 29% increased risk of relapse compared 
to those with a class I mismatch and matched patients (HR = 1.29; 95% Cl 0.67, 
2.48),  whereas  patients  with  a  class  II  mismatch  had  a  51%  reduced  risk  of 
relapse  (HR  =  0.49;  95%  Cl  0.25,  0.96).  Multivariable  analysis  showed 
mismatching for class II alone gave a more reduced risk of relapse (HR = 0.25, 
95% Cl 0.08,0.77), with 26 out of the 62 patients in this group relapsing.
Discussion - including HLA-DP compared with excluding HLA-DP
Independent of whether HLA-DPB1 matching was (as shown in this chapter) or
was not included  (as shown in Chapter 4), the relationship between outcome 
and HLA matching in most scenarios appeared to remain the same.  There was 
no significant relationship between HLA matching and GvHD when HLA-DP 
matching  was  excluded  or  included  (tables  4-4,  4-6,  4-8,  5-5  and  5-6).  The 
greatest  risk  of  reduced  overall  survival  was  associated  with  a  mismatch  at 
HLA class I and class II (table 4-9).  A similar association was seen for disease 
free survival (tables 4-10 and 5-8) and increased relapse incidence (tables 4-12 
and 5-10).  Both when HLA-DP matching was taken into account, and when it 
was not,  the most unfavourable  outcome  in each of these cases was with an
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HLA mismatch at both class I and class II.  The only outcome measure upon 
which the additional locus  matching changed the  association, was transplant 
related mortality.  When HLA matching was excluded, a mismatch at class I 
and class II was independently associated with an increased risk of transplant 
related mortality  (table 4-11),  however,  the inclusion of HLA-DPB1  matching 
meant no significant association was seen at the 5% level (table 5-9).
When HLA-DP matching was excluded, it was possible to compare any HLA 
mismatches  to  the  HLA-A,  -B  -C,  -DRB1,  -DQB1  matched  group.  For  all 
multivariable  analyses  where  a  significant  association  was  found,  the  most 
favourable outcome was associated with the HLA matched group, followed by 
a class II mismatch only, and then a class I mismatch only (tables 4-9, 4-10, 4-11 
and 4-12).  When  HLA-DP  matching was  included,  and  it was  necessary  to 
group  the  matched  and  class  I  mismatch  only  groups,  the  most  favourable 
outcome became  associated  with a class  II  mismatch alone  in cases  where  a 
significant relationship was found  (tables 5-7, 5-8 and 5-10).  However, when 
matched transplants and those mismatched for class I were grouped, it can be 
hypothesised  that  the  unfavourable  effect  of  a  class  I  mismatch  masked  the 
favourable  effect  of  matching  for  all  loci,  making  it  appear  that  a  class  II 
mismatch was more favourable.
Multivariable analysis shows  that an HLA  class  I  and  II  mismatch  gives  the 
least favourable result with respect to  overall  survival,  disease  free  survival, 
and  relapse incidence,  independent of the  presence  of an HLA-DP match  or 
mismatch.  In the analysis of an effect on the risk of transplant related mortality, 
a  class  I  and  II  mismatch  gave  the  least  favourable  result  when  HLA-DPB1 
matching was excluded, but when included, no significant effect was seen.
These  results  indicate  that  the  hierachy  of  mismatches  in  this  study  is  as 
follows;
HLA  class  I  and  class  II  >  HLA  class  I  alone  >  HLA  class  II  alone  >  HLA 
matched
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The effect of an HLA-DPB1 mismatch alone
To  confirm  the  hypothesis  that  HLA-DP  matching  did  not contribute  to  the 
effect on transplant outcome, a group with an HLA-DPB1 mismatch alone (n = 
45),  was  compared  with  matched  transplants  (n  =  15).  No  significant 
association was seen with an HLA-DPB1 mismatch alone and the development 
of acute or chronic GvHD, overall survival or transplant related mortality (data 
not shown).  A study by Petersdorf et al, in patients matched for HLA-A, -B, - 
DRB1 and -DQB1 showed no association between an HLA-DPB1 mismatch and 
increased risk of acute GvHD (Petersdorf et al. 1993a).  However, a more recent 
study, by Varney et al, has shown a significant association with matching for 
HLA-DPB1 and reduced risk of developing acute GvHD (Varney et al. 1999). 
When  HLA-DPB1  matching  alone  was  analysed  to  find  if  there  was  an 
association with outcome a significant effect was seen with disease free survival 
and  relapse  incidence.  Table  5-11  shows  the  result  of  univariable  and 
multivariable analysis of the effect of an HLA-DPB1 mismatch on disease free 
survival.
Univariable analysis showed a patient mismatched with their  donor for  only 
HLA-DPB1  had  a 50%  reduce chance  of death  or relapse compared  to  those 
matched with their donor for HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1  (HR = 
0.50; 95% Cl 0.26, 0.94, p = 0.03, table 5-11).  Multivariable analysis showed an 
HLA-DPB1 mismatch gave a 96% reduced risk of death or relapse (HR = 0.04; 
95% Cl 0.00,0.39, p = 0.01).
212Table 5-11.  The effect of an HLA-DPB1  mismatch on disease free survival
Univariable Result Multivariable Result
Factor Hazard Ratio 95% Confidence Interval P Hazard Ratio 95% Confidence Interval P
HLA all loci matched for all loci 
mismatch for HLA-DPB1
1.00
0.50 0.26  i  0.94
0.03 1.00
0.04 0.00  !   0.39
0.01
Table 5-12. The effect of an HLA-DPB1 mismatch on relapse incidence
Univariable Result Multivariable Result
Factor Hazard Ratio 95% Confidence Interval P Hazard Ratio 95% Confidence Interval P
HLA-DPB1 matched for all loci 
mismatch for HLA-DPB1
1.00
0.31 0.14  ,  0.67
0.003 1.00
0.02 0.00  ,  0.31
0.01
The above analyses were adjusted for type of disease, donor CMV status, patient CMV status, donor age, patient age, donor gender, patient 
gender, whether transplant was T-cell depleted or not and the occurrence of acute and chronic GvHD.CHAPTER 5
The effect of an HLA-DPB1  mismatch alone on relapse incidence is shown in 
table 5-12.  An HLA-DPB1 mismatch was significantly associated with reduced 
risk of relapse when compared to patients matched for all HLA loci with their 
donor (p = <0.01).  A patient with an HLA-DPB1 mismatch had a 69% reduced 
risk of relapse compared to a patient matched with their donor for all loci (HR = 
0.31;  95%  Cl  0.14,  0.67).  When  subjected  to  multivariable  analysis,  an 
HLA-DPB1  mismatch  was  independently  associated  with  reduced  risk  of 
relapse  (p  =  0.01).  A  patient with an HLA-DPB1  mismatch only  had  a 98% 
reduced risk of relapse compared with a patient matched with their donor for 
HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1 (HR = 0.02; 95% Cl 0.00, 0.31).  This 
reduction in risk of relapse with a mismatch for HLA-DPB1 may be due to the 
recognition  of  HLA-DP  antigens  expressed  on  leukaemic  blasts,  by 
HLA-DP-specific T cells, as has been previously described (Ibisch et al. 1999). 
When  HLA-DP  matching  was  analysed  without  correction  for  other  HLA 
mismatches, no significant association was seen with any of the outcomes tested 
(data  not  shown).  This  further  supports  the  theory  that  an  HLA-DPB1 
mismatch does not have the same level of effect as a mismatch at any of the 
other loci tested. However, based on the results shown in table 5-11 and 5-12, it 
can be postulated that a mismatch for HLA-DPB1 may protect from relapse and 
therefore lead to improved disease free survival, in patients matched for HLA- 
A, -B, -C, -DRB1, -DQB1 and -DPB1.  In conclusion, to show a true effect of an 
HLA-DPB1  mismatch on transplant outcome,  a  greater number  of transplant 
pairs  need  to  be  analysed.  Ideally,  in  a  patient  group  who  have  the  same 
disease  and  status,  with  equal  numbers  in  the  matched  and  mismatched 
groups.
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Chapter 6
Minor histocompatibility antigen matching in unrelated 
bone marrow transplantation
Introduction
Minor histocompatibility antigens (mHAg) are peptides which, when bound to 
MHC molecules, are recognised by T cells causing an allogeneic response.  This 
phenomenon  was  discovered  by  Snell  and  co-workers,  when  tumours  were 
transplanted  between  MHC  identical  individuals  and  were  rejected  less 
aggressively than those mismatched for MHC antigens (Counce et al. 1956; Snell 
1948).  Few mHAgs have been described, and can be peptides encoded by genes 
on sex chromosomes,  or  encoded  by  autosomal  or mitochondrial  DNA.  For 
example, the H-Y peptides encoded by genes on the Y chromosome (Vogt et al. 
2000; Wang et al. 1995).  Or non-sex-linked mHAgs encoded by the polymorphic 
genes of adhesion molecules (Behar et al. 1996; Maruya et al. 1998), although the 
effect  of  mismatches  between  these  on  transplant  outcome  has  been 
controversial (Nichols et al. 1996).  The presence of a further set of non-Y-linked 
mHAgs has been described by Goulmy et al, and called HA-1, HA-2, HA-3, HA- 
4 and HA-5 (Van Els et al. 1992).  HA-1, HA-2 and HA-3 were found to occur at 
a frequency of 69-95% in a healthy population, while HA-4 and HA-5 were only 
present in 7-16% of individuals tested (Van Els et al. 1992).
HA-1  is  restricted  by  HLA-A2,  and  has  two  allelic  forms,  HA-1H  which  is 
presented by HLA-A2 and HA-1R , which is not presented by HLA-A2, therefore 
HA-1R  homozygous individuals are said to be HA-1  negative.  Expression of
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HA-1 and HA-2 is limited to the cells of the haematopoietic lineage, whereas H- 
Y, HA-3 and HA-4 have been found ubiquitously expressed  (de Bueger et al. 
1992).  The frequency of HA-1 alleles in the normal Caucasian population has 
been reported as approximately 40% HA-1H and 60% HA-1R  (Tseng et al. 1998). 
On our cohort of patients and donors we found 38%  HA-1H alleles and 62% 
HA-1R  alleles.  Observations in HLA identical sibling transplants have shown 
that a HA-1 mismatch between HLA-A*0201  positive donors and recipients is 
significantly  associated  with  the  development  of  acute  GvHD  (p  =  0.02) 
(Goulmy et al. 1996).  This association has not yet been explored in the unrelated 
bone marrow transplant setting,  and for this reason we chose to  observe the 
effect of an HA-1 on the outcome of transplant in our cohort which contained 57 
HLA-A*0201 donors and recipients.
The effect of HA-1 mismatch on transplant outcome
DNA from 57 recipients and donors from HLA-A*0201 positive unrelated bone
marrow transplant pairs was amplified in a PCR reaction using HA-1H and HA- 
1R  specific primers to discover whether each individual was positive or negative 
for HA-1  (Wilke et al. 1998).  A positive individual was either homozygous or 
heterozygous for HA-1H, whereas a negative individual was homozygous for 
HA-1R  (den Haan et al. 1998).  The results of this typing are shown in figure 6-1.
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Figure  6-1.  HA-1  typing  o f 57  H L A -A *0201  positive  transplant  recipients  and  their  donors.  28
patients received a HA-1  matched transplant (green).  13 HA-1 positive patients received a HA-1 negative 
transplant and  16 HA-1  negative patients received a HA-1  positive transplant.  HA-1  typing was carried 
out using a sequence specific PCR kit (Robbins Scientific) (Wilke et al.  1998).
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Twenty-eight individuals were matched for their HA-1 status.  Of these, 3 were 
completely  negative  for  HA-1  (i.e.  both  recipient  and  donor  HA-1R  
homozygous),  3  had  a  donor  homozygous  for  HA-1H  with  a  heterozygous 
recipient,  2 had a heterozygous  donor with an HA-1H homozygous recipient 
and  20  transplants  were  carried  out  where  both  donor  and  recipient  were 
heterozygous.  The  remaining  transplants  were  carried  out  with  a  HA-1 
positive recipient transplanted with marrow from a HA-1 negative donor, or a 
HA-1 negative recipient transplanted with marrow from a HA-1 positive donor. 
The frequency of the HA-1H and HA-1R  alleles are thought to be 40% and 60% 
respectively in HLA-A*0201 positive individuals (Tseng et al. 1998).  This lower 
frequency  of HA-1H could  explain why  none  of the transplants  in our  study 
consisted of a donor and recipient who were both HA-1H homozygous.  The 
mismatches  in HA-1  status  were correlated with  overall  survival,  the  risk of 
developing acute and chronic GvHD  (where grade II  or higher indicated the 
presence  of  acute  GvHD),  and  the  risk  of  relapse  post  transplant.  HA-1 
negative  (HA-1R  homozygous)  donor/recipient  and  their  donor/recipient 
being  HA-1  positive  defined  a  HA-1  mismatch.  On  transplanting  a  HA-1 
negative  recipient  with  marrow  from  a  HA-1  positive  donor,  a  possible 
outcome would be a host-versus-graft reaction, whereas when transplanting a 
HA-1 positive recipient with HA-1 negative marrow, a possible outcome would 
be GvHD.
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Figure 6-2.  The effect of HA-1  mismatch  on survival.  A  Kaplan  Meier survival plot of percentage 
survival against time in days.  HA-1  matched transplant recipients (green) compared with those who were 
positive for HA-1 transplanted with an HA-1 negative donor (pink), or those who were negative for HA-1 
transplanted  with  an  HA-1  positive  donor (orange).  Significance  was calculated  using the  Log  Rank 
Statistic in a pair wise comparison with recipients whose transplants were matched for HA-1  (green).
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The effect of HA-1 matching on overall survival
Figure  6-2  shows  the  effect  of  an  HA-1  mismatch  on  overall  survival.  The 
estimated  probability  of overall  survival  at 1  year, calculated  using Kaplan- 
Meier methods, for patients with HA-1 matched transplants was 59%  (95% Cl, 
41-78%).  For HA-1  positive patients transplanted with stem cells from HA-1 
positive donors it was 60%  (95%  Cl, 35-83%), and for HA-1  negative patients 
transplanted with stem cells from HA-1 positive donors it was 53% (95% Cl, 25- 
80%).  The  effect  on  overall  survival  was  not  significant.  As  previously 
discussed, our cohort contained 15 recipients of HLA-A, -B, -C, -DRB1, -DQB1 
and -DPB1 matched transplants.  Analysis of minor histocompatibility antigen 
mismatches on this HLA matched background is the most useful way to assess 
if the outcome of the transplant was affected by an HA-1 mismatch.  Of the 15 
HLA  matched  transplants,  9  were  HLA-A*0201  positive  and  only  3  of  these 
were mismatched for HA-1.  Two recipients were HA-1 negative transplanted 
with bone marrow from an HA-1 positive donor, and 1 transplant was carried 
out with an HA-1 positive recipient and an HA-1 negative donor.  At the time 
of  analysis,  one  of  the  2  HA-1  negative  recipients  was  alive  (634  days  post 
transplant) and the other had died 22 days post transplant from infection and 
veno-occlusive  disease  (VOD).  The  HA-1  positive  recipient  of  an  HA-1 
negative transplant was also alive (834 days post transplant).
An  effect  of  HA-1  mismatching  on  the  development  of  GvHD  has  been 
observed post HLA identical sibling transplant (Goulmy et al. 1996; Tseng et al. 
1999).  We assessed the effect of an HA-1 mismatch on the risk of developing 
acute and chronic GvHD  (where grade II or higher indicated the presence of 
acute GvHD), the results of which can be seen in figure 6-3.
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Figure 6-3a.  The effect of HA-1  mismatch on the risk of developing acute GvHD.  A Kaplan Meier 
hazard  plot  of cumulative  hazard  against  time  in  days.  HA-1  matched  transplant  recipients  (green) 
compared with those who were positive for HA-1  transplanted with an  HA-1  negative donor (pink), or 
those who were negative for HA-1  transplanted with an HA-1  positive donor (orange).  Significance was 
calculated using the Log Rank Statistic in a pair wise comparison with recipients whose transplants were 
matched for HA-1 (green).
221C hapter 6
Effect of HA-1 matching on the development of GvHD
In the analysis of our cohort of HLA-A*0201 matched individuals (figure 6-3a), 
the risk of developing acute GvHD appeared to be similar for individuals who 
were HA-1 positive transplanted with an HA-1 negative donor and individuals 
who were matched with their donor for HA-1.  Those HA-1 negative recipients 
of an HA-1 positive transplant had a slightly increased risk of developing acute 
GvHD, although it was not significant.  This result was unexpected in the light 
of previous studies in matched sibling transplants, where bone marrow from an 
HA-1 negative donor transplanted into an HA-1  positive individual increased 
the risk of developing GvHD (Goulmy et al. 1996; Tseng et al. 1999).
There were a small number of transplants evaluable for the time to detection of 
acute GvHD (n = 39), but when the raw data was assessed it was found that 
only  7  of  the  16  HA-1  positive  recipients  of  an  HA-1  negative  transplant 
developed acute GvHD, compared to 10 of the 13 HA-1 negative recipients of 
an HA-1 positive transplant.  In the HA-1 matched group, 15 of 28 individuals 
developed acute GvHD.  None of the 3 HA-1  matched, HLA matched, HLA- 
A*0201  transplant  recipients  were  reported  to  have  developed  acute  GvHD. 
This  data  implies  that  an  HA-1  mismatch  may  not  confer  an  independent 
increase  in the risk  of developing acute  GvHD  after unrelated  bone marrow 
transplantation, although it must be stressed that this analysis was carried out 
on transplants with some known HLA mismatches, and there were only three 
individuals without known HLA mismatches available for analysis.
The effect of an HA-1 mismatch on the risk of developing chronic GvHD was 
also assessed in the individuals (figure 6-3b).
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Figure 6-3b.  The  effect of HA-1  mismatch  on  the  risk  of developing  chronic  GvHD.  A  Kaplan 
Meier hazard plot of cumulative hazard against time in days.  HA-1  matched transplant recipients (green) 
compared with those who were positive  for HA-1  transplanted with an HA-1  negative donor (pink), or 
those who were negative for HA-1 transplanted with an HA-1  positive donor (orange).  Significance was 
calculated using the Log Rank Statistic in a pair wise comparison with recipients whose transplants were 
matched for HA-1 (green).
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In this cohort of HLA-A*0201 positive transplants, the effect of a mismatch for 
HA-1 in either direction was seen to be significant compared with individuals 
matched  for  their  HA-1  status  (figure  6-3b).  HA-1  positive  recipients  who 
received  an HA-1  negative  graft had  the  greatest risk  of developing chronic 
GvHD (p < 0.01, figure 6-3b, pink), with 12 of the 16 recipients in this group 
developing chronic GvHD.  Seven of the 13 HA-1 negative recipients of an HA- 
1 positive graft developed chronic GvHD and only 10 of the 28 HA-1 matched 
individuals.  Of  the  HLA  matched,  HLA-A*0201  positive  individuals 
mismatched  for  HA-1,  chronic  GvHD  was  seen  in  the  only  HA-1  positive 
recipient  of  an  HA-1  negative  transplant.  It  has  been  reported  that  the 
significant effect of an HA-1 mismatch on the development of acute GvHD was 
not observed in recipients under the age of 18 (Goulmy et al. 1996).  Ten of our 
57  HLA-A*0201  positive  transplants  were  carried  out  in  children.  Three  of 
these children were HA-1 positive and transplanted with bone marrow from an 
HA-1 negative donor, none of these recipients developed acute GvHD, but all 
developed  chronic  GvHD.  This  may  suggest  that  the  effect  of  an  HA-1 
mismatch  in  child  recipients  or  generally  in  unrelated  bone  marrow 
transplantation, may elicit a chronic GvHD response as opposed to the acute 
GvHD seen in HLA identical sibling transplantation.
A graft-versus-host response has been associated with a graft-versus-leukaemia 
effect (Gratwohl et al. 1995).  It is also been shown that HA-1-specific CTLs can 
lyse  leukaemic  cells  expressing  HLA-A*0201  restricted  HA-1  antigens 
(Falkenburg et al. 1991; Mutis et al. 1999b).  If this were true in our cohort, we 
would expect to see a reduced risk of relapse in HA-1 positive recipients of an 
HA-1  negative graft.  The effect of an HA-1  mismatch on the risk  of disease 
relapse is shown in figure 6-4.
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Figure 6-4.  The effect of HA-1  mismatch  on  the  risk of relapse.  A  Kaplan  Meier hazard plot of 
cumulative hazard against time in days.  HA-1 matched transplant recipients (green) compared with those 
who  were  positive  for  HA-1  transplanted  with  an  HA-1  negative  donor  (pink),  or  those  who  were 
negative for HA-1 transplanted with an HA-1 positive donor (orange).  Significance was calculated using 
the Log Rank Statistic in a pair wise comparison with recipients whose transplants were matched for HA- 
1  (green).
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Effect of HA-1 matching on relapse
The  lowest risk  of  relapse  seen was  in  HA-1  positive  recipients  of  an HA-1 
negative transplant (figure 6-4, pink), whereas a mismatch in the other direction 
gave  the  highest  risk  of  relapse.  However,  none  of  these  results  were 
statistically  significant.  The  HLA  matched,  HLA-A*0201  positive,  HA-1 
positive  donor  transplanted  with  marrow  from  an  HA-1  negative  recipient 
relapsed,  but after a  DLI  did  develop GvHD, which may  indicate protection 
from a further relapse (Jacobsen et al. 1990).
Due  to  the  low  number  of  HLA  matched,  HLA-A*0201  positive  unrelated 
transplants available for analysis in our cohort, it was not possible to assess the 
effect  of  an  HA-1  mismatch  to  give  any  meaningful  results.  However,  one 
statistically significant result was seen in the risk of developing chronic GvHD 
in HA-1 positive recipients of an HA-1 negative transplant.  To find if recipients 
of HA-1  mismatched  transplants from unrelated  donors had  HA-1  specific T 
cells  present  post  transplant,  as  has  been  seen  in  HLA  identical  sibling 
transplants (Goulmy et al. 1996; Van Els et al. 1992), we collected post transplant 
blood  samples from such recipients and  tested  for HA-l-specific  CTLs  using 
HLA-A*0201 :HA-l tetramers.
Detection of HA-1 specific T cells in bone marrow transplant recipients
In order to assess whether HA-1 antigens were being recognised in an unrelated
transplant  situation  we  collected  PBMCs  post  transplant  from  HLA-A*0201- 
positive recipients  of unrelated  transplants from the Hammersmith Hospital, 
London.  These PBMCs were stained with anti-CD8 and anti-CD4 monoclonal 
antibodies,  and  HLA-A*0201:HA-1  tetramers  we  had  previously  made 
(described in Chapter 2), in order to detect the presence of any donor-derived 
HA-l-specific T cells using flow cytometry.
The  tetramers  were  formed  from  the  extracellular  domains  of  HLA-A*0201 
molecules bound to the HA-1 peptide and human p2-microglobulin.  The exon 
encoding the transmembrane region of the HLA-A*0201 molecule was replaced 
with a C-terminal sequence coding for a biotinylation target.  This complex was
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biotinylated and then tetramerised with Phycoerythrin-labelled Streptavidin. 
The newly formed tetramers had been tested for fidelity  at each stage  of the 
formation procedure, however, HA-l-specific T-cells were not readily available 
to  use  as  a  positive  control.  Therefore,  methods  had  to  be  undertaken  to 
produce  these  cells  in  order  to  test  the  tetramers.  Two  protocols  for  T-cell 
stimulation  were  followed.  Firstly,  a  mixed  lymphocyte  culture/ reaction 
(MLR/MLC)  between  individuals  who  were  HLA-A*0201  positive,  but 
mismatched for their HA-1 status.  Secondly, stimulation of HA-1 negative or 
HA-1  positive  PBMCs  with  autologous  peptide-pulsed  mononuclear  cells 
(described in Chapter 2).
Mixed lymphocyte culture for the formation of HA-l-specific T cells
Blood from two healthy HLA-A*0201 positive donors was available for use in
the mixed  lymphocyte  culture,  AML  (HA-1)  and  RH  (HA-1+),  and  one  pre­
transplant HA-1- donor with an HA-1+  recipient, where PBMCs were stored in 
liquid nitrogen.  Briefly, PBMCs were mixed at a ration of 1:1 (HA-1+  or HA-1' 
responder:  HA-1' or HA-1+   irradiated  stimulator)  and  cultured  for  7  days  at 
37°C in 5% CO2.  One million irradiated stimulator cells were then added, with 
20 units/ ml IL-2.  At day 12, one million cells were removed from each culture 
and  stained  with  anti-CD8-FITC  and  anti-CD3-PE  monoclonal  antibodies 
(Beckton Dickinson) and the HLA-A*0201:HA-1 tetramer.  These cells were then 
analysed  using  a  FACscan  flow  cytometer  and  the  results  analysed  with 
CELLQuest software (Beckton Dickinson).  The results of this staining can be 
seen in figure 6-5.
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Figure 6-5.  HLA-A*0201:HA-1h:PE tetramer staining of PBMCs from  MLR experiments.  MLRs 
were carried out with PBMCs from an HA-1 positive donor against their HA-1 negative recipient, an HA- 
1   positive donor against an HA-1  negative donor and an HA-1  positive donor against an HA-1  negative 
donor.  The cells remaining after  12 days of culture were stained with anti-CD3 and anti-CD8 (y axis) 
monoclonal  antibodies (Beckton Dickinson) and  HLA-A*0201:HA-1h:PE tetramer (x axis,  panels a, b 
and c respectively).  Numbers in the  red  squares represent the percentage of tetramer positive T cells 
(which also gave a positive result when stained with the CD3-PerCP and CD8-FITC  specific antibodies)
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Figure  6-5  represents  the  results  of  tetramer  staining  of  the  live  CD3+   cells 
obtained from the mixed lymphocyte culture of HA-1- or HA-1+  responder cells 
and  HA-1+   or  HA-1-  stimulator  cells  at  day  12.  Numbers  in  the  red  boxes 
represent  the  percentage  of  HA-l-specific  CD3  positive,  CD8  positive  cells 
present in the culture (which would be HA-l-specific T cells).  The only positive 
result seen was less than 0.1 % of the CD8+/ CD3+ cells in the HA-1- donor and 
HA-1+  recipient culture (panel a).  This was the only culture in which any cells 
were seen in the area where HA-l-specific  T cells  should have been present. 
Interestingly, the number of T cells seen in this culture was greater than that 
seen for those from the healthy donors, who were known to have many more 
HLA mismatches than in the case of the recipient and donor (figure 6-5, panels 
b and c).  The tetramer positive cells seen in panel a, however, are probably not 
HA-l-specific, CD3+/CD8+ T cells as there are also CD8- cells present in the area 
below the red box, indicating non-specific background staining.  It was thought 
that  this  method  of  HA-l-specific  T  cell  production  had  too  many 
inconsistencies between responder and stimulator to produce T cells specific for 
a  minor  histocompatibility  antigen,  especially  as  there  were  already  major 
histocompatibility differences present.
Induction of HA-l-specific T cells using synthetic peptide-pulsed APCs
Mutis et al have published a protocol for the ex-vivo induction of HA-l-specific
CTLs  (Mutis  et  al.  1999b).  The  main  problem  with  this  protocol  is  the 
requirement  for  large  numbers  of  autologous  PBMCs  on  a  regular  basis. 
Therefore,  for  the  production  of  the  first  round  of  antigen  presentation,  a 
EUCAPS protocol for the production of dendritic cells from peripheral blood, 
was  used  (see  Chapter  2).  These  antigen  presenting  cells  (APCs)  from  the 
HA-1* and HA-1+  healthy donors (AML and RH respectively) were pulsed with 
synthetically produced HA-1  (lOpg/ml),  and mixed at a ratio of 1:10  APC to 
responder cells.  The cells were cultured in RPMI with 10% autologous plasma 
and 10U/ml IL-2 at 37°C 5% CO2 for 5 days.  lOU/ml IL-2 was added at day 5 
and at day 7, peptide-pulsed adherant monocytes were added at a responder : 
stimulator ratio of 3:1.  Twenty-four hours after each stimulation, lOU/ml IL-2
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was added.  One million cells were removed from each culture for testing with 
the  HLA-A*0201:HA-1H:PE  tetramer  as  before,  two  days  before  each 
restimulation.  A representative result of these stainings can be seen in figure 6- 
6.
HA-1' donor T cell line HA-1+ donor T cell line
Tetramer AP PE —►   Tetramer AP PE
Figure 6-6.  HLA-A*0201:HA-1h:  PE tetramer  staining of T cells stimulated with  HA-1h peptide- 
pulsed mononuclear cells.  Following the published protocol (Mutis et al.  1999b), HA-1  negative (a) or 
positive  (b)  PBMCs  were  stimulated  with  autologous  peptide-pulsed  adherant  cells.  The  resulting  T 
lymphocytes  were  stained  with  anti-CD3-PerCP  and  anti-CD8-FITC  (y-axis)  monoclonal  antibodies 
(Beckton  Dickinson)  and  HLA-A*0201:HA-1h:PE  tetramer  (x-axis).  Numbers  in  the  red  squares 
represent the percentage of tetramer positive T cells (which also gave a positive result when stained with 
the CD3-PerCP and CD8-FITC specific antibodies)
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As seen in figure 6-6 panel a, the population of CD3+/CD8+ cells available at 
the time of analysis was greater for the HA-1- donor than had been seen in the 
previous  experiment  (figure  6-5,  panel  b).  Also,  the  number  of  tetramer 
positive cells was greater in both individuals, however, the presence of CD8- 
cells was still seen in the are below the red box.
The ex-vivo stimulation was not a successful way of inducing HA-l-specific T 
cells.  It was decided that the tetramer should be tested on some post unrelated 
bone  marrow  transplant  samples  from  HA-1+   recipients  who  had  been 
transplanted with HA-1- donors, where a greater percentage of HA-l-specific T 
cells may be present.
Analysis of post transplant PBMCs from HA-1+ recipients of HA-1- bone 
marrow
Whilst  using  in  vitro  experiments  in  an  attempt  to  find  if  my  tetramer  was 
working, Geraldine Aubert, at the Anthony Nolan Research Institute, had also 
produced a HLA-A*0201:HA-1 tetramer following the same protocol (Altman et 
al.  1996).  Geraldine  had  previously  prepared  three  HLA-A*0201  tetramers 
containing different peptides from the CMV surface glycoprotein, pp65 (AE42, 
AE44  and  AE45),  which  are  also  recognised  in  an  HLA-A*0201  restricted 
manner (Meyers et al. 1986; Webster et al. 1993), and which have been shown to 
stain CMV-specific T cells  (Aubert et al.  2000).  All  tetramers  described  were 
produced using the same protocol (Altman et al. 1996).  An HLA-A*0201 :HA- 
1H:PE tetramer was also kindly  provided by  Professor Els Goulmy, who had 
previously  described  its  use  in  the  detection  of HA-l-specific  T  cells  in  post 
transplant PBMC populations from HA-1+  recipients of HLA identical sibling 
HA-1* bone marrow transplants (Mutis et al. 1999a).  These tetramers and their 
abbreviated names are represented in Table 6-1.
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Table 6-1.  Description of tetramers  used  in  the analysis of HA-l-specific T cells.  Tetramers were 
kindly provided by Geraldine Aubert (Anthony Nolan Research Institute, UK) and Professor Els Goulmy 
(Department of Immunohaematology and Blood Bank, Leiden University Hospital, The Netherlands).
Tetramer Originator Components Specificity
APHA-1 Andrea Pay HLA-A*0201  :HA-1  H:PE HLA-A*0201:HA-1h
GAHA-1 Geraldine Aubert HLA-A*0201:HA-1h:PE HLA-A*0201 :HA-11 4
MLHA-1 Els Goulmy HLA-A*0201:HA-1h:PE HLA-A*0201:HA-1h
GACMV Geraldine Aubert HLA-A*0201  :AE42:PE HLA-A*0201 :CMV pp65
Staining of post transplant PBMC samples from two unrelated and one sibling 
recipient  post  HA-1  mismatched  transplant  was  carried  out  with  all  three 
tetramers and a representation of the results is shown in figure 6-7.
HA-1+  recipient of  HA-1+  recipient of  HA-1+  recipient of
HA-1'donor marrow  HA-1'donor marrow  HA-1" donor marrow
Tetramer AP PE—►   Tetramer GAPE—►   Tetramer ML PE—►
Figure  6-7.  HLA-A*0201:HA-1h:PE  tetramer  staining  of  PBMCs  from  an  HA-1+  patient 
transplanted  with  an  HA-F  donor.  PBMCs  from  an  HA-1  positive  recipient  of  HA-1  negative 
unrelated  donor  transplant  stained  with  anti-CD3-PerCP  and  anti-CD8-FITC  (y  axis)  monoclonal 
antibodies  (Beckton  Dickinson)  HLA-A*0201:HA-1h:PE  tetramers  made  by  myself  (AP,  panel  a), 
Geraldine Aubert (GA, panel b) and the originators of the technique from Leiden, Holland (ML, panel c). 
Numbers  in  the  red  squares  represent the  percentage  of tetramer positive  T  cells  (which  also  gave  a 
positive result when stained with the CD3 and CD8 specific antibodies)
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The  first  panel  (a)  in  figure  6-7  shows  staining  of  a  post  transplant  PBMC 
sample from an HA-1+  recipient of an unrelated HLA-A*0201  matched HA-1- 
transplant with the APHA-1 tetramer.  Panel b shows the same sample stained 
with the GAHA-1 tetramer and panel (c) shows the same sample stained with 
the  MLHA-1.  The  MLHA-1  tetramer has been shown to  stain HA-l-specific 
CTLs produced in the same laboratory (Mutis et al. 1999a; Mutis et al. 1999b).  It 
can be  seen from figure  6-6  panel  (c)  that there were  no cells  present in the 
sample which were stained by the MLHA-1  tetramer.  In panels (a) and (b) it 
can be seen that a small percentage of cells were stained by the two tetramers 
made in our laboratory (APHA-1 and GAHA-1), but the number of CD8+  and 
CD8- cells seen inside and below the  red box  respectively are approximately 
equal, indicating that the staining seen is not specific.  The MLHA-1  tetramer 
shows no such staining below the red box, indicating there was no background 
staining  seen.  Due  to  the  lack  of  staining  seen  with  the  tetramer  that  had 
already been shown to stain an HA-l-specific CTL line,  it was thought there 
may have been a problem with the preparation of the samples to be tested.  In 
order  to  eliminate  this  possible  inconsistency,  a  bone  marrow  transplant 
recipient was found whom could be stained with an HA-1 tetramer and a CMV 
tetramer and positive results anticipated for both.
Comparison of HA-1 tetramers with CMV tetramers
To  ensure  that  the  lack  of  staining  seen  with  our  tetramer  was  not  due  to 
problems with the preparation of the post transplant PBMC samples obtained 
from  HA-1+   recipients  of  HA-1-  bone  marrow  grafts,  the  same  sample  was 
tested with APHA-1  and GAHA-1 tetramers and the GACMV tetramer.  This 
sample  was  from  an  HA-1+,  CMV+   recipient  of  an  HA-1-  bone  marrow 
transplant who had reactivated CMV viraemia (MY).  The sample was stained 
with the APHA-1, GAHA-1  and GACMV tetramers.  I myself, to ensure each 
process  was  carried  out  in  the  same  manner,  carried  out  sample  collection; 
preparation;  stainings  and  analyses  simultaneously.  The  results  of  these 
stainings can be seen in figure 6-8.
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Figure 6-8. HLA-A*0201:HA-1h:PE and HLA-A*0201:CMV peptide AE42:PE tetramer staining of 
PBMCs  from  an  HA-1+   patient  transplanted  with  an  HA-1'  donor  who  was  also CMV  positive. 
PBMCs  from  an  HA-1  positive,  CMV  positive  recipient  of HA-1  negative  unrelated  donor transplant 
stained  with  anti-CD3  and  anti-CD8  (y  axis)  monoclonal  antibodies  (Beckton  Dickinson)  HLA- 
A*0201:HA-1h:PE tetramers made by myself (AP, panel a) and Geraldine Aubert (GA, panel b) .  The 
same cells were also stained with another tetramer made by Geraldine Aubert following exactly the same 
protocol, but with a peptide from CMV pp65, AE42 (panel c).  Numbers in the red squares represent the 
percentage  of tetramer positive T cells (which also gave a positive  result when  stained with the CD3- 
PerCP and CD8-FITC specific antibodies)
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In  figure  6-8  it  can  be  seen  that  the  PBMC  sample  from  the  HA-1+,  CMV+  
recipient of an HA-1- transplant showed a comparatively high staining with the 
APHA-1 and GAHA-1 tetramers prepared in our laboratory (red boxes, panels 
a  and  b).  The  same  sample  stained  with  the  GACMV  tetramer  (prepared 
following the same protocol by Geraldine Aubert, as was the tetramer featured 
in panel b) is shown in panel c, where a high percentage of CD3+  and CD8+ 
cells were stained with the tetramer.  This experiment indicates that the lack of 
staining seen with the  APHA-1 tetramers prepared in our laboratory was not 
due to problems with the preparation of the sample, neither were they due to 
the process of preparing the tetramer.  Further tests were required to find if the 
APHA-1 tetramers could stain HA-l-specific T cells.
Testing of HA-1 tetramers with the HA-l-specific CTL line
The final quality control currently available to us for the tetramers produced in
our laboratory was to test them against the HA-l-specific CTL line produced in 
The Netherlands (Mutis et al. 1999a; Mutis et al. 1999b).  We sent a sample of the 
tetramers on dry ice to Dr Tuna Mutis in the Netherlands for testing with their 
CTL  line  in  conjunction  with  their  MLHA-1  tetramer.  The  results  of  this 
staining can be seen in figure 6-9.
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Figure 6-9.  HLA-A*0201:HA-1h:PE  tetramer staining  of an  HA-l-specific  cytotoxic  T cell  clone.
HLA-A*0201:HA-1h:PE tetramers (AP, panel a) were sent to The Netherlands for testing against the only 
known HA-l-specific cytotoxic T cell line available, and the results compared with those for a similar 
tetramer  prepared  in  the  same  institute  (ML,  panel  b).  Numbers  in  the  red  squares  represent  the 
percentage of tetramer positive T cells (which  also gave  a positive result when stained with the CD3- 
PerCP and CD8-FITC specific antibodies)
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Figure 6-9 shows staining of an HA-l-specific T cell line  (Mutis et al.  1999b), 
with the APHA-1 tetramer (panel a) and with the MLHA-1 tetramer produced 
in the same laboratory as the CTL line (Mutis et al. 1999a)(panel b).  It can be 
seen that the cells from the CTL line are not stained the APHA-1 tetramer, but 
approximately 80% of them are stained with the MLHA-1 tetramer prepared in 
The Netherlands.  This indicates that the tetramer produced in our laboratory 
was either not recognised by CTLs specific  for HA-1,  or the  signal from any 
tetramers which were bound was too weak to be detected.  It was therefore not 
possible  for  us  to  find  whether  HA-l-specific  T  cells  were  present  in  the 
peripheral  blood  of  HA-1+   recipients  of  HA-1-  unrelated  bone  marrow 
transplants.
Discussion of the effect of an HA-1 mismatch
Due to the small number of HLA-A*0201  positive,  HLA matched transplants 
available for study in our cohort of donors and recipients, it was not possible to 
analyse  HA-1  matching  on  an  HLA  matched  background  to  get  meaningful 
results.  We therefore carried out the majority of our analyses on HLA-A*0201 
matched transplants  with known HLA mismatches  (n  =  57).  No  statistically 
significant difference was seen between HA-1 matched and HA-1  mismatched 
transplants when overall survival, risk of developing acute GvHD and risk of 
relapsed were analysed (figures 6-2, 6-3a and 6-4).  However, on the analysis of 
the  effect  of  HA-1  matching  on  the  risk  of  developing  chronic  GvHD,  a 
significantly  increased  risk  of  HA-1  mismatching  was  seen  when  compared 
with HA-1 matched transplants (figure 6-3b).  This effect has not been reported 
post sibling,  HA-1  mismatched  transplant,  however,  a  significant  association 
with  the  risk  of  developing  acute  GvHD  has  been  seen  when  an  HA-1+  
individuals  were  transplanted  with  marrow  from  an  HA-1-  sibling  donor 
(Tseng et al. 1999).  It must be recognised, however, that the individuals who 
had an HA-1 mismatched transplant who had chronic GvHD could also have 
had a class II mismatch, which has already been shown to be a significant risk 
factor for the development of chronic GvHD (figure 6-3b).  Twenty-nine of the 
57  transplants  analysed  were  mismatched  for  HA-1  with  19  of  these  29
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developing chronic  GvHD.  89%  of the  HA-1  mismatched  transplants where 
chronic GvHD was reported also had a mismatch at HLA class II, along with 
74% of the HA-1 matched transplants.  This shows that conclusions cannot be 
drawn from this data set with respect to the effect of an HA-1 mismatch on the 
development of chronic GvHD in unrelated bone marrow transplantation.
As these anaylses gave inconclusive results, it was decided to try and detect the 
presence of HA-l-specific T cells in HA-1+  recipients of HA-1' transplants, the 
presence  of which has  been reported  in the HLA  identical  sibling transplant 
situation  (Goulmy  et  al.  1996).  Tetramers  were  formed  as  described  from 
monomers of HLA-A*0201  heavy chain,  (^m light chain and synthetic HA-1H 
peptide,  biotinylated  and  bound  together  with  PE-labelled  Steptavidin  (see 
Chapter 2 for full description protocol) (Altman et al. 1996).  Although during 
the preparation of these reagents, all stages were tested successfully  (Chapter 
2),  there  were  no  HA-l-specfic  T  cells  available  for  testing  the  completed 
reagent.  Attempts were therefore made in order to induce these specific T cells 
in vitro,  using mixed  lymphocyte  reactions  and  autologous  stimulation with 
peptide-pulsed APCs.  However, on staining the few cells recovered from these 
experiments with tetramer,  anti-CD8-FITC  and  anti-CD3-PerCP,  no  tetramer- 
positive cells were seen (figures 6-5 and 6-6).
It was then decided, due to the lack of appropriate positive controls, that the 
tetramers should be tested directly on post transplant PBMC samples from HA- 
1+   recipients  of  HA-1-  transplants.  Another  scientist  at  the  Anthony  Nolan 
Research  Institute,  Geraldine  Aubert,  more  experienced  than  myself  in  the 
preparation of tetramers, also prepared an HLA-A*0201:HA-1H:PE tetramer in 
the same manner, for comparison.  When both these tetramers were tested on a 
relevant  recipient  sample,  no  clear  positive  result  could  be  seen  with  either 
tetramer (figure 6-7 panels a and b).  These two tetramers were also tested on 
the  same  samples  alongside  an  HLA-A*0201:HA-1H:PE  tetramer  prepared  in 
The Netherlands, that had previously shown positive staining with an HA-l- 
specific CTL line prepared in the same laboratory (Mutis et al. 1999a; Mutis et al 
1999b).  No difference was found in the staining of any of the samples between
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the tetramers prepared in out laboratory and those provided by the laboratory 
in  The  Netherlands  figure  6-7).  The  common  denominator  in  all  these 
experiments was the preparation of the samples.  To test whether this was the 
problem, a relevant sample was prepared in the same manner for staining with 
the HA-1 tetramers and an HLA-A*0201:CMV peptide AE42 tetramer.  Staining 
the PBMCs from this HA-1+,  CMV+   recipient of an HA-1- transplant showed 
staining with the CMV tetramer, but not with the HA-1 tetramers (figure 6-8). 
Finally, aliquots of the HA-1 tetramers prepared in our laboratory were sent to 
The Netherlands to be tested for staining of the HA-l-specific CTL line induced 
in their laboratory.  Staining was carried out simultaneously with our tetramer 
and their tetramer.  Our tetramer did not show positive staining with the HA-l- 
specific CTL line (figure 6-9).
Due  to  the  positive  results  seen  in  the  preparation  of  the  HLA-A*0201:HA- 
1H:PE tetramer (Chapter 2), and the similar staining patterns seen with a similar 
tetramer prepared by another, more experienced scientist in the laboratory, it is 
not  thought  that  the  negative  results  seen  are  due  to  problems  in  the 
preparation  of  the  reagent.  The  main  drawback  of  the  formation  of  these 
reagents is the lack of positive controls for testing their quality.  In attempting 
to induce HA-l-specific T cells for quality control purposes, it was found that 
lack  of  HLA-A*0201  positive  HA-1-  donors  was  a  problem.  The  protocol 
described  for  the  ex  vivo  formation  of  HA-l-specific  CTLs  required  large 
numbers of PBMCs on a regular basis which were difficult to acquire (Mutis et 
al. 1999b).  Due to the small number of cells available originally, and the very 
few  APCs  likely  to be  dendritic  cells  formed,  it was  impossible  to  carry  out 
detection methods to prove their phenotype.  Ideally we would have used anti- 
CD3, anti-CD14, anti-CD16 and anti-DR monoclonal antibodies to characterise 
these  antigen-presenting cells  likely  to  be  dendritic  cells,  which  should  have 
been negative for CD3, CD14, CD16 and CD19  and positive for HLA-DR.  The 
cells  ultimately  pulsed  with  peptide  were  originally  adherant,  and  had  a 
"spidery"  appearance.  But there were not enough produced to carry out the 
confirmatory phenotyping and to also use them as APCs for the induction of
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HA-l-specific  T cells.  After  the  initial  stimulation with these  HA-1  peptide- 
pulsed  antigen-presenting  cells,  further  stimulations  were  carried  out  with 
peptide-pulsed  autologous  adherant  monocytes  as  APCs.  These  cells  were 
described as an option for use in this technique, although in the previous study 
they were found not to be as efficient dendritic cells in the induction of HA-l- 
specific T cells (Mutis et al.  1999b).  However, fewer autologous PBMCs were 
required for the stimulation using monocytes, therefore these were the APC of 
choice.  After  three  rounds  of  stimulation  with  peptide-pulsed  adherant 
monocytes, all the cells remaining had to be used in the tetramer analysis.  To 
try  and  induce  HA-l-specific  T  cells  using  fewer  donor  PBMCs,  a  mixed 
lymphocyte  culture  method  was  also  attempted,  but  the  number  of  cells 
recovered for analysis were few, and it was presumed that the HLA difference 
between  the  PBMCs  of  the  individuals  used  led  to  the  induction  of  T  cells 
against  major  histocompatibility  loci  instead.  In  order  for  either  of  these 
techniques to give a sufficient number of HA-l-specific T cells to from a CTL 
line  which  could  be  used  as  a  positive  control  for  the  HA-1  tetramers,  an 
unlimited  supply  of  HLA-A*0201+   HA-1-  and  HA-1+   HLA  identical  PBMCs 
would be required, and presently those resources do not exist at the Anthony 
Nolan Research Institute.
To test the hypothesis that any T cells produced from the mixed  lymphocyte 
cultures were HLA-specific and not HA-l-specific, it would have been desirable 
to  have  carried  out  a  cytotoxicity  test  with  the  targets  radiolabelled  with 
53Chromium.  However, the number of cells recovered were only sufficient for 
testing the HA-1 tetramers.
When our tetramers were finally tested on the HA-l-specific CTL line, and the 
tetramers prepared in The Netherlands were tested on the recipient samples, no 
positive results were seen.  The unlikely explanation is that the tetramers from 
The Netherlands are only specific for the CTL line and our tetramers are not. 
This  is  proven  to  be  untrue,  however,  as  the  HA-1  tetramer  from  The 
Netherlands  has  shown  positive  results  with recipients  samples  (Mutis et  al. 
1999a).  Another explanation could be that the tetramers lose  activity  during
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transport,  either  by  loss  of  the  Phycoerythrin  signal,  or  the  tetramer  or 
monomers falling apart due to changes in temperature or salt concentration due 
to evaporation.  Variations could also be due to differences between the staining 
and storage techniques in the laboratories.  Our tetramers were stored at 4°C for 
four months before testing was carried out in The Netherlands, whereas they 
keep their tetramers at -70°C with 10%  glycerol.  It should however be noted 
that tetramers made with different peptides in our laboratory have been stored 
for longer periods than this, and have still been found to give the same results 
as those prepared freshly.
Experiments using these reagents are continuing, and the next step will be to 
concentrate the remaining tetramer and attempt to stain the HA-l-specific CTL 
line.  I  have  been  invited  to  go  to  The  Netherlands  and  prepare  the  same 
tetramers using our HLA-A*0201  heavy chain, our p2m, our synthetic peptide 
and our PE-labelled Streptavidin in their laboratory.  Both tetramers can then be 
tested on patient samples and the HA-l-specific CTL line in situ to avoid all the 
previously mentioned factors that could affect the efficiency of the tetrameric 
complex.
In conclusion, the detection of HA-l-specific T cells in individuals with acute or 
chronic GvHD post transplant would be a useful tool.  It will give an indication 
of whether it is important to match for the HA-1 antigens in the selection of an 
unrelated donor in the future.
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Chapter 7
Conclusions and Discussion
A  database  of  clinical  information  was  established,  and  a  bank  of  PBMCs, 
plasma and DNA was collected for retrospective analysis of the effect of patient, 
donor  and  transplant  characteristics  on  the  outcome  of  bone  marrow 
transplants from donors provided by the Anthony Nolan Register.  A cohort of 
138  transplants  were  selected  for  analysis  in  a  pilot  study  and  the  level  of 
matching for HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1 alleles was determined 
using RSCA.  HLA matching, type of disease, CMV status of donor and patient, 
age of donor and patient, gender of donor and patient and the T cell depletion 
status of the transplant were included in univariable and multivariable analysis. 
The effect of these variables on the development of acute and chronic GvHD, 
overall  survival,  disease  free  survival  and  transplant  related  mortality  was 
assessed.  The effect of having acute and chronic GvHD was also adjusted for, 
where  relevant.  Factors  found  to  be  independently  associated  with reduced 
overall survival included a diagnosis of AML or other malignancy as compared 
to CML, a male patient receiving stem cells from a female donor, a mismatch for 
HLA class I and class II alleles and the development of acute GvHD.  The risk of 
reduced disease free survival was associated with the patient having CML or 
AML, stem cells transplanted from a same sex donor and an HLA mismatch at 
class I and II, or only class I.  A mismatch for HLA class I and II or class I alone 
were also associated with an increased risk of transplant related mortality, as 
was having acute GvHD.  CML patients had an increased risk of relapse, as did 
those with an HLA class  I  and  II mismatch.  Interestingly,  HLA  mismatches 
were not associated with the  development of acute  or chronic  GvHD,  which
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may have been a reflection of the small number of mismatches found for HLA- 
A, -B, -C, -DRB1  and -DQB1.  The inclusion of HLA-DPB1  matching did not 
appear to alter the effects seen when other mismatches were present.  However, 
matching at the allele level  for all  loci  gave  an increased risk of relapse and 
reduced  disease free survival compared  with patients  mismatched with their 
donor a for HLA-DPB1 only.  These results indicate that a mismatch for HLA- 
DPB1  alone may protect from relapse.  No significant association was seen in 
the  same  group  with  the  risk  of  developing  GvHD  or  increased  risk  of 
transplant related mortality.  Although the sample number was small for the 
analyses  required,  in  the  continuation  of  the  project  more  samples  will  be 
available for analysis and the information from this pilot study can be used as a 
basis for bigger, more informative investigation.
Sample size estimation
The  data  produced  from  this  pilot  study,  in  some  cases,  gave  statistically 
significant results at 5% level.  However, in many cases, the confidence intervals 
seen were wide, indicating a lack of precision in the analysis.  Also, some of the 
outcomes were unexpected, for example, the lack of an effect of HLA mismatch 
on  the  development  of  acute  and  chronic  GvHD.  These  unexpected  or 
imprecise results may be a reflection of the small number of samples included 
in the study.  Other influences may be the inclusion of transplants performed at 
many different centres with different protocols and patient groups.
To  answer  the  question  "does  an  HLA  allele  mismatch  increase  the  risk  of 
developing  acute  GvHD".  When  matched  for  all  HLA  loci,  54%  of  patients, 
developed acute GvHD.  It can be anticipated that a mismatch for an HLA class 
II allele will increase the risk to 61% (as the HR = 1.13, table 4-4). What sample 
size would be required in order to detect such an effect with 80% power at a 5% 
level of statistical significance?
In order to calculate the number of patients required  in each group  (m) for a 
definitive study, where the true effect of HLA matching on the development of 
acute  GvHD  may  be  seen,  a  power  calculation  was  carried  out,  using  the
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formula:
m = 2 x [z(i-a/2) + z(i-p)] 2 
A2
First,  the  standardised  difference, A, was  calculated.  In  the  case  of  two 
proportions, pi (0.61 or 61%) and p2 (0.54 or 54%),
A = pi - p2  where  p =  (pi + p2)  (0.61 + 0.54)  = 0.56
J P X  (1-p)
A = 0.61 -0.54  =  0.07  =  0.143
V0.61 x (1-0.61)  0.49
Using the values for a significance level of 5%, z (i- a / 2) = 1.96, and a power of 
80%, z(i-b) = 0.8416,
m =  2 x [1.96+ 0.8416] 2  =  767.7
0.1432
This means we require 768 transplant pairs in each group to assess the effect of 
a  mismatch  at  HLA  class  II  on  the  development  of  acute  GvHD.  Other 
examples were; the effect on the  development of acute  GvHD,  which would 
require 107 transplant pairs in each group, the effect of an HLA-DPB1 mismatch 
alone  on  overall  survival,  which would  require  148  transplant  pairs  in  each 
group, and the effect of an HLA-DPB1 mismatch alone on the risk of transplant 
related mortality, which would require 246 samples in each group.
Development of the project for future studies
Many  difficulties  were  encountered  and  overcome  during  the  study.  Some 
resolutions were  put in place  and  have  already  been discussed  in  chapter 3.
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Further  development  of  the  project  is  required  for  the  analysis  of  a  greater 
number of transplant pairs.  Detailed in this section are some procedures and 
resources that may be required in order to improve and develop the project to 
analyse a larger number of transplants.
Degraded samples
One  of the main problems found  was  the  poor  quality  of PBMCs  and  DNA 
obtained  from samples  that had  a  long transit  time.  This  was  overcome,  to 
some extent, with the use of transport medium and the introduction of a courier 
service to some locations.  To improve the quality of DNA further, the use of a 
commercially  available  stabilisation  product  could  be  used,  for  example 
PAXgene™  Blood DNA stabilisation tubes  (PreAnalytiX, QIAGEN  Ltd., West 
Sussex, UK), which contain a reagent which it is claimed maintains the integrity 
of genomic DNA in whole blood at room temperature for 14 days.  Another 
option may be  to  use buccal  swabs  as  a  source  of  DNA,  however,  this  may 
require  the  re-optimisation  of  the  PCR  for  lower  quantities  of  DNA  and 
increased  monitoring  of  potential  cross-contamination.  The  quality  of  the 
PBMCs  may  also  be  improved  with  the  use  of  a  BD™  Vacutainer™  Cell 
Preparation Tube™ (BD UK Limited, Oxford, UK) for blood collection.  The tube 
contains  density  gradient  fluid  and  a  gel  plug,  with  a  Sodium  Heparin 
anticoagulant.  The whole  blood  sample  can be  taken  directly  into  the  tube, 
mixed by  inversion and  then centrifuged,  separating the  red  blood  cells  and 
neutrophils from the lymphocytes, monocytes and  plasma with the gel plug. 
The  lymphocytes  and  monocytes  can  be  resuspended  in  the  plasma  for 
transport of the sample, without the threat of contamination from the products 
of red cell lysis.
Database maintenance 
Validation of data
A significant amount of time was taken validating the FileMaker Pro clinical 
database manually, with electronic validation of data fields carried out at the 
time  of analysis  in SPSS.  A  new  database  should  be  created  with  the  same
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fields,  adding  the  validation  processes  listed  in  table  3-1,  then  the  data  re­
entered.  This would allow automatic validation of all current clinical data and 
all the data entered from now onwards.  This would mean all data could be 
directly exported, in a spreadsheet format, into SPSS for analysis without extra 
validation.  Also, any fields added later could be included in the validation on 
entry into the database.
Clinical data collection forms
At the time clinical data analysis for this pilot study, many gaps were found in 
the clinical  data for the  patients  involved.  New  Clinical  data  request forms 
(figure  3-9)  were  send  out  to  the  Transplant  Coordinators  in  an  attempt  to 
collect as much missing data as possible.  In retrospect, the main challenge to 
obtaining clean data was the design of the forms (figures 3-5, 3-6, 3-7 and 3-9), 
these allowed the entry of free text in every field, meaning interpretation was 
required  for  entry  into  the  final  database.  This  could  be  avoided  by  the 
introduction of a form including only check boxes for each field.  For example:
Disease - Leukaemia  CML  E<]
AML  □
ALL  □
CLL  □
Ideally,  electronic  forms  could  be  used,  that  could  be  completed  at  the 
transplant centre in real time, on a secure website, with password entry.  The 
forms  could  be  interfaced  with  the  database.  This  would  avoid  the  large 
amount of paperwork required, and any errors due to illegibility of writing or 
interpretation of information.  An electronic calendar could be associated with 
each record to alert the coordinator by  email  when an update was  due.  An 
electronic link could be created to the Anthony Nolan database, SOLAR, which 
contains donor HLA typing information, avoiding double entry of data.
Time constraints
A lot of time was taken building and distributing sample collection kits to the 
transplant centres, and a lot of reagents and consumables wasted if the patient 
did not agree  to  give  a  sample.  This  could  be  overcome by  obtaining early
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consent from the patient, therefore allowing sample collection kits to be sent 
only  to  those  patients  who  had  agreed  to  give  a  sample.  Outsourcing  the 
building and distribution of the sample collection kits may also save time.
Personnel
One of the major difficulties found throughout the project was trying to obtain 
clinical information.  It would be a great advantage to have a clinician involved 
in the project full time, to liaise with the doctors and transplant coordinators 
and  also,  if  necessary,  to  obtain  the  required  information  from  the  patient 
records.  Access  to  patient records  is  confidential  only  to  clinically  qualified 
professionals.  A practicing bone marrow transplant clinician could also oversee 
the fields in the database, updating them when new conditioning regimens or 
GvHD  prophylaxis  were  introduced  and  advise  on  the  analyses  carried  out. 
The intervention of a clinician would also help with political conflicts in some 
cases.
If the project were to be expanded, to include all transplants carried out with 
Anthony  Nolan  donors,  and  not  only  those  in  the  UK,  it  would  be 
advantageous  to  employ  a  project manager.  The  project manager would  be 
responsible for liaison with the harvest and transplant centres, organise kit and 
sample transit, and work with the technical team.
In order to carry out sample processing and experimental work simultaneously, 
a technician and a clinical scientist would be required.  The technician could 
process the samples and control the storage of the plasma, PBMCs and DNA. 
The clinical scientist would be responsible for the PCR and RSCA running and 
gel analysis.
A data manager would also be required to maintain the database and carry out 
statistical calculations.
In  the  past,  many  studies  have  been  carried  out  to  try  and  understand  the 
complexity and effect on transplant oucome of many different factors.  So far, 
no single study has been able to make a recommendation with regard to HLA 
matching  due  to  unclear  relationships,  or  lack  of  typing resolution for  some
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loci.  Only  global  organisations,  such as  the  International  Histocompatibility 
Workshop,  may be  able  to  gather enough information to  assess  the  effect  of 
individual  loci  by  collecting  data  from  many  centres  aound  the  world.  In 
conclusion,  this  study  has  provided  a  useful  starting  point  for  a  large-scale 
analysis.  This  study  will  ultimately  contribute  to  the  understanding  of  the 
variable factors that influence transplant outcome and will allow optimization 
of donor selection for different patient types at the Anthony Nolan Trust.  For 
example, should HLA-DPB1  matching be included in the selection of donors, 
and is it more important to match for HLA class I alleles compared to HLA class 
II.
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Appendix I - Primers used in PCR amplification
Target Orientaion Name Sequence (5’ -  3’)
HLA-A Sense 5 Ain 1-46 GAAACSGCCTCTGYGGGGAGAAGCAA
HLA-A Antisense 3Ain 3-66 TGTTGGTCCCAATTGTCTCCCCTC
HLA-A Antisense 3A36L TGTTGGTCCCAATTGTCTCCCCTCCTTGTGGGAGGC
HLA-B Sense 3 Bln 1-57 GGGAGGAGCGAGGGGACCSCAG
HLA-B Antisense 3Bin 3-12 GGAGGCCATCCCCGGCGACCTAT
HLA-B Antisense 3BLong GGAGGCCATCCCCGGCGACCTCAMGGA
HLA-C Sense 5CIn 1-61 AGCGAGGKGCCCGCCCGGCGA
HLA-C Antisense 3BCIn 3-12 GGAGATGGGGAAGGCTCCCCACT
HLA-C Antisense 3CLongS GGAGATGGGGAAGGCTCCCCACTGCC
HLA-DRB1 Sense DRB101 5’ CCGGATCCTTCGTGTCCCCACAGCACG
HLA-DRB1 Antisense DRB101 3’ CGCCCCGCGCCGCGCT
HLA-DRB 1 Sense DRB102 5’ TTCCTGTGGCAGCCTAAGAGG
HLA-DRB 1 Antisense DRB102 3’ CCGCCCGCGGCCATGCT
HLA-DQB1 Sense DQBAMP-A CATGTGCTACTTCACCAACGG
HLA-DQB1 Antisense DQBAMP-B CTGGTAGTTGTGTCTGCACAC
HLA-DPB1 Sense DPBAMP-A GAGAGTGGCGCCTCCGCTCAT
HLA-DPB1 Antisense DPBAMP-B GCCGGCCCAAAGCCCTCACTC
MICA exon 3 Sense MICAEX35’ TGGGGGAGGGCCAGGGAGGCGTAC
MICA exon 3 Antisense MICAEX33’ CGATGTGCCAACAGGAAATGCCTT
MICA exon 4 Sense MICAEX45’ CAGACTTGCAGGTCAGGGGTCCCG
MICA exon 4 Antisense MICAEX43’ CAATGACTCTGAAGCACCAGCACT
M  =  A or C  Y  =  C or T
S  =  GorC  K  =  GorT
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Appendix II - Letter to Consultants inviting them participate
Letter  1
Transplant Centre
THE ANTHONY NOLAN 
BONE MARROW TRUST
Wh*** toxoamia rroMs  u match
Date
Dear Consultant
The Royal Frac Mo«x:a 
The Anihony Nolan Research Institute is currently embarking on a study investigating 
the  importtincc  of  HLA  matching  in  unrelated  bone  marrow  transplants.  Recent 
advances in molecular typing have made it jxissible to obtain very high resolution  tissue 
types, but this in turn makes it even more difficult to find a “perfectly’' matched donor. 
As you will be well aware, this is already a vety difficult task and often only a partially 
matched donor is available.
In tire past these techniques were not available and consequently many transplants  were 
performed with seemingly perfectly matched donors which nowadays  would not hold 
up to scrutiny.  Many of these transplants though have very successful outcomes.
The  purpose  of  this  study  is  firstly  to  use  all  available  techniques  to  tissue  type 
patient/donor pairs  to the  highest  possible resolution,  and  secondly,  by  following  the 
outcome of transplant  we  would  then be able  to  correlate  specific  mismatches  with  a 
good or bad transplant outcome.  In the future this will enable us to advise which donor 
should be chosen in live event that  no fully compatible donor is  available and there is a 
choice of partially matched donors.
The  work  involved  would  require  a  small  patient  sample  (50nds  from  adults  or 
whatever  volume  is  appropriate  from  children  -  even  as  little  as  5mls  would  be 
gratefully received) and  regular updates on  the progress  of the  transplant,  and  in  this 
your help would  be essential.  Once  a  transplant  date  lias  heen  set  we  would  be  in 
contact and send universals containing preservative-free heparin and  F-DTA  and  a  pro 
paid box. to try and minimise your workload in this study.  In return we will endeavour 
to keep you informed of any results concerning your patients.
Please could you complete the enclosed consent  form and  return it so  I have a  record 
that your transplant centre will  be prepared  to participate.  Please call  me  if you  have 
any queries ( ).  Thank you very much.
Yours sincerely
Andrea Pay
Purorc Hk Raya l-ixnM ! Tne OiKtets cl Kern. GCVO. T *  Tn»t« a contain?xmiee Ire (uvuxco win ctanly sttluv 
Rcjlscro: Otic* as ibeve. Relucted n  Er^lux!  237929). Chatty rtyi73tcii rxtffiet 993719.
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Appendix III - Study proposal sent to the Ethics Committee
Proposal  for  study  on  donor/paticnt  samples
Our gtoup at the Anthony Nolan Research Institute has developed a novel  technique which can  be  used  foe 
high resolution HLA class I and class II typing and to verify ‘HLA-matched' patient and donor pairs  in  bone 
marow transplantation.  This  technique,  which  we  have  named:  Double  Stnuid  Conformation  Analysis 
(DCSA) involves fluorcsccntly labelling a  locus  spccifx:  reference sense strand nrd hybridising  with  locus 
specific amplified DNA from patient  and donor.  The duplexes  formed are separated by  polyacrylamide gel 
elcctrophoresii.  Results arc quickly obtained using  an automated sequencing  instrument.  Comparison  of 
positions  of doner duplexes with  patient  duplex enables  the  identification  of best  matched  donor.  This 
technique i< being assessed here at the Anthony Nolan Research Institute  for use  in  the final  stage analysis 
of donor and patient before transplant.  We believe this is the most accurate and rapid way to match donors 
and patient DNA samples at the  allelic  level.  It  is a DNA method  analogous  to  the  isoclctric  focusing 
technique  used in  protein separation  and is  ideal  for resolving  allelic  differences  not  found  by  molecular 
typing methods.
We propose to  analyse samples from every  Anthony  Nolan donor/rccipicnl pair which arc transplanted  in 
tlte UK using the DCSA technique to determine the degree of class I  and class II  matching,  and to identify 
mismatches between donor and patient.  Any  samples that  we delect as  being mismatched  will  be retyped 
using either a high resolution  nolccular typing  technique developed  in  our laboratory  known  as  Uniwrsal 
Recombinant Site Targeting Oligonucleotide Procedure (URSTOP) or Sequence Based Typing (SBT).
Once  tlsc  transplant  follow  up  data  has  been  acquitcd  and  mere  is  known  about  die  outcome  of  the 
transplant,  it  will  be possible  to  formulate  future experiments to  analyse  other  factors  as  well  at  MHC 
which affect Bone Marrow Transplant success.
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Appendix IV - Consent form
Protocol N°1
To:  Potential bone marrow donors and recipients
From:  Dr J Alejandro Madrigal 
Research Director 
Anthony Nolan Research Institute
Consent  Form
Re: HI,A matching of Anthony Nolan donors
The Anthony Nolan Research Institute is currently embarking on a study investigating 
the  importance  of IILA   matching  in  unrelated  bone  marrow  transplants.  Recent 
advances in molecular typing have made it possible to obtain very' high resolution tissue 
types, but this in turn makes it even more difficult to find a "pcrfcctly"matchcd donor. 
As you will be well aware, this is already a very difficult task and often only a partially 
matched donor is available.
In tltc past these techniques were not available and consequently many uansplants were 
performed with seemingly perfectly matched donors which nowadays would not hold 
up to scrutiny.  M any of these uansplants though, have very successful outcomes.
The  purpose  of this  study  is  firstly  to  use  all  available  techniques  to  tissue  type 
patient/donor pairs to the highest possible resolution, ami secondly, by following the 
outcome of transplant we would then be able to correlate specific mismatches with a 
successful transplant outcome.  In the future this will enable us to advise which donor 
should be chosen in the event that no fully computable donor is available and there is a 
choice of partially matched donors.
The work involved  would require a blood sample.  The  DNA  extracted  from   this 
sam ple  will  only  be  used  for  m atching  studies  in  our  laboratory.
THE ANTHONY NOIAM 
BONfc MARROW TRUST
•Atw«» loaijtm a moett its match
l he Hoyai iw  
1 am willing to take part in this study and agree to provide the samples requested, I have 
read and understand the details of the study.
Health  C art  witness  Patient  ur  Bum;  M arrua. llnaur
S igned.........................................................................  S igned............................ ...............................................
N am e.............................................................................  N am e......................................................................
P osition     .....................................  H ospital...........................................................................
>4>rfityW Ftiiftmm TlwOtnhHf o*Kwti, GCW. The TuW'v ■ ?  coKipAAy Utvtcd 4*yty/dor-lc*xv^h  VA»m. 
«?.<».a *   »o Cryl^nrJ r i>rn>jr 7379?$CJ, Chtafjr rvgiWatVifl nurfeff 803 7 tv.
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Appendix V - Harvest Centres used by the Anthony Nolan Trust
London Clinic 
20 Devonshire Place 
London 
WIN 2DH
Royal Free Hospital 
Pond Street 
Hampstead 
London 
NW3 2QG
University College Hospital 
25 Grafton Way 
London 
WC1E
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A b b rev ia tio n s
ABMDR Australian Bone Marrow Donor Registry
ALL Acute Lymphocytic Leukaemia
AML Acute Myeloid Leukaemia
ANBMT Anthony Nolan Bone Marrow Trust
APC Antigen presenting cell
B-LCL B-lymphocyte cell line
BMT Bone marrow transplant
CD Cluster of differentiation
CLIP Class II associated invariant chain peptide
CML Chronic Myeloid Leukaemia
CY Cyclophosphamide
CMV Cytomegalovirus
51Cr Chromium-51 radioactive isotope
CR Complete Remission
CTL Cytotoxic T-lymphocyte
CTLp Cytotoxic T-lymphocyte precursor
DIG Di-Digoxygenin
DLI Donor lymphocyte infusion
DMSO Dimethyl sulfoxide
DN Double negative
DNA Deoxyribonucleic acid
DP Double positive
dNTP Deoxynucleotide Triphosphate
EDTA Ethylene diamine tetra acetic acid
EUCAPS European  Union  Concerted  Action  Program  for  Peptide 
Sensitisation
FCS Foetal Calf Serum
FLR Fluorescent labelled reference
FPLC Fast performance liquid chromatography
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GvHD Graft-versus-host disease
GvL Graft-versus-leukaemia
HIV Human Immunodeficiency virus
HL-A Human Leukocyte Locus A
HLA Human Leukocyte Antigen
HR Hazard Ratio
HTL Helper T-lymphocyte
HTLp Helper T-lymphocyte precursor
HVR Hypervariable region
IFN-a Interferon-alpha
Ig Immunoglobulin
IHWS International Histocompatibility Workshop
KIR Killer immunoglobulin-like receptor
LCMV Lymphocytic choriomeningitis virus
MDS Myelodysplastic syndrome
mHag Minor Histocompatibility Antigen
MHC Major Histocompatibility Complex
MIC MHC class I chain related gene
MLC Mixed Lymphocyte Culture
MLR Mixed Lymphocyte Reaction
MIIC MHC class II compartment
NK Natural Killer
NHL Non-Hodgkins Lymphoma
OD Optical density
OR Odds Ratio
PAGE Polyacrylamide gel electropheresis
PBL Peripheral blood lymphocyte
PBMC Peripheral blood mononuclear cell
PCR Polymerase chain reaction
PLT Primed Lymphocyte Test
RCLB Red cell lysis buffer
RNA Ribonucleic Acid
RSCA Reference strand mediated conformation analysis
SBT Sequence based typing
SCID Severe Combined Immunodeficiency
SDS Sodium dodecyl sulphate
255ABBREVIATIONS
SPSS Statistical computer package
s s o Sequence specific oligotyping
SSP Sequence specific primers/PCR
TBE Tris buffered EDTA
TBI Total body irradiation
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